<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<base target="_blank">
<link rel=File-List href="demans_dosyalar/filelist.xml">
<link rel=Edit-Time-Data href="demans_dosyalar/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>DEMANS SENDROMU, ALZHEIMER HASTALI&#286;I ve ALZHEIMER DI&#350;I
DEMANSLAR</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:HideSpellingErrors/>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-alt:\BC14\D0D5;
	mso-font-charset:129;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\5B8B\4F53;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;
	mso-font-alt:\65B0\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-alt:"\FF2D\FF33 \30B4\30B7\30C3\30AF";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\B3CB\C6C0;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\9ED1\4F53;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;
	mso-font-alt:\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134742016 16 0 1048576 0;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;
	mso-font-alt:\660E\671D;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\AD74\B9BC;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 151388160 16 0 524288 0;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 3 5 7 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:16777217 0 0 0 65536 0;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Latha;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1048579 0 0 0 1 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:67110535 0 0 0 159 0;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:131075 0 0 0 1 0;}
@font-face
	{font-family:Shruti;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:262147 0 0 0 1 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2097155 0 0 0 1 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:4194307 0 0 0 1 0;}
@font-face
	{font-family:"Estrangella Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Cambria;
	mso-font-alt:"Palatino Linotype";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482993 6144 0 0 31 0;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147476737 14699 0 0 63 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870009 1073741843 0 0 415 0;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147459005 0 128 0 1 0;}
@font-face
	{font-family:"MV Boli";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 256 0 1 0;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421663 -2147483648 8 0 66047 0;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 5 6 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Menlo Regular";
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Lucida Grande";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Calibri;
	mso-font-charset:162;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750139 0 0 159 0;}
@font-face
	{font-family:"Nimbus Sans L";
	mso-font-alt:Arial;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"DejaVu Sans";
	mso-font-charset:128;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:255;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"\@Batang";
	mso-font-charset:129;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"\@Nimbus Sans L";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
h1
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:21.6pt;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-21.6pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	font-family:Arial;
	font-weight:bold;}
h2
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:28.8pt;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-28.8pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:12.0pt;
	font-family:Arial;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:36.0pt;
	text-indent:-36.0pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:13.0pt;
	font-family:Arial;
	font-weight:bold;}
h6
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:57.6pt;
	text-indent:-57.6pt;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:64.8pt;
	text-indent:-64.8pt;
	mso-pagination:widow-orphan;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoList, li.MsoList, div.MsoList
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:Batang;
	mso-hansi-font-family:"Arial Unicode MS";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{margin-top:14.0pt;
	margin-right:0cm;
	margin-bottom:14.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Arial Unicode MS";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.heading, li.heading, div.heading
	{mso-style-name:heading;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Nimbus Sans L";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Arial Unicode MS";
	mso-bidi-font-family:"Times New Roman";}
p.caption, li.caption, div.caption
	{mso-style-name:caption;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-style:italic;}
p.ndex, li.ndex, div.ndex
	{mso-style-name:ndex;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.balloontext, li.balloontext, div.balloontext
	{mso-style-name:balloontext;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.decimalaligned, li.decimalaligned, div.decimalaligned
	{mso-style-name:decimalaligned;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.commenttext, li.commenttext, div.commenttext
	{mso-style-name:commenttext;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.commentsubject, li.commentsubject, div.commentsubject
	{mso-style-name:commentsubject;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
p.listparagraph, li.listparagraph, div.listparagraph
	{mso-style-name:listparagraph;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.authors1, li.authors1, div.authors1
	{mso-style-name:authors1;
	margin-top:3.6pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:33.0pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.source1, li.source1, div.source1
	{mso-style-name:source1;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:33.0pt;
	margin-bottom:.0001pt;
	line-height:12.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.list2, li.list2, div.list2
	{mso-style-name:list2;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	text-indent:-14.15pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.bodytext2, li.bodytext2, div.bodytext2
	{mso-style-name:bodytext2;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	line-height:200%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.text, li.text, div.text
	{mso-style-name:text;
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.bodytext3, li.bodytext3, div.bodytext3
	{mso-style-name:bodytext3;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.bodytextndent2, li.bodytextndent2, div.bodytextndent2
	{mso-style-name:bodytextndent2;
	margin:0cm;
	margin-bottom:.0001pt;
	text-indent:35.4pt;
	line-height:200%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.plaintext, li.plaintext, div.plaintext
	{mso-style-name:plaintext;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";}
p.date, li.date, div.date
	{mso-style-name:date;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.fulltext-references, li.fulltext-references, div.fulltext-references
	{mso-style-name:fulltext-references;
	margin-top:14.0pt;
	margin-right:0cm;
	margin-bottom:18.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.affiliation2, li.affiliation2, div.affiliation2
	{mso-style-name:affiliation2;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:6.0pt;
	line-height:14.4pt;
	mso-pagination:widow-orphan;
	font-size:9.5pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.pmid3, li.pmid3, div.pmid3
	{mso-style-name:pmid3;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:12.0pt;
	margin-left:6.0pt;
	line-height:14.4pt;
	mso-pagination:widow-orphan;
	font-size:9.5pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";}
p.tablecontents, li.tablecontents, div.tablecontents
	{mso-style-name:tablecontents;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.tableheading, li.tableheading, div.tableheading
	{mso-style-name:tableheading;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
p.framecontents, li.framecontents, div.framecontents
	{mso-style-name:framecontents;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.citation, li.citation, div.citation
	{mso-style-name:citation;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.authlist, li.authlist, div.authlist
	{mso-style-name:auth_list;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.title, li.title, div.title
	{mso-style-name:title;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.rprtbody, li.rprtbody, div.rprtbody
	{mso-style-name:rprtbody;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.aux, li.aux, div.aux
	{mso-style-name:aux;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.ww8num4z0
	{mso-style-name:ww8num4z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num4z1
	{mso-style-name:ww8num4z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num4z2
	{mso-style-name:ww8num4z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num5z0
	{mso-style-name:ww8num5z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num5z1
	{mso-style-name:ww8num5z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num5z2
	{mso-style-name:ww8num5z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num6z0
	{mso-style-name:ww8num6z0;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num6z2
	{mso-style-name:ww8num6z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num6z3
	{mso-style-name:ww8num6z3;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num7z0
	{mso-style-name:ww8num7z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num7z2
	{mso-style-name:ww8num7z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num7z4
	{mso-style-name:ww8num7z4;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num8z0
	{mso-style-name:ww8num8z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num8z1
	{mso-style-name:ww8num8z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num8z2
	{mso-style-name:ww8num8z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num9z0
	{mso-style-name:ww8num9z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num9z1
	{mso-style-name:ww8num9z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num9z2
	{mso-style-name:ww8num9z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num10z0
	{mso-style-name:ww8num10z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num10z1
	{mso-style-name:ww8num10z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num10z2
	{mso-style-name:ww8num10z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num11z0
	{mso-style-name:ww8num11z0;
	font-weight:normal;
	font-style:italic;}
span.ww8num11z7
	{mso-style-name:ww8num11z7;
	color:windowtext;}
span.ww8num12z0
	{mso-style-name:ww8num12z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num12z1
	{mso-style-name:ww8num12z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num12z2
	{mso-style-name:ww8num12z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num13z0
	{mso-style-name:ww8num13z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num13z1
	{mso-style-name:ww8num13z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num13z2
	{mso-style-name:ww8num13z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num14z0
	{mso-style-name:ww8num14z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num14z1
	{mso-style-name:ww8num14z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num14z2
	{mso-style-name:ww8num14z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num15z0
	{mso-style-name:ww8num15z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num15z1
	{mso-style-name:ww8num15z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num15z2
	{mso-style-name:ww8num15z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num16z0
	{mso-style-name:ww8num16z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num16z1
	{mso-style-name:ww8num16z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num16z2
	{mso-style-name:ww8num16z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num17z0
	{mso-style-name:ww8num17z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num17z1
	{mso-style-name:ww8num17z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num17z2
	{mso-style-name:ww8num17z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num18z0
	{mso-style-name:ww8num18z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num18z1
	{mso-style-name:ww8num18z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num18z2
	{mso-style-name:ww8num18z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num19z0
	{mso-style-name:ww8num19z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num19z1
	{mso-style-name:ww8num19z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num19z2
	{mso-style-name:ww8num19z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num20z0
	{mso-style-name:ww8num20z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num20z1
	{mso-style-name:ww8num20z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num20z2
	{mso-style-name:ww8num20z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num21z0
	{mso-style-name:ww8num21z0;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.ww8num21z1
	{mso-style-name:ww8num21z1;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num21z2
	{mso-style-name:ww8num21z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num22z0
	{mso-style-name:ww8num22z0;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.ww8num22z2
	{mso-style-name:ww8num22z2;
	font-family:Wingdings;
	mso-ascii-font-family:Wingdings;
	mso-hansi-font-family:Wingdings;}
span.ww8num22z3
	{mso-style-name:ww8num22z3;
	font-family:Symbol;
	mso-ascii-font-family:Symbol;
	mso-hansi-font-family:Symbol;}
span.heading1char
	{mso-style-name:heading1char;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.heading2char
	{mso-style-name:heading2char;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.heading3char
	{mso-style-name:heading3char;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.heading6char
	{mso-style-name:heading6char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.heading7char
	{mso-style-name:heading7char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.balloontextchar
	{mso-style-name:balloontextchar;
	font-family:"Lucida Grande";
	mso-ascii-font-family:"Lucida Grande";
	mso-hansi-font-family:"Lucida Grande";}
span.footnotetextchar
	{mso-style-name:footnotetextchar;
	font-family:Tahoma;
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
span.footnotecharacters
	{mso-style-name:footnotecharacters;
	vertical-align:super;}
span.subtitlechar
	{mso-style-name:subtitlechar;
	font-family:Batang;
	mso-ascii-font-family:Batang;
	mso-fareast-font-family:Batang;
	font-weight:bold;}
span.headerchar
	{mso-style-name:headerchar;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-hansi-font-family:Cambria;}
span.bodytextchar
	{mso-style-name:bodytextchar;
	font-family:Arial;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-bidi-font-family:Arial;
	font-weight:bold;}
span.bodytextndentchar
	{mso-style-name:bodytextndentchar;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.subtleemphasis
	{mso-style-name:subtleemphasis;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	color:gray;
	font-style:italic;}
span.footerchar
	{mso-style-name:footerchar;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
span.commenttextchar
	{mso-style-name:commenttextchar;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
span.commentsubjectchar
	{mso-style-name:commentsubjectchar;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;
	font-weight:bold;}
span.bodytext2char
	{mso-style-name:bodytext2char;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-hansi-font-family:Cambria;}
span.bodytext3char
	{mso-style-name:bodytext3char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.bodytextndent2char
	{mso-style-name:bodytextndent2char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.plaintextchar
	{mso-style-name:plaintextchar;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:"Courier New";}
span.datechar
	{mso-style-name:datechar;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.reference-journal-title2
	{mso-style-name:reference-journal-title2;
	font-style:italic;}
span.reference-volume2
	{mso-style-name:reference-volume2;
	font-weight:bold;}
span.msons
	{mso-style-name:msons;
	text-decoration:underline;
	text-underline:single;}
span.footnotecharacters0
	{mso-style-name:footnotecharacters0;
	vertical-align:super;}
span.msons0
	{mso-style-name:mso\0131ns;
	text-decoration:underline;
	text-underline:single;}
span.msodel0
	{mso-style-name:msodel;
	color:red;
	text-decoration:line-through;}
span.src
	{mso-style-name:src;}
span.jrnl
	{mso-style-name:jrnl;}
p.ListParagraph0, li.ListParagraph0, div.ListParagraph0
	{mso-style-name:"List Paragraph";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
p.ListParagraph0CxSp\0130lk, li.ListParagraph0CxSp\0130lk, div.ListParagraph0CxSp\0130lk
	{mso-style-name:"List ParagraphCxSp\0130lk";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
p.ListParagraph0CxSpOrta, li.ListParagraph0CxSpOrta, div.ListParagraph0CxSpOrta
	{mso-style-name:"List ParagraphCxSpOrta";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
p.ListParagraph0CxSpSon, li.ListParagraph0CxSpSon, div.ListParagraph0CxSpSon
	{mso-style-name:"List ParagraphCxSpSon";
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-fareast-font-family:Cambria;
	mso-bidi-font-family:"Times New Roman";}
ins
	{mso-style-type:export-only;
	text-decoration:none;}
span.msoIns
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:underline;
	text-underline:single;}
span.msoDel
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:line-through;
	color:red;}
@page Section1
	{size:954.15pt 595.25pt;
	mso-page-orientation:landscape;
	margin:90.0pt 184.3pt 90.0pt 72.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
@page Section2
	{size:594.95pt 841.85pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section2
	{page:Section2;}
 /* List Definitions */
 @list l0
	{mso-list-id:22632108;
	mso-list-template-ids:-1188518058;}
@list l0:level1
	{mso-level-start-at:41;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1
	{mso-list-id:54668218;
	mso-list-type:hybrid;
	mso-list-template-ids:1913673250 67698703 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l1:level1
	{mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2
	{mso-list-id:71511021;
	mso-list-template-ids:-1648340346;}
@list l2:level1
	{mso-level-start-at:15;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l3
	{mso-list-id:95488971;
	mso-list-template-ids:905204900;}
@list l3:level1
	{mso-level-start-at:12;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4
	{mso-list-id:287198514;
	mso-list-template-ids:-1987382328;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l4:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l4:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l5
	{mso-list-id:418137551;
	mso-list-template-ids:-1568099352;}
@list l5:level1
	{mso-level-start-at:18;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6
	{mso-list-id:429594025;
	mso-list-template-ids:1960314602;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l7
	{mso-list-id:455560122;
	mso-list-template-ids:-1503637094;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l8
	{mso-list-id:455831629;
	mso-list-template-ids:-287022200;}
@list l8:level1
	{mso-level-start-at:23;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9
	{mso-list-id:499275716;
	mso-list-template-ids:-1892014798;}
@list l9:level1
	{mso-level-start-at:27;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10
	{mso-list-id:523636168;
	mso-list-template-ids:-1346844508;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l11
	{mso-list-id:577178543;
	mso-list-template-ids:-806462730;}
@list l11:level1
	{mso-level-start-at:14;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12
	{mso-list-id:598564829;
	mso-list-template-ids:-872669832;}
@list l12:level1
	{mso-level-start-at:33;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l13
	{mso-list-id:627932391;
	mso-list-template-ids:-16901844;}
@list l13:level1
	{mso-level-start-at:7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l14
	{mso-list-id:675351984;
	mso-list-template-ids:-1613578048;}
@list l14:level1
	{mso-level-start-at:16;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l15
	{mso-list-id:690375151;
	mso-list-template-ids:545572744;}
@list l15:level1
	{mso-level-start-at:9;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l16
	{mso-list-id:723019854;
	mso-list-template-ids:-1624367020;}
@list l16:level1
	{mso-level-start-at:20;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l17
	{mso-list-id:726758960;
	mso-list-template-ids:-1663766038;}
@list l17:level1
	{mso-level-start-at:28;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l18
	{mso-list-id:726807471;
	mso-list-template-ids:-698612664;}
@list l18:level1
	{mso-level-start-at:29;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l19
	{mso-list-id:739403674;
	mso-list-template-ids:-1876767758;}
@list l19:level1
	{mso-level-start-at:10;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l20
	{mso-list-id:864756265;
	mso-list-template-ids:1518120352;}
@list l20:level1
	{mso-level-start-at:5;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l21
	{mso-list-id:931553093;
	mso-list-template-ids:1553658298;}
@list l21:level1
	{mso-level-start-at:22;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22
	{mso-list-id:932937119;
	mso-list-template-ids:201618086;}
@list l22:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l22:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l22:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l23
	{mso-list-id:968240070;
	mso-list-template-ids:-20925398;}
@list l23:level1
	{mso-level-start-at:19;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l24
	{mso-list-id:1026784376;
	mso-list-template-ids:-1743231660;}
@list l24:level1
	{mso-level-start-at:37;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l25
	{mso-list-id:1065570284;
	mso-list-template-ids:-1501796202;}
@list l25:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l26
	{mso-list-id:1123231621;
	mso-list-template-ids:-1065314434;}
@list l26:level1
	{mso-level-start-at:26;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27
	{mso-list-id:1197083778;
	mso-list-template-ids:794581648;}
@list l27:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l27:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l27:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l28
	{mso-list-id:1210192157;
	mso-list-template-ids:1814063790;}
@list l28:level1
	{mso-level-start-at:2;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l29
	{mso-list-id:1238058996;
	mso-list-template-ids:749791040;}
@list l29:level1
	{mso-level-start-at:13;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l30
	{mso-list-id:1250962438;
	mso-list-template-ids:780466432;}
@list l30:level1
	{mso-level-start-at:11;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l31
	{mso-list-id:1270506292;
	mso-list-template-ids:514508248;}
@list l31:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l32
	{mso-list-id:1282296507;
	mso-list-template-ids:2010409602;}
@list l32:level1
	{mso-level-start-at:21;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l33
	{mso-list-id:1299796289;
	mso-list-type:hybrid;
	mso-list-template-ids:-618130462 279076514 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l33:level1
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-weight:bold;}
@list l34
	{mso-list-id:1399596011;
	mso-list-template-ids:1452053616;}
@list l34:level1
	{mso-level-start-at:38;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35
	{mso-list-id:1410809325;
	mso-list-template-ids:-339070558;}
@list l35:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l35:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l35:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l36
	{mso-list-id:1423145308;
	mso-list-template-ids:669840636;}
@list l36:level1
	{mso-level-start-at:40;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l37
	{mso-list-id:1446802422;
	mso-list-template-ids:-858496434;}
@list l37:level1
	{mso-level-start-at:30;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l38
	{mso-list-id:1488666849;
	mso-list-template-ids:2089732170;}
@list l38:level1
	{mso-level-start-at:32;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l39
	{mso-list-id:1496415823;
	mso-list-template-ids:-632785860;}
@list l39:level1
	{mso-level-start-at:25;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l40
	{mso-list-id:1598634602;
	mso-list-template-ids:-2021612344;}
@list l41
	{mso-list-id:1679580029;
	mso-list-template-ids:1260661088;}
@list l41:level1
	{mso-level-start-at:31;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l42
	{mso-list-id:1698505120;
	mso-list-template-ids:1258720590;}
@list l42:level1
	{mso-level-start-at:36;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l43
	{mso-list-id:1765297627;
	mso-list-template-ids:123217036;}
@list l43:level1
	{mso-level-start-at:4;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44
	{mso-list-id:1778984947;
	mso-list-template-ids:-1335443562;}
@list l44:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l44:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l44:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l45
	{mso-list-id:1784298159;
	mso-list-template-ids:716858502;}
@list l45:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l46
	{mso-list-id:1904098004;
	mso-list-template-ids:1225659884;}
@list l46:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l46:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l46:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l47
	{mso-list-id:1974404884;
	mso-list-template-ids:1358719256;}
@list l47:level1
	{mso-level-start-at:8;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l48
	{mso-list-id:2064714324;
	mso-list-template-ids:-1294727452;}
@list l48:level1
	{mso-level-start-at:39;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l49
	{mso-list-id:2066903052;
	mso-list-template-ids:-1886469080;}
@list l49:level1
	{mso-level-start-at:24;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l50
	{mso-list-id:2078281634;
	mso-list-template-ids:-91453248;}
@list l50:level1
	{mso-level-start-at:3;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="12290"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body bgcolor=white lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><a name="OLE_LINK1"><b><span lang=TR
style='font-size:14.0pt;font-family:Tahoma;mso-ansi-language:TR'>DEMANS
SENDROMU, ALZHEIMER HASTALI&#286;I ve ALZHEIMER DI&#350;I DEMANSLAR</span></b></a><span
style='mso-bookmark:OLE_LINK1'></span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;. Hakan Grvit</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Son Gncelle&#351;tirme Tarihi: <b>12.5.2010</b></span><span
lang=FR style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>G&#304;R&#304;&#350;</span></b><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>T&#305;bbi pratikte demans kavram&#305; belli bir
asgari bulgular toplulu&#287;u olarak bir sendroma kar&#351;&#305;l&#305;k
gelir. rne&#287;in, nas&#305;l nefropati sendromunun alt&#305;nda
hipertansiyondan diyabete ok say&#305;da etyolojik neden s&#305;ralanabilirse,
demans sendromu da uzun bir listeye ancak s&#305;&#287;d&#305;r&#305;labilecek
bir dizi etyolojik etmenin sonucu olarak geli&#351;ir.&nbsp; Liste uzun olsa
da, ilerleyen blmlerde ayr&#305;nt&#305;yla grlece&#287;i gibi, tm
demanslar&#305;n te ikisinden fazlas&#305; <i>Alzheimer
hastal&#305;&#287;&#305;</i>na (AH) ba&#287;l&#305;d&#305;r.&nbsp; Bu yksek
oran, klinik pratikte belli bir ay&#305;r&#305;c&#305; tan&#305;
kolayl&#305;&#287;&#305; sa&#287;larken (demans sendromunu tan&#305;yan
klinisyen ileri gitmeksizin AH tan&#305;s&#305; koyarsa % 65 do&#287;ru
tan&#305; koymu&#351; olacakt&#305;r), AHnin do&#287;as&#305;ndan kaynaklanan
nedenlerle de, kendine zg glkler ta&#351;&#305;r: diabetes mellitustaki
yksek kan &#351;ekeri dzeyi gibi, AHnin bir biyolojik i&#351;aretleyicisi
olmad&#305;&#287;&#305; iin kesin tan&#305; ancak nropatolojik yntemlerle
mmkndr.&nbsp; Bu durumda klinisyen grd&#287; klinik tablo iin AH
de&#287;il, fakat <i>Alzheimer Tipi Demans</i> (bundan byle &#304;ngilizce
kar&#351;&#305;l&#305;&#287;&#305; olan <i>Dementia of Alzheimer Type</i>
k&#305;saltmas&#305; DAT olarak kullan&#305;lacak) sendromu, ya da bu tablonun
kesin olmasa da, yksek olas&#305;l&#305;kla AHye ba&#287;l&#305;
oldu&#287;unu d&#351;nd&#287;n gsterir biimde Muhtemel Alzheimer
Hastal&#305;&#287;&#305; (bundan byle &#304;ngilizce
kar&#351;&#305;l&#305;&#287;&#305; olan <i>Probable Alzheimers Disease</i>
k&#305;saltmas&#305; PRAD olarak kullan&#305;lacak) tan&#305;s&#305;
koyabilecektir.&nbsp;A&#351;a&#287;&#305;da Alzheimer Hastal&#305;&#287;&#305;
blmnde ayr&#305;nt&#305;yla gzden geirilece&#287;i gibi, DAT terimi&nbsp;
DSM-IV, PRAD ise NINCDS-ADRDA tan&#305; kriterleri olarak
kullan&#305;ld&#305;&#287;&#305;nda seilen zgl tan&#305; etiketleridir.
Aralar&#305;ndaki ufak nanslarla birlikte DAT ve PRAD byk lde rt&#351;rler.
Bu blmde PRAD ve DAT kavramlar&#305; zgl tan&#305; kriterlerinin
kar&#351;&#305;l&#305;klar&#305; olarak b&#305;rak&#305;lacak, gnlk
kullan&#305;mda AHyle ilintili demans iin ise Alzheimer tipi demans (ATD)
terimi kullan&#305;lacakt&#305;r. Bu durum ilk bak&#305;&#351;ta demansla kar&#351;&#305;la&#351;an
klinisyenler a&#305;s&#305;ndan ciddi bir zorluk gibi grnse de, geni&#351;
nekropsi serilerinde, klinik olarak PRAD ya da DAT tan&#305;s&#305; konulan
olgular&#305;n %90&#305;n&#305;n kesin AH patolojik tan&#305;s&#305;
ald&#305;klar&#305; grlm&#351;tr.&nbsp; Bir ba&#351;ka deyi&#351;le, ATD
sendromu %10 gibi kk bir olas&#305;l&#305;kla ba&#351;ka demans etmenleriyle
de ortaya &#305;kabilmektedir.&nbsp; Gnlk pratikte, ilk ad&#305;mda demans
sendromunu zihinsel bozuklukla kendini gsteren di&#287;er sendromlardan
ay&#305;rabilmek, demansa karar verildi&#287;i takdirde ikinci ad&#305;mda
demanslar iinde AHnin ayr&#305;cal&#305;kl&#305; yeri nedeniyle, AHye zg
tipik sendromu, di&#287;er demans nedenlerinin klinik nanslar&#305;ndan
ay&#305;rdedebilmek esast&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu blmde nce demans sendromu kavramsal olarak
tan&#305;mlanacak, normal ya&#351;l&#305;l&#305;ktan ve di&#287;er zihinsel
bozukluklardan fark&#305; ortaya konulacak ve sonras&#305;nda demans muayenesi,
demanslar&#305;n ay&#305;r&#305;c&#305; tan&#305;s&#305; zerinde
durulacakt&#305;r.&nbsp; Ard&#305;ndan zgl demans nedenlerine geilecek ve AH
ile AH-d&#305;&#351;&#305; demanslar incelenecektir.&nbsp; AH
k&#305;sm&#305;nda klinik tablo, tan&#305; kriterleri, seyir, epidemiyoloji,
genetik, patoloji-patogenez, ve tedavi, alt k&#305;s&#305;mlarda
ayr&#305;nt&#305;yla ele al&#305;nacakt&#305;r.&nbsp; AH-d&#305;&#351;&#305;
demanslar k&#305;sm&#305;nda AH d&#305;&#351;&#305; nrodejeneratif demans
hastal&#305;klar&#305; aras&#305;nda olan <i>Lewy cisimcikli demans</i> (LCD), <i>fronto-temporal
Demans</i> (FTD) ve <i>Pick Kompleksi</i> kavram&#305;, <i>prion
hastal&#305;klar&#305;</i> ve zellikle <i>Creutzfeldt-Jacob
hastal&#305;&#287;&#305;</i> (CJH), hareket bozukluklar&#305;yla birlikte
demans, sekonder demanslar aras&#305;nda zellikle <i>vaskler demans</i> (VaD)
incelenecek, di&#287;er nadir demans nedenleri k&#305;saca
zetlenecektir.&nbsp; T&#305;p &#287;rencileri iin byk puntolarla
yaz&#305;lm&#305;&#351; olan k&#305;s&#305;mlar esasken, kk punto ile
yaz&#305;lm&#305;&#351; k&#305;s&#305;mlar ileri okuma olarak
tasarlanm&#305;&#351;t&#305;r.<b>&nbsp;</b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;mso-ansi-language:TR'>DEMANS SENDROMU</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>BIR KL&#304;N&#304;K KAVRAM OLARAK DEMANS<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Dilimizde popler kullan&#305;m&#305;yla <i>bunama</i>
ad&#305; verilen demans kelimesi, etimolojik olarak Latince zihin anlam&#305;na
gelen mens kelimesinden tremi&#351;tir ve demens zihnin yitirilmesi
anlam&#305;na gelir.&nbsp; Latincedeki kullan&#305;m biimiyle
yerle&#351;mi&#351;, varolan, edinilmi&#351; olan zihnin sonradan yitirilmesi
anlam&#305;n&#305; ta&#351;&#305;maktad&#305;r. Bu biimiyle edinilecek
olan&#305;n, yani zihnin hi edinilememesi durumundan
farkl&#305;d&#305;r.&nbsp; Bylelikle, demans&#305; zihinsel gerilikler ya da
Yunancas&#305;yla oligofreni (yetersiz zihin), Latincesiyle amensiyadan (zihin
yoklu&#287;u) etimolojik ve semantik olarak da ay&#305;rabiliriz.&nbsp;
Herhangi bir zaman kesitinde bir demansl&#305; hasta ile bir oligofrenik
hastan&#305;n zihinsel zrllk, ya da yeterlilik dzeyleri i&#351;levsel
olarak benzerlik gsterebilir, ancak demansl&#305;n&#305;n edinsel nedenlerle
(genetik ya da evresel, s&#305;kl&#305;kla da ikisinin birlikte etkileriyle)
kendinde mevcut olan kapasiteyi yitirdi&#287;ini, oligofrenin ise
geli&#351;imsel nedenlerle bu kapasiteyi yetersiz edindi&#287;ini
syleyebiliriz.&nbsp; yleyse demans&#305;n tan&#305;m&#305;na, eri&#351;kin
merkezi sinir sisteminin hasarlanmas&#305; sonucu geli&#351;en zihinsel
yeteneklerde bozulma &#351;eklinde ba&#351;layabiliriz.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Zihinsel yeteneklerde hangi tarz bozulma demans
kavram&#305;n&#305; kar&#351;&#305;lar?&nbsp; Zihinsel yeteneklerde demansa
zg tarzda bozulma iinde, bozulan zihinsel yeteneklerin (ya da teknik
terminolojiyle kognitif i&#351;levlerin) say&#305;s&#305;, bu bozulman&#305;n
ba&#351;lang&#305; tarz&#305;, &#351;iddeti, sresi ve do&#287;al seyri, onu
di&#287;er bozulma tarzlar&#305;ndan ay&#305;rdedici olmaktad&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans olarak nitelendirilebilecek bir zihinsel
bozulma, tan&#305;m&#305; gere&#287;i, ncelikle birden fazla kognitif
i&#351;levi bozmal&#305;d&#305;r.&nbsp; Bu tan&#305;m uyar&#305;nca,
rne&#287;in serebro-vaskler olaylar sonucu geli&#351;en sol ya da sa&#287;
hemisfer hasarlar&#305;na e&#351;lik eden izole kognitif bozukluklar (afazi,
ihmal, amnezi, vb.) demans erevesinde de&#287;erlendirilmezler.&nbsp;&nbsp;
Oysa ki, orta ve byk apl&#305; arterlerin birbirini izleyen
t&#305;kanmalar&#305; sonucunda geli&#351;en serebral infarktsler demans dzeyinde
birden fazla kognitif alan bozuklu&#287;una neden olabilir&nbsp; (bu tr bir
demans VaD alt&#305;nda <i>Multi-infarkt Demans</i>  MID olarak
s&#305;n&#305;flan&#305;r).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans olarak nitelendirilebilecek bir zihinsel
bozulma, tan&#305;m&#305; gere&#287;i, mesleki performans, sokakta, mali
i&#351;lerde ba&#287;&#305;ms&#305;zl&#305;k, s&#305;radan ayg&#305;tlar&#305;n
kullan&#305;m&#305;, hobiler, ev i&#351;leri, kendine bak&#305;m ile
zetlenebilecek <i>gnlk ya&#351;am aktivitelerinde (GYAlar) kayda de&#287;er
bir bozulmaya yol aacak &#351;iddette olmal&#305;d&#305;r</i><u>.</u>&nbsp;
rne&#287;in, AHli bir hastan&#305;n GYAlar&#305;, erken evrede&nbsp;mesleki
performans&#305;ndaki bozulma i&#351; arkada&#351;lar&#305; taraf&#305;ndan
farkedilir, kendine yabanc&#305; mekanlarda yolunu kaybedebilir, evde
yeme&#287;ini s&#305;k s&#305;k yakabilir dzeyde bozulabilecekken, ileri
evrede bu bozulma giyinme, y&#305;kanma gibi temel aktivitelerde yard&#305;ma
gereksinecek dzeye ula&#351;abilir.&nbsp; Merkez sinir sisteminin birok
hastal&#305;&#287;&#305;na, bu arada rne&#287;in Parkinson
hastal&#305;&#287;&#305; ya da multipl skleroza da s&#305;kl&#305;kla kognitif
bozulmalar e&#351;lik eder.&nbsp; Bu hastalar, hastal&#305;klar&#305; ncesine
gre daha unutkan, zihinsel tepkileri a&#305;s&#305;ndan daha yava&#351;, yeni
problemlere daha g zm retir durumda olabilirler.&nbsp; Nropsikolojik
muayeneleri yap&#305;ld&#305;&#287;&#305;nda, bu yak&#305;nmalar&#305;n&#305;
yans&#305;t&#305;r dzeyde, bellek, dikkat ve yrtc i&#351;levler
alanlar&#305;nda bozulmalar saptanabilir.&nbsp; Ancak, yine s&#305;kl&#305;kla
bu hastalar&#305;n GYAlar&#305;, szkonusu kognitif sorunlar&#305; nedeniyle
kayda de&#287;er biimde k&#305;s&#305;tlanmam&#305;&#351; (parezi ve
bradikinezi gibi motor sorunlara ba&#287;l&#305; k&#305;s&#305;tlanma ihmal
edilmelidir) ve ba&#287;&#305;ms&#305;zl&#305;klar&#305;n&#305; srdryor
olacaklard&#305;r (an&#305;lan iki hastal&#305;kta da bazen kognitif
bozulman&#305;n &#351;iddeti demans dzeyine ula&#351;abilir).&nbsp;&nbsp; Bu
durumda sz konusu olan demans de&#287;il, fakat frontal yrtc
bozukluktur.&nbsp;<i>Ya&#351;l&#305;l&#305;kla ilintili unutkanl&#305;k</i>
(age associated memory impairment  AAMI) ve <i>hafif kognitif bozukluk</i>
(mild cognitive impairment  MCI) kavramlar&#305; demansla ayr&#305;lmas&#305;
gereken di&#287;er durumlard&#305;r ve ayr&#305; alt k&#305;s&#305;mlarda daha
ayr&#305;nt&#305;l&#305; ele al&#305;nacaklard&#305;r.&nbsp; AHnin patogenezi
k&#305;sm&#305;nda ayr&#305;nt&#305;s&#305;yla gzden geirilece&#287;i gibi,
AHnin patogenetik ba&#351;lang&#305;c&#305;ndan, kendisini ATD &#351;eklinde
klinik olarak ortaya koyana kadar 20 y&#305;ll&#305;k bir sre gerekebilece&#287;i
hesaplanmaktad&#305;r.&nbsp; Hastal&#305;k limbik sistemde ba&#351;layacak ve
uzun y&#305;llar buraya s&#305;n&#305;rl&#305; kald&#305;ktan sonra neokortikal
asosiasyon alanlar&#305;na geecek ve giderek bu blgedeki hasar&#305;n
&#351;iddetini artt&#305;racakt&#305;r.&nbsp; Nrodejenerasyon
limbik-paralimbik alanlara s&#305;n&#305;rl&#305; kald&#305;&#287;&#305; srece
bu alanlarda temsil edilen epizodik bellek sistemi giderek
i&#351;levsizle&#351;ece&#287;inden bu durum bir ilerleyici, izole
unutkanl&#305;k olarak yans&#305;yacakt&#305;r. Ancak, nrodejenerasyon
neokortikal heteromodal kortekslere s&#305;rad&#305;&#287;&#305;nda, bu
alanlarda temsil edilen dil ve grsel-mekansal i&#351;levler de bozulmaya
ba&#351;layaca&#287;&#305;ndan demans&#305;n asgari ko&#351;ulu olan birden
fazla kognitif bozukluk kriteri doldurulmu&#351; olacakt&#305;r.
&#304;&#351;te AAMIler ve MCIlar&#305;n bir blm, muhtemelen limbik ve
paralimbik dnemlere kar&#351;&#305;l&#305;k gelecek &#351;ekilde, AHnin
demans ncesi pre-klinik ve prodromal evrelerini olu&#351;turmakta, ATD ise bu
sreklilikte demans evresine kar&#351;&#305;l&#305;k gelmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans olarak nitelendirilebilecek bir zihinsel
bozulma, tan&#305;m&#305; gere&#287;i, do&#287;al seyri a&#305;s&#305;ndan
kal&#305;c&#305; ve s&#305;kl&#305;kla da ilerleyici olmal&#305;d&#305;r.&nbsp;
yknn ba&#351;lang&#305; ve seyir zellikleri gz nne
al&#305;nmaks&#305;z&#305;n, salt zihinsel durum a&#305;s&#305;ndan
yap&#305;lacak bir kar&#351;&#305;la&#351;t&#305;rmada, rne&#287;in akut
konfzyonel durum (psikiyatrik terminolojide s&#305;kl&#305;kla delirium) ile
demans yzeysel bir benzerlik ta&#351;&#305;yabilir; hatta demans&#305;n ileri
evreleri dikkatin ileri derecede bozuldu&#287;u bir kronik konfzyonel durum
zelli&#287;i gsterebilir.&nbsp; Oysa ki, <i>akut konfzyonel durum</i>un
(AKD) akut ba&#351;lang&#305; ve gnler, bazen de haftalar srp, yine bazen
kendili&#287;inden tmyle dzelme tarz&#305;ndaki seyri onu demans&#305;n
tarz&#305;ndan kolayl&#305;kla ay&#305;r&#305;r.&nbsp; Demanslar, zellikle de
AH, s&#305;kl&#305;kla sinsi ba&#351;lang&#305;l&#305; ve y&#305;llar iinde
yava&#351; ve srekli ilerleyici seyirlidir.&nbsp; Akut olarak demans
&#351;iddetinde bir zihinsel bozuklu&#287;a neden olabilecek etmenler de
vard&#305;r: yeterince &#351;iddetli bir kafa travmas&#305;, kognitif
i&#351;levler a&#305;s&#305;ndan stratejik bir konumdaki inme, global serebral
iskemi ya da anoksi, klinik profil a&#305;s&#305;ndan demans zellikleri
gsteren bir zihinsel bozuklu&#287;a neden olabilirler.&nbsp; Bu durumlarda,
akut ba&#351;lang&#305; sonras&#305; zihinsel bozuklu&#287;un &#351;iddeti en
fazla olarak en erken evrede grlecek, hasta izleyen aylarda, serebral
plastisitenin devreye girmesiyle, 1. y&#305;l sonuna kadar srebilecek&nbsp;
bir dzelme e&#287;ilimi gsterecek, sonras&#305;nda ise dzelme tam
olmam&#305;&#351;sa arta kalan klinik tablo sekel olarak kal&#305;c&#305;
olacakt&#305;r.&nbsp; Bu sekel halen demans &#351;iddetinde olabilir, ancak
AHden farkl&#305; olarak, klinik ve nropsikolojik olarak y&#305;ldan
y&#305;la farkl&#305;l&#305;k gstermeyen bir statik demans zelli&#287;i
gsterecektir.&nbsp; Nroloji literatr ve pratik kullan&#305;mda bu tr
statik tablolara demans yerine <i>ensefalopati </i>(iskemik/anoksik) ya da kafa
travmas&#305;na ba&#287;l&#305; olanlarda <i>travmatik beyin hasar&#305;</i>
&#351;eklinde adland&#305;rma e&#287;ilimi vard&#305;r.&nbsp; Bunlara,
zaman&#305;nda mdahale edilmemi&#351; ya da yetersiz tedavi edilmi&#351;,
ba&#351;ta Herpes simpleks ensefaliti ve tbc meningoensefaliti gibi MSS
infeksiyonlar&#305;n&#305;n bu tr statik demanslarla sonlanaca&#287;&#305;
eklenebilir. VaDlar aras&#305;nda MID ya da stratejik infarkt demanslar&#305;,
AHden farkl&#305; olarak akut ba&#351;larlar.&nbsp; AHnin srekli ilerleyici
seyrine kar&#351;&#305;n VaD&#305;n mutad seyri basamaks&#305; ilerleme
&#351;eklindedir (iki inme aras&#305;nda de&#287;i&#351;meden kalan bir plato
dnemi, sonras&#305;nda inmeyi izleyen ani ktle&#351;me).&nbsp; AHnin
y&#305;llar iinde ilerleme &#351;eklindeki yava&#351; seyrine
kar&#351;&#305;l&#305;k rne&#287;in CJH 1 y&#305;l iinde yata&#287;a
ba&#287;&#305;ml&#305; nihai evreye ula&#351;ma ve lm &#351;eklinde ok
h&#305;zl&#305; bir seyir gsterir. Bir ba&#351;ka deyi&#351;le, sinsi
ba&#351;lang&#305;, kronik yava&#351; seyirli demanslar&#305;n prototipi, byle
bir seyre sahip ok say&#305;da demans hastal&#305;&#287;&#305; aras&#305;nda
nas&#305;l AH ise, h&#305;zl&#305; seyirli demanslar, prototipi CJH olan ve
ok say&#305;da hastal&#305;ktan olu&#351;an ayr&#305; bir alt ba&#351;l&#305;k
olarak s&#305;n&#305;fland&#305;r&#305;labilir. Bu tarz bir
yakla&#351;&#305;mla, ilk durumda AHyi alt&#305;n standart olarak alarak
mevcut durumda grlen olgunun ne lde standart bir AH tablosuyla
rt&#351;t&#287;, ne lde ayr&#305;ld&#305;&#287;&#305; temelinde bir
ay&#305;r&#305;c&#305; tan&#305; ak&#305;l yrtmesi yap&#305;lacakken, ikinci
durumda bu kez alt&#305;n standart tipik CJH zellikleri olacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans tan&#305;s&#305; bilin
bulan&#305;kl&#305;&#287;&#305; olmayan hastada konulur.&nbsp; AKDlere yukarda
sz edilen seyirleri yan&#305;s&#305;ra s&#305;kl&#305;kla bilin
bulan&#305;kl&#305;&#287;&#305; da e&#351;lik eder.&nbsp; AKDler patogenetik
olarak, uyan&#305;kl&#305;k, fark&#305;ndal&#305;k ve global dikkatin nral
kar&#351;&#305;l&#305;&#287;&#305; olan retikler formasyonun i&#351;levini
bozarak ortaya &#305;karlar.&nbsp; Dolay&#305;s&#305;yla, klinik tablo bilin
dalgalanmalar&#305; yan&#305;s&#305;ra, nropsikolojik olarak ba&#351;l&#305;ca
global dikkat bozuklu&#287;u ve tm kognitif i&#351;levlerde buna sekonder
bozulmalard&#305;r.&nbsp; AKDyi demansa yzeysel olarak benzer k&#305;lan
zellik bu global bozulma durumudur.&nbsp; Demans durumlar&#305;n&#305;n
toksik-metabolik ensefalopatilerin AKDsinden ay&#305;rmak ve muayene
bulgular&#305;n&#305;n dikkat bozuklu&#287;una sekonder geici nitelikte
bulgular de&#287;il, fakat o i&#351;levin nral altyap&#305;s&#305;n&#305;n
primer bozuklu&#287;unu yans&#305;tt&#305;&#287;&#305;n&#305; syleyebilmek
iin tan&#305; muayenesinin bilin dalgalanmas&#305; olmayan bir hastada
yap&#305;lmas&#305; ko&#351;ulu demans tan&#305;m&#305;na giren bir
lttr.&nbsp; Ancak, klinik pratikte demans ve AKD durumlar&#305;n&#305;n ak
ve kara gibi kutupsall&#305;klar olmad&#305;&#287;&#305; ve seyrek olmayarak i
ie geebileceklerini unutmamak gerekir.&nbsp; Bunun ba&#351;l&#305;ca nedeni
demans patogenezinin yaratt&#305;&#287;&#305; nronal rezervdeki
a&#351;&#305;r&#305; k&#305;s&#305;tlanma sonucu demans hastas&#305;n&#305;n
toksik-metabolik durumlar ya da sistemik&nbsp;infeksiyonlar s&#305;ras&#305;nda
AKDye ok daha yatk&#305;n olmas&#305;d&#305;r.&nbsp; Byle bir durumda, AKD
demans seyrinin zerine binerek tabloyu bir sre iin akut olarak
a&#287;&#305;rla&#351;t&#305;racakt&#305;r.&nbsp; Titiz al&#305;nm&#305;&#351;
bir yk, sinsi seyirli bir zihinsel y&#305;k&#305;m&#305;n seyrinde aniden
geli&#351;en ve GYAlar&#305; h&#305;zla bozan bir&nbsp;tabloyu ifade
edecektir.&nbsp; Ayr&#305;ca, LCDde dikkat dalgalanmalar&#305;n&#305;n,
genellikle bir AKD dzeyinde olmasa da, daha ba&#351;lang&#305;tan itibaren klinik
tablonun asli bile&#351;enlerinden biri oldu&#287;u
hat&#305;rlanmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu kez, an&#305;lan ltleri de katarak daha tam
bir tan&#305;ma giri&#351;elim:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans, eri&#351;kin MSSnin hasarlanmas&#305;
sonucu, bilin bulan&#305;kl&#305;&#287;&#305; olmaks&#305;z&#305;n, birden
fazla kognitif alan&#305;n bozulmas&#305;, bununla ilintili olarak gnlk
ya&#351;am aktivitelerinin eski dzeyinde srdrlememesine neden olan,
do&#287;al seyri a&#305;s&#305;ndan kal&#305;c&#305;, s&#305;kl&#305;kla da
ilerleyici bir klinik tablodur</span></i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANSLARIN SINIFLANDIRILMASI<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demanslar ncelikle primer&nbsp;ve
sekonder&nbsp;olarak s&#305;n&#305;flan&#305;rlar <b>(Tablo 1</b>).&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AHnin de dahil oldu&#287;u ve en byk blm
olu&#351;turan primer demanslar, demansa neden olan MSSnin nrodejeneratif
hastal&#305;klar&#305;n&#305; ierir.&nbsp; Nrodejeneratif hastal&#305;k,
zihinsel i&#351;levlerin alt yap&#305;s&#305;n&#305; olu&#351;turan limbik ve
asosiasyon alanlar&#305;nda, s&#305;kl&#305;kla kendine zg patolojik izi
b&#305;rakarak (rne&#287;in, AHde senil plak ve nrofibriler yumaklar, LCDde
Lewy cisimcikleri) buralarda nron ve sinaps kayb&#305;yla dejenerasyona yol
aar ve i&#351;levini bozar.&nbsp; Bu patogenez belli bir yay&#305;l&#305;m
a&#351;amas&#305;nda klini&#287;e demans olarak yans&#305;r.&nbsp;
Nrodejenerasyon, AHde oldu&#287;u gibi an&#305;lan alanlara
s&#305;n&#305;rl&#305; kalma e&#287;ilimindeyse, demans izole ya da
a&#287;&#305;rl&#305;kl&#305; klinik tablo olarak kal&#305;r; oysa ki, motor sistem
de dejenerasyona dahil olursa LCDde oldu&#287;u gibi parkinsonizm, Huntington
hastal&#305;&#287;&#305;nda oldu&#287;u gibi kore, demansla birlikte, bazen
daha da nnde&nbsp;klinik tablonun a&#287;&#305;rl&#305;kl&#305; bir
paras&#305;d&#305;r.&nbsp; Dolay&#305;s&#305;yla, primer demanslar klinik
grn&#351;lerine gre, kendi ilerinde primer izole demanslar ve motor
bozuklukla birlikte olan primer demanslar olarak
s&#305;n&#305;flanabilirler.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>nceki k&#305;s&#305;mdaki nihai tan&#305;m&#305;
hat&#305;rlayal&#305;m: Demans...birden fazla kognitif
alan&#305;n..bozulmas&#305;na yolaan.... bir klinik tablodur.&nbsp;Bu
tan&#305;m uyar&#305;nca, bozulan ve salim kalan kognitif alanlar&#305;n tarz&#305;na
gre de s&#305;n&#305;flamay&#305; ilerletebiliriz.&nbsp; Nrodejenerasyon,
yukarda an&#305;lan alanlarda e&#351;zamanl&#305; ba&#351;lay&#305;p sregiden
bir seyir izlemez, fakat patogenezin kendine zg bir tarz&#305;
vard&#305;r.&nbsp; rne&#287;in, AH, daha nce de de&#287;inildi&#287;i gibi
y&#305;llarca limbik alanlara s&#305;n&#305;rl&#305; kald&#305;ktan sonra neokortikal
alanlara geer.&nbsp; Ancak, neokortikal asosiasyon alanlar&#305;na gei&#351;
de e&#351;zamanl&#305; bir yay&#305;l&#305;m de&#287;ildir, fakat yine zgl
bir zamansal seyir gsterir: posterior heteromodal alanlar prefrontal
korteksten nispeten daha nce tutulur.&nbsp; Bu zamansal tarz, erken ve orta
evrelerinde AHnin kendine zg nropsikolojik profilini belirler: tipik AH
sendromu (ATD) yak&#305;n bellek (limbik), dilsel (sol hemisfer posterior
heteromodal) ve grsel-mekansal (sa&#287; hemisfer posterior heteromodal)
i&#351;levlerin bozuldu&#287;u, prefrontal kortekse zg yrtc i&#351;levler
(planlama, soyutlama, zihinsel esneklik, vb.) ve ki&#351;ili&#287;in greli
salim kald&#305;&#287;&#305; bir profile sahiptir.&nbsp; Buna
kar&#351;&#305;l&#305;k fronto-temporal demans (rne&#287;in, Pick hastal&#305;&#287;&#305;)
an&#305;lan seyrin tersine, ncelikle ve bazen de yaln&#305;zca prefrontal
korteksi tutar, limbik ve posterior neokortikal alanlar salim kal&#305;r.&nbsp;
FTD bu patogenezi yans&#305;t&#305;r bir klinik profile sahiptir: erken dnemde
yrtc i&#351;levlerde bozulma, ki&#351;ilik de&#287;i&#351;ikli&#287;i, buna
kar&#351;&#305;l&#305;k yak&#305;n bellek ve mekan oryantasyonu, navigasyonel
i&#351;levlerde (grsel-mekansal i&#351;levler) greli korunma.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sistemik, nrolojik ya da psikiyatrik bir
hastal&#305;&#287;&#305;n seyri s&#305;ras&#305;nda, mutad klinik
gsterilerinin yan&#305; s&#305;ra demansa da neden olmas&#305; durumunda, sz
konusu demans sekonder demanslar alt&#305;nda s&#305;n&#305;flan&#305;r.
Sekonder demanslar&#305;n en s&#305;k nedeni VaDdir.&nbsp; Gerek orta ve byk
apl&#305; serebral arterlerin birbirini izleyen t&#305;kanmalar&#305; (MID),
gerek hipertansif serebral kk damar hastal&#305;&#287;&#305; (Binswanger hastal&#305;&#287;&#305;)
ve gerekse de stratejik lokalizasyonlu tek infarktlar VaD nedeni
olabilir.&nbsp; Normal nronal i&#351;levin gereksindi&#287;i, ekstraseller
ortam&#305;n glukoz ieri&#287;i, oksijenizasyon dzeyi, hormonal durum ve
elektrolit dengesini bozabilecek herhangi bir sistemik veya metabolik bozukluk
(diyabet, kalp yetmezli&#287;i, hipotiroidi, kronik obstrktif akci&#287;er
hastal&#305;&#287;&#305;, bbrek yetmezli&#287;i, karaci&#287;er
yetmezli&#287;i) ya da normal sinaptik iletimi bozabilecek herhangi bir
teraptik amal&#305; ila, a&#287;&#305;r metallere maruz kalma gibi durumlarda
toksik-metabolik ensefalopati ortaya &#305;kar.&nbsp; Toksik-metabolik
ensefalopatiler, byk s&#305;kl&#305;kla AKD olarak grnseler de bazen daha
yava&#351; seyirli bir tabloyla demansa da benzeyebilirler.&nbsp;
&#304;nflamatuar sreler (Nro-Behet sendromu, primer MSS vaskliti,
granlomatz anjiitis, sistemik lupus, paraneoplastik limbik ensefalit),
infeksiyonlar (Tbc meningoensefaliti, Herpes simpleks ensefaliti, HIV, Lyme,
Whipple, nrosifilis, vb), nrolojik hastal&#305;klar iinde multipl skleroz,
primer ya da sekonder beyin tmrleri, kronik subdural hematom, normal bas&#305;nl&#305;
hidrosefali gibi yer kaplay&#305;c&#305; lezyonlar demansa da neden
olabilirler.&nbsp; Psikiyatrik hastal&#305;klar iinde zellikle <i>ya&#351;l&#305;l&#305;k
depresyonu</i>, afektif bulgular&#305;n&#305; gizleyen,
a&#287;&#305;rl&#305;kl&#305; biimde motivasyonel ve kognitif bulgulardan
olu&#351;an bir demans (baz&#305; yazarlara gre psdo-demans) tablosu
&#351;eklinde kendini gsterebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Primer demanslar&#305;n, bu arada AHnin klinik
tan&#305;s&#305; iin sekonder demanslar&#305;n ekarte edilebiliyor olmas&#305;
gerekir.&nbsp; Nitekim, AH iin yay&#305;nlanm&#305;&#351; olan klinik
tan&#305; kriterleri iinde, gerek PRAD ve gerekse DAT tan&#305;lar&#305; iin
bu ko&#351;ulun yerine getiriliyor olmas&#305; esast&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 1. </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Demans
Hastal&#305;klar&#305;n&#305;n S&#305;n&#305;fland&#305;r&#305;lmas&#305;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=329 valign=top style='width:246.4pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Primer
  (Dejeneratif)</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=350 valign=top style='width:262.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sekonder</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width=329 valign=top style='width:246.4pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
  hastal&#305;&#287;&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lewy cisimcikli demans</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fronto-temporal demans</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>FTD-davran&#305;&#351;sal varyant</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;lerleyici tutuk afazi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Semantik demans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>FTD-ALS</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hareket bozuklu&#287;uyla
  birlikte</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:49.65pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Parkinson hastal&#305;&#287;&#305; demans&#305; </span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kortiko-bazal dejenerasyon</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Progresif suprankleer paralizi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Huntington hastal&#305;&#287;&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multi-sistem atrofiler</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Wilson hastal&#305;&#287;&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nroakantositoz</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion hastal&#305;klar&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Creutzfeldt-Jacob hastal&#305;&#287;&#305;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gerstmann-Strussler-Scheinker hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Fatal familyal insomni</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>e&#351;itli pediyatrik
  demanslar</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kufs hastal&#305;&#287;&#305;</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Metakromatik lkodistrofi</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Gaucher hastal&#305;&#287;&#305;</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Niemann-Pick hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er ender demanslar</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Limbik demans</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Poliglukozan cisimcik hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Arjirofilik tah&#305;l hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;</span><span lang=DE style='font-family:Tahoma;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=350 valign=top style='width:262.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vaskler
  demans</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multi-infarkt demans</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Binswanger hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Stratejik infarkt demans&#305;</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>CADASIL</span><span lang=DE style='font-family:Tahoma;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal bas&#305;nl&#305;
  hidrosefali</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
  DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toksik-metabolik demanslar</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Wernicke-Korsakoff hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>B12 vitamin eksikli&#287;i</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Hipotiroidi</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kronik karaci&#287;er hastal&#305;&#287;&#305;</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Organik zclere maruz kalma</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&#304;lalar</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyonlar</span><span
  lang=DE style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Herpes simpleks ensefaliti</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Nrosifilis</span><span lang=DE style='font-family:
  Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Kronik menenjitler</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>HIV-demans kompleksi</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Whipple hastal&#305;&#287;&#305;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kafa ii yer
  kaplay&#305;c&#305; hastal&#305;klar</span><span lang=DA style='font-family:
  Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Neoplastik durumlar</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Subdural hematom</span><span lang=DA style='font-family:
  Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Otoimmun-inflamatuar
  hastal&#305;klar</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Multipl skleroz</span><span lang=DA style='font-family:
  Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Behet hastal&#305;&#287;&#305;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Paraneoplastik limbik ensefalit</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>VGKC ve NMDAR kanalopatileri</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Granlomatz anjitis</span><span lang=FR
  style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Primer sinir sistemi vaskliti</span><span lang=FR
  style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>NAIM sendromu</span><span lang=FR style='font-family:
  Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:9.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Bu tabloda demansa neden olan tm nedenlerin
s&#305;ralanmas&#305; amalanmam&#305;&#351;t&#305;r. Byk bir
k&#305;sm&#305;n&#305;n ad&#305; gemekle birlikte as&#305;l ama primer ve
sekonder demans kavramlar&#305;na a&#305;kl&#305;k getirmektir.
K&#305;saltmalar: VGKC: Voltaj kap&#305;l&#305; potasyum kanal&#305;; NMDAR:
N-metil D-aspartat reseptr; NAIM: Non-vasklitik otoimmun meningoensefalit.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANSTA YK ZELL&#304;KLER&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bir zihinsel y&#305;k&#305;m tablosu olarak
tan&#305;mlad&#305;&#287;&#305;m&#305;z demans sendromunu olu&#351;turan
hastal&#305;klar, esas olarak primer sensoryel-motor alanlarla ilintili
blgeleri de&#287;il, fakat zihinsel i&#351;levlerin alt yap&#305;s&#305; olan
blgeleri (limbik ve asosiasyon alanlar&#305;) hasarlar.&nbsp;
Dolay&#305;s&#305;yla, demansa zg belirtiler gszlk, hissizlik, grme
alan&#305; kay&#305;plar&#305; gibi klasik nrolojik muayeneyle
bulgular&#305;n&#305; ortaya koymaya al&#305;&#351;t&#305;&#287;&#305;m&#305;z
belirtiler de&#287;il; unutkanl&#305;k, konu&#351;ma bozuklu&#287;u, yn bulma
gl&#287;, yarg&#305;lama-problem zme glkleri, tan&#305;ma
bozuklu&#287;u, el becerilerinde bozukluk, ki&#351;ilik
de&#287;i&#351;iklikleri, anksiyete, disfori, hezeyan ve halsinasyonlar gibi
belirtiler olacakt&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunun semptomatolojisi,  ana (kardinal)
kategoride s&#305;n&#305;flanabilir:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>1. Kognitif, <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>2. Davran&#305;&#351;sal, <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>3. &#304;&#351;levsel
(GYAlar).&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans yks, bu  kardinal alana zg
yak&#305;nmalar&#305;n bir sistematik iinde sorgulanmas&#305; ile
al&#305;n&#305;r.&nbsp; Bunlar&#305;n yan&#305;s&#305;ra <i>motor, otonom
sistemler ve uyku</i> <i>bozukluklar&#305;</i>na ili&#351;kin yak&#305;nma ve
belirtilerin sorgulanmas&#305; da baz&#305; demans sendromlar&#305;
a&#305;s&#305;ndan nem ta&#351;&#305;r ve kardinal alanlar&#305;n
yan&#305;s&#305;ra bu alanlar da ikincil alanlar olarak
d&#351;nlebilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>yk mmknse hastadan birinci derecede sorumlu
bir hasta yak&#305;n&#305;n&#305;n da varl&#305;&#287;&#305;nda, paralel olarak
al&#305;nmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yak&#305;nmalar&#305;n ba&#351;lang&#305; (sinsi,
akut veya subakut) ve ilerleme tarz&#305; (statik, kronik srekli veya
basamaks&#305;, h&#305;zl&#305;) belirlenip kaydedilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif belirtiler</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda mutlak olmasa da
en s&#305;k rastlan&#305;lan belirti bellek alan&#305;na aittir.&nbsp; Hasta ya
da yak&#305;n&#305; ayn&#305; sorular&#305;n, ayn&#305; konular&#305;n
tekrarlanmas&#305;, zel e&#351;yan&#305;n kaybedilmesi, randevular&#305;n
unutulmas&#305;, yeme&#287;in ocakta, oca&#287;&#305;n a&#305;k
unutulmas&#305;ndan yak&#305;nmaktad&#305;r.&nbsp; Grsel-mekansal
i&#351;levlere ait bozulma kendini nce yabanc&#305; mekanlarda, giderek bildik
mekanlarda yn bulma gl&#287; ve bazen kaybolma &#351;eklinde
gsterir.&nbsp; Dil bozuklu&#287;u erken dnemde adland&#305;rma gl&#287;,
kelime hazinesinde daralmayla ba&#351;lay&#305;p, giderek AHde daha mutad
oldu&#287;u gibi anlaman&#305;n da bozuldu&#287;u bir ak&#305;c&#305; afaziye,
ya da ilerleyici tutuk afazide daha mutad oldu&#287;u gibi gramer
yap&#305;s&#305;n&#305;n da bozuldu&#287;u bir tutuk afaziye
dn&#351;r.&nbsp; Semantik demansta ise s&#305;radan nesnelerin
anlamlar&#305;n&#305;n kayboldu&#287;u bir tek kelime anlama bozuklu&#287;u sz
konusudur. &#304;lerleyici afazisi olan bir hastan&#305;n kelime bulma
gl&#287; olan temel yak&#305;nmas&#305;n&#305;n da s&#305;kl&#305;kla hasta
ve hasta yak&#305;n&#305; taraf&#305;ndan unutkanl&#305;k olarak ifade
edilece&#287;i gz nnde bulundurulmal&#305;d&#305;r. yk derinle&#351;tirildike
bu trden bir unutkanl&#305;k yak&#305;nmas&#305;n&#305;n adresinin limbik
yak&#305;n bellek sistemi de&#287;il de sol hemisferik dil sistemi
oldu&#287;unun alt&#305; izilir. Praktik bozukluklar (apraksiler) nedeniyle,
basit gncel ayg&#305;tlar&#305;n (tarak, makas, di&#351; f&#305;ras&#305;,
sofra ayg&#305;tlar&#305;, vb.)&nbsp; manipulasyonlar&#305; bozulabilir.&nbsp;
Gnostik bozukluklar (agnoziler), nesnelerin ve yzlerin
tan&#305;nmas&#305;n&#305;, mekanda bir nesnenin, di&#287;er nesnelere gre
pozisyonunun belirlenmesini bozabilir.&nbsp; Yrtc i&#351;levler
alan&#305;ndaki bozukluk nedeniyle hasta zihinsel esnekli&#287;ini kaybetme
e&#287;ilimindedir; metaforlar&#305;n soyut anlamlar&#305;n&#305; kavramakta,
davran&#305;&#351;lar&#305;n&#305; planlamakta, bireysel ve toplumsal sorunlar
zerine ak&#305;l yrtmekte, gnlk ya&#351;amda
kar&#351;&#305;la&#351;t&#305;&#287;&#305; problemlere uygun zmler retmekte
zorlan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal belirtiler</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda, apatiye
varacak &#351;ekilde kendili&#287;indenli&#287;in kayb&#305;, disinhibisyona
varacak &#351;ekilde drt kontrolnde bozukluklar (hiperseksalite, hiperfaji)
say&#305;labilir.&nbsp; Apati spektrumundaki hasta giderek daha az spontanite
rnekleri sergiler.&nbsp; &#304;nisiyatif gstermez, kendili&#287;inden bir
&#351;ey talep etmez, kendisine ynelinmedi&#287;inde konu&#351;maz.&nbsp;
evresinde olup biten hibir &#351;ey ilgisini ekmez gibidir.&nbsp;
Disinhibisyon kendini ncelikle sosyal uygunsuz davran&#305;&#351; olarak
adland&#305;r&#305;lan sosyal konumla ba&#287;da&#351;mayan rahat
davran&#305;&#351;lar, al&#305;&#351;&#305;lmad&#305;k giri&#351;kenlik,
&#351;akac&#305;l&#305;k, ocuksulukla gsterir; hasta yak&#305;nlar&#305; bu
de&#287;i&#351;iklikleri s&#305;kl&#305;kla aile iin bir utan vesilesi olarak
aktar&#305;rlar.&nbsp; Hiperseksalite hastan&#305;n o zamana kadar
edindi&#287;i sosyal normlar d&#305;&#351;&#305;nda cinsel ierikli imalar ta&#351;&#305;yan
sz ve davran&#305;&#351;lar sergilemesinden uygunsuz cinsel taleplere kadar
varan &#351;iddetlerde grlebilir.&nbsp; Hiperfaji hastan&#305;n
al&#305;&#351;&#305;lagelen a&#287;&#305;z tad&#305;n&#305;n
de&#287;i&#351;mesi, oburla&#351;mas&#305; ve zellikle &#351;ekerlemeye
d&#351;knle&#351;mesi &#351;eklinde ba&#351;lar ve ay po&#351;eti, kendi
feesi gibi yenilmeyecek nesnelerin dahi a&#287;za
t&#305;k&#305;&#351;t&#305;r&#305;labildi&#287;i &#351;iddetlere ula&#351;abilir.&nbsp;
Psikotik belirtiler d&#351;nce ve alg&#305; bozukluklar&#305; &#351;eklinde
ortaya &#305;kar. D&#351;nce bozukluklar&#305; zellikle
h&#305;rs&#305;zl&#305;k (bak&#305;c&#305; param&#305; al&#305;yor),
sadakatsizlik (e&#351;im beni bir ba&#351;kas&#305;yla aldat&#305;yor) ve
terkedilme (beni bak&#305;mevine atacaks&#305;n&#305;z) hezeyanlar&#305;,
misidentifikasyon buras&#305; benim evim de&#287;il, eve gidelim ve Capgras
hezeyan&#305; (tan&#305;&#351; olmas&#305; gereken ki&#351;i onun yerine
gemi&#351; bir taklidi) &#351;eklinde ortaya &#305;kar. Alg&#305;
bozukluklar&#305; ise tm duysal modalitelerde olabilecekleri gibi zellikle
grsel halsinasyonlar &#351;eklindedir. Bunlar evresel uyaranlar&#305;n
yanl&#305;&#351; yorumland&#305;&#287;&#305; illzyonlar, mekanda bir
varl&#305;&#287;&#305;n mevcudiyeti hissi gibi forme olmayan halsinasyonlar
veya canl&#305; ryalar gibi ok hafif alg&#305; bozukluklar&#305;ndan
nesneler, insan ve hayvanlar gibi forme halsinasyonlar&#305;n oldu&#287;u daha
a&#287;&#305;r durumlara de&#287;i&#351;ir. Alg&#305; bozukluklar&#305;
a&#287;&#305;rla&#351;t&#305;ka igr kaybolur ve geceye
s&#305;n&#305;rl&#305;yken giderek gndzleri de grlmeye
ba&#351;larlar.&nbsp; Duygudurum bozukluklar&#305; aras&#305;nda depresyon
zellikle s&#305;k olabilir ve afektif-motivasyonel ynleri
sorgulanmal&#305;d&#305;r.&nbsp; Anksiyete, huzursuzluk, yerinde duramama,
srekli yer ve mekan de&#287;i&#351;tirme, ok abuk s&#305;k&#305;lma
&#351;eklinde ortaya &#305;kabilir; zel bir e&#351;idi de yakla&#351;an
randevularla artan anksiyetedir.&nbsp; Mani, klasik psikiyatrik tablosundan ok
uygunsuz ne&#351;e ve/veya fke, duygudurum dalgalanmalar&#305;, grandiozite,
sald&#305;rganl&#305;k &#351;eklindeki gsterilerin bir veya
birka&#305;n&#305;n toplam&#305; &#351;eklinde grlebilir.&nbsp; Fobiler,
hastaya zg e&#351;itlilikler gsterebilece&#287;i gibi, zellikle de
e&#351;in gz nnden uzakla&#351;mas&#305; endi&#351;esi ve bu nedenle
e&#351;in pe&#351;inden ayr&#305;lmama veya yaln&#305;z kalma korkusu
&#351;eklindedir.&nbsp; Fiziksel veya verbal &#351;iddeti de ieren ajitasyon,
amas&#305;z-tekrarlay&#305;c&#305; hareketler (amas&#305;z
dola&#351;ma-ad&#305;mlama, dolaplar&#305; a&#305;p-kapama, ar&#351;af&#305;
katlay&#305;p-ama gibi ayn&#305; hareketi tekrarlama, uygunsuz yerlere,
toplama, istif etme) gzlenebilir davran&#305;&#351;sal sorunlar
aras&#305;ndad&#305;r. Gzlenebilir davran&#305;&#351;sal bozukluklar da
&#351;iddetlendike ba&#351;lang&#305;ta gne&#351; batma fenomeni ad&#305;
verilen geceye s&#305;n&#305;rl&#305; olmaktan, giderek gne yay&#305;lma
e&#287;ilimi gsterirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel alana ait belirtiler</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>, i&#351;ini srdrmek,
ev d&#305;&#351;&#305;nda yolculuk, al&#305;&#351;veri&#351;, mali
i&#351;leri&nbsp; (fatura demeleri, banka i&#351;leri, vb.) ekip evirmek,
gnlk ayg&#305;tlar&#305; kullanmak, hobilerini srdrmek, ev i&#351;lerini
yrtmek, kendine bak&#305;m veya hijyene (giyinmek, y&#305;kanmak, beslenmek,
tuvalet, vb.) muktedir olmak &#351;eklinde rneklenebilecek zellikleri
bozabilir (i&#351;levsel alana ait belirtilerin AHde bozulma hiyerar&#351;isi
iin ilerdeki <i>Alzheimer Hastal&#305;&#287;&#305;n&#305;n Klinik Evreleri</i>
k&#305;sm&#305;na bak&#305;n&#305;z).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Motor bozukluklar</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda ba&#351;ta
yry&#351; bozuklu&#287;u olmak zere ekstrapiramidal bulgulara atfedilecek
yak&#305;nmalar&#305;n sorgulanmas&#305; (kk ad&#305;mlarla yrme, donma,
istemeden h&#305;zlanma, d&#351;me, dengesizlik, hareketlerde yava&#351;lama,
tremor, konu&#351;ma ve yutma bozuklu&#287;u) nemlidir. Vaskler demansa
parezi sekellerinin, fronto-temporal demansa amiyotrofinin e&#351;lik
edebilece&#287;i ak&#305;lda tutulmal&#305; ve zaaf, kas erimesi gibi temel
belirtileri sorgulanmal&#305;d&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Otonom bozukluklar</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda ise riner
inkontinans&#305;n bulunup bulunmamas&#305; nem ta&#351;&#305;r.&nbsp;
&#304;drara yeti&#351;me gl&#287; (urgency) dzeyinde hafif bir
inkontinans&#305;n dahi kaydedilmesi gerekir.&nbsp; Ortostatizm
yak&#305;nmalar&#305;, senkopal e&#287;ilim, kronik konstipasyon, impotans
demans sendromlar&#305;n&#305;n ay&#305;rt edilmesinde nem ta&#351;&#305;yan
di&#287;er otonomik yak&#305;nmalar aras&#305;ndad&#305;r.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Parasomniler</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> aras&#305;nda zellikle REM
uykusu s&#305;ras&#305;nda tonik inhibitr aktivitenin zlmesi sonucu ortaya
&#305;kan ryalar&#305;n yatakta s&#305;rama, dvnme, d&#351;me,
konu&#351;ma, hayk&#305;rma &#351;eklinde d&#305;&#351;avurumu olan REM uykusu
davran&#305;&#351; bozuklu&#287;u (RUDB) belirtileri nem
ta&#351;&#305;r.&nbsp; Uykuya dalma gl&#287;, kesintili uyuma, sabah ok
erken uyanma gibi insomnia belirtileri ve insomnian&#305;n veya uyku apnesinin
sonucu olarak veya ba&#287;&#305;ms&#305;z bir fenomen olarak
a&#351;&#305;r&#305; gndz uyuklamas&#305;, gerek ay&#305;r&#305;c&#305;
tan&#305;daki nemleri ve gerekse de tm demans hastalar&#305;n&#305;n zihinsel
performanslar&#305;na belirgin olumsuz etkileri ve greli olarak da kolay
tedavi hedefleri olma zellikleriyle titizlikle sorgulanmal&#305; ve
kaydedilmelidirler. Demansta yk zellikleri iin <b>Tablo 2</b>ye
bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>yk sonunda klinisyen temel sorunu saptayarak
ekirdek kognitif bulguyu ba&#351;lang&#305; ve seyriyle belirlemi&#351;
olmal&#305;, buna kognitif alandan varsa di&#287;er kat&#305;l&#305;mlar&#305;,
ekirdek ve ikincil kognitif bozukluklar&#305;n GYAlar&#305; etkileme
dzeyini, davran&#305;&#351;sal ve di&#287;er (ikincil) alanlar&#305;n
kat&#305;l&#305;m zamanlamalar&#305;n&#305; ve &#351;iddetlerini
canland&#305;rabilmelidir. &#304;yi al&#305;nm&#305;&#351; bir yk zellikle
tipik olgularda ay&#305;r&#305;c&#305; tan&#305;y&#305; daha bu a&#351;amada
byk lde zece&#287;i ve hastal&#305;k &#351;iddetini a&#351;a&#287;&#305;
yukar&#305; belirleyece&#287;i gibi, mental durum muayenesi iin
kullan&#305;lacak standart testlerin yan&#305;s&#305;ra zellikle
odaklan&#305;lmas&#305; gereken kognitif alanlar iin zgl testlerin
esneklikle seimine de rehberlik edecektir. Dolay&#305;s&#305;yla, sinsi
ba&#351;lay&#305;p, y&#305;llar iinde ilerlemi&#351;, zaman iinde kelime
bulma ve d&#305;&#351; mekanda ynn bulma glklerinin eklendi&#287;i, bu
nedenle hastan&#305;n son zamanlarda art&#305;k yaln&#305;z ba&#351;&#305;na
soka&#287;a &#305;kamad&#305;&#287;&#305;, ancak evinde y&#305;kanma, giyinme
gibi temel GYAlar&#305;n&#305; halledebildi&#287;i bir yk
kar&#351;&#305;s&#305;nda klinisyen orta evrede bir AHli hasta ile
kar&#351;&#305; kar&#351;&#305;ya oldu&#287;unu rahatl&#305;kla ngrp muayene
sonular&#305;n&#305;n da bu ngrsn destekleyece&#287;ini tahmin
edebilirken, temel sorunu bellek de&#287;il de mekanda ynn bulmak, gznn
nndeki nesneleri bulamamak olan bir hasta kar&#351;&#305;s&#305;nda bu kez
ok daha ender bir nrodejeneratif antite olan posterior kortikal atrofinin
ilerleyici simultanagnozisinin ifade edilmekte oldu&#287;unu ay&#305;rdedip
normalde standart muayenesinin iinde yeralmayabilecek simultanagnozi
testlerini semeye karar verebilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANSTA Z VE SOYGEM&#304;&#350; ZELL&#304;KLER&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demansl&#305; hastan&#305;n yks
s&#305;ras&#305;nda zgemi&#351;i iinde belirli genel medikal, nrolojik,
psikiyatrik ve toksik zelliklerin soru&#351;turulmas&#305; nemlidir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genel medikal zgemi&#351; iinde vaskler risk
faktrleri (hipertansiyon, iskemik kalp hastal&#305;&#287;&#305;, diyabet),
endokrin-metabolik bozukluklar (zellikle hipotirodi, B12 vitamini
yetmezli&#287;i), kronik infeksiyonlar (tberkloz, sifilis, AIDS), sistemik
otoimmun-inflamatuar hastal&#305;klar (Sistemik lupus, Sjgren, romatoid
artrit, Behet), sistemik neoplazi, genel anestezi kullan&#305;lm&#305;&#351;
cerrahi giri&#351;imler, zellikle kardiyak giri&#351;imler
kaydedilmelidir.&nbsp; Bunlardan bir blm sekonder demanslar&#305;n nedenleri
olabilece&#287;i gibi, B12 eksikli&#287;i, hipotiroidi, vaskler risk faktrleri,
genel anestezi gibi durumlar AHyi komplike eden ve kontrol edilebilecek
komorbid durumlar da olabilirler.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Nrolojik zgemi&#351;te geli&#351;imsel
bozukluklar, geirilmi&#351; hemorajik-iskemik inme ya da geici iskemik
ataklar, zellikle &#351;uur kay&#305;pl&#305; kafa travmas&#305;, subdural
hematom, MSS infeksiyonlar&#305; (menenjit, ensefalit), epilepsi, beyin tmr,
hidrosefali gibi durumlar&#305;n varl&#305;&#287;&#305;
sorgulanmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Geirilmi&#351; depresyon, psikoz, eski
psikiyatrik hospitalizasyonlar sorgulan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Toksik zgemi&#351; zellikleri aras&#305;nda
a&#287;&#305;r metallere maruz kalma kronik toksik ensefalopatilerin nedenleri
aras&#305;ndad&#305;r.&nbsp; Kronik alkolizm ve/veya madde kullan&#305;m&#305;
kaydedilmelidir.&nbsp; Geriyatrik poplasyon zellikle polifarmasinin
yayg&#305;n oldu&#287;u bir gruptur.&nbsp; Benzodiazepinler, trisiklik antidepresanlar
ve di&#287;er anti-kolinerjik ajanlar, alfa-metil-dopa, reserpin gibi
antihipertansif ilalar kognitif bozuklu&#287;un tek ba&#351;&#305;na nedeni ya
da a&#287;&#305;rla&#351;t&#305;r&#305;c&#305; etkeni olarak bulunabilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Soygemi&#351; zellikleri sorgulan&#305;rken
zellikle primer dejeneratif demanslar&#305;n byk lde genetik ve evresel
faktrlerin karma&#351;&#305;k bir etkile&#351;iminin rn olduklar&#305; gz
nnde bulundurulmal&#305;d&#305;r. Nro-genetikteki byk ilerlemelere
ra&#287;men AH ve FTD gibi ailede demans varl&#305;&#287;&#305;n&#305;n nemli
bir risk faktr oldu&#287;u durumlarda hala ke&#351;fedilmeyi bekleyen
Mendelyen gei&#351; ve yatk&#305;nl&#305;k genleri bulunmaktad&#305;r.
rne&#287;in, bu iki durum iin hala gsterilmi&#351; bir resesif gei&#351;
geni yoktur ve akraba evlili&#287;inin greli s&#305;kl&#305;&#287;&#305;yla
lkemizdeki demans prati&#287;i bu a&#305;dan gelecekteki byle bir bulu&#351;
iin avantajl&#305; olabilir. Birinci derece akrabalar aras&#305;nda demans,
Parkinson hastal&#305;&#287;&#305;, motor nron hastal&#305;&#287;&#305; gibi
nrolojik, depresyon, psikoz, alkolizm gibi psikiyatrik hastal&#305;klar&#305;n
mevcudiyeti zellikle sorgulanmal&#305;d&#305;r. Ana-baban&#305;n akraba veya
ayn&#305; kyden olup olmad&#305;&#287;&#305;,&nbsp;ana-baba ve
karde&#351;lerin sa&#287; olup olmad&#305;klar&#305;, ldlerse
ya&#351;lar&#305; ve lm nedenleri ayr&#305; ayr&#305; kaydedilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:14.2pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Tablo 2</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>. Demansta 3 kardinal ve 3 ikincil alan&#305;n
sorgulanmas&#305;<o:p></o:p></span></p>

<div style='margin-left:14.2pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-14.2pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=113 valign=top style='width:3.0cm;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:0cm;margin-right:-7.2pt;margin-bottom:
  0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kognitif</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=189 valign=top style='width:5.0cm;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dikkat</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dil</span></b><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Grsel-mekansal i&#351;levler</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yrtc i&#351;levler</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Praksis</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gnosis</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=408 valign=top style='width:305.8pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yak&#305;n:
  yak&#305;n gemi&#351;e ait ki&#351;isel ve aktel olaylar;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Uzak: ilkokul &#287;retmeni,
  okudu&#287;u okullar, evlilik, emeklilik tarihleri, vb.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dalgalanma, konsantrasyon,
  elinebilirlik</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kelime bulma, anlama, okuma,
  yazma, hesaplama glkleri</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yabanc&#305;/tan&#305;d&#305;k
  mekanlarda dola&#351;abilme, yaz&#305; karakterinde (ortografik)
  de&#287;i&#351;iklik</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Problem zme,
  yarg&#305;lama, soyutlama bozukluklar&#305;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alet kullanma, giyinme,
  oturma-yrme glkleri</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nesneleri tan&#305;ma,
  mekanda birbirinden ay&#305;rma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=189 valign=top style='width:5.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;ilik
  de&#287;i&#351;iklikleri</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Duygudurum bozukluklar&#305;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alg&#305; bozukluklar&#305;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D&#351;nce
  bozukluklar&#305;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=408 valign=top style='width:305.8pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Apati,
  disinhibisyon, sosyal uygunsuzluk</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Keder, isteksizlik,
  huzursuzluk, yerinde duramama, sinirlilik, uygunsuz ne&#351;e, e&#351;in
  pe&#351;inden ayr&#305;lmama</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Grsel ve di&#287;er
  halsinasyonlar</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>H&#305;rs&#305;zl&#305;k,
  sadakatsizlik, Capgras ve di&#287;er trden hezeyanlar</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=189 valign=top style='width:5.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sokakta
  GYAlar</span></b><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evde GYAlar</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kendine bak&#305;m</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=408 valign=top style='width:305.8pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;
  ya&#351;am&#305;, yolculuk, mali i&#351;ler, al&#305;&#351;veri&#351;, sosyal
  ili&#351;kiler</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hobiler, ev
  ayg&#305;tlar&#305;n&#305; kullanma, yemek pi&#351;irme, di&#287;er ev
  i&#351;leri, kk tamirat, gazete-TV ilgisi</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yemek yeme, y&#305;kanma,
  giyinme, makyaj, tra&#351; olma, tuvalet mekani&#287;i, sfinkter kontrol</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Motor</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=597 colspan=2 valign=top style='width:447.55pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yry&#351;
  bozuklu&#287;u, d&#351;meler, donmalar, dengesizlik, hareket
  yava&#351;l&#305;&#287;&#305;, gszlk, erime, seyirme</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Otonom</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=597 colspan=2 valign=top style='width:447.55pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nkontinans,
  empotans, ortostatizm, konstipasyon, terleme</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;mso-yfti-lastrow:yes'>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:solid black 1.0pt;
  border-bottom:solid black 1.0pt;border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Uyku</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=597 colspan=2 valign=top style='width:447.55pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>REM-davran&#305;&#351;
  bozuklu&#287;u, a&#351;&#305;r&#305; gndz uykusu, uyku apne sendromu</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANS MUAYENES&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif ve/veya davran&#305;&#351;sal
yak&#305;nmalar&#305;n&#305; ileten hastan&#305;n muayenesi demans sendromunun
mevcut olup olmad&#305;&#287;&#305;n&#305;, mevcutsa demans sendromlar&#305;
iinde tipik bir tabloya uyup uymad&#305;&#287;&#305;n&#305; saptamaya ynelik
olmal&#305;d&#305;r.&nbsp; Demans muayenesi:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>1. Davran&#305;&#351;sal
gzlemler, <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>2. Mental durum muayenesi
(MDM), <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>3. Somatik nrolojik muayene
alt ba&#351;l&#305;klar&#305;yla kaydedilebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal Gzlemler</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastan&#305;n muayene s&#305;ras&#305;ndaki
davran&#305;&#351;lar&#305; gerek MDMden al&#305;nacak sonular&#305;n
de&#287;erlendirilmesinde nem ta&#351;&#305;rken, gerekse de baz&#305;
durumlarda tan&#305; koydurucu olabilir.&nbsp; Bu alt ba&#351;l&#305;k
alt&#305;nda apati, sosyal uygunluk gibi llmesi zor ya da mmkn olmayan
bulgular zerine muayene edenin yarg&#305;lar&#305; belirtilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Motivasyon</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>un optimal olmas&#305; MDM
sonular&#305;n&#305;n uygun de&#287;erlendirilebilmesi iin gerek
&#351;artlar&#305;n ba&#351;&#305;nda gelir.&nbsp; Muayene edenin tecrbe ve
mahareti, muayene tekniklerini iyi uygulayabilmesinin yan&#305;s&#305;ra
hastan&#305;n&nbsp; muayene boyunca motivasyonunu korumas&#305;n&#305;
sa&#287;layabilmesini de gerektirir.&nbsp; Motivasyonsuzluk, gerek
drtsellik/elinebilirlik, ve gerekse de apati &#351;ekillerinde muayeneye
i&#351;birli&#287;ini bozacak ve a&#287;&#305;rl&#305;&#287;&#305; lsnde
MDMyi istenildi&#287;i dzeyde uygulanamaz k&#305;lacakt&#305;r.&nbsp;
Motivasyonsuzluk, apati ynnde muayene s&#305;ras&#305;nda hastadan
beklenen&nbsp; normal inisiyatif dzeyinin gzlenememesi &#351;eklinde bir
kendili&#287;indenlik azalmas&#305;ndan, oturdu&#287;u yerde evresine tmden
ilgisizli&#287;e kadar de&#287;i&#351;ebilir.&nbsp;Di&#287;er yandan
drtsellik ve dikkatin elinebilirli&#287;i de, MDMde optimal performans iin
gereken sebatl&#305;l&#305;&#287;&#305; bozacak perseveratif cevaplar&#305;
artt&#305;racakt&#305;r.&nbsp;AHde erken evrelerde motivasyonun korunmu&#351;
olmas&#305; ya da muayene performans&#305;n&#305; bozmayacak dzeyde bir
kendili&#287;inden davran&#305;&#351;ta azalma beklenirken, ileri evrede apati
ya da elinebilirlik nedeniyle formel muayene mmkn olmayabilir. FTD daha
erken evrelerden itibaren apati ve/veya drtsellik ile karakterizedir.&nbsp;
Bu nedenle baz&#305; FTD hastalar&#305; ba&#351;lang&#305;tan itibaren
muayeneye izin vermeyebilirler.&nbsp; Yine motivasyon bozuklu&#287;unun,
zellikle geriyatrik poplasyonda kendi ba&#351;&#305;na ya da dejeneratif
demanslarla birlikte oldu&#287;unda, depresyonun ba&#351;l&#305;ca belirtisi
oldu&#287;u sylenebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayene eden, <i>duygudurum ve afekt</i> zerine
gzlemlerini de kaydetmelidir.&nbsp; Kendili&#287;inden gzlenebilen
parmaklar&#305;yla ya da giysileriyle oynamaktan, koltukta oturamay&#305;p
srekli dola&#351;ma ya da oday&#305; terketme iste&#287;ine kadar
de&#287;i&#351;en huzursuz, anksiyz davran&#305;&#351; bizzat muayenedeki
performans bozuklu&#287;uyla da ortaya &#305;kabilir.&nbsp; &#304;ritabilite,
kolay sinirlenme, negativizm, disfori e&#287;ilimi, kederli ruh hali, kolay
a&#287;lamayla kendini gsterecektir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;gr bozuklu&#287;u inkar e&#287;ilimiyle
ba&#351;layabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sosyal uygunluk</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>, muayene edenin hastan&#305;n
genel davran&#305;&#351;&#305;n&#305;n geldi&#287;i sosyal evrenin
normlar&#305;ndan bekledi&#287;i davran&#305;&#351;a ne derecede uygun
d&#351;t&#287; zerine yarg&#305;s&#305;d&#305;r.&nbsp;&nbsp;Disinhibisyonun
bir paras&#305; olan uygunsuz davran&#305;&#351;lar alayc&#305;l&#305;k
e&#287;iliminden sald&#305;rganl&#305;&#287;a kadar de&#287;i&#351;ebilir.&nbsp;
AHde sosyal uygunluk ileri evrelere kadar korunurken FTDde en erken dnemden
itibaren bozulan tan&#305; koydurucu zelliklerdendir. Kullanma
davran&#305;&#351;&#305; yine ba&#351;l&#305;ca FTDye zg bir disinhibisyon
zelli&#287;idir. Kullanma davran&#305;&#351;&#305; sergileyen hasta muayene edenin
masas&#305;n&#305; kar&#305;&#351;t&#305;racak, kalemlerini alma,
dosyalar&#305;n&#305; dzenleme, ka&#287;&#305;tlar&#305;n&#305; okuma gibi
davran&#305;&#351;lar sergileyecektir; masa stnde bulunabilecek refleks
ekici, gzlk gibi nesneler yoklan&#305;p kullan&#305;lmaya
al&#305;&#351;&#305;lacakt&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mental Durum Muayenesi</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mental durum muayenesi (MDM) kendi iinde yatak
ba&#351;&#305; testleri ve tarama testleri olarak
s&#305;n&#305;flanabilir.&nbsp; Gerekti&#287;inde davran&#305;&#351;sal
belirtilerin a&#287;&#305;rl&#305;&#287;&#305;n&#305; saptayacak, i&#351;levsel
durumu nicelle&#351;tirecek, demans &#351;iddetini belirleyecek lekler de
kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yatak Ba&#351;&#305; Testleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MDM, yatak ba&#351;&#305;&nbsp; testlerinden
olu&#351;an bir k&#305;sa nropsikolojik muayene olarak
d&#351;nlebilir.&nbsp; Nropsikoloji laboratuar&#305;nda standart normlara
gre uygulanan ve de&#287;erlendirilen nropsikolojik muayenenin tersine, hastan&#305;n
yk, sosyokltrel durum ve davran&#305;&#351;sal zelliklerine gre muayene
edenin esnek biimde de&#287;i&#351;tirebilece&#287;i genellikle basit, nicel
skorlardan ok nitel performans de&#287;erlendirmelerine dayanan testlerden
olu&#351;ur.&nbsp; Ama, limbik-paralimbik ve heteromodal alanlarda temsil edilen
kognitif i&#351;levler ve unimodal alanlarda temsil edilen karma&#351;&#305;k
alg&#305;sal ve motor i&#351;levlerin etkilenme dzeyleri zerine yorum
yap&#305;labilecek kadar test edebilmektir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu i&#351;levler, 1. Dikkat, 2.Dil, 3.
Grsel-mekansal i&#351;levler, 4. Bellek,<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>5. Yrtc i&#351;levler, 6. Gnosis, 7. Praksis
alt ba&#351;l&#305;klar&#305;nda s&#305;ralanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Nrolojik muayenede normal ve anormal bulgular
olduka kesindir.&nbsp; Bireysel ve kltrel varyasyonlar genellikle ihmal
edilebilir dzeydedir. Oysa MDM sonular&#305;n&#305; de&#287;erlendirirken
kognitif i&#351;levlerin birbirinden ayr&#305;ld&#305;&#287;&#305;
s&#305;n&#305;rlar&#305;n o kadar a&#351;ikar olmad&#305;&#287;&#305;,
testlerin e&#287;itim dzeyi ve ya&#351;tan byk lde etkilendi&#287;i
hesaba kat&#305;lmal&#305;d&#305;r.&nbsp; A&#287;&#305;r dikkat bozuklu&#287;u
nedeniyle kay&#305;t gl&#287; olan hastan&#305;n yak&#305;n bellek
testlerindeki gerek performans&#305;n&#305; de&#287;erlendirmek mmkn
olmayabilir. Yine adland&#305;rmay&#305; bozacak bir dil bozuklu&#287;u,
genellikle bir kelime listesi &#287;renmek tarz&#305;nda olan yak&#305;n
bellek muayenesini verbal olmayan yollara uyarlamay&#305; zorunlu k&#305;lar.&nbsp;
E&#287;itimsiz bir ki&#351;ide saptanan bir performans bozuklu&#287;u o
e&#287;itim dzeyi iin normal s&#305;n&#305;rlarda kalabilecekken, yksek
e&#287;itimli bir ki&#351;inin bozuklu&#287;unu ortalama testler ortaya
koymayabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayenenin sonunda n planda ve ikincil dzeyde
bozulan alanlarla korunan alanlar&#305;n bildirilece&#287;i bir kognitif profil
belirlenir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tarama Testleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tarama testleri, zellikle AHde kognitif
y&#305;k&#305;m&#305;n a&#287;&#305;rl&#305;&#287;&#305;n&#305; saptamak,
y&#305;k&#305;m&#305;n zaman iindeki ilerleme h&#305;z&#305;n&#305; ve ilaca
cevab&#305; izlemekte kullan&#305;lan k&#305;sa global kognitif muayene
aralar&#305;d&#305;r.&nbsp; Epidemiyolojik al&#305;&#351;malar gibi
geni&#351; saha al&#305;&#351;malar&#305;nda duyarl&#305;l&#305;k ve zgllk
oranlar&#305; uyar&#305;nca normalleri demansl&#305;lardan ay&#305;rmak iin
kullan&#305;lsalar da, ofiste tek bir hastan&#305;n muayenesinde, hi bir zaman
as&#305;l MDMnin yerine tan&#305; amal&#305; olarak kullan&#305;lmamal&#305;,
as&#305;l i&#351;levlerinin uzunlamas&#305;na izlemede tek bir hastadaki
de&#287;i&#351;imi nicel olarak belgelemek olduklar&#305;
unutulmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu tr birok test geli&#351;tirilmi&#351;se de,
uluslararas&#305; literatrde en fazla ad&#305; geen ve yurdumuzda da teden
beri yayg&#305;n olarak kullan&#305;lanlar&#305;n ba&#351;&#305;nda Mini Mental
Durum Muayenesi (MMSE), Blessed Oryantasyon Bellek Konsantrasyon Testi (BOMC),
K&#305;sa Mental Durum Testi (STMS) say&#305;labilir. Montreal Kognitif
De&#287;erlendirme Testi (MoCA) ve Addenbrook Kognitif
Muayenesi-Yenilenmi&#351; (ACE-R) yukarda an&#305;lan nispeten eski testlerin
zaaflar&#305;n&#305;n giderilmesine ynelik olarak tasarlanm&#305;&#351;,
yak&#305;n tarihlerde kullan&#305;lmaya ba&#351;lanan tarama testleridir. Bu
yeni testlerin demans ncesi kognitif bozuklu&#287;u (yani, MCI) normal
kognisyondan ay&#305;rma yetenekleri oldu&#287;u ileri srlmektedir.
ACE-R&#305;n 40 y&#305;la yakla&#351;an bir sredir en yayg&#305;n olarak
kullan&#305;lan test olmas&#305;yla btn zaaflar&#305;na ra&#287;men
terkedilemeyen MMSE maddelerini iinde bar&#305;nd&#305;rmas&#305; ve bir alt
skor olarak MMSE skorunu da belirlemesinin bir avantaj&#305; oldu&#287;u
sylenebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal lekler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal belirtilerin
a&#287;&#305;rl&#305;&#287;&#305;n&#305; saptamak, zaman iindeki seyirlerini
ve ilaca cevaplar&#305;n&#305; izlemekte davran&#305;&#351;sal lekler de
kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Alzheimer Hastal&#305;&#287;&#305;nda
Davran&#305;&#351;sal Bozukluklar le&#287;i (BEHAVE-AD), AHde bu amaca
hizmet eden kullan&#305;l&#305;&#351;l&#305; bir testtir.&nbsp; Nropsikiyatrik
Envanter (NPI) tm demanslarda kullan&#305;labilecek &#351;ekilde
geli&#351;tirilmi&#351; son &#351;ekliyle 12 davran&#305;&#351;sal ekseni
sorgulayan bir lektir.&nbsp; Frontal Davran&#305;&#351; Envanteri (FBI)
zellikle FTD'li hastalar&#305;n davran&#305;&#351;sal bozukluklar&#305;n&#305;n
lm iin geli&#351;tirilmi&#351;tir. Geriyatrik Depresyon le&#287;i
(Geriatric DS),&nbsp;demansl&#305; poplasyonda di&#287;er depresyon lm
aralar&#305;na gre daha gvenilir bir ara olabilir. Orijinal &#351;ekli olan
30 madde, 15 maddeye k&#305;salt&#305;larak (GDS-15) yo&#287;un bir pratikte
daha da kullan&#305;&#351;l&#305; k&#305;l&#305;nm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel lekler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif y&#305;k&#305;ma ba&#287;l&#305; olarak
Tablo 2de gsterilen GYAlardaki bozulmay&#305; nicel olarak saptamay&#305;
hedefleyen leklerdir.&nbsp; Bunlar aras&#305;nda, Gnlk ya&#351;am
Aktiviteleri/Enstrmental Gnlk Ya&#351;am Aktiviteleri le&#287;i
(ADL/IADL), Blessed Demans Derecelendirme le&#287;iCERAD versiyonu
(BDRS-CERAD) ve Alzheimer Hastal&#305;&#287;&#305; &#304;&#351;birli&#287;i
al&#305;&#351;mas&#305;Gnlk Ya&#351;am Aktiviteleri le&#287;i (ADCS-ADL)
say&#305;labilir.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Parasomni lekleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gerekti&#287;inde RUDB ve insomniaya neden olan huzursuz
bacak ve uyku apne gibi durumlar&#305; nicelle&#351;tiren Mayo Uyku
Soru&#351;turusu (MSQ) ve a&#351;&#305;r&#305; gndz uykululu&#287;unu
nicelle&#351;tiren Epworth Uykululuk le&#287;i (ESS) kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Nrolojik Muayene</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Di&#287;er nrolojik hastal&#305;klarda
oldu&#287;u gibi, do&#287;al olarak demans hastal&#305;klar&#305;n&#305;n
muayenesine de tam bir somatik nrolojik muayenenin e&#351;lik etmesi
beklenir.&nbsp; Bununla birlikte baz&#305; demans sendromlar&#305;yla zellikle
baz&#305; nrolojik bulgular birlikte gitti&#287;i iin sz konusu bulgular&#305;n
bulunup bulunmamas&#305; nem ta&#351;&#305;r.&nbsp; Bunlar aras&#305;nda
ekstrapiramidal sistem bulgular&#305;n&#305;n (EPS) zel bir yeri
vard&#305;r.&nbsp; Gz hareketleri muayenesinde ortaya konabilecek
a&#351;a&#287;&#305; bak&#305;&#351; felci, yry&#351; bozuklu&#287;u varsa
bunun Parkinsonyen ve/veya ataktik niteli&#287;i, geirilmi&#351; inmelere ait
fokal nrolojik bulgular&#305;n tm de demans sendromlar&#305;n&#305;n
ay&#305;rt edilmesinde kullan&#305;lacaklard&#305;r. zellikle EPSnin
nicelle&#351;tirilmesi amac&#305;yla Parkinson hastal&#305;&#287;&#305;n&#305;n
(PH) belirti ve bulgular&#305; iin geli&#351;tirilen UPDRS isimli le&#287;in
K&#305;s&#305;m III alt blm kullan&#305;labilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANS SENDROMUNUN FENOMENOLOJ&#304;K AYIRICI
TANISI<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunun tan&#305;s&#305;nda, daha nce
de belirtildi&#287;i gibi,  kardinal semptomatolojik kategori aras&#305;nda
i&#351;levsel alanda bozulma &#351;artt&#305;r.&nbsp; Demans&#305;n
ay&#305;r&#305;c&#305; tan&#305;s&#305;, i&#351;levsel bozulmaya yol aan
kognitif alana ait bozulman&#305;n profili, davran&#305;&#351;sal alana ait
bozuklu&#287;un olup olmamas&#305;, mevcut ise tabloya kat&#305;lma
zamanlamas&#305; ve a&#287;&#305;rl&#305;&#287;&#305;, yine motor
bozuklu&#287;un mevcudiyeti ve tabloya kat&#305;lma zamanlamas&#305;,
a&#287;&#305;rl&#305;&#287;&#305; de&#287;erlendirilerek
yap&#305;l&#305;r.&nbsp; rne&#287;in, ATD yks a&#287;&#305;rl&#305;kl&#305;
olarak, izole kognitif demans olarak ba&#351;lar; davran&#305;&#351;sal ve
motor bulgular tabloya ileri evrelerde kat&#305;l&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Nropsikolojik Profil</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans&#305;n nropsikolojik profili patogenezin
nral co&#287;rafyadaki
yatk&#305;nl&#305;&#287;&#305;n&#305;&nbsp;yans&#305;t&#305;r ve
dolay&#305;s&#305;yla hastal&#305;&#287;&#305; yksek olas&#305;l&#305;kla
tahmin ettirir.&nbsp; Daha nce de de&#287;inildi&#287;i gibi, demans daha
yak&#305;n zamana kadar tasarland&#305;&#287;&#305; gibi, MSSnin yayg&#305;n
hasar&#305;yla geli&#351;en global bir zihinsel y&#305;k&#305;m de&#287;ildir.
Farkl&#305; nrodejeneratif etyopatogenetik sreler farkl&#305; nroanatomik
yatk&#305;nl&#305;klar gsterirler.&nbsp; Nropsikolojik profilleri de, bu
yatk&#305;nl&#305;&#287;&#305; yans&#305;tacak &#351;ekilde, kognitif ve
davran&#305;&#351;sal alanlar&#305;n bazen izole, ama s&#305;kl&#305;kla da
kendine zg bile&#351;imlerinden olu&#351;an bozukluklar&#305;n&#305;n
ifadesidir.&nbsp; Nropsikolojik profil, bozulan ve greli korunan alanlar&#305;
belgeleyerek, nroanatomiyi dolayl&#305; olarak sergiler.&nbsp; Hasarl&#305;
oldu&#287;u varsay&#305;lan anatomik alan daima tek bir etyopatogeneze
kar&#351;&#305;l&#305;k gelmeyebilir.&nbsp; Farkl&#305; sreler, benzer bir
anatomik yatk&#305;nl&#305;k gsterebilirler.&nbsp; Ancak, gnmze kadar
biriken nropatolojik veriler, farkl&#305; nropsikolojik profillerin,
dolay&#305;s&#305;yla anatomik yatk&#305;nl&#305;klar&#305;n belli
hastal&#305;k srelerine kar&#351;&#305;l&#305;k gelme ya da tmyle
d&#305;&#351;lama olas&#305;l&#305;klar&#305;n&#305; gvenilir biimde ortaya
koyabilmektedir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Farkl&#305; nrodejeneratif
sreler,&nbsp;genellikle bir e&#351;it nihai ortak yola sahiptirler.&nbsp;
Dolay&#305;s&#305;yla, hastal&#305;&#287;&#305;n ok ilerledi&#287;i,
a&#287;&#305;r ve yayg&#305;n y&#305;k&#305;m&#305;n gerekle&#351;ti&#287;i
son evrede nropsikolojik olarak farkl&#305; profiller ay&#305;rmak mmkn
olmayabilir.&nbsp;Nropsikolojik profiller, zellikle erken evrede anlaml&#305;
farkl&#305;l&#305;klar sergileyeceklerdir.&nbsp; Bu profiller
s&#305;kl&#305;kla, en az&#305;ndan ba&#351;lang&#305;ta simetrik ya da
asimetrik olarak fokal kalacak olan dejenerasyonu yans&#305;t&#305;rlar.&nbsp;
Altta yatan patolojik srecin niteli&#287;ine gre, hastal&#305;&#287;&#305;n
nihai evrelerinde dejenerasyon fokal zelli&#287;ini b&#305;rak&#305;p
yayg&#305;nla&#351;&#305;rken, klinik tablo da global bir y&#305;k&#305;m
zelli&#287;i edinecektir.&nbsp; Pick hastal&#305;&#287;&#305; (PiH) gibi
baz&#305; sreler ise btn evrelerinde daima fokal kalabilirler.&nbsp;
Mesulam ve Weintraub, zellikle erken evre profillerini vurgulayarak, demanslar
iin 4 farkl&#305; nropsikolojik profil tan&#305;mlar:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>1.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Progresif amnestik disfonksiyon (PAD)</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>2.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Primer progresif afazi (PPA)&nbsp;</span><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>3.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Progresif grsel-mekansal Bozukluk (PGMB)</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>4.</span><span lang=TR style='font-size:7.0pt;font-family:
Tahoma;mso-ansi-language:TR'> </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>Progresif davran&#305;&#351;sal/yrtc bozukluk
(PDB/PYB) ya da progresif frontal &#351;ebeke sendromu&nbsp;&nbsp;</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam ve Weintraubun bu 4 tablosuna progresif
apraksiyi de mmkn bir 5. tablo olarak eklemek listeyi daha
kapsay&#305;c&#305; bir hale getirecektir.&nbsp; Yazarlar&#305;n da i&#351;aret
etti&#287;i gibi, bunlar demans&#305;n mmkn ba&#351;lang&#305;
gsterilerinin tm de&#287;ildir ve baz&#305; olgular bu 4 ya da 5 tabloya
gre s&#305;n&#305;flanamayabilir.&nbsp; Baz&#305; patolojik srelerde biri n
planda olmak zere bu tablolar bir arada grnebilir (rne&#287;in FTDde 2 ve
4 ya da FTDnin semantik demans varyant&#305;nda 2, 4 ve 3den zellikler,&nbsp;KBDde
4 ve 5).&nbsp; Yine de, gnlk demans prati&#287;inde byk lde
kapsay&#305;c&#305; zelli&#287;iyle bu yakla&#351;&#305;m, hem
ay&#305;r&#305;c&#305; tan&#305;da pratik bir yol olmakta, hem de hasta ve
hasta yak&#305;nlar&#305;na yap&#305;lacak non-farmakolojik e&#287;itici mdahalelerrde,
bozulan ve korunan niteliklerinin belirlenmesiyle yol gstermekte
yard&#305;mc&#305; olmaktad&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam, tan&#305;mlad&#305;&#287;&#305;
tablolar&#305;n tan&#305; kriterlerinin ortak zellikleri olarak k&#305;saca,
tabloya ad&#305;n&#305; veren bozuklu&#287;un en az iki y&#305;l boyunca
ilerleyici (progresif) izole bozukluk olarak kalmas&#305;n&#305; (primer) ve bu
sre iinde GYAlar&#305; bozan yegane neden olmas&#305;n&#305; ileri
srer.&nbsp; Bu iki y&#305;ll&#305;k sre sonras&#305;nda di&#287;er kognitif
alanlardaki bozulmalar da tabloya kat&#305;labilir.&nbsp;A&#351;a&#287;&#305;da
s&#305;ralanan nropsikolojik profillerde Mesulam ve Weintraubun nerileri
temel al&#305;nmakla birlikte, ad&#305; geen neride primer s&#305;fat&#305;
iin gerekli ko&#351;ul olan en az 2 y&#305;l izole bozukluk kriteri
s&#305;k&#305; bir &#351;ekilde korunmam&#305;&#351;, bunun yerine primer
s&#305;fat&#305; izole olsun ya da olmas&#305;n, en a&#287;&#305;r olarak bozulan
veya profilin ekirde&#287;inde bulunan kognitif bozuklu&#287;u nitelemek amac&#305;yla
kullan&#305;lm&#305;&#351;t&#305;r. Dolay&#305;s&#305;yla, burada
s&#305;ralanan profiller ayr&#305; ayr&#305; antiteler olarak de&#287;il fakat
ay&#305;r&#305;c&#305; tan&#305; amal&#305;, en gl ihtimalle belli
nrodejeneratif hastal&#305;klara kar&#351;&#305;l&#305;k gelmesi beklenen
klinik sendromlar olarak anla&#351;&#305;lmal&#305;d&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Amnestik Disfonksiyon (PAD)</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ba&#351;ka bir kognitif bozukluk
olmaks&#305;z&#305;n yak&#305;n bellekte saptanan ilerleyici karakterli
bozukluk GYAlar&#305; da bozmaktad&#305;r.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tipik bir hasta, genellikle 65
ya&#351;&#305;n&#305;n zerindedir.&nbsp; Unutkanl&#305;ktan yak&#305;nan hasta
ve/veya yak&#305;n&#305; bunu zel e&#351;yalar&#305;n&#305; kaybetmek,
ayn&#305; sorular&#305; ve konular&#305; tekrarlamak, okuduklar&#305;n&#305;
akl&#305;nda tutamamak, randevular&#305;n&#305;, al&#305;&#351;veri&#351;
listesini, yeni grd&#287; mekan ve yzleri unutmak &#351;eklinde
rneklendirir.&nbsp; Unutkanl&#305;&#287;&#305; genellikle i&#351;
arkada&#351;lar&#305; ve ailesi taraf&#305;ndan da farkedilmektedir.&nbsp;
Bunlar d&#305;&#351;&#305;nda, sokakta ve sosyal ortamlarda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;
k&#305;s&#305;tlanmam&#305;&#351;t&#305;r.&nbsp; D&#305;&#351; mekanda eskisi
gibi kaybolmadan dola&#351;&#305;r, mali i&#351;lerini ve
al&#305;&#351;veri&#351;i ancak listeyle eskisi gibi halleder.&nbsp; Ev
i&#351;lerinde zaman zaman yemek yak&#305;yor olmak d&#305;&#351;&#305;nda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; srdrr, hobilerini devam
ettirir.&nbsp; Nropsikolojik olarak kayda de&#287;er bir verbal ve grsel
yak&#305;n bellek bozuklu&#287;u saptan&#305;rken, di&#287;er alanlardaki
performans korunmu&#351; ya da normal s&#305;n&#305;ra yak&#305;n
dzeylerdedir.&nbsp; &#304;kinci bir kognitif alan&#305;n da bozulmas&#305; ve
bunun gnlk ya&#351;ama yans&#305;mas&#305;yla birlikte art&#305;k PRAD ya da
DAT kriterleri doldurulur hale gelir.&nbsp; Nropsikolojik olarak en erken,
yak&#305;n bellek bozuklu&#287;una eklenen demansa ili&#351;kin bulgular szel
ak&#305;c&#305;l&#305;kta kategori ak&#305;c&#305;l&#305;&#287;&#305;n&#305;n
(rne&#287;in 1 dakikada mmkn oldu&#287;unca fazla hayvan ismi sylemek),
leksikal ak&#305;c&#305;l&#305;&#287;a (rne&#287;in 1er dakikada K, A ve S
harfleriyle ba&#351;layan mmkn oldu&#287;unca fazla cins isim sylemek) gre
daha erken ve a&#287;&#305;r bozulmas&#305; ve karma&#351;&#305;k
grsel-mekansal i&#351;levlerde bozulma olmaktad&#305;r.&nbsp; Zaman iinde
uzunlamas&#305;na izlenen bir hastada nceleri bu i&#351;levler korunurken
sonradan bozulduklar&#305;n&#305;n gsterilmesi, art&#305;k nrodejenerasyonun
limbik sistemin d&#305;&#351;&#305;na, sol ve sa&#287; temporo-parietal
heteromodal neokortekse geti&#287;i anlam&#305;na gelir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu tablo demanslar&#305;n erken evreleri iinde en
s&#305;k rastlan&#305;lan tablodur.&nbsp; PAD'&#305;n ilerde daha
ayr&#305;nt&#305;l&#305; tart&#305;&#351;&#305;lacak olan MCI tablosu ile
pratik olarak ayn&#305; anlama geldi&#287;i sylenebilir.&nbsp; Nadiren ok
uzun y&#305;llar boyunca, ya da btn seyri boyunca ayn&#305; kalsa da byk
s&#305;kl&#305;kla AHnin henz PRAD/DAT kriterlerinin
doldurulamad&#305;&#287;&#305; erken veya prodromal evresine
kar&#351;&#305;l&#305;k gelmektedir. Grntleme al&#305;&#351;malar&#305;nda,
zellikle MRG ile volmetrik olarak hippokampal atrofi saptanabilir.&nbsp;<b>(&#350;ekil
1)</b>&nbsp; Son y&#305;llarda geli&#351;tirilen PET ile amiloid grntleme
tekni&#287;i, PAD sergileyen hastalar aras&#305;nda yo&#287;un serebral amiloid
yk ta&#351;&#305;yanlar&#305; ay&#305;rt ederek ilerde ATD geli&#351;tirecek,
bir di&#287;er deyi&#351;le pre-demans veya prodromal AHyi ngrebilir. Yine,
BOSta total tau ve fosfo-tau proteini dzeyleri ile amiloid-beta fragman&#305;
dzeyi benzer bir i&#351;lev grebilir. Hippokampus volmetrisi, PET ile
amiloid grntleme ve BOSta an&#305;lan protein dzeyleri ilerde AHnin
potansiyel biyoi&#351;aretleyicileri blmnde ayr&#305;nt&#305;yla tart&#305;&#351;&#305;lacakt&#305;r.
Nropatoloji simetrik olarak limbik sistemde ve a&#287;&#305;rl&#305;kla da,
hippokampal-entorinal yap&#305;lardad&#305;r.&nbsp; An&#305;lan blgelere
yatk&#305;nl&#305;&#287;&#305; dolay&#305;s&#305;yla, tahmin edilebilece&#287;i
gibi, beklenen hastal&#305;k yksek ihtimalle AH'dir.&nbsp; Non-spesifik
dejenerasyon, PiH, LCD, arjirofilik tah&#305;l hastal&#305;&#287;&#305; veya
sadece yumak demans&#305; di&#287;er nadir asosiasyonlard&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&#350;ekil 1.</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Hippokampus Grntlemesi,</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans1a.JPG">&#350;ekil 1a.</a> 73
ya&#351;&#305;nda normal ya&#351;l&#305; hippokampuslar&#305;;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
sa&#287; hippokampusun normalde biraz daha byk grnd&#287;ne dikkat ediniz
(Hippokampus ba&#351;&#305;ndan geen T1 a&#287;&#305;rl&#305;kl&#305; koronal
kesit).</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans1b.JPG">&#350;ekil 1b.</a> 75
ya&#351;&#305;nda hafif demansl&#305; kad&#305;n hasta</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>; hippokampus
ba&#351;lar&#305;ndaki hacim kayb&#305;na dikkat ediniz (Hippokampus
ba&#351;&#305;ndan geen T2 a&#287;&#305;rl&#305;kl&#305; kesit).</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span style='font-family:Tahoma'><a href="demans1c.JPG"><b><span
lang=TR style='font-size:10.0pt;mso-ansi-language:TR'>&#350;ekil 1c.</span></b></a></span><span
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <b><span
lang=TR>Ayn&#305; olgunun 5 y&#305;l sonraki MRGsi</span></b><span lang=TR>;
demans art&#305;k a&#287;&#305;r evrede ve hippokampal atrofi ok daha belirgin
hala gelmi&#351; (&#350;ekil 1b ile ayn&#305; zellikte kesit.</span></span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Afazi (PA)</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici dil bozuklu&#287;unun, izole olarak
veya di&#287;er kognitif ve/veya davran&#305;&#351;sal bozukluklarla birlikte
ekirdek bozukluk oldu&#287;u tablolard&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tipik bir hasta, genellikle 65
ya&#351;&#305;n&#305;n alt&#305;ndad&#305;r.&nbsp; Konu&#351;ma
bozuklu&#287;undan yak&#305;nan hasta, bunu kelime bulma, nesneleri ve
ki&#351;ileri adland&#305;rma, bazen d&#351;ncelerini yaz&#305;l&#305; ve
szl ifade etme, bazen de yaz&#305;l&#305; ve szl ifadeleri anlama, okuma
gl&#287; &#351;eklinde rneklendirir.&nbsp; zel bir alt tipi olan <i>semantik
demans</i>ta (SD) tek tek kelimelerin anlamsal ierikleri
bo&#351;alm&#305;&#351;t&#305;r. Hastalar s&#305;radan nesnelerin isimlerini
ilk kez duyuyorlarm&#305;&#351; gibi davran&#305;rlar. Dil kullanmak
gerekmedi&#287;i durumlarda sokakta ve evde
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; k&#305;s&#305;tlayacak gnlk
olaylar&#305; hat&#305;rlama, d&#305;&#351; mekanda yolunu bulma, gnlk
olaylar zerine ak&#305;l yrtme, hobilerini srdrme gibi sorunlar&#305; yoktur.
Di&#287;er bir alt tip olan logopenik PAl&#305; (LPA) hastalar hesaplama
gl&#287;nden yak&#305;n&#305;rlar. SDli hastalar progresif afazilerinin
yan&#305;s&#305;ra a&#351;ina yzleri tan&#305;ma gl&#287; ve disinhibisyon
belirtileri sergileyebilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Nropsikolojik profil, tutuk ya da ak&#305;c&#305;
afazi tarz&#305;ndad&#305;r.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yerle&#351;mi&#351; bir tutuk afazi profili,
klasik Broca afazisini and&#305;ran tarzda agramatik spontan konu&#351;ma ve
tekrarlama bozuklu&#287;u ile birlikte anlaman&#305;n greli korundu&#287;u bir
tarzd&#305;r. Bununla birlikte, klasik afazik sendromlar&#305;n, tablonun akut
olarak yerle&#351;ti&#287;i ve zaman iinde dzelmeye yz tuttu&#287;u
biimlerinin tersine ilerleyici afazilerin sinsi ba&#351;lang&#305;l&#305;,
tedrici ilerleyici seyirleri gz nne al&#305;nmal&#305;d&#305;r.
Dolay&#305;s&#305;yla, erken dnemdeki bir ilerleyici tutuk afazi&#287;in
klasik afazi muayenesiyle ay&#305;rt edilemeyebilece&#287;i, klasik afazik
sendromlar&#305;n olmazsa olmaz ko&#351;ullar&#305;ndan konfrontasyon
adland&#305;rmas&#305;n&#305;n dahi salim kalabilece&#287;i kaydedilmelidir. Bu
erken dnem hastalar spontan konu&#351;malar&#305;nda kelime bulma glkleri,
fonemik parafaziler, dizartrik, bazen kekelemeli konu&#351;ma tarz&#305;,
prozodilerinde sanki bir yabanc&#305;n&#305;n aksanl&#305;
konu&#351;mas&#305;ym&#305;&#351;cas&#305;na de&#287;i&#351;me ve kelime
ak&#305;c&#305;l&#305;klar&#305;nda, zellikle de leksikal ak&#305;c&#305;l&#305;klar&#305;nda
bozulma ile ay&#305;rt edileceklerdir. &#304;lerleyici tutuk afazi (progressive
non-fluent aphasia-PNFA) bir FTD alt tipidir. Hastal&#305;k seyri
s&#305;kl&#305;kla y&#305;llarca izole dil bozuklu&#287;u &#351;eklinde
kalabilirken (yani, Mesulam PPAs&#305;), daha erken dnemde yrtc bozukluk
zelikleri de e&#351;lik edebilir. KBD tarz&#305; bir asimetrik sa&#287;
hemiparkinsonizm ve amiyotrofik lateral skleroz (ALS) muhtemel motor
e&#351;likilerdendir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici ak&#305;c&#305; afazi SD veya LPA
&#351;ekillerinde sunulur. SDde a&#287;&#305;r konfrontasyon
adland&#305;rmas&#305; bozuklu&#287;u bir nesne agnozisini and&#305;r&#305;r
zellik ta&#351;&#305;r.&nbsp; Hasta iin kelimeler anlam&#305;n&#305;
yitirmi&#351;tir.&nbsp; Nesneleri adland&#305;ramayan (anomi) hasta bir
Wernicke afazi&#287;inin aksine bir blmnn ne i&#351;e
yarad&#305;&#287;&#305;n&#305; da syleyemez (agnozi). Bununla birlikte,
kar&#351;&#305;l&#305;kl&#305; ileti&#351;im genellikle mmknken, karma&#351;&#305;k
gramerin kullan&#305;ld&#305;&#287;&#305; emirlerle de anlaman&#305;n
korundu&#287;u grlr.&nbsp;SDli hastan&#305;n semantik bellek testleri
(rne&#287;in, Piramidler ve Palmiye A&#287;alar&#305; Testi) ve me&#351;hur
yzleri tan&#305;ma testleri de bozulmu&#351;tur. LPA bir ilerleyici anomi
olarak d&#351;nlebilir. Spontan konu&#351;ma kelime bulma glkleriyle
giderek yoksulla&#351;&#305;r. Anlama korunmu&#351;tur. Anomik hasta
ayr&#305;ca nesne agnozisi, semantik bellek ve yz tan&#305;ma
bozukluklar&#305; gibi SD zellikleri sergilemez. Akalkuli ba&#351;ta olmak
zere, sa&#287;-sol disoryantasyonu ve parmak agnozisi gibi Gerstmann sendromu
zellikleri grlebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gerek PNFAda ve gerekse de ak&#305;c&#305;
trlerde verbal dolay&#305;ml&#305; testler, zellikle de kelime listesi
&#287;renme gibi klasik bellek testleri, dil bozuklu&#287;una sekonder olarak
bozuk bulunabilir.&nbsp; Ancak&nbsp;dil dolay&#305;m&#305;na dayanmayan grsel
bellek, sa&#287; hemisfer grsel-mekansal i&#351;levleri iyi
korunmu&#351;tur.&nbsp;Bununla birlikte, LPAn&#305;n ileri
a&#351;amalar&#305;nda simultanagnoziye varan a&#287;&#305;r grsel-mekansal
bozukluklar grlebilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PNFAda BT ve MRG ile asimetrik sol peri-sylvien
geni&#351;leme, <b>(&#350;ekil 2)</b> bazen sol fronto-temporal atrofi, SPECT
ve PET ile ad&#305; geen blgede hippoperfzyon veya hipometabolizma, EEG ile
sol temporal yava&#351;lama saptanabilir.&nbsp;SDnin ay&#305;r&#305;c&#305;
zelli&#287;i MRGde byk s&#305;kl&#305;kla solda bask&#305;n, zellikle
koronal T1 kesitlerde rahatl&#305;kla ay&#305;rt edilebilen temporopolar (TP)
atrofidir <b>(&#350;ekil 3</b>). rTVde atrofi tam tersine sa&#287;da
bask&#305;nd&#305;r <b>(&#350;ekil 4).</b> LPAn&#305;n nropatolojik
kar&#351;&#305;l&#305;&#287;&#305; olan sol anguler girus atrofisi yap&#305;sal
grntlemede gzden kaabilirse de SPECT veya PET ile fonksiyonel grntleme
asimetrik bir sol parietal hipoperfzyon/metabolizmay&#305; ortaya
koyacakt&#305;r <b>(&#350;ekil 5).</b>&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PNFA s&#305;kl&#305;kla KBD, PSP ve FTD
spektrumuna dahil taupatilerle ili&#351;kiliyken, ALS e&#351;lik etti&#287;i
durumlarda beklenen nropatoloji bir tau-/ubikutin+ (T-/Ub+) proteinopati veya
ubikutinize proteinin ad&#305;yla bir TDP-43 proteinopatisidir. SD hemen daima
bir TDP-43 proteinopatidir. LPAn&#305;n AHnin atipik sunumlar&#305;ndan biri
oldu&#287;una dair deliller birikmektedir. PNFA, dvFTD, parkinsonizm ve ALS
bile&#351;imlerinin ailevi biimlerinin genetik kar&#351;&#305;l&#305;klar&#305;
a&#351;a&#287;&#305;da progresif davran&#305;&#351;sal bozukluk iinde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r. SDnin ailevi biimi
bildirilmemi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Wernicke afazisine benzer anlaman&#305;n da erken
dnemde bozuldu&#287;u bir ilerleyici tutuk afazi izole biimde de&#287;il
fakat s&#305;kl&#305;kla, bellek ve di&#287;er kognitif bozukluk bulgular&#305;
aras&#305;nda dil bozuklu&#287;unun n planda oldu&#287;u tablolar bir atipik
sunum olarak AH ile ilintili olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;page-break-before:always;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans2.JPG">&#350;ekil 2.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;lerleyici tutuk afazide
asimetrik sol peri-sylvien atrofi</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sol frontal
operkulum ve sol anterior insula atrofisine ba&#287;lanabilecek asimetrik sol
peri-sylvien geni&#351;leme (st s&#305;ra, sa&#287;), bir st kesitte de
hafife daha geni&#351; sol ventrikl frontal boynuzuyla birlikte (st
s&#305;ra, sol) grlyor. Sol lateral ventrikl de sa&#287;a k&#305;yasla hafife
daha geni&#351; (alt s&#305;ra).</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans3.JPG">&#350;ekil 3.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Semantik demansta asimetrik sol
bask&#305;n temporopolar atrofi</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>T2
a&#287;&#305;rl&#305;kl&#305; koronal kesitlerde sol frontopolar
a&#287;&#305;r, sa&#287;da daha hafif atrofi (st s&#305;ra), mezial temporal
blgeden geen kesitlerde 2 yanl&#305; amigdala atrofisi (alt s&#305;ra).</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans4.JPG">&#350;ekil 4.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sa&#287; temporal varyant
semantik demans grntlemesi.</span><span lang=FR style='font-family:Tahoma;
mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>T12
a&#287;&#305;rl&#305;kl&#305; aksiyel ve koronal kesitlerde sa&#287;da
bask&#305;n, 2 yanl&#305; temporopolar atrofi</span><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans5.JPG">&#350;ekil 5.</a> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Logopenik
progresif afazide SPECT.</span><span lang=FR style='font-family:Tahoma;
mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tc<sup>99</sup> HMPAO-SPECT ile MRGsinde ay&#305;rt
edilebilir bir bulgu olmayan logopenik progresif afazili bir olguda asimetrik
a&#287;&#305;r sol parietal hipoperfzyon.</span><span lang=FR
style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=FR style='font-family:Tahoma;mso-ansi-language:
FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Grsel-Mekansal Bozukluk (PGMB)</span></i><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></i></b><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu profilin ba&#351;l&#305;ca zellikleri grsel
i&#351;leme bozukluklar&#305;d&#305;r.&nbsp; Nrodejenerasyon iki yanl&#305;
oksipitoparietal blgededir.&nbsp; &#304;lk belirtiler s&#305;kl&#305;kla,
bildik yerler dahil d&#305;&#351; mekanda yolunu bulamama,
arad&#305;&#287;&#305; bir nesneyi gznn nnde oldu&#287;u halde di&#287;er
nesnelerden ay&#305;r&#305;p bulamama,&nbsp;okurken sat&#305;rlar&#305;n
birbirine kar&#305;&#351;mas&#305;, yaz&#305; karakterinin bozulmas&#305; ve
giyinme gl&#287;dr.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayenede Balint sendromunun bile&#351;enleri
(a&#287;&#305;rl&#305;kla simultanagnozi ve daha silik olarak optik ataksi,
okler apraksi) ile giyinme apraksisi saptan&#305;r.&nbsp; Nropsikolojik
olarak grsel-mekansal testlerde a&#287;&#305;r bozukluk grlr ve spesifik
testlerle bak&#305;ld&#305;&#287;&#305;nda simultanagnozi ortaya konulur.&nbsp;
Bellek&nbsp; korunmu&#351;tur.&nbsp; Yrtc i&#351;levler ve dilsel
i&#351;levlerde hafif bozukluklar e&#351;lik edebilir.&nbsp; Nrodejenerasyon
inferior parietal loblleri de tuttu&#287;unda sol mekan ihmali ve Gerstmann
sendromu zellikleri de (sa&#287;-sol disoryantasyonu, parmak agnozisi, agrafi,
aleksi, akalkuli) tabloya kat&#305;labilir ve LPAy&#305; and&#305;ran bir
anomi yerle&#351;ebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Grntleme al&#305;&#351;malar&#305;nda bu
profili yans&#305;t&#305;r &#351;ekilde iki yanl&#305; oksipito-parietal atrofi
(zellikle, MRG koronal T1 kesitlerde ay&#305;rt edilen), hipoperfzyon ve
hipometabolizma saptan&#305;r <b>(&#350;ekil 6 </b>ve <b>7).</b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yay&#305;nlanm&#305;&#351; az say&#305;daki otopsi
olgular&#305;nda non-spesifik dejenerasyonun yan&#305;s&#305;ra
s&#305;rad&#305;&#351;&#305; olarak parietal neokortekste
yo&#287;unla&#351;m&#305;&#351; nrofibriller yumaklarla AH
say&#305;labilir.&nbsp;Fokal atrofiler iinde en az Pick kompleksi
patolojileri, tersine en fazla AH ile ilintili oland&#305;r. H&#305;zl&#305;
seyirli oldu&#287;unda tipik bir CJH sunumu olabilir. Ailevi biimleri
bilinmemektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans6.JPG">&#350;ekil 6.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Posterior kortikal atrofide
MRG.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Posterior
kortikal atrofili koronal T1 kesitlerde simetrik dorsal parietal atrofi</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans7.JPG">&#350;ekil 7.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Posterior kortikal atrofide
SPECT.</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Posterior kortikal atrofili bir olguda Tc<sup>99</sup>
HMPAO-SPECT incelemesinin koronal kesitleri. st s&#305;ra frontal kesitlerden
alt s&#305;ra oksipital kesitlere do&#287;ru nden arkaya do&#287;ru
izlendi&#287;inde, 2. s&#305;ra 1. kesitte sa&#287; frontoparietal olarak
asimetrik ba&#351;layan hipoperfzyon ayn&#305; s&#305;radaki 4. kesitte
simetrikle&#351;iyor ve 3. s&#305;radaki dorsal parietal ve alt s&#305;ra 1.
kesitteki oksipitoparietal kesitlerde a&#287;&#305;rla&#351;&#305;yor</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Davran&#305;&#351;sal/Yrtc Bozukluk
(PDB/PYB)</span></i><span lang=DA style='font-family:Tahoma;mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Prefrontal sisteme atfedilen i&#351;levlerin
ilerleyici bozuklu&#287;u bu tablonun temel zelli&#287;idir.&nbsp; Tipik bir
hasta 65 ya&#351;&#305;n&#305;n alt&#305;ndad&#305;r.&nbsp; Toplumsal konumuyla
ba&#287;da&#351;mayan tarzda davran&#305;&#351;lar, normlara
ald&#305;r&#305;&#351;s&#305;zl&#305;k, ocuksuluk, uygunsuz cinsel imalar,
beslenme al&#305;&#351;kanl&#305;&#287;&#305;nda de&#287;i&#351;iklik ya da
oburluk, dikkatin kolayca elinebilir olmas&#305;, igr kayb&#305;,
inisiyatif kullan&#305;m&#305;n&#305;n azalmas&#305; erken belirtilerdir.&nbsp;
Hasta unutkan gibi grnebilir, fakat&nbsp;&nbsp; muayene sonucu bunun dikkat
bozuklu&#287;una ikincil oldu&#287;u ortaya konacakt&#305;r.&nbsp; Sokakta
kaybolmadan dola&#351;abilir.&nbsp; Baz&#305; durumlarda sokaktaki
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; yitirmi&#351; gibi
grnebilir, fakat uygun bir sorgulamayla bunun mekan oryantasyonuyla ilgili
de&#287;il, fakat sosyal uygunsuz davran&#305;&#351;lar&#305;n sonucu olarak
hasta yak&#305;nlar&#305;n&#305;n d&#305;&#351;ar&#305; &#305;kmay&#305;
k&#305;s&#305;tlamas&#305; nedeniyle oldu&#287;u grlecektir.&nbsp; Bu tablo,
izole ilerleyici bir tablo gibi seyredebilece&#287;i gibi, bazen PNFA tipi, bir
dil bozuklu&#287;u da eklenebilir. Bu tablo PNFA ve SD ile birlikte FTLD
tan&#305; kriterlerinde bir nc alt tip olarak belirlenmi&#351;tir ve
davran&#305;&#351;sal varyant olarak da adland&#305;r&#305;l&#305;r (dvFTLD).
Sa&#287; temporal varyant olarak adland&#305;r&#305;lan SD (RTV-SD) tipinde
tablo dvFTLDden ay&#305;rt edilemeyen bir davran&#305;&#351;sal bozuklukla
ba&#351;layabilir fakat hemen daima daha ba&#351;lang&#305;tan itibaren veya
k&#305;sa zaman iinde eklenen bir a&#351;ina yzleri tan&#305;ma gl&#287;
ile daha geri planda SD tipi bir dil bozuklu&#287;u bulunacakt&#305;r. dvFTLDye
e&#351;lik edebilecek motor bozukluklar ise asimetrik akinetik-rijid veya
aksiyel postral bozukluklarla parkinsonizm veya ALS olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>elinebilirlik (distraktibilite), drtsellik
(impulsivite) ve motivasyon gl&#287; (apati) nedeniyle bu hastalar&#305;n
nropsikolojik muayeneleri son derece g olabilir.&nbsp; Bu nedenlerle
performans&#305; de&#287;erlendirmek mmkn olamayabilece&#287;i gibi, gerek
ya&#351;amda zellikle kar&#351;&#305;la&#351;&#305;lan yeni problemler
kar&#351;&#305;s&#305;nda ok ciddi sorunlar&#305; olan bir hastan&#305;n ofis
performans&#305; dolay&#305;s&#305;yla bunlar nropsikolojik testlerle ortaya
konulamayabilir ve testler tmyle normal s&#305;n&#305;rlarda olabilir.&nbsp;
Ancak, tipik bir hastada yrtc i&#351;levlerle ilgili testlerde ak&#305;l
yrtme, planlama, soyutlama, zihinsel esneklik ve sebatl&#305;l&#305;kta
bozukluk, uygunsuz cevab&#305; bask&#305;layamama, perseverasyonlar gibi
bulgular&nbsp;saptan&#305;r.&nbsp; Grsel-mekansal i&#351;levler ve PA
e&#351;lik etmiyorsa dilsel i&#351;levler korunmu&#351;tur.&nbsp; Yak&#305;n
bellek testlerinde kay&#305;t ve serbest hat&#305;rlamada glklere
kar&#351;&#305;n tan&#305;man&#305;n korundu&#287;u grlr.&nbsp; Bu hastalarda
limbik sistem salim, dolay&#305;s&#305;yla uzun sreli bellek
kay&#305;tlar&#305; mmkn, ancak prefrontal ar&#351;ivleyici sistem bozuk
oldu&#287;undan bu kay&#305;tlara kendili&#287;inden etkin bir biimde
ula&#351;mak g olmaktad&#305;r.&nbsp; Bazen ekstrapiramidal motor bulgular
asimetrik veya aksiyel bask&#305;n, asimetrik apraksi, ALS
varl&#305;&#287;&#305; durumunda 1. ve 2. motor nron bulgular&#305; (el
intrensek kaslar&#305;nda atrofi, bulber zaaf, fasiklasyonlar, piramidal
bulgular) saptanabilir. ok nadiren inklzyon cisimci&#287;i miyoziti ve Paget
hastal&#305;&#287;&#305; (IBM/Paget) bulgular&#305; saptanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MRGde simetrik veya asimetrik, frontal loblara
s&#305;n&#305;rl&#305; veya birlikte anterior temporal loblar&#305; da ieren
atrofi saptan&#305;r. RTV-SDde, klasik SDnin tam tersine sa&#287;da
bask&#305;n temporopolar atrofi izlenir. Asimetrik parkinsonizm e&#351;lik
etti&#287;inde parkinsonizmin kontrlateralindeki hemisferde bask&#305;n
asimetrik fronto-parietal atrofi daha muhtemeldir. SD ve RTV-SDde MRG
zellikle koronal T1 kesitler ierdi&#287;inde hemen daima tek ba&#351;&#305;na
yeterli olurken, izole PDB ve asimetrik parkinsonizmli PDB bazen MRG ile
ay&#305;rt edilemeyebilir. Byle durumlarda SPECT veya PET ile izole PDBde
frontal loblara s&#305;n&#305;rl&#305;, parkinsonizm durumunda asimetrik
fronto-parietal perfzyon ya da metabolizma azalmas&#305;n&#305; gstermek
yararl&#305; olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Bu klinik tablonun alt&#305;nda en s&#305;k
rastlan&#305;lan nropatoloji e&#351;it oranlarda denebilecek &#351;ekilde
taupati ve TDP-43 proteinopatidir. ALS ve SD e&#351;li&#287;i hemen daima
TDP-43 ile ili&#351;kiliyken PNFA veya parkinsonizm e&#351;li&#287;i hemen
daima taupati ili&#351;kilidir. Saf davran&#305;&#351;sal varyant&#305;n geriye
kalan %10luk bir hasta grubunda ubikutinize protein yak&#305;n zamanlara kadar
tan&#305;mlanamam&#305;&#351;t&#305; ve atipik ubikuitin pozitif FTLD
(aFTLD-U), aksonal sferoidli nronal orta boy (intermediate) filaman
hastal&#305;&#287;&#305; (NIFID) ve bazofilik inklzyon cisimci&#287;i
hastal&#305;&#287;&#305; (BIBD) olarak e ayr&#305;lmaktayd&#305;. Bu
tan&#305;mlanamayan proteinin de yak&#305;n tarihlerde fused in sarkoma (FUS)
proteini oldu&#287;u bulundu. Davran&#305;&#351;sal varyant&#305;n &#351;imdiye
kadar AH patolojisiyle ili&#351;kisi bildirilmemi&#351;tir.&nbsp;&nbsp;H&#305;zl&#305;
seyirli biimleri, CJH ve FTD-ALS akla getirmelidir.&nbsp; Ailevi taupatiler
17. kromozomda kodlanan tau proteini genindeki (<i>17q21 MAPT</i>) mutasyonlar
sonucuyken, ailevi TDP-43 proteinopatileri (s&#305;kl&#305;kla parkinsonizmli
davran&#305;&#351;sal varyant &#351;eklinde sunulurlar) yine 17. kromozomda
kodlanan progranulin proteini genindeki (<i>17q24 PGRN</i>) mutasyonlarla
ili&#351;kilidir. FTD-ALS, 9. kromozomda p21 lokusundaki henz bilinmeyen bir
gendeki ve 3. kromozomda kodlanan kromatin modifiye edici protein genindeki (<i>3p
CHMP2B</i>) mutasyonlarla ili&#351;kilidir. Nihayet, IBM/Paget ve dvFTLD 9.
kromozomda kodlanan valozin ieren protein genindeki (<i>9p13 VCP</i>)
mutasyonlar sonucu geli&#351;ir. 16. kromozomda kodlanan FUS ve 1. kromozomda
kodlanan TDP-43 gen mutasyonlar&#305;n&#305;n (<i>TARDP</i>)
a&#287;&#305;rl&#305;kla saf ailevi ALSye neden olduklar&#305;
gsterilmi&#351;tir (FALS). Sadece bir <i>TARDP</i> mutasyonlu olgu ALS
olmaks&#305;z&#305;n PDB fenotipine e&#351;lik eden vertikal bak&#305;&#351;
paralizisi ve koreyle sunulmu&#351;tur. <i>FUS </i>mutasyonlu bir olguda ise
FTD-ALS fenotipi bildirilmi&#351;tir</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Progresif Apraksi</span></i><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>S&#305;kl&#305;kla asimetrik olarak tek bir
ekstremiteye ait ilerleyici beceriksizlik, sakarl&#305;k bu tablonun temel
zelli&#287;idir.&nbsp; 65 ya&#351;&#305;n alt&#305;nda pre-senil
ba&#351;lang&#305; daha mutadd&#305;r.&nbsp; Hasta elini eskisi gibi
kullanamad&#305;&#287;&#305;ndan, eline ald&#305;&#287;&#305; nesneleri
d&#351;rebildi&#287;inden yak&#305;nmaktad&#305;r.&nbsp;
atal-ka&#351;&#305;k kullanmak, d&#287;me iliklemek gibi iki elin
koordinasyonunu gerektiren eylemler gle&#351;mi&#351;tir.&nbsp; Dominan el
apraktik oldu&#287;unda do&#287;al olarak zorluklar daha da artmaktad&#305;r:
yaz&#305; yazmak, alet kullanmak ncelikle bozulanlard&#305;r.&nbsp; Aksiyel kaslar
kat&#305;ld&#305;&#287;&#305;nda yatma, oturma, yrme ve giyinme gibi
eylemlerin, beden eksenini nesnelere gre ayarlayamamaktan kaynaklanan
bozukluklar&#305; ortaya &#305;kar. Yatakta dnmek
zorla&#351;m&#305;&#351;t&#305;r.&nbsp; Hasta koltu&#287;a i&#287;reti,
d&#351;ecekmi&#351; gibi oturur. Yry&#351; s&#305;ras&#305;nda dz yoldaki
basamak, tmsek gibi dzensizliklere ad&#305;mlar&#305;n&#305;
ayarlayamaz.&nbsp; D&#351;ebilir ya da basamaklar&#305; iki&#351;er, er
ad&#305;mlayabilir.&nbsp; Kap&#305;lara, engellere arpabilir. Giyinmek
gle&#351;mi&#351;tir.&nbsp; Ters dnm&#351; bir giysiyi dzeltemez,
kollar&#305;n&#305; bulmakta, d&#287;melerini iliklemekte&nbsp; glk
eker.&nbsp; &#304;lerlemi&#351; olgularda apraktik el yabanc&#305; el
sendromunda oldu&#287;u gibi tmyle denetimden &#305;kabilir.&nbsp;
&#304;leri a&#351;amadaki bir ba&#351;ka grnmde tutulan elin srekli bir
distonik postrde kullan&#305;&#351;s&#305;z el durumuna gelmesidir. Bu tablo
saf&nbsp; ilerleyici bir tarzda seyredebilece&#287;i gibi, daha s&#305;kl&#305;kla
ki&#351;ilik de&#287;i&#351;ikli&#287;i, depresyon ve PNFA tablonun bir
paras&#305; olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Muayenede genellikle asimetrik taraf apraksisi ve
gvde apraksisi tek ba&#351;&#305;na ya da tutuk afazi, yrtc bozukluk ve
bazen de grsel-mekansal bozukluk bulgular&#305;yla birliktedir.&nbsp; Bellek
greli olarak korunmu&#351; veya dikkate sekonder olarak
bozulmu&#351;tur.&nbsp; Ekstrapiramidal sistem tutulumunu i&#351;aretleyen
motor bulgular da s&#305;kl&#305;kla apraktik taraftad&#305;r.&nbsp; Bazen iki
nokta ayr&#305;m&#305;nda bozukluk, agrafestezi, astereognozi gibi kortikal
duyu kusurlar&#305; da mevcuttur. Bu tabloya kotikobazal sendrom (KBS)
ad&#305; da verilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Grntleme al&#305;&#351;malar&#305;nda
fronto-parietal, s&#305;kl&#305;kla asimetrik bir atrofi ve/veya
hipoperfzyon-hipometabolizma saptan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu klinik tablo, tipik &#351;ekliyle kortiko-basal
dejenerasyonun (KBD) en iyi bilinen klinik sendromudur.&nbsp;
A&#287;&#305;rl&#305;k aksiyel tutulumda oldu&#287;unda bazen progresif
suprankleer paralizi (PSP) de byle bir tablonun nedeni olabilir.&nbsp;
Sporadik olgular byk lde KBD tarz&#305; bir taupati olmakla birlikte
ailevi olgular Kr-17 <i>PGRN </i>mutasyonu ile ili&#351;kili TDP-43
proteinopatisi sonucu olabilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Andrew Kertesz davran&#305;&#351;sal,
dilsel ve motor varyantlardan biriyle ba&#351;layan ve s&#305;kl&#305;kla zaman
iinde n planda olan zelli&#287;e di&#287;erlerinin de eklenmesiyle ilerleyen
bu tablolar&#305;n tmn iermek zere Pick Kompleksi kavram&#305;n&#305;
nermi&#351;tir. </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 3: </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ekirdek Nropsikolojik
Profillerin Ay&#305;r&#305;c&#305; Tan&#305;s&#305;<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.25pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=140 valign=top style='width:104.65pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 0cm 0cm 0cm'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>ekirdek Progresif Sendrom</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 0cm 0cm 0cm'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amnezi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=297 colspan=3 valign=top style='width:222.6pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 0cm 0cm 0cm'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Afazi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Agnozi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
  text-align:center;layout-grid-mode:char'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Apraksi</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Ana semptom</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Unutkanl&#305;k</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kelime bulma, konu&#351;ma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kelime anlam&#305;n&#305;n kayb&#305;, me&#351;hur yzlerin
  tan&#305;namamas&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kelime bulma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Apati, disinhibisyon</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Yn bulma, gznn nndeki nesneleri ay&#305;rt edememe</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sakarl&#305;k</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Kognitif tarz</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Bozuk tan&#305;ma belle&#287;i, semantik ak&#305;c&#305;l&#305;k</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Agramatizm, anomi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Anomi, grsel agnozi, prosopagnozi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Anomi, akalkuli</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Yrtc</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Simultanagnozi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Apraksi, yrtc</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Nrolojik muayene</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal, bazen asimetrik parkinsonizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal, bazen parkinsonizm/ALS</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Normal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik parkinsonizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>MRG</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Hippokampal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol peri-sylvien geni&#351;leme</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik anterior temporal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol parietal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Frontal, fronto-temporal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Simetrik dorsal parietal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik fronto-parietal atrofi</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Anatomik yatk&#305;nl&#305;k </span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Limbik</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Anterior peri-sylvien</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol temporo-polar</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Sol inferiyor parietal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Prefrontal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Bilateral oksipito-parietal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Asimetrik fronto-parietal, basal ganglia</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Hastal&#305;k</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Alzheimer </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>FTLD-PNFA</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>FTLD-SD</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Logopenik PA (Atipik AH)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>FTLD-dv (KBD, PSP, ALS)</span><span lang=DE style='font-family:Tahoma;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Posterior kortikal atrofi (Atipik AH, LCD, CJH)</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>KBD</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Nropatoloji</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>AP, NFY</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>T+NI, GCI, </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Ub+/T- DN</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>NFY (?)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>T+NI, Ub+/T-&nbsp; NCI, NII, DN, Ub+T-TDP- NCI</span><span lang=FR
  style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>AP, NFY, DLDH, PrP+, LC</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>GCI</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:29.85pt'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Proteinopati</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#946;-Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>TDP-43</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#946;-Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Tau, TDP-43 veya FUS</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>A&#946;-Tau, &#945;-SN, PrP<sup>Sc</sup></span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:29.85pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Tau</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;mso-yfti-lastrow:yes'>
  <td width=140 valign=top style='width:104.65pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>Genetik</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>PS1, PS2, APP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>MAPT, PGRN, CHMP2B, VCP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>?</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=85 valign=top style='width:63.75pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>?</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>MAPT, PGRN, CHMP2B, VCP, </span></i><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>9p, <i>TARDP, FUS</i></span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>?, PRNP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;layout-grid-mode:
  char'><i><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>MAPT, PGRN, CHMP2B, VCP</span></i><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar: </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#946;:
amiloid beta protein fragman&#305;; AH: Alzheimer hastal&#305;&#287;&#305;;
ALS: amiyotrofik lateral skleroz; AP: amiloid plak; APP: amiloid prekrsr
protein geni;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CHMP2B: kromatin modifiye edici protein 2B geni; CJH: Creutzfeldt-Jacob
hastal&#305;&#287;&#305;; dv: davran&#305;&#351;sal varyant; DN: distrofik
nritler; FTLD: &nbsp;&nbsp; fronto-temporolobar dejenerasyon;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FUS: fused in sarkoma;
GCI: glial sitoplazmik inklzyon; KBD: kortiko-basal dejenerasyon; LCD: Lewy
cisimcikli demans; MAPT: mikrotbl asosiye tau geni; NCI: nronal sitoplazmik
inklzyonlar; NII: nronal intrankleer inklzyonlar; NFY: nro-fibriller
yumak; NI: nronal inklzyon; PGRN: progranulin geni; PNFA: ilerleyici tutuk
afazi; PRNP: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prion proteini geni;
PrP: prion proteini; PS1: presenilin 1 proteini geni; PS2: presenilin 2
proteini geni; PSP: progresif suprankleer paralizi; T: tau proteini; TARDP:
TDP-&nbsp;&nbsp; 43 geni; Ub: ubikutin proteini; VCP: valosin ieren protein
geni<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demansta Davran&#305;&#351;sal zellikler</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunun kognitif veya motor olmayan ve
semiyolojik olarak genel psikiyatrinin alan&#305;na giren semptomatolojisini
adland&#305;rma konusunda ya&#351;l&#305;l&#305;k ve demans alan&#305;nda
terminolojik bir glk izlenmektedir.&nbsp; Baz&#305; yazarlar demans&#305;n
non-kognitif belirtileri tan&#305;m&#305;n&#305; tercih etseler de kognitif
olmayan zellikler yaln&#305;zca psikopatoloijk de&#287;il ayn&#305; zamanda da
motor, otonom ve uyku bozukluklar&#305;n&#305; da kapsad&#305;&#287;&#305; iin
bu terim kast&#305;n&#305; a&#351;maktad&#305;r.&nbsp; Daha fazla
rastlan&#305;lan terim demans&#305;n davran&#305;&#351;sal zellikleri &#351;eklindedir.&nbsp;
Bu blmde de szkonusu terim tercih edilmi&#351; olmakla birlikte, bu
literatrle bir uzla&#351;&#305;m ihtiyac&#305; gere&#287;idir.&nbsp;
Davran&#305;&#351;sal terimi genel psikolojide insan
davran&#305;&#351;&#305;n&#305;n gzlenebilir zelliklerini
kar&#351;&#305;lamak zere kullan&#305;l&#305;r ve do&#287;al olarak alg&#305;lama
ve d&#351;nce srelerine ili&#351;kin isel ya&#351;ant&#305;lamalar&#305;
d&#305;&#351;ta b&#305;rak&#305;r.&nbsp; Oysa ki bizim
kullan&#305;m&#305;m&#305;zda demans&#305;n davran&#305;&#351;sal zellikleri
gzlenebilir davran&#305;&#351;sal bozukluklar&#305;n yan&#305;s&#305;ra
duygudurum, alg&#305; ve d&#351;nce bozukluklar&#305;n&#305; da ierecek
&#351;ekildedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Duygudurum bozukluklar&#305;</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> anksiyete, depresyon,
mani, fobiler gibi majr bozukluklar ve bunlara e&#351;lik edebildikleri gibi
yaln&#305;z ba&#351;&#305;na da grlebilen emosyonel labilite, iritabilite,
disfori, fori, ajitasyon gibi duygudurum halleridir.&nbsp; &#304;lgili blmde
daha ayr&#305;nt&#305;l&#305; sz edilece&#287;i gibi demans sendromu
tan&#305;s&#305; konulmadan 10 y&#305;l kadar nceye giden depresyon AH iin
ba&#351;l&#305; ba&#351;&#305;na bir risk faktrdr.&nbsp; Depresyon AHde
s&#305;kl&#305;kla erken evrede grlr.&nbsp; Depresyon kaybolmakta olan
zihinsel yeteneklere kar&#351;&#305; psi&#351;ik reaksiyon olarak ortaya
&#305;kabilece&#287;i gibi depresif ve depresif olmayan AHli olgular&#305;n
otopsilerinin kar&#351;&#305;la&#351;t&#305;r&#305;lmas&#305;n&#305;n
gsterdi&#287;i zere nrotransmitter kay&#305;plar&#305;na ikincil biyolojik
nedenli de olabilir.&nbsp; An&#305;lan al&#305;&#351;malarda depresif
olgular&#305;n beyinsap&#305;nda noradrenerjik locus ceruleus, serotonerjik
dorsal raphe ve dopaminerjik substantia nigra ve ventral tegmental Tsai
ekirdeklerinde depresif olmayan olgulara k&#305;yasla nron kayb&#305;n&#305;n
anlaml&#305; dzeyde fazla oldu&#287;u grlm&#351;tr.&nbsp; Gen depresif
hastalardaki keder, lm d&#351;nceleri, sululuk ve de&#287;ersizlik
hisleri, karamsarl&#305;k ile karakterize afektif, isteksizlik, hevessizlik,
kendili&#287;indenlikte azalma, sosyal ekilme ile karakterize motivasyonel
bile&#351;enleri demansl&#305; hastalarda al&#305;&#351;agelen biimde
ay&#305;rt etmek her zaman kolay olmayabilir.&nbsp; Bazen motivasyonel
zellikler affektif olanlar&#305; glgeleyip depresyon tan&#305;s&#305;n&#305;
geciktirebilece&#287;i gibi kendine zg nral alt yap&#305;s&#305; ile
demanslar&#305;n apati spektrumunda apayr&#305; bir davran&#305;&#351;sal
gsterisi olabilen motivasyonel bozukluklar depresyonla
kar&#305;&#351;t&#305;r&#305;labilir.&nbsp; Saf <i>motivasyonel bozukluklar </i>AHde
orta-ileri evrelerde grlrken FTDnin erken dneminin ba&#351;l&#305;ca
zelliklerindendir.&nbsp; &#304;nsomni ve gndz uyuklamalar&#305;
&#351;eklindeki diurnal ritm bozukluklar&#305; AHde erken evrelerden itibaren
depresyon erevesinde veya izole olarak grlebilir ve performans
bozuklu&#287;una ciddi katk&#305;da bulunabilir.&nbsp; Anksiyete
&nbsp;depresyon erevesinde izlenebilece&#287;i gibi AHde orta evreden
itibaren primer olarak da grlr.&nbsp; Kognitif bozukluk artt&#305;ka
&#351;iddeti de artar.&nbsp; Genellikle huzursuzlukla birlikte amas&#305;z
dolanma, bulunulan mekan&#305; terketme iste&#287;iyle birlikte grlr.&nbsp;
fori, iritabilite gibi duygudurum halleri yine orta evreden itibaren
bask&#305;n hale gelir.&nbsp; Bazen uykusuzluk, grandiozite,
sald&#305;rganl&#305;k e&#351;li&#287;i ile a&#351;ikar bir mani halini
alabilir.&nbsp; Ajitasyon terimi iritabilite ve genellikle verbal ve fiziksel
&#351;iddet gsterilerinin eklenebildi&#287;i
sald&#305;rganl&#305;&#287;&#305;n e&#351;lik etti&#287;i mani benzeri tablolar
iin kullan&#305;l&#305;r.&nbsp; AHde fobiler yine orta evrenin zellikleri
aras&#305;ndad&#305;r.&nbsp; Yaln&#305;z kalma/b&#305;rak&#305;lma, banyo gibi
temalar ierebilir.&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hezeyanlar AHde duygudurum bozukluklar&#305;ndan
sonra 2. s&#305;kl&#305;kta gzlenen <i>d&#351;nce bozukluklar&#305;</i>na
ili&#351;kin gsterilerdir.&nbsp; Hezeyanlar da AHde orta evrenin
zelliklerindendir.&nbsp; Buna kar&#351;&#305;l&#305;k LCDde destekleyici
tan&#305; kriterleri aras&#305;nda yeralmalar&#305;ndan
anla&#351;&#305;laca&#287;&#305; gibi ilk evrede grlmeleri
mutadd&#305;r.&nbsp; Daha nce de szedildi&#287;i gibi
h&#305;rs&#305;zl&#305;k hezeyan&#305; en s&#305;kt&#305;r.&nbsp; Bununla birlikte
e&#351;in sadakatsizli&#287;i, kendisine ktlk yap&#305;laca&#287;&#305;,
misidentifikasyon/Capgras, terkedilme hezeyanlar&#305; da izlenir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Halsinasyonlar <i>alg&#305; bozukluklar&#305;</i>na
ili&#351;kin gsterilerdir.&nbsp; AHde yine orta evreden itibaren
grlrler.&nbsp; &#350;izofrenide en s&#305;k i&#351;itsel halsinasyonlar
kaydedilirken, demans sendromlar&#305;nda grsel halsinasyonlar daha
s&#305;kt&#305;r, i&#351;itsel modalite onu izler.&nbsp; Olfaktor, gustatuar ve
taktil halsinasyonlar da izlenebilir.&nbsp; LCDde ise grsel halsinasyonlar
temel tan&#305; kriterleri, di&#287;er modalitelerdeki halsinasyonlar ise
destekleyici zellikler aras&#305;nda yeral&#305;r.&nbsp;
Dolay&#305;s&#305;yla, LCDde hem erken evrenin zelliklerindendirler, hem de
AHye gre ok daha s&#305;k grlrler.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ki&#351;ilik de&#287;i&#351;ikli&#287;i</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> yukarda szedilen
motivasyonel bozukluk spektrumunda apati &#351;eklinde grlebilece&#287;i gibi
hiperseksalite ve oburluk tarz&#305; drt kontrol bozukluklar&#305;
&#351;eklinde de grlebilir.&nbsp; FTDde klinik tablonun temel
zelli&#287;ini olu&#351;turan ki&#351;ilik de&#287;i&#351;ikli&#287;i, bu iki
utan biri ya da di&#287;erinin izole olarak ortaya &#305;kmas&#305;
&#351;eklinde grlebilece&#287;i gibi s&#305;kl&#305;kla birinin bask&#305;n
oldu&#287;u her ikisinden de zellikler ta&#351;&#305;yan tablolar
&#351;eklinde izlenirler.&nbsp; AHde drt kontrol bozukluklar&#305; apatiye
k&#305;yasla daha seyrektir.&nbsp; Hiperseksalitenin de oburlu&#287;a
k&#305;yasla daha seyrek oldu&#287;u sylenebilir. LCD/PHDde drt kontrol
kusurlar&#305; dopaminerjik replasman tedavisinin (DRT) bir komplikasyonu
olarak dopamin disreglasyon sendromu (DDS) erevesinde grlr. Patolojik
kumar DDSin bir paras&#305; olarak veya izole &#351;ekilde bir drt kontrol
kusuru olarak ortaya &#305;kabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gzlenebilir <i>davran&#305;&#351;sal bozukluklar</i>
AHnin orta-ileri evrelerinin zellikleridir.&nbsp; Amas&#305;z
ad&#305;mlama/dolanma &#351;eklinde hiperaktivite en s&#305;k grlendir.&nbsp;
Amas&#305;z tekrarlay&#305;c&#305; hareketler de s&#305;k izlenir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans E&#351;likisi Motor ve Di&#287;er Bulgular</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> temel alan&#305;n yan&#305;s&#305;ra, motor
belirtiler de baz&#305; demanslar&#305;n ana bile&#351;enlerinden
olabilirler.&nbsp; Yukar&#305;da szedildi&#287;i gibi, motor bulgularla
birilikte olan demanslar, demans s&#305;n&#305;flamas&#305;n&#305;n temel
kategorilerindendir.&nbsp; Bu tr demanslar&#305;n klinik tablosunda motor
bulgular, s&#305;kl&#305;kla demansa gre daha a&#287;&#305;rl&#305;kl&#305; ya
da e&#351;de&#287;er nitelikte olurlar.&nbsp; Motor bulgular
a&#287;&#305;rl&#305;kla ekstrapiramidal sisteme ait hipokinetik bir hareket
bozuklu&#287;u zelli&#287;i gsterirler: bradikinezi, rijidite, parkinsonyen
yry&#351;, postral denge bozuklu&#287;u.&nbsp; multi-sistem atrofilerde
(MSAlar), zellikle de parkinsonyen formunda (MSA-P), simetrik akinetik-rijid
sendrom, a&#287;&#305;rl&#305;k ve zamanlama olarak demans&#305;n nndedir;
serebellar ve otonom bulgular e&#351;lik edebilir.&nbsp;&nbsp; Kortiko-basal
ganglionik dejenerasyonda (KBD) belirgin bir asimetrik akinezi sz
konusudur.&nbsp; Akinetik taraf s&#305;kl&#305;kla apraksiden, a&#287;&#305;r
distoni ve yabanc&#305; el fenomenine kadar de&#287;i&#351;en zellikler
gsterir ve ayn&#305; tarafta kortikal duyu kusuru saptanabilir.&nbsp; KBD
bazen demans, bazen de hareket bozuklu&#287;u &#351;eklinde ba&#351;layabilir.&nbsp;&nbsp;
Motor nron hastal&#305;&#287;&#305;na (MNH) bazen FTD &#351;eklinde ve
h&#305;zl&#305; seyirli bir demans da e&#351;lik edebilir (FTD-MNH).&nbsp; Bu
durumda, MNHye zg intrensek el kaslar&#305;nda atrofi, hafif yutma
gl&#287; &#351;eklinde bulgular demans&#305;n gerisinde gizlenebilir.&nbsp;
NPHda yrme gl&#287; ve sfinkter kusuru demansla
e&#351;zamanl&#305;d&#305;r.&nbsp; Binswanger sendromunda yine NPHya ok
benzer bir triad (demans, yrme gl&#287;, sfinkter kusuru) grlr.&nbsp;
Buradaki yrme gl&#287; alt beden yar&#305;s&#305; parkinsonizmi ya da
vaskler parkinsonizm ad&#305; verilen &#351;eklindedir ve derin kk
infarktlara ba&#287;l&#305;d&#305;r.&nbsp; Gerek parkinsonizm ve gerekse de
sfinkter kusuru AHye hastal&#305;&#287;&#305;n ileri evrelerinden itibaren
kat&#305;l&#305;r.&nbsp; Multi-infarkt demansta hemiparezi sekelleri, grme
alan&#305; kusurlar&#305; saptanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans sendromunda motor bulgular&#305;n
varl&#305;&#287;&#305; byk s&#305;kl&#305;kla subkortikal i&#351;lev
bozuklu&#287;unu i&#351;aret eder. Bu i&#351;lev bozuklu&#287;unun nedeni
subkortikal gri (lakner durum) ya da beyaz madde (Binswanger
Hastal&#305;&#287;&#305;, CADASIL) yap&#305;lar&#305;nda ok say&#305;da
iskemik vaskler hasar sonucu olabilece&#287;i gibi do&#287;rudan bazal
ganglia-serebellum sistemlerinin nrodejenerasyonu sonucu da olabilir.&nbsp;
Gerekten de, primer&nbsp; (nrodejeneratif) demanslar motor bulgularla
birlikte oldu&#287;unda bir ka istisna d&#305;&#351;&#305;nda bu bulgular
hemen daima&nbsp; bir ekstrapiramidal sendrom (EPS) niteli&#287;ini
ta&#351;&#305;r.&nbsp; MSAn&#305;n serebellar formunda (MSA-C), ba&#351;ta
gvde ve ekstremite ataksisi ve dizartri olmak zere serebellar bulgular
a&#287;&#305;rl&#305;kl&#305; bulgulard&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Daha nce de de&#287;inildi&#287;i gibi, patolojik
de&#287;i&#351;ikli&#287;in kortikal ya da subkortikal
a&#287;&#305;rl&#305;&#287;&#305;na gre tabloda motor bulgular kognitif
bulgulara gre, geri ya da n planda, bazen de e&#351;it dzeyde olurlar.&nbsp;
Baz&#305; hastal&#305;klar bu a&#287;&#305;rl&#305;k a&#305;s&#305;ndan
uniform nitelikte olurlarken (rne&#287;in, AH, PSP, Huntington), di&#287;er
baz&#305; hastal&#305;klar&#305;n kendi iinde, dejenerasyonun
yatk&#305;nl&#305;&#287;&#305; bazen kortikal, bazen ise subkortikal ynde
bozulabilir (rne&#287;in, LCD, KBD).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>DEMANS TANISINDA YARDIMCI LABORATUAR
YNTEMLER&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tan&#305; ve ay&#305;r&#305;c&#305; tan&#305;da
kognitif, davran&#305;&#351;sal ve i&#351;levsel alanlar&#305; sorgulayan titiz
al&#305;nm&#305;&#351; bir yknn yan&#305;s&#305;ra mental durum muayenesi ve
zellikle fokal bulgular, yry&#351; bozukluklar&#305; ve ekstrapiramidal
bulgulara dikkat edilecek nrolojik muayeneden olu&#351;an klinik yntem esas
olmakla birlikte, asgari dzeyde laboratuar incelemeleri de
duyarl&#305;l&#305;&#287;&#305; artt&#305;racakt&#305;r.&nbsp; Amerikan
Nroloji Akademisinin (AAN) 1995te yay&#305;nlad&#305;&#287;&#305; Uygulama
Elkitab&#305;n&#305;n Demans Tan&#305; ve De&#287;erlendirmesi<sup> </sup>blmnde
a&#351;a&#287;&#305;daki biyokimyasal testlerin rutin olarak
yap&#305;lmas&#305; gerekti&#287;i sylenir: tam kan say&#305;m&#305;,
elektrolitler, kalsiyum, glukoz, BUN/kreatinin, karaci&#287;er testleri, tiroid
testleri, serum B12 vitamin dzeyi ve sifilis serolojisi.&nbsp;
Klini&#287;imizdeki rutin uygulamada sifilis serolojisine de ihtiyari olarak
ba&#351;vurulmaktad&#305;r <b>(Tablo 4</b>).&nbsp; Elkitab&#305;nda di&#287;er
biyokimyasal testler, grntleme (BT/MRG), nropsikolojik muayene, EEG ve
lomber ponksiyon gibi inceleme yntemlerinin, rutin d&#305;&#351;&#305;nda
kalan zel durumlarda yap&#305;labilece&#287;i belirtilmektedir.&nbsp; BT ya da
MRGnin, klinik de&#287;erlendirme tecrbeli bir klinisyen elinde
yap&#305;ld&#305;&#287;&#305;nda veya hasta tipik olarak 60
ya&#351;&#305;n&#305;n zerinde, sinsi ba&#351;lang&#305;l&#305;, fokal bulgular,
nbetler ya da yry&#351; bozukluklar&#305;&nbsp;gstermeyen bir demans
tablosu sergiledi&#287;inde nadiren gerekece&#287;i kaydedilir.&nbsp; Yine de,
ok erken olgularda al&#305;&#351;k&#305;n bir gz MRGnin koronal T1
kesitlerinde grd&#287; hippokampal atrofiyle klinik olarak arada
kald&#305;&#287;&#305; bir olguda DAT/PRAD karar&#305; verebilir. Yukarda
ekirdek Nropsikolojik Sendromlar blmnde de&#287;inilen ve
a&#351;a&#287;&#305;da Alzheimer D&#305;&#351;&#305; Demanslar blmnde daha
ayr&#305;nt&#305;l&#305; gzden geirilecek olan zgl atrofi tarzlar&#305;n&#305;n
saptanmas&#305; Alzheimer d&#305;&#351;&#305; demanslar&#305;n
tan&#305;s&#305;nda de&#287;erli olabilir. ykde bir ya da daha fazla lober
hematomla birlikte MRGde gradyan eko tekni&#287;iyle saptanan mikro-kanamalar
demans&#305; serebral amiloid anjiyopatiyle (CAA) ili&#351;kilendirebilir.
Yine, h&#305;zl&#305; seyirli bir demansta ba&#351;ta difzyon
a&#287;&#305;rl&#305;kl&#305; grntlemede (DWI) olmak zere FLAIRde de
grlebilen kortikal ve bazal ganglionik-talamik yksek sinyal CJHyi
i&#351;aretleyebilir. Ancak, s&#305;kl&#305;kla rutin bir MRG taramas&#305;na
dahil edilmedikleri iin atrofi de&#287;erlendirilmek istendi&#287;inde koronal
T1 kesitlerin, CAA veya CJHdan ku&#351;kulan&#305;ld&#305;&#287;&#305;nda
gradyan eko veya DWI teknikli incelemelerin dahil edilmesi radyoloji
laboratuar&#305;ndan zel olarak talep edilmelidir. Nropsikolojik muayene
temel olarak erken demans&#305; de&#287;erlendirmekte, demans ve depresyonu
ay&#305;rmakta, hukuki ehliyetin dokmantasyonunda yararl&#305;
olacakt&#305;r.&nbsp; EEGye, nbetlerin varl&#305;&#287;&#305;nda,
Creutzfeldt-Jacob hastal&#305;&#287;&#305; ku&#351;kusunda
ba&#351;vurulabilir.&nbsp; Lomber ponksiyon, metastatik kanser, MSS infeksiyonu
ku&#351;kusu, reaktif sifilis serolojisi, hidrosefali, gen demans,
h&#305;zl&#305; seyirli ve atipik demans, immunosupresyon ve MSS vaskliti
ku&#351;kusu durumlar&#305;nda rutin olarak yap&#305;lmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Rutin ve tek olgu incelemesi
d&#305;&#351;&#305;nda kalan, zellikle AHde ara&#351;t&#305;rma amal&#305;
bir dizi yntemden de szedilebilir.&nbsp; MRG-volmetri ile hippokampus, entorhinal
korteks ve superior temporal sulkus volmetrisi yntemi, zellikle normal
ya&#351;lanma-MCI-AH devaml&#305;l&#305;&#287;&#305;n&#305;n
ayr&#305;m&#305;nda giderek rafine edilmektedir <b>(&#350;ekil 1</b>).&nbsp;
MR-Spektroskopi (MRS) yntemi ile bir nronal i&#351;aretleyici olan N-asetil
aspartat miktar&#305;nda meziyal temporal blgelerden yap&#305;lan
lmlerde&nbsp; saptanan azalman&#305;n yine hippokampal volm ile korele
etti&#287;i gsterilmi&#351;tir.&nbsp; MRS ile NAA/Cr dzeyleri nron
kayb&#305;yla karakterize olan AH, FTLD ve VaD gibi demanslarda d&#351;er.
MI/Cr dzeyleri ise AH ve FTLD gibi gliozis ile karakterize demanslarda
ykselir. Nihayet, Cho/Cr dzeyleri AH ve LCD gibi a&#287;&#305;r kolinerjik
kay&#305;p ile karakterize demanslarda ykselir. &#304;&#351;aretli glukoz
kullanan klasik FDG-PET ile pariyeto-temporal hipometabolizma, SPECT ile
ayn&#305; blgelerde hipoperfzyon bulgular&#305;n&#305;n AHde
duyarl&#305;l&#305;&#287;&#305; yksek olsa da yeterince zgl
de&#287;ildirler.&nbsp; FDG-PET ile posterior singulat
hipometabolizmas&#305;n&#305;n AHnin en erken bulgular&#305;yla korele
etti&#287;ine ili&#351;kin bildirimler mevcuttur.&nbsp; Yeni geli&#351;mekte
olan PET-amiloid grntlemenin potansiyeline daha nce PAD blmnde
de&#287;inilmi&#351;ti. BOSta baz&#305; A&#946; fragmanlar&#305; dzeylerinde
azalma, yine total ve fosfo-tau proteini dzeyinde artma mit vaadeden
laboratuar yntemleri aras&#305;nda ayn&#305; blmde sz edilmi&#351;ti.&nbsp;
Genetik inceleme ile AHde bir risk faktr olan APO-E e4 alellerinin
saptanmas&#305; art&#305;k atipik olgularda d&#351;nlebilir.&nbsp;Familyal
gibi duran olgularda genetik analizin yarar&#305; a&#351;ikard&#305;r. Kognitif
elektrofizyoloji zel olarak tasarlanm&#305;&#351; ve analiz edilmi&#351; olaya
ili&#351;kin potansiyeller (O&#304;P) biiminde AHnin erken dneminde
ay&#305;rt edici bir yntem olarak kullan&#305;m alan&#305; bulabilir.
Ba&#351;lang&#305;ta ucuz ve basit bir yntem olarak umut
vaadeden&nbsp;anti-kolinerjik damla (tropicamide) ile anormal pupiller cevab&#305;n
zgll&#287; kabul edilir bulunmam&#305;&#351;t&#305;r.&nbsp;<b>&nbsp;</b>Gnmzde
sadece ara&#351;t&#305;rmalara s&#305;n&#305;rl&#305; gibi grnen bu
yntemlerden baz&#305;lar&#305; gelecekte AH rutininde kullan&#305;labilecek
potansiyel biyo-i&#351;aretleyiciler aras&#305;ndad&#305;rlar. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a href="tablo4.JPG">Tablo 4.</a></span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Demans
tan&#305;s&#305;nda rutin laboratuvar</span><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'>&nbsp;</span></b><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
14.0pt;font-family:Tahoma;mso-ansi-language:TR'>ALZHEIMER HASTALI&#286;I</span></b><span
lang=FR style='font-family:Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=FR style='font-family:
Tahoma;mso-ansi-language:FR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Demans antik a&#287;lardan beri bilinen bir
hastal&#305;kt&#305;r.&nbsp; Ancak, Alzheimer hastal&#305;&#287;&#305;n&#305;n
(AH) ilk olgusu olma onuru bayan Auguste D.ye aittir. <span style='color:black'>Auguste
D 1850 May&#305;s&#305;nda do&#287;mu&#351;tu. 1890lar&#305;n sonlar&#305;na
do&#287;ru bellek ve dil bozukluklar&#305; &#351;eklinde tan&#305;mlanan demans
semptomlar&#305; geli&#351;tirmeye ba&#351;lad&#305;. K&#305;sa zamanda ciddi
psikotik zellikler ve ajitasyon eklendi ve Kas&#305;m 1901de, Alois Alzheimer
taraf&#305;ndan muayene edilece&#287;i Frankfurt Ak&#305;l Hastanesine
getirildi, 8 Nisan 1906da bu hastanede ld. Alzheimer 1902de Kraepelinin
daveti zerine nce Heidelberge gitmi&#351;, 1 y&#305;l sonra da yine
Kraepelin ile birlikte Mnihe gemi&#351;ti. Auguste D.nin lmn duyan
Alzheimer eski al&#305;&#351;ma arkada&#351;lar&#305;ndan klinik kay&#305;tlar&#305;n&#305;
ve beyin dokusunu rica etti. 3 Kas&#305;m 1906da, Tbingendeki Gneydo&#287;u
Alman Psikiyatri Derne&#287;inin 37. Toplant&#305;s&#305;nda Auguste D.nin
klinik ve nropatolojik bulgular&#305;n&#305; &quot;ber einen eigenartigen,
schweren Erkrankungsprozess der Hirnrinde&quot; isimli 11. bildiriyle sundu.
Hastan&#305;n ya&#351;&#305;n&#305;n gen olmas&#305; dolay&#305;s&#305;yla
hastal&#305;k bir pre-senil demans biimi olarak de&#287;erlendirilecektir.
Beynin nropatolojik incelemesinde serebral korteksin normale gre
incelmi&#351; oldu&#287;unu grd. Ayr&#305;ca, daha sonra amiloid plaklar
olarak adland&#305;r&#305;lacak miliyer odaklar&#305; ve yine daha sonra
nrofibriler yumaklar ad&#305;n&#305; alacak intraseller fibril
birikintilerini tan&#305;mlad&#305;. </span>Auguste D. ile ilk kez
tan&#305;mlanm&#305;&#351; olan klinik olarak demans ile nropatolojik olarak
NFY ve AP bugn hala AHnin ana diyagnostik triad&#305;n&#305;
olu&#351;turmaktad&#305;r.&nbsp;Hocas&#305; ve al&#305;&#351;ma
arkada&#351;&#305;, &#351;izofreninin de isim babas&#305; Emil Kraepelin <i>Psychiatrie:
Ein Lehrbuch fr Studierende und Aerzte </i>adl&#305; dneminin en nl ders
kitab&#305;n&#305;n 1913teki 8. bask&#305;s&#305;nda bu tr olgulara
Alzheimerin ad&#305;n&#305; verdi.&nbsp;Tuhaf olan bunca yayg&#305;n bir
hastal&#305;&#287;&#305;n Havva olgusu olarak adland&#305;r&#305;labilecek
olan ilk olgunun atipik bir olgu olmas&#305;d&#305;r.&nbsp; Gerek erken
ba&#351;lang&#305; ve gerekse de, asl&#305;nda erken
ba&#351;lang&#305;l&#305; AH olgular&#305;nda ayk&#305;r&#305; olmayacak
&#351;ekilde, davran&#305;&#351;sal belirtilerin n planda oldu&#287;u klinik
tablo ATDnin tipik tablosu de&#287;ildir.&nbsp; 1970ler ortalar&#305;na kadar
AHnin Pre-senil demanslar kategorisi alt&#305;nda PiHle birlikte nadir
hastal&#305;klardan biri olarak s&#305;n&#305;fland&#305;r&#305;lmas&#305;
byk lde bu nedenledir.&nbsp; Bir as&#305;rl&#305;k tarihinin son
eyre&#287;inde asl&#305;nda ok daha s&#305;k grlen ve kronik organik beyin
sendromu ya da serebral skleroz gibi adlar da verilen senil
demans&#305;n&nbsp;AH ile ayn&#305; patolojik de&#287;i&#351;iklikleri
payla&#351;an bir ve ayn&#305; antite oldu&#287;u
kavranm&#305;&#351;t&#305;r.&nbsp; Robert Katzman&#305;n 1976da senil demans
AHdir demesiyle AH tarihinin moderan a&#287;&#305;na geilmi&#351; olur.
Gnmzde, zellikle ortalama ya&#351;am beklentisinin giderek
artt&#305;&#287;&#305; geli&#351;mi&#351; lkelerde, henz etyolojisinin
ayd&#305;nlat&#305;lamam&#305;&#351; ve kesin tedavisinin bulunamam&#305;&#351;
olmas&#305; nedenleriyle de, en nde gelen morbidite ve mortalite nedenlerinden
biri olmaktad&#305;r. Alzheimer anahtar kelimesi ile Pub Medde bir
ara&#351;t&#305;rma yap&#305;larak son yar&#305;m yzy&#305;l&#305;n 10ar
y&#305;ll&#305;k dilimlerindeki yay&#305;n say&#305;s&#305;na
bak&#305;ld&#305;&#287;&#305;nda bulunan nerdeyse logaritmik art&#305;&#351;
ok arp&#305;c&#305;d&#305;r: 1960-69: 28, 1970-79: 327, 1980-89: 5464,
1990-99: 17328, 2000-09: 29738.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>KL&#304;N&#304;K TABLO<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tan&#305; Kriterleri</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yukar&#305;da yeri geldi&#287;ince
tart&#305;&#351;&#305;ld&#305;&#287;&#305; gibi ATD, merkezini limbik sistem
dejenerasyonuna ba&#287;l&#305; yak&#305;n bellek bozuklu&#287;unun
olu&#351;turdu&#287;u, sinsi ba&#351;lang&#305;l&#305;, yava&#351; seyirli bir
tempoyla neokortikal tutulumun da kat&#305;lmas&#305;yla di&#287;er kognitif
i&#351;levlerin de bozuldu&#287;u bir demans sendromudur (GYAlar&#305; bozan
sinsi ba&#351;lang&#305;, yava&#351; seyirli en az iki kognitif
bozukluk).&nbsp;Bu tan&#305;mdan anla&#351;&#305;laca&#287;&#305; gibi demans
AH nrodejenerasyonunun greli ge bir gsterisidir.&nbsp; AHnin klinik
tan&#305;s&#305; iin yay&#305;nlanm&#305;&#351; olan ve bugn yayg&#305;n
biimde kullan&#305;lan NINCDS-ADRDA (National Institute of Neurological and
Communicative&nbsp; Disorders and Stroke-Alzheimers Disease and Related Disorders
Association) ve DSM-IV (Diagnostic and Statistical Manual of Mental Disorders,
4th edition) kriterlerinin her ikisi de (<b>Tablo 5 </b>ve<b> Tablo 6)</b> bir
tak&#305;m nanslar&#305;na kar&#351;&#305;n zetle yukardaki
ko&#351;ullar&#305;n doldurulmas&#305;n&#305; AHye zg tipik&nbsp; sendromun
tan&#305;s&#305; iin zorunlu tutmaktad&#305;rlar.&nbsp; Byle bir tabloya yolaabilecek
sekonder nedenlerin (sistemik, nrolojik, psikiyatrik) ekarte edilebiliyor
olmas&#305; da her ikisi iin zorunlu d&#305;&#351;lama kriteridir.&nbsp; Bu
ko&#351;ullar&#305;n&nbsp; gerekle&#351;tirildi&#287;i tipik tabloya DSM-IV
Alzheimer Tipi Demans (DAT) ad&#305;n&#305; vermektedir.&nbsp; NINCDS-ADRDA
iin ise ayn&#305; tablonun ad&#305; Muhtemel Alzheimer
Hastal&#305;&#287;&#305; (PRAD) olmaktad&#305;r.&nbsp;&nbsp; Her iki sisteme
gre de son kliniko-patolojik serilerdeki tan&#305; zgll&#287; %90a
yakla&#351;maktad&#305;r.&nbsp; Bir ba&#351;ka deyi&#351;le PRAD/DAT
tan&#305;s&#305; %10 ihtimalle AH d&#305;&#351;&#305; durumlara
yanl&#305;&#351; olarak konulmakta veya AH d&#305;&#351;&#305; nedenler
PRAD/DAT tablosunu taklit ederek sunulmaktad&#305;rlar.&nbsp; Tipik klinik
tablonun duyarl&#305;l&#305;&#287;&#305; tm AH olgular&#305;n&#305;n yine %90
kadar&#305;n&#305; kapsamaktad&#305;r.&nbsp; Bir ba&#351;ka deyi&#351;le AH
hastalar&#305;n&#305;n %10u atipik klinik tablolar gsterdikleri iin PRAD/DAT
tan&#305;s&#305; alamamaktad&#305;rlar. NINCDS-ADRDA, ba&#351;lang&#305; ve
seyirde beklenmedik zellikler (akut ba&#351;lang&#305; ve/veya
h&#305;zl&#305; seyir), demansa neden olabilecek fakat klinisyenin demans
nedeni olarak d&#351;nmedi&#287;i 2. bir durumun varl&#305;&#287;&#305;
(rne&#287;in, inme, hipotiroidi, vb.) ve izole tek bir ilerleyici kognitif
bozukluk olarak s&#305;ralad&#305;&#287;&#305; atipik tablolar iin Mmkn
Alzheimer Hastal&#305;&#287;&#305; (Possible AD-PosAD) ad&#305;n&#305;
kullan&#305;r.&nbsp; PosAD tan&#305;s&#305;yla duyarl&#305;l&#305;k artar, yani
tan&#305; konulmayan olgular&#305;n say&#305;lar&#305; azal&#305;rken zgllk
azalmakta, yani yanl&#305;&#351; tan&#305;lar&#305;n say&#305;s&#305;
artmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Her iki yakla&#351;&#305;m da AHnin demans
a&#351;amas&#305;n&#305;n tan&#305;nmas&#305; iin zellikle
duyarl&#305;l&#305;k ve bir lde de zgllk a&#305;s&#305;ndan kabul
edilebilir dzeyler sa&#287;lasalar da tan&#305;sal kesinlikten uzak olduklar&#305;
da a&#305;kt&#305;r.&nbsp;Nitekim, her 2 kriter dizisi de AHnin greli ge
bir a&#351;amas&#305;na kar&#351;&#305;l&#305;k gelen bir klinik tablo, sendrom
tan&#305;mlamaktad&#305;r. NINCDS-ADRDA kriterlerinde a&#305;ka ifade
edildi&#287;i gibi kesin tan&#305; nropatologa b&#305;rak&#305;lmaktad&#305;r.
Bir ba&#351;ka deyi&#351;le mevcut durumda klinisyenler de&#287;il, sadece
patologlar Alzheimer hastal&#305;&#287;&#305; tan&#305;s&#305; koyabilirler.
Hastal&#305;&#287;&#305;n seyrine mdahale olanaklar&#305;n&#305;n
s&#305;n&#305;rl&#305; oldu&#287;u yak&#305;n tarihlere kadar bu durumun pek de
sak&#305;nca yaratt&#305;&#287;&#305; sylenemezdi. Bununla birlikte,
hastal&#305;&#287;&#305;n nrobiyolojisinin kavranmas&#305;ndaki ba&#351;
dndrc geli&#351;meler do&#287;rudan etyopatogenetik mekanizmalar&#305;
hedefleyen nedene ynelik tedavilerin ara&#351;t&#305;r&#305;labilir
olmas&#305;na olanak sa&#287;lad&#305;. A&#351;a&#287;&#305;da daha
ayr&#305;nt&#305;l&#305; gzden geirilece&#287;i gibi, bu amala s&#305;nanan
ve byk maddi kaynaklar ayr&#305;larak klinik al&#305;&#351;malar&#305;n
olgun a&#351;amalar&#305;na kadar gelebilen ok say&#305;da molekl nihai
engelde tak&#305;larak ipi g&#287;sleyemedi. Bu st ste hayal
k&#305;r&#305;klar&#305;n&#305;n nedenleri aras&#305;nda mutad
al&#305;&#351;ma tasar&#305;m&#305;ndan kaynaklanan nedenler ve etkisizlik
yan&#305;s&#305;ra kuvvetle muhtemel bir di&#287;eri ise bu klinik
al&#305;&#351;malar&#305;n an&#305;lan kriterlerle tan&#305; konmu&#351;
demans evresindeki hastalar&#305; toplamas&#305; gibi grnyor; oysa ki
do&#287;rudan bir etyopatogenetik mekanizma basama&#287;&#305;n&#305;
hedefleyen bir ajan iin yerle&#351;mi&#351; demans ajan&#305;n gerek
potansiyelini sergileyebilmesi iin ok ge kal&#305;nm&#305;&#351; bir
a&#351;ama olabilir. AHnin demans a&#351;amas&#305;n&#305; kanserin metastatik
a&#351;amas&#305;na benzetip tedavi ba&#351;ar&#305;s&#305; beklentisi
a&#305;s&#305;ndan bir analoji kurabiliriz. Bu nedenle AHnin daha demans
ncesi a&#351;amada tan&#305;ya ynelik biyo-i&#351;aretleyicilerin de
yard&#305;m&#305;yla gvenilir bir &#351;ekilde ay&#305;rt edilmesi, AH
tan&#305;s&#305;n&#305;n bizzat klinisyen taraf&#305;ndan konulmas&#305;
giderek artan bir nem arzetmektedir. A&#351;a&#287;&#305;da, AHde
yard&#305;mc&#305; tan&#305; yntemleri ve potansiyel biyo-i&#351;aretleyiciler
gzden geirildikten sonra yak&#305;nlarda bir neri olarak sunulan bylesi bir
yeni tan&#305; kriterleri dizisi tan&#305;t&#305;lacakt&#305;r. Ayr&#305;ca
benzer bir perspektifle her 2 kriter dizisinin gzden geirilmekte oldu&#287;u,
NINCDS-ADRDAin NIA-AA (Ulusal Ya&#351;l&#305;l&#305;k Enstits  Alzheimer
Derne&#287;i) &#351;ekliyle 2010 sonlar&#305;nda DSM-IV2n DSM-V olarak 2011
iinde yenilenmesinin beklendi&#287;i kaydedilmelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 5.</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'> NINCDS-ADRDA Alzheimer
Hastal&#305;&#287;&#305;n&#305;n Klinik Tan&#305; Kriterleri (McKhann et al.
1984)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>I.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MUHTEMEL Alzheimer Hastal&#305;&#287;&#305; klinik tan&#305; kriterleri
&#351;unlar&#305; ierir:</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Klinik muayene ile saptanan,
Mini-Mental Test, Blessed Demans le&#287;i ya da benzer bir test ile
dokmante edilen ve nropsikolojik testlerle de do&#287;rulanan demans tablosu;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&#304;ki ya da daha fazla
kognitif srete bozulma;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Bilin bozuklu&#287;u yok;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Ba&#351;lang&#305; 40-90
ya&#351;lar&#305; aras&#305;nda, byk s&#305;kl&#305;kla da 65
ya&#351;&#305;ndan sonra;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Bellek ya da di&#287;er
bili&#351;sel srelerde ilerleyici bozuklu&#287;a yolaabilecek sistemik ya da
beyne ait ba&#351;ka bir hastal&#305;k yok.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>II.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MUHTEMEL Alzheimer Hastal&#305;&#287;&#305; tan&#305;s&#305; &#351;unlarla
desteklenir:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Dil (afazi), motor yetenekler
(apraksi) ve alg&#305; (agnozi) gibi zgl kognitif i&#351;levlerde ilerleyici
bozulma;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Gnlk ya&#351;am
aktivitelerinde bozulma ve davran&#305;&#351; biiminde de&#287;i&#351;me;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Ailede benzer bozukluk yks
(zellikle patolojik olarak kan&#305;tlanm&#305;&#351;sa);</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Laboratuarda:</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Standart tekniklerle normal lomber ponksiyon,</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
EEGnin normal olmas&#305; yada yava&#351; dalga aktivitesinde art&#305;&#351;
gibi non-spesifik de&#287;i&#351;iklikler,</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BTde serebral atrofiye ili&#351;kin bulgular ve seri incelemelerde bu
bulgular&#305;n ilerleyi&#351;i.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-47.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>III.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Alzheimer hastal&#305;&#287;&#305; d&#305;&#351;&#305;ndaki nedenler
d&#305;&#351;land&#305;ktan sonra, MUHTEMEL Alzheimer Hastal&#305;&#287;&#305;
tan&#305;s&#305; ile uyumlu olabilecek di&#287;er klinik zellikler
&#351;unlard&#305;r:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-47.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Hastal&#305;&#287;&#305;n
seyrinde platolar;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Depresyon, uykusuzluk,
inkontinans, hezeyan, illzyon ve halsinasyonlar, verbal, emosyonel ya da
fiziksel katastrofik patlamalar, cinsel bozukluklar ve kilo kayb&#305; gibi
e&#351;liki bulgular;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Baz&#305; hastalarda, zellikle
hastal&#305;&#287;&#305;n ileri dnemlerinde, kas tonusunda art&#305;&#351;,
miyoklonus ya da yrme gl&#287; gibi di&#287;er nrolojik bozukluklar;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Hastal&#305;&#287;&#305;n ileri
evresinde nbetler;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Ya&#351; iin normal BT.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>IV.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>MUHTEMEL
Alzheimer Hastal&#305;&#287;&#305; tan&#305;s&#305;n&#305;
belirsizle&#351;tiren ya da ihtimal d&#305;&#351;&#305;na &#305;karan
zellikler &#351;unlard&#305;r:</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&#304;nme tarz&#305;nda ani
ba&#351;lang&#305;;</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Hemiparezi, duysal kay&#305;p,
grme alan&#305; defektleri ve inkoordinasyon gibi fokal nrolojik
bulgular&#305;n hastal&#305;&#287;&#305;n erken evrelerinde bulunmas&#305;;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Nbetler ya da yry&#351;
bozukluklar&#305;n&#305;n, daha ba&#351;lang&#305;ta ya da
hastal&#305;&#287;&#305;n ok erken evrelerinde bulunmas&#305;;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>V.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MMKN
Alzheimer Hastal&#305;&#287;&#305; tan&#305; kriterleri &#351;unlard&#305;r:</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Demansa neden olabilecek
di&#287;er nrolojik, psikiyatrik ya da sistemik bozukluklar
olmaks&#305;z&#305;n, ba&#351;lang&#305;, prezantasyon ya da klinik seyirde
varyasyonlar&#305;n bulunmas&#305; durumunda konulabilir;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Demansa neden olabilecek, ancak
demans&#305;n nedeni gibi grnmeyen ikinci bir sistemik ya da beyin
hastal&#305;&#287;&#305;n&#305;n bulunmas&#305; durumunda konulabilir;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Di&#287;er belirlenebilir
nedenlerinin d&#305;&#351;land&#305;&#287;&#305;, tek ve yava&#351; ilerleyici
bir bili&#351;sel bozuklu&#287;un bulunmas&#305; durumunda, ara&#351;t&#305;rma
al&#305;&#351;mas&#305; amal&#305; olarak kullan&#305;labilir.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:47.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-47.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>VI.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KES&#304;N
Alzheimer Hastal&#305;&#287;&#305; tan&#305;s&#305; kriterleri
&#351;unlard&#305;r:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Muhtemel Alzheimer
Hastal&#305;&#287;&#305; klinik kriterleri;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:71.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Biyopsi ya da otopsiyle elde
edilen histopatolojik kan&#305;tlar.</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:45.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:2.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<b>Tablo 6. </b>DSM-IV Alzheimer Tipi Demans
&#304;in Tan&#305; Kriterleri (1995)<o:p></o:p></span></p>

<div style='margin-left:24.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-24.0pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Birden fazla kognitif alan&#305; ieren bozukluk kendini
a&#351;a&#287;&#305;daki iki maddeyi de kapsayacak &#351;eklinde ortaya
&#305;kar:</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bellek bozuklu&#287;u (yeni bir bilgi &#287;renme ve &#287;renilmi&#351; eski
&nbsp;&nbsp; bir bilgiyi hat&#305;rlama yetene&#287;inin bozulmas&#305;)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A&#351;a&#287;&#305;da
s&#305;ralanan kognitif bozuklardan en az biri:</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(a)&nbsp;&nbsp;&nbsp;&nbsp; Afazi (dil
bozuklu&#287;u)</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(b)&nbsp;&nbsp;&nbsp;&nbsp; Apraksi
(motor i&#351;levlerin normal olmas&#305;na kar&#351;&#305;n belirli motor
eylemlerin yerine getirilmesi yetene&#287;inde &nbsp; bozulma)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(c)&nbsp;&nbsp;&nbsp;&nbsp; Agnozi
(duysal i&#351;levlerin salim olmas&#305;na kar&#351;&#305;n
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nesneleri
tan&#305;makta glk)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(d)&nbsp;&nbsp;&nbsp;&nbsp;Yrtc
i&#351;levlerde bozulma (planlama, organize etme, s&#305;ralama, soyutlama)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A1 ve A2 kriterlerinde tan&#305;mlanan bili&#351;sel bozukluklar toplumsal ve
mesleki i&#351;levselli&#287;i ciddi biimde bozmakta ve eski i&#351;levsellik
dzeyine gre anlaml&#305; bir gerilemeyi temsil etmektedir.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:49.65pt;margin-bottom:.0001pt;text-align:justify;text-indent:-49.65pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Seyir, sinsi ba&#351;lang&#305; ve yava&#351; ilerleyici kognitif
y&#305;k&#305;m zelliklerindedir.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A1
ve A2 kriterlerinde tan&#305;mlanan bili&#351;sel bozukluklar
a&#351;a&#287;&#305;da s&#305;ralanan nedenlerden herhangi birine
ba&#287;l&#305; de&#287;ildir:</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bellek ve di&#287;er bili&#351;sel i&#351;levlerde ilerleyici bozulmaya neden
olabilecek &nbsp; merkezi sinir sistemine ait di&#287;er durumlar (rne&#287;in
serebrovaskler hastal&#305;k, Parkinson hastal&#305;&#287;&#305;, Huntington
hastal&#305;&#287;&#305;, subdural hematom, normal bas&#305;nl&#305;
hidrosefali, beyin tmr)</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Demansa neden olabilece&#287;i bilinen sistemik durumlar (rne&#287;in
hipotiroidizm, B12 vitamini ya da folik asid eksikli&#287;i, niasin
eksikli&#287;i, hiperkalsemi, nrosifilis, HIV infeksiyonu)</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;lalar ve madde kullan&#305;m&#305; ile ilgili durumlar</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>E.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bozukluklar delirium seyri d&#305;&#351;&#305;nda ortaya
&#305;km&#305;&#351;t&#305;r.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>F.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bozukluk
ba&#351;ka bir Eksen I hastal&#305;&#287;&#305; ile a&#305;klanabilir
nitelikte de&#287;ildir.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><a name="OLE_LINK2"></a><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
Hastal&#305;&#287;&#305;n&#305;n Pre-Demans Evreleri: Normal
Ya&#351;lanma-Ya&#351;la &#304;lintili Unutkanl&#305;k-Hafif Kognitif
Bozukluk-Demans Devaml&#305;l&#305;&#287;&#305;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici hastal&#305;klar patogenetik sreleri
iinde belli bir e&#351;i&#287;i getikleri a&#351;amada klinik olarak
saptanabilir olurlar.&nbsp; Bu e&#351;ik de hemen daima normal kabul
edilemeyecek bir belirtidir.&nbsp; rne&#287;in, glioblastoma yeterince byyp
kafa ii bas&#305;nc&#305;n&#305; artt&#305;rarak
ba&#351;a&#287;r&#305;s&#305;na neden olana kadar sub-klinik olarak
ilerler.&nbsp; Ba&#351;a&#287;r&#305;s&#305; kadar a&#351;ikar bir anormal
belirti olmayan unutkanl&#305;k durumunda sub-klinik dnemle klinik dnem daha
kal&#305;n izgilerle iie girer.&nbsp; Alzheimer
hastal&#305;&#287;&#305;n&#305;n zamansal evrimi bunun en gzel
rneklerindendir.&nbsp;AH demans a&#351;amas&#305;na ula&#351;madan nce uzun
y&#305;llar (baz&#305; hesaplamalara gre 15-20 y&#305;l) klini&#287;e
ilerleyici unutkanl&#305;k &#351;eklinde yans&#305;yan bir demans ncesi veya
prodromal evreden geecektir. Bununla birlikte, unutkanl&#305;k ya&#351;l&#305;l&#305;kta
son derece s&#305;kl&#305;kla duyulmaya al&#305;&#351;&#305;lm&#305;&#351;,
gayet normal kabul edilen bir yak&#305;nmad&#305;r.&nbsp; Bellek de dahil olmak
zere baz&#305; kognitif yeteneklerde ya&#351;lanmayla birlikte beklenen
normal azalma nropsikolojik standardizasyonda e&#287;itimle birlikte gz
nne al&#305;nmas&#305; gereken temel zelliklerindendir.&nbsp; Bir yak&#305;n
bellek testinde yetmi&#351;li ya&#351;lar&#305;n normal de&#287;eri yirmili
ya&#351;lar&#305;n normalinin yar&#305;s&#305; olabilir.&nbsp; Normal
ya&#351;lanma kavram&#305; bellek de dahil kognitif kapasitelerini hi
yitirmeyen kk bir az&#305;nl&#305;&#287;&#305; da ierse de,
a&#287;&#305;rl&#305;kla nropsikolojik testlerde ya&#351;a gre uyarlanm&#305;&#351;
dzeylerde bir performansa kar&#351;&#305;l&#305;k gelir.&nbsp; MRG/BTde
kortikal sulkuslar ve ventrikl sistemi geni&#351;lemeye
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; Bu tr grntlemelerin
raporlar&#305;n&#305;n sonu blmnde s&#305;kl&#305;kla ya&#351;la ilintili
atrofi yazacakt&#305;r.&nbsp; Kognitif a&#305;dan normal ki&#351;ilerin<b> </b>otopsileri,
tmyle normal olabilece&#287;i gibi 50li ya&#351;lar&#305;n
ba&#351;lar&#305;ndan itibaren neokortekste gev&#351;ek nitelikli amiloid
plaklar ve bazen bunlara e&#351;lik eden entorhinal kortekste NFYlerin
grlebilece&#287;ini ortaya koymaktad&#305;r. Sa&#287;duyu bu 2. gruba ait
beyinlerde AH nrodejenerasyonun ba&#351;lad&#305;&#287;&#305; fakat henz
klinik belirti e&#351;i&#287;ini gemedi&#287;ini d&#351;ndrmelidir.
Ba&#351;ka bir deyi&#351;le, 2. grup de&#287;i&#351;iklikleri gstermeye
ba&#351;layan beynin sahibi yeterince uzun ya&#351;asayd&#305;,
yak&#305;nmalar&#305;n&#305;n zaman iinde grnr olup sonunda AH klinik
kriterlerini dolduraca&#287;&#305; ileri srlebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans8.JPG">&#350;ekil 8.</a> </span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal ya&#351;lanmadan
a&#287;&#305;r demansa bellek bozuklu&#287;u sreklili&#287;i</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sosyal ya&#351;amda ba&#351;ka a&#305;lardan
sa&#287;l&#305;kl&#305; bir ya&#351;l&#305;n&#305;n zel isimleri unutuyor,
zel e&#351;yalar&#305;n&#305; kolayl&#305;kla bulam&#305;yor olmas&#305;
anormal kabul edilmez.&nbsp; Ayn&#305; sorular&#305; tekrarlar olmas&#305;
yak&#305;nlar&#305; aras&#305;nda ku&#351;ku uyand&#305;rmaya
ba&#351;lar.&nbsp; &#304;&#351;ini srdremez olmas&#305;, ya da yabanc&#305;
bir mekanda kaybolmas&#305; ise art&#305;k normal olarak kabul edilemez
olur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;Ya&#351;la &#304;lintili Bellek Bozuklu&#287;u
(AAMI) kavram&#305; tam da yukar&#305;daki paragrafta anormal bulunmayan
unutkanl&#305;k durumuna kar&#351;&#305;l&#305;k gelmektedir.&nbsp; Daha nceki
y&#305;llarda Selim Ya&#351;l&#305;l&#305;k Unutkanl&#305;&#287;&#305;
kavram&#305;yla kar&#351;&#305;lanmaya al&#305;&#351;&#305;lan ve isminin de
a&#287;r&#305;&#351;t&#305;rd&#305;&#287;&#305; gibi demansa ilerlemeyecek iyi
huylu unutkanl&#305;&#287;a kar&#351;&#305;l&#305;k gelecek &#351;ekilde
kullan&#305;lan sz konusu durum iin Amerikan Ulusal Zihinsel Sa&#287;l&#305;k
Enstits (NIMH) 1986 y&#305;l&#305;nda ara&#351;t&#305;rma amal&#305;
tan&#305; kriterleri yay&#305;nlad&#305; <b>(Tablo 7</b>).&nbsp; AAMI
tan&#305;m&#305;na uygun d&#351;en yak&#305;nmalar&#305; olan bir
ya&#351;l&#305; gnlk ya&#351;am&#305;nda tmyle
ba&#287;&#305;ms&#305;zd&#305;r.&nbsp; Bu ki&#351;inin nropsikolojik
muayenesinde zellikle yak&#305;n bellek testlerinde ya&#351;a gre normal
s&#305;n&#305;rlarda, fakat gen eri&#351;kinlere gre ortalama de&#287;erlerin
1 standart sapma (SD) alt&#305;nda yer ald&#305;&#287;&#305;
saptanacakt&#305;r.&nbsp;Hangi ya&#351;l&#305; selim ya&#351;l&#305;l&#305;k
de&#287;i&#351;ikliklerini gstermekte, hangisi ise AHnin en erken izlerini
ta&#351;&#305;maktad&#305;r sorular&#305;n&#305;n cevab&#305;n&#305;
&#351;imdiki durumda ne salt klinik fenomenoloji ne de mevcut nropatolojik
kavray&#305;&#351; ile vermek mmkn de&#287;ildir. AAMI tan&#305;s&#305; alan
bir ki&#351;i yak&#305;nmalar&#305; karakter de&#287;i&#351;tirmeden
ld&#287; takdirde beyni tmyle normal bulunabilece&#287;i gibi, <i>Nropatoloji</i>
k&#305;sm&#305;nda ayr&#305;nt&#305;s&#305;yla grlece&#287;i gibi, limbik
sisteminde az say&#305;da nrofibriler yumak&nbsp; ve neokorteksinde
gev&#351;ek karakterli amiloid plaklar ta&#351;&#305;yor olabilir.&nbsp; PET tekniklerinde
yeni geli&#351;melerle sadece amiloid plaklara (PIB-PET) ve hem plaklara hem
yumaklara (FDDNP-PET) ba&#287;lanan ligandlarla bu tr patolojik
de&#287;i&#351;iklikleri ta&#351;&#305;yan ve ta&#351;&#305;mayan kognitif
olarak normal ya&#351;l&#305; ki&#351;ileri saptamak mmkn olmaktad&#305;r.
Uzunlamas&#305;na izlenen kognitif olarak normal veya AAMI tan&#305;s&#305;
alan ya&#351;l&#305;lar&#305;n PIB/FDDNP+ olanlar&#305;, PIB/FDDNP- olanlara
gre anlaml&#305; olarak daha fazla demans geli&#351;tirdikleri
gsterildi&#287;i takdirde bu yntem prodromal/pre-klinik AHnin bir
i&#351;aretleyicisi olarak yerle&#351;ebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ya&#351;l&#305;l&#305;kta pre-demans kognitif
bozuklu&#287;u tan&#305;mlama gayretiyle bir dizi daha kavram ve kriterler
dizisi ileri srlm&#351; olsa da tm de demansa ilerleyen bir bellek
bozuklu&#287;u kavray&#305;&#351;&#305;ndan ziyade demans kadar &#351;iddetli
olmayan bir hafif kognitif bozukluku e&#351;itli isimlerle
tan&#305;mlam&#305;&#351;lard&#305;r. Bunlar aras&#305;nda 1990lar boyunca
tan&#305;mlanan ICD-10un minimal kognitif bozukluk  MCD, DSM-IVn hafif
nro-kognitif bozukluk  MNCD, Uluslararas&#305; Psikogeriyatri Birli&#287;inin
Ya&#351;la &#304;lintili Kognitif Bozukluk  AACD ve Kanada
Sa&#287;l&#305;kl&#305; Ya&#351;lanma al&#305;&#351;mas&#305; (CSHA)
erevesinde kullan&#305;lan demans olmayan kognitif bozukluk  CIND
kavramlar&#305; say&#305;labilir. Tm bu tan&#305;mlamalar, belli
nanslar&#305;na ra&#287;men, tan&#305;mlad&#305;klar&#305; demans
&#351;iddetinde olmayan kognitif bozukluk durumunu esas olarak statik zerk
antiteler olarak grmektedirler; yle ki, bunlar aras&#305;ndan bir
k&#305;s&#305;m hasta dzelip normale dnebilece&#287;i gibi, bir
k&#305;sm&#305; ise ilerleyip demans geli&#351;tirdi&#287;inde nitelik
de&#287;i&#351;tirip ba&#351;ka bir antiteye dn&#351;m&#351; gibi kabul
edilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<b>Tablo 7. </b>NIMH-AAMI Tan&#305;
Kriterleri</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-3.9pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=576 valign=top style='width:431.65pt;border:solid gray 1.0pt;
  padding:2.0pt 2.0pt 2.0pt 2.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ya&#351;
  &gt; 50.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gnlk ya&#351;amda
  belle&#287;e ili&#351;kin yak&#305;nmalar.</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gen eri&#351;kinlere gre 1
  standart sapma daha d&#351;k nesnel bellek performans&#305;.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Demans mevcut de&#287;il.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal ya da normalin st
  zeka seviyesi.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span><span lang=DE style='font-family:Tahoma;mso-ansi-language:
  DE'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DE style='font-family:
Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gerekte, AAMI tan&#305;s&#305; alan
ya&#351;l&#305;lar&#305;n AH nrodejenerasyonuna sahip bir blm daha da
ktle&#351;ecek ve bellek yak&#305;nmalar&#305; yak&#305;nlar&#305;n&#305;n da
dikkatini ekmeye ba&#351;layacakt&#305;r. Gene de byle bir ki&#351;i
an&#305;lan bellek problemlerinin yaratt&#305;&#287;&#305;, ancak listeyle
al&#305;&#351;veri&#351;e &#305;kar olmak gibi genellikle stesinden
gelebildi&#287;i glkler d&#305;&#351;&#305;nda, gnlk ya&#351;am&#305;nda
halen ba&#287;&#305;ms&#305;zd&#305;r.&nbsp; Nropsikolojik muayenesinde
a&#287;&#305;rl&#305;kla bazen de tek ba&#351;&#305;na bellek
alan&#305;nda,&nbsp; anlaml&#305; dzeyde d&#351;k performans gsterir.&nbsp;
Bu tabloya Hafif Kognitif Bozukluk (MCI) ad&#305; verilir <b>(Tablo 8</b>).&nbsp;
Orijinal biimiyle bu tan&#305;m, prodromal AH olmas&#305; muhtemel, ATDye
dn&#351;me riski ta&#351;&#305;yan bir alt grubu ara&#351;t&#305;rma ve
mmknse tedavi hedefi yapmak zere belirlenmi&#351;se de sonradan revize
edilen biimiyle amnestik olmayan demanss&#305;z kognitif bozukluklar da dahil
edilerek prodromal AHye olan vurgu abas&#305; kapsay&#305;c&#305;l&#305;k
ad&#305;na zay&#305;flam&#305;&#351; grnmektedir <b>(Tablo 9</b>).&nbsp;
&#304;lgili tablodan da grlece&#287;i gibi, s&#305;n&#305;flama tmyle
bellek bozuklu&#287;unun bulunup bulunmamas&#305;na ve mevcut kognitif bozuklu&#287;un
tek veya o&#287;ul olma durumuna gredir. Bu farkl&#305; tablolar&#305;n
ilerledikleri takdirde en mutad olarak belli demans hastal&#305;klar&#305;na
dn&#351;ecekleri beklenir. &#304;lk bak&#305;&#351;ta bu s&#305;n&#305;flama
yukarda tan&#305;mlanan ekirdek sendromlar yakla&#351;&#305;m&#305;n&#305;n
bir benzeri gibi d&#351;nlebilirse de burdaki mevcut MCI tablosu-ilerdeki
demans sendromu ili&#351;kisi ok daha indirgemeci bir ak&#305;l yrtmedir.
ekirdek sendromlar&#305;n anatomik adreslerinden bu anatomik adrese
yatk&#305;nl&#305;k sergileyen en muhtemel proteinopati tarz&#305; bir
ak&#305;l yrtme esnekli&#287;i sergileyemez. rne&#287;in, progresif
simultanagnozi-simetrik dorsal parietal alanlar-amiloidopati silsilesi
progresif simultanagnozinin bu s&#305;n&#305;flamadaki
kar&#351;&#305;l&#305;&#287;&#305; olan izole non-amnestik MCI ile, bu MCI alt
s&#305;n&#305;f&#305;n&#305;n AHye dn&#351;mesi beklenmedi&#287;inden
sa&#287;lanamaz. Dahas&#305;, ekirdek sendrom yakla&#351;&#305;m&#305;yla,
ilerde demansa dn&#351;p dn&#351;meyece&#287;ine
bak&#305;lmaks&#305;z&#305;n anatomik yatk&#305;nl&#305;k ve muhtemel
proteinopatiden yola &#305;karak hastal&#305;k tan&#305;s&#305;na varmak
mmknken, MCI tan&#305;m&#305; ile ancak demans a&#351;amas&#305;nda bir
hastal&#305;ktan szedilebilecek durumla normallik aras&#305;nda
kalm&#305;&#351; bir gei&#351; a&#351;amas&#305; tasarlanm&#305;&#351;
olmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Uzunlamas&#305;na izlenen byk serilerde MCI&#305;n demansa dn&#351;me
h&#305;z&#305; y&#305;ll&#305;k %8-14ken 5 y&#305;ll&#305;k izlemlerde %50
kadard&#305;r.&nbsp; Oysa ki, normal poplasyonda demans insidans&#305;
%1-2dir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Grntleme al&#305;&#351;malar&#305;nda mezyal temporal patoloji bu
hastalar&#305; normallerden ay&#305;rmaktad&#305;r.&nbsp; MRG-volmetride
baz&#305; al&#305;&#351;malarda hippokampus, di&#287;er baz&#305;lar&#305;nda
ise entorhinal korteks atrofisi MCIl&#305; serilerde ya&#351;la
e&#351;lenmi&#351; normal kontrollere gre anlaml&#305; dzeyde
grlmektedir.&nbsp; FDG-PETle yap&#305;lan al&#305;&#351;malarda
ba&#351;lang&#305; noktas&#305;nda ba&#351;l&#305;ca posterior singulat
hipometabolizmaya sahip olman&#305;n izlemde dn&#351;menin anlaml&#305; bir
ngrcs oldu&#287;u ortaya konmu&#351;tur.&nbsp; PIB-PET ile yap&#305;lan
al&#305;&#351;malarda ATDlilerin hemen tm PIB tutulumu gsterirken
MCIlar&#305;n yar&#305;s&#305;ndan fazlas&#305;nda ve enteresan olan&#305;
normal ya&#351;l&#305;lar&#305;n da kk bir blmnde grlmektedir.
Dahas&#305; gerek MCIl&#305;lar ve gerekse de normallerde PIB tutulumu
gsteren grupta PIB yk ile bellek skorlar&#305; korele etmektedir. Bu bulgu
MCI ve normal olarak s&#305;n&#305;flanm&#305;&#351; olan PIB tutulumuna sahip
bu bireylerin gerekte s&#305;ras&#305;yla prodromal ve pre-klinik AH
ta&#351;&#305;d&#305;klar&#305; &#351;eklinde yorumlanabilir. Ay&#305;rt edici
ba&#351;ka bir bulgu ise nritik plaklara ba&#287;lanan PIB ligand&#305; ile ancak
demans a&#351;amas&#305;nda mezyal temporal tutulum grlrken MCI ve
normallerde grlmemesidir. Buna kar&#351;&#305;l&#305;k NFYlere de
ba&#287;lanan FDDNP-PET ile normal ya&#351;l&#305;larda ve MCIl&#305;larda
bellek skorlar&#305;yla korele eden bulgular saptanmaktad&#305;r. FDDNP-PET ile
bu bulgu da PIB-PET ile yukar&#305;daki yoruma benzer bir &#351;ekilde
yorumlanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>MCI otopsilerinde normalden hafif PRAD patolojilerine kadar
de&#287;i&#351;en bir spektrum izlenmekle birlikte, NFYnin halen
limbik-paralimbik alanlara s&#305;n&#305;rl&#305; ancak say&#305;sal olarak
normallere gre anlaml&#305; dzeyde artm&#305;&#351; olmas&#305; en
tutarl&#305; bulgu gibi grnmektedir.&nbsp; Nritik plaklar henz limbik
sistemde grlmemektedir. APOE-&#949;4 alel s&#305;kl&#305;&#287;&#305; ve
BOSta total tau ve fosfo-tau proteini dzeylerinde art&#305;&#351; ile
&#946;-amiloid<sub>42</sub> dzeylerinde d&#351;&#351;n, entorhinal ve/veya
hippokampal atrofi yan&#305;s&#305;ra demansa dn&#351;ecekleri
dn&#351;meyenlerden ay&#305;ran ngrcler oldu&#287;u ileri
srlmektedir.&nbsp; MCI&#305;n bir klinik antite olarak yani prodromal AH
olarak daha iyi s&#305;n&#305;rlar&#305;n&#305;n izilmesi, bu evrede etkili
olacak&nbsp; tedavilerle demansa dn&#351;menin geciktirilmesi ya da nne
geilmesi, gnmzde AHnin yknn azalt&#305;lmas&#305;nda temel bir hedef
gibi grnmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:16.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 8.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Petersen-Mayo MCI
Kriterleri</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-3.9pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=449 valign=top style='width:336.95pt;border:solid gray 1.0pt;
  padding:2.0pt 2.0pt 2.0pt 2.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp; Hasta
  yak&#305;n&#305; taraf&#305;ndan da do&#287;rulanan bellek
  yak&#305;nmas&#305;.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp; Genel kognitif
  i&#351;levlerde bozulma yok.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp; Gnlk ya&#351;am
  aktivitelerinde bozulma yok.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp; Ya&#351; ve
  e&#287;itim normlar&#305;na gre saptanan bellek bozuklu&#287;u.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5.&nbsp; Demans mevcut
  de&#287;il.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yukar&#305;daki paragrafta tan&#305;mlanan,
art&#305;k sa&#287;duyunun da normal kabul edemedi&#287;i, gnlk ya&#351;amda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; srdremeyecek dzeyde
bozulma durumunda art&#305;k demanstan szedilebilir.&nbsp; Bu duruma
kar&#351;&#305;l&#305;k gelen otopsilerde NFYler art&#305;k neokortekse
yay&#305;lm&#305;&#351;, gev&#351;ek biimden nritik biime
de&#287;i&#351;mi&#351; APler limbik sistemde grlr olmu&#351; durumdad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a href="tablo9.JPG">Tablo 9.</a> Revize MCI
Kriterleri ve Muhtemel Demans &#304;zd&#351;mleri</span></b><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;Alzheimer Tipi Demans&#305;n Evreleri</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerleyici bir hastal&#305;ktan
szetti&#287;imize gre klinik tabloyu statik bir profille tarif
edemeyiz.&nbsp; Yine sa&#287;duyu ile amatr bir yakla&#351;&#305;m dahi
ilerleyen bir tablonun hafif, orta ve a&#287;&#305;r olarak
s&#305;n&#305;fland&#305;r&#305;lmas&#305; gerekti&#287;ini ngrebilir.&nbsp;
Formel evreleme leklerinin de taklit etti&#287;i yntem bundan farkl&#305;
de&#287;ildir.&nbsp; Zihinsel y&#305;k&#305;m&#305;n demans dzeyine
ula&#351;mas&#305; gnlk aktivitelerde bozulma ile belirlendi&#287;ine gre,
evrelemeyi de GYAlara gre kabaca yapabiliriz: AAMIy&#305; sbjektif bellek
yak&#305;nmalar&#305;,&nbsp;MCIy&#305; GYAlar&#305;n korundu&#287;u ama
yak&#305;n ki&#351;ilerin fark&#305;nda oldu&#287;u bir bellek bozulmas&#305;
olarak tarif etmi&#351;tik; bu durumda devaml&#305;l&#305;k ltn gznnde
tutarak hafif demans&#305; i&#351;te ve ev d&#305;&#351;&#305;nda
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n bozulmaya
ba&#351;lad&#305;&#287;&#305;, orta demans&#305;, bunlar tmyle
ba&#287;&#305;ml&#305;la&#351;&#305;rken ev ya&#351;am&#305; ve kendine
bak&#305;mda sorunlar&#305;n ba&#351;lad&#305;&#287;&#305;, a&#287;&#305;r
demans&#305; ise srekli bak&#305;m gereken, hastan&#305;n tmyle
ba&#287;&#305;ml&#305; oldu&#287;u bir durum olarak tarif edebiliriz.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bugn yayg&#305;n olarak kullan&#305;lan iki
evreleme sisteminden biri olan Global Bozulma le&#287;i (Global
Deterioration Scale-GDS)nin de geli&#351;tiricisi olan Reisberg, AHdeki
ilerleyici y&#305;k&#305;m srecini, bebeklik-erken ve ge ocukluk ve ergenlik
&#351;eklindeki insan&#305;n ilerleyici
bireyselle&#351;me-ba&#287;&#305;ms&#305;zla&#351;ma geli&#351;imsel srecinin
tam tersine evrilmesi oldu&#287;unu ileri srer ve bu ilerleyici
y&#305;k&#305;m&#305; retrogenez olarak adland&#305;r&#305;r. Buna gre
AAMI-MCIl&#305; ya&#351;l&#305; byk lde ba&#287;&#305;ms&#305;z olsa da
baz&#305; kararlar&#305; iin eri&#351;kin gzetimine gerek duyan ergene, hafif
demansl&#305;, evinde ve ev d&#305;&#351;&#305;nda tan&#305;d&#305;k mekanlarda
belli bir ba&#287;&#305;ms&#305;zl&#305;&#287;&#305; kazanm&#305;&#351;, ancak
sosyal ili&#351;kiler, muhakeme gerektiren karma&#351;&#305;k i&#351;levlerde
halen denetim gereksinen 7-12 ya&#351;lar&#305;ndaki okul ocu&#287;unu
and&#305;r&#305;r.&nbsp; Orta demansl&#305; ise kabaca, ev ya&#351;am&#305; ve
giyinme, y&#305;kanma, yemek yeme gibi temel GYAlarda henz gzetim gereken
2-6 ya&#351;lar&#305; aras&#305;ndaki okul ncesi ocu&#287;u gibidir.&nbsp;
A&#287;&#305;r demansl&#305;, ya&#351;am&#305;n&#305; srdrmek iin 24 saat
ana-babaya (bak&#305;c&#305;ya) tmyle ba&#287;&#305;ml&#305; 0-2 ya&#351;
bebe&#287;ine benzer.&nbsp; A&#287;&#305;r evrenin kendisi de, yani giderek tm
motor ve verbal yeteneklerin kaybedildi&#287;i yata&#287;a tam
ba&#287;&#305;ml&#305; nihai dneme do&#287;ru y&#305;k&#305;m, oturma, yrme,
konu&#351;ma, sfinkter kontrolnn geli&#351;ti&#287;i bebekli&#287;in dinamik
geli&#351;iminin tam tersi olarak kavran&#305;p alt evrelere
ayr&#305;labilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>GDS szedildi&#287;i gibi AHyi evrelemeye yarayan
leklerden birisidir.&nbsp; AH d&#305;&#351;&#305; demanslarda AHye
zgll&#287; dolay&#305;s&#305;yla kullan&#305;lamaz.&nbsp; GDS evreleri 1
ila 7 aras&#305;nda de&#287;i&#351;ir.&nbsp; Kabaca, GDS1 hi yak&#305;nmas&#305;
ve bulgusu olmayan normal ya&#351;l&#305;ya kar&#351;&#305;l&#305;k
gelirken&nbsp; GDS2ye AAMI, GDS3e ise MCI evreleri denilebilir.&nbsp; GDS
4-5-6-7 ise hafif, orta, a&#287;&#305;r ve ok a&#287;&#305;r olmak zere
AHnin klinik evreleridir.&nbsp; Demans&#305;n Klinik Evrelendirilmesi
(Clinical Dementia Rating Scale-CDR) ise yayg&#305;n olarak kullan&#305;lan 2.
lektir.&nbsp; CDRda bellek yine merkezi nemde olmakla birlikte, ok eksenli
tasar&#305;m&#305;yla di&#287;er demanslar&#305;n evrelenmesinde de
kullan&#305;labilir.&nbsp; CDR evreleri 0-0,5-1-2-3 olarak
s&#305;ralan&#305;rlar.&nbsp; CDR 0, AAMI&#305; da ierecek &#351;ekilde
normal ya&#351;l&#305;l&#305;&#287;a kar&#351;&#305;l&#305;k gelir.&nbsp; CDR
0,5 MCIya kar&#351;&#305;l&#305;k gelir ve ku&#351;kulu demans evresi
ad&#305;n&#305; al&#305;r.&nbsp; CDR 1, 2 ve 3 s&#305;ras&#305;yla hafif, orta
ve a&#287;&#305;r evrelerdir <b>(Tablo 10, 11</b>).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hafif evredeki demansl&#305; hasta halen
al&#305;&#351;maktaysa art&#305;k i&#351;inde verimlili&#287;ini
yitirmi&#351;tir.&nbsp; Yarat&#305;c&#305;l&#305;k gerektirmeyen tekdze
i&#351;ler ba&#351;lang&#305;ta srdrlebilse de, i&#351;
arkada&#351;lar&#305; performans d&#351;kl&#287;nn
fark&#305;ndad&#305;rlar ve k&#305;sa sre iinde emeklilik
ka&#305;n&#305;lmaz olur.&nbsp; Yak&#305;n gemi&#351;e ait olaylar&#305;n
hat&#305;rlanmas&#305;ndaki glk, ayn&#305; sorular&#305;n
tekrarlanmas&#305;, kelime bulma glkleri yak&#305;nlar&#305;n dikkatini
eken ba&#351;l&#305;ca zelliklerdir.&nbsp; Halen bildik mekanlarda
dola&#351;abilse ve yolculuk yapabilse de, yabanc&#305; mekanlarda
kaybolabilir.&nbsp; Araba kullan&#305;rken sinyalizasyona dikkatsizlik,
tepkilerde yava&#351;lama, ynleri kar&#305;&#351;t&#305;rma gibi glkler
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; Banka i&#351;leri, fatura demeleri gibi
mali i&#351;lerde hatalar olmaktad&#305;r.&nbsp; Banka kart&#305;, cep telefonu
gibi yenilikleri &#287;renip kullanmay&#305; ba&#351;aramaz.&nbsp; Hobiler
(diki&#351;-nak&#305;&#351;, bahecilik, sanatsal u&#287;ra&#351;&#305;lar,
yetenek oyunlar&#305;, vb.) srdrlemez olmu&#351;tur.&nbsp; Yemek lezzetinde
bozulmalar gibi mutfak i&#351;lerinde glkler
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; ama&#351;&#305;r, bula&#351;&#305;k
gibi ev i&#351;lerini srdrebilse de, bunlarda eski zenini bir lde
yitirmi&#351;tir.&nbsp; Okumak ve gazete-TV arac&#305;l&#305;&#287;&#305;yla
aktaliteye ilgi azalm&#305;&#351;t&#305;r.&nbsp; Giyinmek, y&#305;kanmak,
sofra al&#305;&#351;kanl&#305;klar&#305; ve temel hijyende henz bir sorun
yoktur.&nbsp; &#304;ritabilite, duygulan&#305;mda kntle&#351;me ve inkar
e&#287;ilimi ile kendili&#287;indenli&#287;in azalmas&#305;
d&#305;&#351;&#305;nda davran&#305;&#351;sal belirtiler yoktur ve sosyal
uygunluk iyi korunmu&#351;tur.&nbsp; Uyku kalitesi bozulmaya ba&#351;lar.&nbsp;
Cinsel ilgi ve i&#351;tah bozulur.&nbsp; Eksikliklerin farkedilmesinin de
katk&#305;s&#305;yla baz&#305; olgularda depresyon belirtileri n planda
olabilir.&nbsp; Ancak depresyon s&#305;kl&#305;kla keder ifadesi gibi afektif
belirtilerden ok, isteksizlik gibi motivasyonel belirtilerle kendini
gsterir.&nbsp; Muayenede yak&#305;n bellek n planda olmak zere,
grsel-mekansal bozukluk, uzak bellekte bozulmalar, adland&#305;rma glkleri,
dikkat ve soyutlama-planlamada bozulmalar saptan&#305;r.&nbsp; Praksis
muayenesinde beden-paras&#305;-nesne-gibi cevaplar al&#305;n&#305;r.&nbsp;
Henz gnostik bir kusur saptanmaz.&nbsp; Somatik nrolojik muayene
normaldir.&nbsp;&nbsp; MMSE skoru kabaca 20-26 aras&#305;nda olabilir.&nbsp;
S&#305;kl&#305;kla GDS 4, CDR 1 olarak evrelenirler.&nbsp; Bu hastalar&#305;n
otopsilerinde heteromodal kortekste NFYler, limbik sistemde nritik SPler
saptan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Orta demans evresine
ula&#351;&#305;ld&#305;&#287;&#305;nda, hasta ev d&#305;&#351;&#305;ndaki
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; art&#305;k tmyle
yitirmi&#351;tir.&nbsp; Gzetimle soka&#287;a &#305;kabilse de, yaln&#305;z
kald&#305;&#287;&#305; takdirde yolunu bulamaz.&nbsp;
Ba&#351;kalar&#305;n&#305;n evinde odalar&#305; kar&#305;&#351;t&#305;rabilir.&nbsp;
Yeni &#287;renme art&#305;k hemen hi mmkn olamamaktad&#305;r.&nbsp; Anlama,
okuma ve yazma giderek bozulur; evrenin sonlar&#305;na do&#287;ru imzas&#305;
tan&#305;nmaz olabilir. &nbsp;Birinci derece yak&#305;nlar&#305;
hakk&#305;ndaki bilgiyi genellikle korusa da, torunlar&#305;n&#305;n
say&#305;s&#305;, isimleri, okullar&#305; gibi bilgileri
kar&#305;&#351;t&#305;rmaktad&#305;r.&nbsp; Evdeki i&#351;levselli&#287;i son
derece yzeyselle&#351;mi&#351;tir.&nbsp;&nbsp; Ancak sofray&#305; toplamaya
veya sebze do&#287;ramaya yard&#305;m dzeyinde olabilir.&nbsp; Giyinme
s&#305;ras&#305;nda mevsime ya da gnn saatine uygun giysiyi semede zorlanma,
giysilerin s&#305;ras&#305;n&#305; kar&#305;&#351;t&#305;rma (gmle&#287;in
zerine i ama&#351;&#305;r&#305; gibi), d&#287;meleri yanl&#305;&#351;
ilikleme gibi glkler ba&#351;lar.&nbsp; Sofrada ncelikle
b&#305;a&#287;&#305; kullanamaz oldu&#287;unda yemeklerinin nceden kesilmesi
gerekir.&nbsp; Giderek dkp saarak yemek belirginle&#351;ir.&nbsp;
atal-b&#305;a&#287;&#305; kar&#305;&#351;t&#305;rmak, s&#305;v&#305;lar&#305;
atalla almaya al&#305;&#351;mak gibi hatalar grlebilir.&nbsp;
Y&#305;kanmakta ncelikle s&#305;ca&#287;&#305; so&#287;u&#287;u ayarlamakla
ba&#351;layan yard&#305;m gereksinimi ortaya &#305;kar.&nbsp;&nbsp;&nbsp;
Henz sfinkter kontrol seyrek gece ka&#305;rmalar&#305;
d&#305;&#351;&#305;nda sorunsuzdur.&nbsp; Tuvalet mekani&#287;i, elini yzn
y&#305;kamak gibi i&#351;levleri kendi ba&#351;&#305;na yapabilir.&nbsp;
Davran&#305;&#351;sal belirtiler art&#305;k vurgulanmaya
ba&#351;lam&#305;&#351;t&#305;r.&nbsp; H&#305;rs&#305;zl&#305;k, terkedilme ve
sadakatsizlik hezeyanlar&#305; olabilir.&nbsp; Yaln&#305;z kalmaktan rker ve
yak&#305;n&#305;n&#305; (e&#351;i, ocu&#287;u) srekli gznn nnde
ister.&nbsp; Hekim vizitleri gibi yakla&#351;an randevular a&#351;ikar bir
beklenti anksiyetesine yolaabilir.&nbsp; Uyku-uyan&#305;kl&#305;k ritiminde
bozulma art&#305;k belirginle&#351;mi&#351;tir.&nbsp; Gece s&#305;k uyanmalar
ve gndz s&#305;k uyuklamalarla geer.&nbsp; Muayenede hafif evre
bulgular&#305; biraz daha a&#287;&#305;rla&#351;m&#305;&#351;t&#305;r.&nbsp;
Dilsel i&#351;levlere ait bulgular&#305;n a&#287;&#305;rla&#351;mas&#305; dile
dayanan testlerin yap&#305;lamaz olmas&#305;na neden olabilir.&nbsp; Praksis
bozuklu&#287;u taraf apraksisi dzeyine ula&#351;abilir.&nbsp; Gnostik
bozukluklar, zellikle sofrada gz nndeki nesneyi di&#287;erleri
aras&#305;ndan ay&#305;r&#305;p bulamamak (simultanagnozi) &#351;eklinde
olabilir.&nbsp; Temel nrolojik muayenede hafif parkinsonyen
de&#287;i&#351;iklikler saptanabilir.&nbsp; MMSE skoru 10-19 aras&#305;nda
de&#287;i&#351;ir.&nbsp; GDS 5, CDR 2 olarak evrelenirler. Bu hastalar&#305;n
otopsilerinde NFYler unimodal asosiasyon kortekslerine de
yay&#305;lm&#305;&#351; olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>A&#287;&#305;r demans evresinde bellekte
art&#305;k sadece parac&#305;klar sz konusudur.&nbsp; Yak&#305;n&#305;n&#305;
(e&#351;i, ocu&#287;u) ana-babas&#305;yla kar&#305;&#351;t&#305;rabilir,
aynadaki kendi yzn tan&#305;yamayabilir.&nbsp; Giyinmek, y&#305;kanmak,
yemek gibi temel GYAlarda art&#305;k tam bir gzetim gerekmektedir.&nbsp;
Evrenin sonlar&#305;nda yutma gl&#287; de ortaya &#305;kar.&nbsp; Kelime
hazinesi son derece fakirle&#351;mi&#351;tir.&nbsp; Evrenin sonlar&#305;nda tm
verbal yetenekler yitirilir.&nbsp; Ambulasyon giderek zorla&#351;&#305;r ve
sonlara do&#287;ru giderek oturmak dahi mmkn olmaz hale gelir.&nbsp;
Televizyondaki ki&#351;ileri ev iindeymi&#351; gibi san&#305;p konu&#351;mak,
aynadaki kendi hayaliyle yabanc&#305;ym&#305;&#351; gibi konu&#351;mak
gzlenebilir.&nbsp; Ambulasyonun korundu&#287;u s&#305;rada amas&#305;z
dola&#351;ma, istifilik, amas&#305;z tekrarlay&#305;c&#305; hareketler
izlenebilir.&nbsp; Tuvalet mekani&#287;inde bozulmalar (idrar ya da gaita
sonras&#305; uygun biimde temizlenme, sifonu ekme sorunlar&#305;), idrar
ka&#305;rma giderek belirginle&#351;ir.&nbsp; Epileptik nbetler ortaya
&#305;kabilir.&nbsp; A&#287;&#305;r evredeki hastalar&#305;n formel muayenesi
son derece gtr ve mmkn olamayabilir.&nbsp; Yap&#305;labildi&#287;inde
global bir y&#305;k&#305;m saptan&#305;r.&nbsp; Temel nrolojik muayenede&nbsp;
tonus de&#287;i&#351;iklikleri, yry&#351; bozukluklar&#305; &#351;eklinde
parkinsonyen bulgular biraz daha ortaya &#305;km&#305;&#351;t&#305;r.&nbsp;
MMSE 0-9 aras&#305;ndad&#305;r.&nbsp; GDS 6-7, CDR 3 olarak evrelenirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#350;ekil 9</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>da AHnin klinik ve bir dizi
laboratuar ltnn pre-klinik evreden ba&#351;layarak a&#287;&#305;r demans
evresine kadar gsterdi&#287;i de&#287;i&#351;kenlik gsterilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans9b.JPG">&#350;ekil 9.</a> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n evreleri boyunca klinik ve laboratuar
gstergelerinin de&#287;i&#351;imi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BOS A&#946; dzeyi daha preklinik evrede PIB-PET ile
amiloid yknn saptanabilmesinden nce d&#351;meye ba&#351;lar; klinik
evrelerden itibaren PIB-PET ile amiloid yk fazlaca de&#287;i&#351;mez.
AAMIdan itibaren kognisyon bozulmaya, BOS tau dzeyleri artmaya ba&#351;lar.
MCI evresinde FDG-PET ile blgesel metabolizma azalmas&#305; izlenir olur ve
sonras&#305;nda demans evreleri boyunca yayg&#305;nla&#351;arak &#351;iddetlenir.
Hippokampus hacmi AAMIdan itibaren klmeye ba&#351;lar. &#304;&#351;levsel
bozukluk (GYAlar) tan&#305; gere&#287;i demans a&#351;amas&#305;ndan itibaren
ba&#351;lar ve ilerleyici olarak ktle&#351;ir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b style='mso-bidi-font-weight:
normal'><span lang=TR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;
font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar: </span></b><span
lang=TR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Tahoma;
mso-ansi-language:TR'>AAMI: ya&#351;la ilintili bellek bozuklu&#287;u; BOS:
beyin-omurilik s&#305;v&#305;s&#305;; FDG-PET: i&#351;aretli glukoz pozitron
emisyon tomografisi; GYAlar: gnlk ya&#351;am aktiviteleri; MCI: hafif
kognitif bozukluk; PIB: Pittsburgh bile&#351;eni<o:p></o:p></span></p>

</div>

<span lang=TR style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:
Tahoma;mso-fareast-font-family:"Times New Roman";mso-ansi-language:TR;
mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=all
style='page-break-before:always;mso-break-type:section-break'>
</span>

<div class=Section2>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 10.</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> Demans&#305;n Klinik
Evrelendirilmesi le&#287;i -CDR (Morris 1997)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=114 valign=top style='width:85.5pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CDR</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1.
  Bellek&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2.
  Oryantasyon</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3.
  Yarg&#305;lama </span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Problem zme</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek
  kayb&#305; yok ya da hafif ve belirsiz unutkanl&#305;k</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tmyle
  oryante</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gnlk problemler ve
  al&#305;&#351;ma hayat&#305; ve&nbsp;mali i&#351;lerle ilgili problemleri
  iyi zer;&nbsp;yarg&#305;lama iyidir</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0,5</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hafif
  fakat a&#351;ikar unutkanl&#305;k;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>olaylar&#305;n k&#305;smen
  hat&#305;rlanabilmesi; &quot;selim&quot;
  unutkanl&#305;k&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Zaman
  ili&#351;kilerinde hafif glk d&#305;&#351;&#305;nda tmyle oryante</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Problem zme, benzerlik ve
  farkl&#305;l&#305;klar&#305; kavramakta hafif bozukluk</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Orta
  dzeyde unutkanl&#305;k, yak&#305;n</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>dnem olaylar&#305; iin daha
  belirgin; &nbsp;unutkanl&#305;k gnlk aktiviteleri&nbsp;etkiliyor</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Zamanda
  orta dzeyde glk;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>muayene s&#305;ras&#305;nda mekana
  oryante, d&#305;&#351;ar&#305;da co&#287;rafi disoryantasyonu olabilir</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Orta
  dzeyde bozukluk; toplumsal</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>yarg&#305;lama genellikle
  korunmu&#351;tur</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#287;&#305;r dzeyde
  unutkanl&#305;k; yaln&#305;zca ok iyi &#287;renilmi&#351; materyel
  tutulabilir; yeni materyel h&#305;zla yitirilir</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Zaman
  ili&#351;kilerinde a&#287;&#305;r dzeyde</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>glk; genellikle zamana,
  s&#305;kl&#305;kla da mekana disoryante</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#287;&#305;r
  dzeyde bozukluk; genellikle</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>toplumsal yarg&#305;lama da
  bozuktur</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#287;&#305;r
  dzeyde unutkanl&#305;k; yaln&#305;zca parac&#305;klar kal&#305;r</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yaln&#305;zca
  ki&#351;ilere oryante</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yarg&#305;lama
  ve problem zme tmyle bozuk</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CDR</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.
  Ev d&#305;&#351;&#305;nda i&#351;levsellik</span></b><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5.
  Ev ya&#351;am&#305;  Hobiler</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>6.
  Ki&#351;isel bak&#305;m</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;te,
  al&#305;&#351;veri&#351;te, gnll gruplar ve toplumsal gruplar iinde her
  zamanki dzeyde ba&#287;&#305;ms&#305;z i&#351;levsellik</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  ya&#351;am&#305;, hobiler ve entelektel</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ilgiler iyi korunmu&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kendine
  bak&#305;ma tmyle muktedir</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0,5</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>An&#305;lan
  aktivitelerde hafif bozulma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  ya&#351;am&#305;, hobiler ve entelektel</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ilgilerde hafif bozulma</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>An&#305;lan
  aktivitelerden baz&#305;lar&#305;n&#305; halen srdrse de,
  ba&#287;&#305;ms&#305;z i&#351;lev grememe; yzeysel bir bak&#305;&#351;la
  hala normal grnebilir</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evdeki
  i&#351;levlerde hafif fakat a&#351;ikar</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>bozulma; g ev i&#351;leri,
  karma&#351;&#305;k</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>hobiler ve ilgiler
  terkedilmi&#351; durumda</span><span lang=DA style='font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gayrete
  getirilmesi gerekiyor</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  d&#305;&#351;&#305;nda ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; tmyle
  &nbsp;yitirmi&#351; / Ev d&#305;&#351;&#305;nda aktivitelere gtrlebilecek
  kadar iyi grnr</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yaln&#305;zca
  basit i&#351;ler yap&#305;labiliyor; ilgiler son derece
  s&#305;n&#305;rl&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Giyinme,
  hijyen ve di&#287;er ki&#351;isel bak&#305;m iin yard&#305;m gerekiyor</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=248 valign=top style='width:185.8pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ev
  d&#305;&#351;&#305;nda ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; tmyle
  yitirmi&#351; / Ev d&#305;&#351;&#305;nda aktivitelere gtrlemeyecek kadar
  hasta grnr</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=274 valign=top style='width:205.85pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evde
  kayda de&#287;er bir i&#351;levselli&#287;i yok</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=276 valign=top style='width:206.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;isel
  bak&#305;m iin nemli lde yard&#305;m gerekir; genellikle
  inkontinand&#305;r</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Evrelendirme: Bellek ekseninin d&#305;&#351;&#305;ndaki eksenlerden
en az  bellek ekseninden farkl&#305; de&#287;ilse, evre bellek ekseniyle
ayn&#305;d&#305;r.&nbsp; Farkl&#305; oldu&#287;u durumda ise, evre bellek
ekseninin stnde ya da alt&#305;nda kalan bu 3 eksenin derecesidir.&nbsp; Bu
kural&#305;n tek istisnas&#305; bellek ekseni d&#305;&#351;&#305;nda kalan 5
eksenden nn belle&#287;in bir taraf&#305;nda geri kalan&nbsp;ikisinin
di&#287;er taraf&#305;nda olmas&#305;d&#305;r ki bu durumda da evre bellek
ekseniyle ayn&#305;d&#305;r.&nbsp; Bellek ekseni 0,5 ise evre 0 olamaz;
di&#287;er eksenlerin derecesine ba&#287;l&#305; olarak 0,5 ya da 1
olmal&#305;d&#305;r.&nbsp; Bellek 0, fakat en az iki eksen 1 ya da daha fazla
ise, evre 0,5 olmal&#305;d&#305;r.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
<br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<b>Tablo 11.</b> Global Bozulma
le&#287;i GDS (Reisberg et al. 1998)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=52 valign=top style='width:39.15pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek
  kusuruna ili&#351;kin yak&#305;nma yok.</span><span lang=FI style='font-family:
  Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Klinik gr&#351;me ile
  bellek kusuru saptanm&#305;yor.</span><span lang=FI style='font-family:Tahoma;
  mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek
  kusuruna ait, zellikle a&#351;a&#287;&#305;da s&#305;ralanan alanlarda
  yak&#305;nmalar var:</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  e&#351;yalar&#305;n&#305; koydu&#287;u yerleri unutuyor;</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nceden iyi
  bildi&#287;i isimleri unutuyor.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Klinik gr&#351;mede bellek kusuruna ait nesnel bir kan&#305;t yok.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &#304;&#351; ve toplumsal ortamlarda nesnel bir bozukluk yok.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Semptomatolojiye ynelik uygun dzeyde endi&#351;e
  ta&#351;&#305;yor.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>En
  erken gsterilebilir bozukluk bulgular&#305;.</span><span lang=DE
  style='font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  A&#351;a&#287;&#305;daki alanlarda birden fazla bulgu:</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iyi
  bilmedi&#287;i evrelere gitti&#287;inde kaybolabiliyor.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; i&#351;
  arkada&#351;lar&#305;, hastan&#305;n bozulmaya yztutan al&#305;&#351;ma
  performans&#305;n&#305;n fark&#305;ndalar.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kelime
  ve isim bulma glkleri yak&#305;nlar&#305; taraf&#305;ndan fark ediliyor.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bir kitap
  yada yaz&#305;y&#305; okudu&#287;unda eskisi gibi hat&#305;r&#305;nda
  kalm&#305;yor.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yeni
  tan&#305;&#351;t&#305;&#287;&#305; insanlar&#305;n isimlerini
  hat&#305;rlamakta gl&#287; var.</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  de&#287;erli bir nesne kaybedilmi&#351; yada konulmamas&#305; gereken bir
  yere konmu&#351;.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; konsantrasyon
  eksikli&#287;i klinik testler s&#305;ras&#305;nda a&#351;ikar.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify;text-indent:-1.0cm;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bellek bozuklu&#287;una ili&#351;kin, ancak yo&#287;un bir gr&#351;meden
  sonra ortaya konulabilen nesnel bulgular.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  U&#287;ra&#351;&#305; gerektiren i&#351; ko&#351;ullar&#305; yada toplumsal
  ortamlarda d&#351;k performans.</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Hastada inkar mekanizmas&#305; belirgin hale gelir olmu&#351;.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
  ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Belirtilere
  &#305;l&#305;ml&#305;&nbsp; yada orta dzeyde bir anksiyete e&#351;lik
  edebilir.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dikkatli
  bir klinik gr&#351;me sonras&#305;nda ortaya konulan a&#351;ikar bozukluk
  bulgular&#305;.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bozukluk a&#351;a&#287;&#305;daki alanlarda ortaya konuyor:</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gnlk ve
  yak&#305;n gemi&#351;e ait olaylara ili&#351;kin bilgide azalma.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ki&#351;isel
  gemi&#351;e ait baz&#305; bellek problemleri.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  &#305;karma dizileriyle ortaya konulan konsantrasyon bozuklu&#287;u.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yolculuk
  yapma, para i&#351;leriyle u&#287;ra&#351;ma gibi yeteneklerde azalma.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  A&#351;a&#287;&#305;daki alanlar genellikle sorunsuz:</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yer ve zaman
  oryantasyonu</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bildik
  ki&#351;i ve yzlerin tan&#305;nmas&#305;.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bilinen
  yerlere yolculuk yapabilme.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Karma&#351;&#305;k i&#351;levlerin yerine getirilemez olmas&#305;.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bask&#305;n savunma mekanizmas&#305; olarak inkar kullan&#305;l&#305;yor.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>Duygulan&#305;mda kntle&#351;me ve
  s&#305;k&#305;nt&#305; yaratan durumlardan ka&#305;nma.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ya&#351;amlar&#305;n&#305;
  srdrebilmeleri iin yard&#305;m gerekmektedir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Hasta gncel ya&#351;am&#305;na ili&#351;kin temel zelliklerden birini
  hat&#305;rlayam&#305;yor. rne&#287;in:</span><span lang=TR style='font-family:
  Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  y&#305;llard&#305;r kullanmakta oldu&#287;u adres yada telefon
  numaras&#305;n&#305;.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yak&#305;n
  aile yelerinin isimlerini (torunlar gibi).</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mezun
  oldu&#287;u lise yada yksek okulun ad&#305;n&#305;.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Zaman (gn, haftan&#305;n gn, mevsim, v.b) yada mekan oryantasyonunda
  bozulmalar.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  E&#287;itimli bir ki&#351;i, 40'tan geriye 4er, yada 20'den geriye 2'&#351;er
  saymakta glk ekebilir.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Bu evredeki ki&#351;iler kendilerine ve di&#287;erlerine ait temel gereklere
  ili&#351;kin bilgiyi korurlar.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Kendi isimlerini daima, e&#351; ve ocuklar&#305;n&#305;nkileri genellikle
  bilirler.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:53.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-53.0pt;
  text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Temizlenmek
  ve yemek yemekte yard&#305;m gerekmez, ancak uygun giysiyi semekte
  glkleri&nbsp;&nbsp; olabilir.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>6</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bazen,
  ya&#351;amlar&#305;n&#305; srdrmek iin tmyle ba&#287;&#305;ml&#305;
  olduklar&#305; e&#351;lerinin ismini&nbsp; unutabilirler.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Ya&#351;amlar&#305;ndaki yak&#305;n gemi&#351;e ili&#351;kin olay ve
  deneyimlerin tmnden byk lde habersizdirler.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  evreye ili&#351;kin baz&#305; bilgiler korunabilir; y&#305;l, mevsim, v.b.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  10'dan geriye, bazen de ileriye do&#287;ru 1'er saymakta glkleri olabilir.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Gnlk ya&#351;am aktivitelerinde yard&#305;m gerekir:</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; idrar
  inkontinans&#305; olabilir.</span><span lang=TR style='font-family:Tahoma;
  mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yolculuk iin
  yard&#305;m gerekir, fakat bazen bildik yerlere gidebilirler.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Diurnal ritm s&#305;kl&#305;kla bozulmu&#351;tur.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Hemen daima kendi isimlerini hat&#305;rlarlar.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Genellikle, evrelerindeki tan&#305;d&#305;k ki&#351;ileri yabanc&#305;lardan
  ay&#305;rabilirler.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Ki&#351;ilik ve emosyon de&#287;i&#351;iklikleri grlr.&nbsp; Bunlar
  olduka de&#287;i&#351;kendir ve &#351;unlar&#305; ierir:</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;
  (a)&nbsp;&nbsp;&nbsp;&nbsp; hezeyan davran&#305;&#351;&#305;, rn.,
  e&#351;lerini taklit olmakla sulayabilirler; evredeki
  hayali&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ki&#351;ilerle, yada
  aynadaki kendi imgeleriyle konu&#351;abilirler.</span><span lang=TR
  style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp; (b)&nbsp;&nbsp; obsesif
  belirtiler olabilir, rn., hasta srekli olarak&nbsp; basit bir temizlik hareketini
  tekrarlayabilir.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;
  (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;anksiyete belirtileri, ajitasyon
  ve daha nce mevcut olmayan tarzda bir sald&#305;rganl&#305;k&nbsp;
  grlebilir.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
  TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;
  (d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kognitif abuli, rn., amaca ynelik bir
  davran&#305;&#351;&#305;n uygulanmas&#305; iin gerekli d&#351;ncenin
  yeterli sre ta&#351;&#305;namamas&#305; nedeniyle irade gcnn kayb&#305;.</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=52 valign=top style='width:39.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=766 valign=top style='width:574.85pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bu
  evre srecinde tm verbal yetenekler kaybedilir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bu evrenin erken dneminde
  baz&#305; kelime ve cmleler sylenebilse de konu&#351;ma son derece
  s&#305;n&#305;rlanm&#305;&#351;t&#305;r.</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Evrenin ilerlemesiyle,
  homurdanmak d&#305;&#351;&#305;nda, konu&#351;ma tmyle yitirilir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;drar inkontinans&#305;;
  temizlik ve yemek yemek iin yard&#305;m gerekir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Temel psikomotor yetenekler
  (rn. yrmek) evrenin ilerlemesiyle kaybedilir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Beyin bedene ne yapmas&#305;
  gerekti&#287;ini syleme yetene&#287;ini art&#305;k yitirmi&#351; gibidir.</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genel ve kortikal nrolojik
  bulgu ve belirtiler bu evrede genellikle mevcuttur.</span><span lang=DA
  style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>EP&#304;DEM&#304;YOLOJ&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Prevalans ve &#304;nsidans</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Dnyada &#351;imdiye kadar yap&#305;lan prevalans
(belli bir zaman kesitinde bulunan tm olgular&#305;n nfusa oran&#305;)
al&#305;&#351;malar&#305;n&#305;n metaanalizi 65-70 ya&#351;lar&#305;
aras&#305;nda %4-5 kadar olan AHnin her 5 y&#305;lda bir katlanarak art&#305;p
90l&#305; ya&#351;larda %50ye kadar ula&#351;t&#305;&#287;&#305;n&#305;
ortaya koymaktad&#305;r.&nbsp;Trkiyeden ilk al&#305;&#351;ma
diyebilece&#287;imiz Istanbul, Kad&#305;kyde gerekle&#351;tirilen TAPS
isimli prevalans al&#305;&#351;mas&#305;n&#305;n sonular&#305; <b>Tablo 12</b>de
gsterilmi&#351;tir. 90l&#305; ya&#351;lardan sonraki prevalans konusunda
henz bir uzla&#351;&#305;m olmamakla birlikte art&#305;&#351;&#305;n devam
etmeyip bu oran&#305;n plato izdi&#287;i (AH ya&#351;la ilintilidir)
gr&#351; ile srekli ykseldi&#287;i (AH ya&#351;lanmayla ilintilidir)
gr&#351; aras&#305;ndaki tart&#305;&#351;ma tam olarak
zmlenmemi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ya&#351;a-zgl insidans, ya da belli bir zaman
aral&#305;&#287;&#305;nda ortaya &#305;kan yeni olgular&#305;n
say&#305;s&#305; da ya&#351; aral&#305;klar&#305; artt&#305;ka h&#305;zla
artar.&nbsp; Jorm ve Jolleyin 1998 tarihli bir meta-analizlerinde 65-69 ile
ba&#351;lay&#305;p 85-89 ile sonlanan 5er y&#305;ll&#305;k 5 ya&#351;
katman&#305;nda insidans %1.6, %3.5, %7.8, %14.8 ve %26.0 &#351;eklinde yine
katlanarak artmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 12.</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> TAPS
al&#305;&#351;mas&#305;nda ya&#351;a ve cinsiyete gre
katmanland&#305;r&#305;lm&#305;&#351; prevelans oranlar&#305;<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid windowtext 1.0pt;
 mso-padding-alt:0cm 0cm 0cm 0cm;mso-border-insideh:1.0pt solid windowtext;
 mso-border-insidev:1.0pt solid windowtext'>
 <tr style='mso-yfti-irow:0'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PRAD</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toplam
  AH</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Toplam
  demans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ya&#351;
  gruplar&#305; bir arada</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tm</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%11</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%16</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%20</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:25.5pt'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:25.5pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Erkek</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%9</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%13</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%17</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>Kad&#305;n</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%13</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%17</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%22</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Cinsiyet
  gruplar&#305; bir arada</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-74</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%9</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%14</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%18</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>75-79</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%14</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%19</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%22</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>80+</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%13</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%17</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%23</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Erkek</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-74
  </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%8</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%12</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%16</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>75-79</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%9</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%12</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%15</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>80+</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%11</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%16</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%20</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kad&#305;n</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>70-74</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%10</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%15</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%19</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>75-79</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%18</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%23</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%26</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;mso-yfti-lastrow:yes'>
  <td width=209 valign=top style='width:157.05pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-left:36.0pt;text-align:justify;layout-grid-mode:
  char'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
  TR'>80+</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=69 valign=top style='width:51.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%15</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=105 valign=top style='width:78.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%20</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=139 valign=top style='width:104.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext 1.0pt;mso-border-left-alt:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>%25</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PRAD: muhtemel Alzheimer
hastal&#305;&#287;&#305;; toplam AH: PRAD art&#305; mmkn AH; toplam demans:
toplam AH art&#305; non-AH demanslar. (Kaynak 15den
uyarlanm&#305;&#351;t&#305;r.)<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Risk Faktrleri (Tablo 13)</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gnmzde ya&#351;am beklentisindeki dramatik
art&#305;&#351; global bir fenomendir.&nbsp; Bat&#305;l&#305; lkeler
ba&#351;ta olmak zere, tm dnyada ya&#351;l&#305; nfusun genel nfusa
oran&#305;n&#305;n giderek artmas&#305; bir toplumsal sorun olarak AHnin
nemini de artt&#305;rmaktad&#305;r.&nbsp;Hastal&#305;&#287;&#305;n toplumsal
maliyetinin demans &#351;iddetiyle do&#287;ru orant&#305;l&#305; oldu&#287;unu
gsteren al&#305;&#351;malar mevcuttur.&nbsp;TAPSta da ya&#351; bir risk
faktr olarak ortaya konmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bir risk faktr olarak cinsiyet
tart&#305;&#351;mal&#305;d&#305;r. Bir ok al&#305;&#351;ma AH
prevalans&#305;n&#305;n kad&#305;nlarda erkeklere gre daha fazla oldu&#287;unu
gstermektedir.&nbsp; Ancak bu prevalans farkl&#305;l&#305;&#287;&#305;
genellikle kad&#305;nlarda ya&#351;am beklentisinin daha uzun olmas&#305;yla
a&#305;klanmaktad&#305;r.&nbsp; Bununla birlikte strojen beyinde bir
nrotrofik faktr olarak i&#351;lev grmekte, erkeklerde mr boyu mevcut olan
testosteron beyinde strojene evrilip i&#351;levini srdrrken, kad&#305;nlar
menopoz sonras&#305; strojensiz kalmaktad&#305;rlar. Bu durum
ya&#351;am&#305;n ikinci yar&#305;s&#305;nda bir nrotrofik faktrden yoksun
kalan kad&#305;nlar&#305;n neden demans iin daha fazla risk
ta&#351;&#305;d&#305;klar&#305;n&#305;n a&#305;klamalar&#305;ndan biri
olabilir. Nitekim, epidemiyolojik al&#305;&#351;malarda post-menopozal dnemde
strojen replasman&#305; kullanan kad&#305;nlarda kullanmayanlara gre demans
prevalans&#305;n&#305;n daha d&#351;k olmas&#305; bu varsay&#305;m&#305;
destekler niteliktedir. Cinsiyetin gerek anlamda bir risk olup
olmad&#305;&#287;&#305;na daha iyi bir cevap verebilecek olan insidans
al&#305;&#351;malar&#305;n&#305;n sonular&#305; ise eli&#351;kilidir.&nbsp;
Bir al&#305;&#351;ma 85 ya&#351;&#305;n&#305;n zerindeki erkeklerde AH
insidans&#305;n&#305; y&#305;lda %2.7, buna kar&#351;&#305;l&#305;k
kad&#305;nlarda %8.9 oldu&#287;unu bulmu&#351;tur.&nbsp; Ba&#351;ka bir
al&#305;&#351;mada ise bir AHlinin 1. derece kad&#305;n
akrabalar&#305;n&#305;n 1. derece erkek akrabalar&#305;na gre ya&#351;am boyu
hastal&#305;k riskinin daha fazla oldu&#287;u gsterilmi&#351;tir. Ancak ok
say&#305;da ba&#351;ka al&#305;&#351;mac&#305; grubu bu farkl&#305;l&#305;&#287;&#305;
do&#287;rulamayarak herhangi bir farkl&#305;l&#305;k
bulmam&#305;&#351;lard&#305;r.&nbsp; TAPS al&#305;&#351;mas&#305;nda da
kad&#305;nlarda prevalans daha yksek olsa da cinsiyetin bir risk faktr
olmad&#305;&#287;&#305; grlm&#351;tr. Bununla birlikte,&nbsp; drt
ayr&#305; prospektif Avrupa al&#305;&#351;mas&#305;n&#305;n
havuzlanm&#305;&#351; verilerini analiz eden EURODEM Insidens
Ara&#351;t&#305;rma Grubu kad&#305;n cinsiyetin 85 ya&#351; ile birlikte bir
risk faktr olarak belirdi&#287;ini, 90 ya&#351; zerinde bu riskin daha da
artt&#305;&#287;&#305;n&#305; bildirmi&#351;lerdir. TAPS al&#305;&#351;mas&#305;nda
85 ve 90 ya&#351; zeri tabakalardaki birey say&#305;s&#305;n&#305;n azl&#305;&#287;&#305;
bizim al&#305;&#351;mam&#305;zdaki negatif sonucun a&#305;klamas&#305;
olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yorumu yine tart&#305;&#351;mal&#305; olsa da
d&#351;k e&#287;itimin ba&#351;l&#305; ba&#351;&#305;na bir risk faktr
oldu&#287;u art&#305;k yerle&#351;mi&#351; bir bilgidir.&nbsp;E&#287;itim
deneyimindeki art&#305;&#351;&#305;n bireyin kognitif rezervinin
geni&#351;lemesine yolaarak&nbsp;hastal&#305;&#287;&#305;n ortaya
&#305;k&#305;&#351; e&#351;i&#287;ini ykseltmesi ekici bir a&#305;klama
gibi durmaktad&#305;r.&nbsp;TAPS al&#305;&#351;mas&#305;nda da d&#351;k
e&#287;itim demans iin bir risk faktr olarak belirlenmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>TAPS al&#305;&#351;mas&#305;nda elektro-manyetik
alan (EMF) maruziyeti de AH iin bir risk faktr olarak ortaya konmu&#351;tur.
Elektrikiler, tamirciler, santral operatrleri, teknisyenleri,
kaynak&#305;lar, marangozlar, terziler gibi elektrikli aletlerle
al&#305;&#351;anlar a&#351;&#305;r&#305; d&#351;k frekansl&#305; (ELF) EMF
maruziyeti iin risk alt&#305;nda meslek gruplar&#305;d&#305;r. Bizim
al&#305;&#351;mam&#305;z&#305; da ieren ELF-EMF maruziyeti ve AH
ili&#351;kisi ile ilgili 12 al&#305;&#351;man&#305;n meta-analizi olan bir
al&#305;&#351;mada bu ili&#351;kinin ba&#287;&#305;ms&#305;z bir risk
oldu&#287;u kabullenilmekle birlikte mevcut al&#305;&#351;malarda maruziyet
dozu ile risk art&#305;&#351;&#305; ve maruziyet ile cinsiyetlerin ili&#351;kisinin
belirlenememi&#351; olmas&#305; dolay&#305;s&#305;yla daha fazla
al&#305;&#351;man&#305;n gerekti&#287;inin alt&#305; izilmi&#351;tir. Maruz
kal&#305;nan di&#287;er toksik ve zararl&#305; durumlar aras&#305;nda organik
zcler, alminyum ve genel anestezi n plana &#305;kar gibi
grnmektedir.&nbsp; Ancak bunlar&#305;n yerle&#351;mi&#351;
tutarl&#305;l&#305;kta bulgular oldu&#287;u sylenemez. Sigara ienlerde,
kolinerjik nikotinik reseptrlerin st-reglasyonu ve bunun sonucu olarak
A&#946; dzeylerinin d&#351;mesi ile a&#305;klanan biimde AHnin daha az
grld&#287; bulgusu, ba&#351;lang&#305;ta sigara ienlerin ileri
ya&#351;lara gelmeden di&#287;er hastal&#305;klar nedeniyle lmeleri ve
vaskler demansa daha yatk&#305;n olmalar&#305; &#351;eklinde metodolojik
olarak ele&#351;tirilmi&#351;ken, son zamanlardaki Rotterdam ve New York
al&#305;&#351;malar&#305;nda tam tersine AH riskini bir ka kez
artt&#305;rd&#305;&#287;&#305; ynnde bulgular elde edilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ayr&#305; bir alt ba&#351;l&#305;kta
tart&#305;&#351;&#305;lacak olan otozomal dominant gei&#351;li familyal AH
olgular&#305; yan&#305;s&#305;ra, ailede demans yks AH iin kendi
ba&#351;&#305;na bir risk faktrdr.&nbsp;AHli hastalar&#305;n karde&#351;lerinde
ya&#351;am boyu hastal&#305;k riski beklentisi ikiye katlanarak %23ten %48e
&#305;kar.&nbsp; Monozigotik ikizlerde dizigot ikizlere oranla AH
birlikteli&#287;i anlaml&#305; oranda fazlad&#305;r.&nbsp;APOE-&#949;4 aleli
ile AH ili&#351;kisi &quot;genetik&quot; altba&#351;l&#305;&#287;&#305;
alt&#305;nda tart&#305;&#351;&#305;lacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yine genetik ba&#351;l&#305;&#287;&#305;
alt&#305;nda szedilecek olan Down sendromu ve AH ili&#351;kisi
yan&#305;s&#305;ra, Down sendromu aile yks AH riskini 2 ila 3 misli
artt&#305;rmaktad&#305;r.&nbsp; Ayr&#305;ca enteresan bir bulgu, Down sendromlu
ocuk do&#287;uran annelerin AH riskinin, di&#287;er tiplerde mental retarde
ocuklar do&#287;uran annelere gre 5 misli artmas&#305;d&#305;r.&nbsp; Bu
farkl&#305;l&#305;k anne ya&#351;&#305;n&#305;n do&#287;umda 35in alt&#305;nda
oldu&#287;u durumlarda ortaya &#305;kmaktad&#305;r.&nbsp; Down
babalar&#305;nda AH iin ayr&#305;ca bir risk sz konusu de&#287;ildir.&nbsp;
Bu bulgu, AH geli&#351;tirmek ve 35 ya&#351;&#305;n&#305;n alt&#305;nda Down
sendromlu ocuk do&#287;urmak aras&#305;nda payla&#351;&#305;lan bir genetik
yatk&#305;nl&#305;k olas&#305;l&#305;&#287;&#305; ynnde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kafa travmas&#305; yks ile AH aras&#305;nda
ili&#351;ki bildiren nemli al&#305;&#351;malar olmakla birlikte
(rne&#287;in, EURODEM) bunu reddenler de vard&#305;r (rne&#287;in, Rotterdam
al&#305;&#351;mas&#305; ve Kanada Sa&#287;l&#305;k ve Ya&#351;lanma
al&#305;&#351;mas&#305;). Bilin kayb&#305;na neden olmu&#351; &#351;iddetteki
kafa travmalar&#305;n&#305;n bir risk faktr olarak de&#287;erlendirilmesi
mevcut al&#305;&#351;malardaki eli&#351;ik sonular&#305; a&#351;abilir.
APOE-&#949;4 yk ile kafa travmas&#305;n&#305;n AHnin ba&#351;lang&#305;
ya&#351;&#305; zerine birlikte etkisi oldu&#287;unu ileri sren
al&#305;&#351;malar&nbsp; mevcuttur.&nbsp; Bir al&#305;&#351;mada ise tek
ba&#351;&#305;na etkisiz grnrken, normalde iki misli artm&#305;&#351; olan
APOE-&#949;4 heterozigotlar&#305;n&#305;n riskini 10 misline
artt&#305;rd&#305;&#287;&#305; ortaya konmu&#351;tur.&nbsp; Kafa travmas&#305;n&#305;n
etkisinin &#946;-amiloid metabolizmas&#305; zerinden olmas&#305; muhtemel
grnmektedir. Dementia pugilistica geli&#351;tiren boksrlerin otopsilerinde
saptanan gev&#351;ek neokortikal amiloid plaklar bu varsay&#305;m&#305;
destekler niteliktedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>z gemi&#351;te 10 y&#305;la kadar geriye giden
tedavi gerektirmi&#351; bir depresyon yks AH riskini 3 kat
artt&#305;r&#305;r.&nbsp; Depresyonun hastal&#305;&#287;&#305;n erken bir
gsterisi oldu&#287;unu iddia eden al&#305;&#351;malar vard&#305;r.&nbsp;Jorm
taraf&#305;ndan yap&#305;lan 2001 tarihli meta-analizde
ya&#351;l&#305;l&#305;kta depresyon zgemi&#351;inin demans geli&#351;tirme
riskini ikiye katlad&#305;&#287;&#305; bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K&#305;s&#305;tl&#305; sosyal ili&#351;kiler
Kungsholmen, &#304;sve ve Kuzey Manhattan, ABD gibi nemli toplum temelli
kesitsel ve uzunlamas&#305;na gzlem al&#305;&#351;malar&#305;nda
ba&#287;&#305;ms&#305;z bir risk faktr olarak ortaya konmu&#351;tur. Sosyal
ili&#351;kiler akraba ve arkada&#351; ili&#351;kilerinin zenginli&#287;i,
sinema, lokanta, klp, dernek faaliyetleri amal&#305; soka&#287;a
&#305;kmalar olarak zetlenebilir. Honolulu-Asya Ya&#351;lanma
al&#305;&#351;mas&#305;nda bu risk orta ya&#351;lar&#305;ndan itibaren sosyal
aktiviteleri d&#351;en bireylerle s&#305;n&#305;rl&#305; bulunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Vaskler olaylar aras&#305;nda miyokard iskemisi,
hipertansiyon, diyabet ve inme yks ile metabolik sendrom mevcudiyetinin AH
riskini anlaml&#305; biimde artt&#305;rd&#305;&#287;&#305; bir ok
al&#305;&#351;mada gsterilmi&#351;tir.&nbsp; Bu bulgular o denli gldr ki,
daha yak&#305;n zamanlara kadar 2. s&#305;kl&#305;kta demans nedeni olarak
gsterilen vaskler demans&#305;n AHden ba&#287;&#305;ms&#305;z bir antite
olarak varl&#305;&#287;&#305; bile son y&#305;llarda tart&#305;&#351;ma konusu
olmu&#351;tur. Ayn&#305; zamanda bir inme risk faktr olan yksek plazma
homosistein dzeyinin AH iin de ba&#287;&#305;ms&#305;z bir risk faktr
oldu&#287;u bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kk kafa evresi ile AH aras&#305;nda baz&#305;
al&#305;&#351;malarda gsterilen ili&#351;ki, e&#287;itim ile olan
ili&#351;kide oldu&#287;u gibi kognitif rezerv teorisiyle a&#305;klanmaya
al&#305;&#351;&#305;lmaktad&#305;r. &nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hipotirodinin gerek genel olarak demans ve gerekse
de AH ile ili&#351;kisi ortaya konmu&#351;tur.&nbsp; AH ile ili&#351;kisinin
mekanizmas&#305; a&#351;ikar olmasa da potansiyel olarak dzeltilebilir bir
durum olmas&#305; bak&#305;m&#305;ndan nemlidir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yorumu yine tart&#305;&#351;mal&#305; olsa da
d&#351;k e&#287;itimin ba&#351;l&#305; ba&#351;&#305;na bir risk faktr
oldu&#287;u art&#305;k yerle&#351;mi&#351; bir bilgidir.&nbsp;E&#287;itim
deneyimindeki art&#305;&#351;&#305;n bireyin kognitif rezervinin
geni&#351;lemesine yol aarak&nbsp;hastal&#305;&#287;&#305;n ortaya
&#305;k&#305;&#351; e&#351;i&#287;ini ykseltmesi ekici bir a&#305;klama
gibi durmaktad&#305;r.&nbsp;TAPS al&#305;&#351;mas&#305;nda da d&#351;k
e&#287;itim demans iin bir risk faktr olarak belirlenmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>TAPS al&#305;&#351;mas&#305;nda elektro-manyetik alan
(EMF) maruziyeti de AH iin bir risk faktr olarak ortaya konmu&#351;tur.
Elektrikiler, tamirciler, santral operatrleri, teknisyenleri,
kaynak&#305;lar, marangozlar, terziler gibi elektrikli aletlerle
al&#305;&#351;anlar a&#351;&#305;r&#305; d&#351;k frekansl&#305; (ELF) EMF
maruziyeti iin risk alt&#305;nda meslek gruplar&#305;d&#305;r. Bizim
al&#305;&#351;mam&#305;z&#305; da ieren ELF-EMF maruziyeti ve AH
ili&#351;kisi ile ilgili 12 al&#305;&#351;man&#305;n meta-analizi olan Garcia
ve arkada&#351;lar&#305;n&#305;n 2008 tarihli makalelerinde bu ili&#351;kinin
ba&#287;&#305;ms&#305;z bir risk oldu&#287;u kabullenilmekle birlikte mevcut
al&#305;&#351;malarda maruziyet dozu ile risk art&#305;&#351;&#305; ve
maruziyet ile cinsiyetlerin ili&#351;kisinin belirlenememi&#351; olmas&#305;
dolay&#305;s&#305;yla daha fazla al&#305;&#351;man&#305;n neminin alt&#305;
izilmi&#351;tir. Maruz kal&#305;nan di&#287;er toksik ve zararl&#305; durumlar
aras&#305;nda organik zcler, aluminyum ve genel anestezi n plana
&#305;kar gibi grnmektedir.&nbsp; Ancak bunlar&#305;n yerle&#351;mi&#351;
tutarl&#305;l&#305;kta bulgular oldu&#287;u sylenemez. Sigara ienlerde,
kolinerjik nikotinik reseptrlerin st reglasyonu ve bunun sonucu olarak
A&#946; dzeylerinin d&#351;mesi ile a&#305;klanan biimde AHnin daha az
grld&#287; bulgusu, ba&#351;lang&#305;ta sigara ienlerin ileri
ya&#351;lara gelmeden di&#287;er hastal&#305;klar nedeniyle lmeleri ve
vaskler demansa daha yatk&#305;n olmalar&#305; &#351;eklinde metodolojik
olarak ele&#351;tirilmi&#351;ken, son zamanlardaki Rotterdam ve New York al&#305;&#351;malar&#305;nda
tam tersine AH riskini bir ka kez artt&#305;rd&#305;&#287;&#305; ynnde
bulgular elde edilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ayr&#305; bir alt ba&#351;l&#305;kta
tart&#305;&#351;&#305;lacak olan otozomal dominan gei&#351;li familyal AH
olgular&#305; yan&#305;s&#305;ra, ailede demans yks AH iin kendi
ba&#351;&#305;na bir risk faktrdr.&nbsp;AHli hastalar&#305;n
karde&#351;lerinde ya&#351;am boyu hastal&#305;k riski beklentisi ikiye
katlanarak %23ten %48e &#305;kar.&nbsp; Monozigotik ikizlerde dizigot
ikizlere oranla AH birlikteli&#287;i anlaml&#305; oranda
fazlad&#305;r.&nbsp;APOE-&#949;4 aleli ile AH ili&#351;kisi &quot;genetik&quot;
altba&#351;l&#305;&#287;&#305; alt&#305;nda tart&#305;&#351;&#305;lacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Yine genetik ba&#351;l&#305;&#287;&#305;
alt&#305;nda sz edilecek olan Down sendromu ve AH ili&#351;kisi
yan&#305;s&#305;ra, Down sendromu aile yks AH riskini 2 ila 3 misli
artt&#305;rmaktad&#305;r.&nbsp; Ayr&#305;ca enteresan bir bulgu olarak, Down sendromlu
ocuk do&#287;uran annelerin AH riskinin, di&#287;er tiplerde mental retarde
ocuklar do&#287;uran annelere gre 5 misli artmas&#305;d&#305;r.&nbsp; Bu
farkl&#305;l&#305;k anne ya&#351;&#305;n&#305;n do&#287;umda 35in alt&#305;nda
oldu&#287;u durumlarda ortaya &#305;kmaktad&#305;r.&nbsp; Down
babalar&#305;nda AH iin ayr&#305;ca bir risk sz konusu de&#287;ildir.&nbsp;
Bu bulgu, AH geli&#351;tirmek ve 35 ya&#351;&#305;n&#305;n alt&#305;nda Down
sendromlu ocuk do&#287;urmak aras&#305;nda payla&#351;&#305;lan bir genetik
yatk&#305;nl&#305;k olas&#305;l&#305;&#287;&#305; ynnde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kafa travmas&#305; yks ile AH aras&#305;nda
ili&#351;ki bildiren nemli al&#305;&#351;malar olmakla birlikte (rn.,
EURODEM) bunu reddedenler de vard&#305;r (rn., Rotterdam
al&#305;&#351;mas&#305; ve Kanada Sa&#287;l&#305;k ve Ya&#351;lanma
al&#305;&#351;mas&#305;). Bilin kayb&#305;na neden olmu&#351; &#351;iddetteki
kafa travmalar&#305;n&#305;n bir risk faktr olarak de&#287;erlendirilmesi mevcut
al&#305;&#351;malardaki eli&#351;ik sonular&#305; a&#351;abilir.
APOE-&#949;4 yk ile kafa travmas&#305;n&#305;n AHnin ba&#351;lang&#305;
ya&#351;&#305; zerine birlikte etkisi oldu&#287;unu ileri sren
al&#305;&#351;malar&nbsp; mevcuttur.&nbsp; Bir al&#305;&#351;mada ise tek
ba&#351;&#305;na etkisiz grnrken, normalde iki misli artm&#305;&#351; olan
APOE-&#949;4 heterozigotlar&#305;n&#305;n riskini 10 misline
artt&#305;rd&#305;&#287;&#305; ortaya konmu&#351;tur.&nbsp; Kafa travmas&#305;n&#305;n
etkisinin &#946;-amiloid metabolizmas&#305; zerinden olmas&#305; muhtemel
grnmektedir. Dementia pugilistica geli&#351;tiren boksrlerin otopsilerinde
saptanan gev&#351;ek neokortikal amiloid plaklar bu varsay&#305;m&#305;
destekler niteliktedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>z gemi&#351;te 10 y&#305;la kadar geriye giden
tedavi gerektirmi&#351; bir depresyon yks AH riskini 3 kat
artt&#305;r&#305;r.&nbsp; Depresyonun hastal&#305;&#287;&#305;n erken bir
gsterisi oldu&#287;unu iddia eden al&#305;&#351;malar vard&#305;r.&nbsp;Jorm
taraf&#305;ndan yap&#305;lan 2001 tarihli meta-analizde
ya&#351;l&#305;l&#305;kta depresyon zgemi&#351;inin demans geli&#351;tirme
riskini ikiye katlad&#305;&#287;&#305; bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>K&#305;s&#305;tl&#305; sosyal ili&#351;kiler
Kungsholmen, &#304;sve ve Kuzey Manhattan, ABD gibi nemli toplum temelli
kesitsel ve uzunlamas&#305;na gzlem al&#305;&#351;malar&#305;nda
ba&#287;&#305;ms&#305;z bir risk faktr olarak ortaya konmu&#351;tur. Sosyal
ili&#351;kiler akraba ve arkada&#351; ili&#351;kilerinin zenginli&#287;i,
sinema, lokanta, klp, dernek faaliyetleri amal&#305; soka&#287;a
&#305;kmalar olarak zetlenebilir. Honolulu-Asya Ya&#351;lanma
al&#305;&#351;mas&#305;nda bu risk orta ya&#351;lar&#305;ndan itibaren sosyal
aktiviteleri d&#351;en bireylerle s&#305;n&#305;rl&#305; bulunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Vaskler olaylar aras&#305;nda miyokard iskemisi,
hipertansiyon, diyabet ve inme yks ile metabolik sendrom mevcudiyetinin AH
riskini anlaml&#305; biimde artt&#305;rd&#305;&#287;&#305; bir ok
al&#305;&#351;mada gsterilmi&#351;tir.&nbsp; Bu bulgular o denli gldr ki,
daha yak&#305;n zamanlara kadar 2. s&#305;kl&#305;kta demans nedeni olarak
gsterilen vaskler demans&#305;n AHden ba&#287;&#305;ms&#305;z bir antite
olarak varl&#305;&#287;&#305; bile son y&#305;llarda tart&#305;&#351;ma konusu
olmu&#351;tur. Ayn&#305; zamanda bir inme risk faktr olan yksek plazma
homosistein dzeyinin AH iin de ba&#287;&#305;ms&#305;z bir risk faktr
oldu&#287;u bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kk kafa evresi ile AH aras&#305;nda baz&#305;
al&#305;&#351;malarda gsterilen ili&#351;ki, e&#287;itim ile olan
ili&#351;kide oldu&#287;u gibi kognitif rezerv teorisiyle a&#305;klanmaya
al&#305;&#351;&#305;lmaktad&#305;r. &nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hipotirodinin gerek genel olarak demans ve gerekse
de AH ile ili&#351;kisi ortaya konmu&#351;tur.&nbsp; AH ile ili&#351;kisinin
mekanizmas&#305; a&#351;ikar olmasa da potansiyel olarak dzeltilebilir bir
durum olmas&#305; bak&#305;m&#305;ndan nemlidir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Koruyucu faktrler</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Epidemiyolojik al&#305;&#351;malar bir dizi
faktrle AH aras&#305;nda, bu faktrlerin koruyucu olabilece&#287;ini
d&#351;ndrecek &#351;ekilde ters bir ili&#351;ki gstermi&#351;tir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>D&#351;k e&#287;itim dzeyi AH iin bir riskken,
do&#287;al olarak yksek e&#287;itim dzeyi ve profesyonel aktivite bir
koruyucu olarak ortaya &#305;kmaktad&#305;r.&nbsp; Benzer biimde APOE-&#949;4
aleli risk iken &#949;2 aleli baz&#305; al&#305;&#351;malarda koruyucu gibi
grnmekteyse de &#949;2nin bu olumlu rol, &#949;4n olumsuz rol kadar
sa&#287;lam bir bulgu olarak yerle&#351;memi&#351;tir.&nbsp; Birinci durum
yukarda szedilen kognitif rezerv kavram&#305; ile a&#305;klan&#305;rken, 2.
durumda &#949;2nin &#946;-amiloid fragman&#305;n&#305;n temizlenmesinde etkin
bir alternatifi temsil etti&#287;i d&#351;nlmektedir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>zellikle dejeneratif hastal&#305;klarda oksidatif
gerilim ve eksitotoksisite mekanizmalar&#305;n&#305;n a&#305;klay&#305;c&#305;
olarak devreye girmesinden sonra, bu mekanizmalar&#305; tersine evirdi&#287;i
iddia edilen teraptik ajanlar&#305;n poplaritesi de
artm&#305;&#351;t&#305;r.&nbsp;Anti-oksidanlar aras&#305;nda zellikle de E
vitamininin koruyucu etkisi zerinde durulmu&#351;, Rotterdam ve Kanada
Ya&#351;lanma gibi nemli al&#305;&#351;malarda C vitaminiyle birlikte bir
koruyucu etkileri varm&#305;&#351; gibi grnse de Washington Heights-Inwood
Columbia niversitesi Ya&#351;lanma al&#305;&#351;mas&#305; ve Honolulu
al&#305;&#351;mas&#305; gibi di&#287;er nemli al&#305;&#351;malarda ise bir
etki gsterilememi&#351;tir.&nbsp;&nbsp;nceden Sano ve arkada&#351;lar&#305;n&#305;n
(bir klinik al&#305;&#351;mas&#305;nda (1997) 2000 IU/gn dozunda E vitamininin
AHlilerin hastal&#305;k seyirlerini yava&#351;latt&#305;&#287;&#305;n&#305;n
gsterilmesiyle AH tedavisinin bir paras&#305; olarak nerilmekte olan E
vitaminin poplaritesi daha yak&#305;n tarihli bir al&#305;&#351;mada
(Petersen ve ark. 2005) MCIdan demansa dn&#351;meyi engelleyemedi&#287;inin
grlmesiyle kaybolmu&#351; gibi durmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Anti-inflamatuar ajan kullananlar aras&#305;nda AH
s&#305;kl&#305;&#287;&#305;n&#305;n daha az oldu&#287;u bir ok gzlemsel
al&#305;&#351;mada gsterilmi&#351;tir.&nbsp; Bu bulgu, sz konusu
ajanlar&#305;n AHdeki inflamatuar sreci tersine evirmeleri &#351;eklinde
yorumlanm&#305;&#351;t&#305;r. Ancak, zgl olarak sa&#287;l&#305;kl&#305;
ya&#351;l&#305;larda demans geli&#351;imini engellemek veya AHlilerde
hastal&#305;k seyrini yava&#351;latmak amal&#305; tasarlanan anti-inflamatuar
klinik al&#305;&#351;malar&#305; ba&#351;ar&#305;l&#305; olamam&#305;&#351;t&#305;r.&nbsp;
strojen kullanan post-menapozal kad&#305;nlarda AHnin daha az grlmesi,
strojenin koruyuculu&#287;u zerine yo&#287;un bir tart&#305;&#351;ma
ba&#351;latm&#305;&#351;t&#305;r.&nbsp; Ancak, Kad&#305;n
Sa&#287;l&#305;&#287;&#305; &#304;nisiyatifi al&#305;&#351;mas&#305;nda
ya&#351;l&#305; kad&#305;nlarda strojen replasman&#305;n&#305;n jinekolojik
kanserlerde artman&#305;n yan&#305;s&#305;ra, ayr&#305;ca demans riskini
d&#351;rmek bir yana tam tersine artt&#305;rd&#305;&#287;&#305;
bulunmu&#351;tur. Yine, kolesterol d&#351;rc ilalar, zellikle de statin
grubu kullananlarda AH prevalans&#305; kullanmayanlara gre daha
d&#351;ktr.&nbsp; Son zamanlarda bu etkinin kolesterol d&#351;rc etkinin
tesinde, statinlerin do&#287;rudan &#945;-sekretaz proteolitik yolunu
uyararak, sAPP olu&#351;umunu artt&#305;rmalar&#305;yla ilintili oldu&#287;una
ili&#351;kin deneysel deliller bulunmu&#351;tur.&nbsp; Yine de, AHlilerde
klinik al&#305;&#351;malarda s&#305;nanan statin tedavisinin faydas&#305;
gsterilememi&#351;tir. Anti-hipertansif ve anti-diabetiklerin vaskler risk
faktrlerinin kontrol arac&#305;l&#305;&#287;&#305;yla demansa kar&#351;&#305;
koruyucu olabilece&#287;i sa&#287;duyuyla da &#305;kar&#305;mlanabilir.
Nitekim, bu ngr anti-hipertansifler a&#305;s&#305;ndan bir ka prospektif
al&#305;&#351;mada do&#287;rulanm&#305;&#351;t&#305;r. &#304;nslin degrade
edici enzimin (IDE) A&#946; klirensinde bir &#351;aperon olarak i&#351;lev
grd&#287; bilinmektedir. &#304;nsuline direnli tip II diyabetiklerde, IDE
beyinde i&#351;lev grmek yerine periferde artan inslini paralamak iin
kullan&#305;lmaktad&#305;r. Dolay&#305;s&#305;yla, zgl olarak inslin
direncini d&#351;rerek i&#351;lev gren peroksizom proliferatr ile aktive
reseptr gamma (PPAR-&#947;) agonistleri s&#305;n&#305;f&#305;
anti-diyabetikler vaskler risk kontrol yan&#305;s&#305;ra potansiyel olarak
zgl anti-Alzheimer etki de gsterebilirler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Birok al&#305;&#351;mada hafif-orta alkol
tketiminin koruyuculu&#287;u bildirilmi&#351;, giderek bu etkinin bir U
e&#287;risi sergiledi&#287;i yksek tketimde kayboldu&#287;u ileri
srlm&#351;tr. Alkoll ikiler iinde zellikle k&#305;rm&#305;z&#305;
&#351;arap zerinde durulmaktad&#305;r. K&#305;rm&#305;z&#305;
&#351;arab&#305;n ierdi&#287;i polifenoller ve zellikle de bir uzun mr
faktr olarak A&#946;n&#305;n etkilerini tersine eviren sirtuin
sinyallemesinde rol oynayan resveratrol son zamanlar&#305;n ilgi
oda&#287;&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Akdeniz diyeti bir koruyucu faktr olarak son
y&#305;llardaki en popler evresel faktr ara&#351;t&#305;rma
konular&#305;ndan biridir. Akdeniz diyeti (MeDi) ile tah&#305;llar, sebzeler,
meyvalar, peynir, st, zellikle bal&#305;k, zeytinya&#287;&#305; ve
k&#305;rm&#305;z&#305; &#351;araptan zengin bir diyet kastedilmektedir.
Columbia niversitesi MeDi al&#305;&#351;mas&#305;, New Yorkta MeDi uyumuna
gre d&#351;k, orta ve yksek olarak
s&#305;n&#305;fland&#305;rd&#305;&#287;&#305; 1393 normal
ya&#351;l&#305;n&#305;n MCI ve 482 MCIl&#305;n&#305;n demans geli&#351;tirme
sonlanma noktalar&#305;nda yksek uyum grubunun d&#351;k uyum grubuna gre
avantajl&#305; oldu&#287;unu gstermi&#351;tir. Rotterdam ve Chicago
Sa&#287;l&#305;k ve Ya&#351;lanma Projesi gibi 2 byk al&#305;&#351;mada
bal&#305;k tketiminin daha yava&#351; kognitif bozulmayla ili&#351;kisi
gsterilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Son olarak, zihinsel ve fiziksel aktivitenin
koruyuculu&#287;undan szedilebilir. Osteoporotik Fraktrler
al&#305;&#351;mas&#305;nda uzunlamas&#305;na izlenen 6000 65 ya&#351; zeri
kad&#305;n aras&#305;nda en fazla yryen st eyrek, en az yryen alt
eyrekle kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda, 6-8
y&#305;l sonra daha az kognitif kay&#305;p sergilemekteydiler. Colcombe ve
Kramerin meta-analizinde (2003) egzersize tabi tutulan sedanter
ya&#351;l&#305;lar&#305;n tutulmayanlarla kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda
k&#305;sa sreli kognitif dzelme sergiledikleri ortaya konmu&#351;tur.
Fiziksel aktivite bir yandan vaskler riskin kontrolu
arac&#305;l&#305;&#287;&#305;yla, di&#287;er yandan da e&#287;itim iin
oldu&#287;u gibi zengin uyarana maruz kalman&#305;n kognitif rezervi
artt&#305;rmas&#305; yoluyla etki ediyor olabilir. ok say&#305;da
al&#305;&#351;ma, okumak, sanatsal faaliyette bulunmak, oyun oynamak gibi
zihinsel aktivite gsteren ya&#351;l&#305;lar&#305;n AH geli&#351;tirme
risklerinin daha d&#351;k oldu&#287;unu ileri srmektedir. Wilson ve
arkada&#351;lar&#305; Chicagoda ortalama 5.3 y&#305;l izledikleri 4000
ya&#351;l&#305; aras&#305;nda, kognitif olarak stimle edici faaliyetlere daha
s&#305;k kat&#305;lan ya&#351;l&#305;lar&#305;n daha d&#351;k ihtimalle
kognitif bozulma sergilediklerini gsterdiler. Zihinsel aktivite de daha zengin
kognitif rezerv olu&#351;turarak etki ediyor olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 13.</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp; Alzheimer
Hastal&#305;&#287;&#305;nda Rol Oynayan Faktrler<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=300 valign=top style='width:225.15pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Risk faktrleri</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=266 valign=top style='width:199.45pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Koruyucu faktrler</span></b><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;mso-yfti-lastrow:yes'>
  <td width=300 valign=top style='width:225.15pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Ya&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Kad&#305;n cinsiyet</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; D&#351;k e&#287;itim</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Ailede demans yks</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Genetik etkenler (APOE-&#949;4)</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Bilin kay&#305;pl&#305; kafa
  travmas&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Down sendromu</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Majr depresyon yks</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Vaskler olaylar</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Plazma homosistein dzeyi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Kk kafa evresi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Hipotiroidi</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt;text-autospace:
  ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Baz&#305; toksik ve zararl&#305;
  durumlara maruz kalma</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=266 valign=top style='width:199.45pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  layout-grid-mode:char;text-autospace:ideograph-numeric'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;
  Yksek e&#287;itim</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; APOE-&#949;2 </span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Anti-oksidan
  kullan&#305;m&#305; (?)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;
  Anti-inflammatuar kullan&#305;m&#305; (?)</span><span lang=FI
  style='font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; strojen
  kullan&#305;m&#305; (?)</span><span lang=FI style='font-family:Tahoma;
  mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Statin
  kullan&#305;m&#305; (?)</span><span lang=FI style='font-family:Tahoma;
  mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;
  K&#305;rm&#305;z&#305; &#351;arap</span><span lang=FI style='font-family:
  Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Akdeniz diyeti</span><span
  lang=FI style='font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
  margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-36.0pt;
  text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp; Fiziksel ve
  zihinsel aktivite</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genetik</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AHde genetik faktrler byk oranda
hastal&#305;&#287;&#305;n geli&#351;imi iin evresel faktrlere bir
yatk&#305;nl&#305;k zemini yaratacak &#351;ekilde birer risk faktr niteli&#287;indedirler.&nbsp;
AH bu zelli&#287;iyle Huntington hastal&#305;&#287;&#305;nda oldu&#287;u gibi
Mendelyen yasalar&#305;n etkisinde basit&nbsp; genetik belirlenimli de&#287;il
de, genetik ve evresel faktrlerin karma&#351;&#305;k bir etkile&#351;imi
sonucu ortaya &#305;kan kompleks nrolojik hastal&#305;klardand&#305;r.&nbsp;
Yine de, tm AH olgular&#305;n&#305;n uluslararas&#305; literatrde %5ine
yakla&#351;an bir oran&#305; basit Mendelyen otozomal dominant gei&#351;le
hastal&#305;&#287;a yakalan&#305;rlar.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genetik a&#305;dan genel olarak kompleks
nrolojik bir hastal&#305;k olarak nitelenmesinin yan&#305;s&#305;ra, AH
Mendelyen gei&#351; a&#305;s&#305;ndan da heterojenite gsteren
polijenik/multialelik bir hastal&#305;kt&#305;r: birden fazla kromozomdaki gen
lokuslar&#305;n&#305;n ok say&#305;da farkl&#305; mutasyonlar&#305; ayn&#305;
hastal&#305;&#287;a yolaar.&nbsp; Otozomal dominant (OD) gei&#351;ten sorumlu
olan &#351;imdiye kadar 3 ayr&#305; gen bulunmu&#351;tur: amiloid prekrsr
protein (APP) geni (<i>APP, </i>21. kromozom), presenilin 1 geni (<i>PSEN1, </i>14.
kromozom) ve presenilin 2 geni (<i>PSEN2, </i>1. kromozom).&nbsp;&nbsp; Bu
genlerin kodlad&#305;&#287;&#305; 3 protein de normal i&#351;levleri ok iyi
bilinmeyen, nronal plastisitede rol oynad&#305;klar&#305; ynnde
varsay&#305;mlar ileri srlen transmembran proteinlerdir.&nbsp; An&#305;lan
genlerdeki mutasyonlar her durumda APP proteolizini A&#946;
fragman&#305;n&#305;n retiminin art&#305;&#351;&#305;na neden olacak yola
kayd&#305;r&#305;rlar.&nbsp; <i>APP</i> mutasyonu ta&#351;&#305;yan aileler ok
az say&#305;da olsa da, bu mutasyonlar bir yandan amiloid metabolizmas&#305;
zerinden hastal&#305;&#287;&#305;n patogenezine &#305;&#351;&#305;k tutarken,
bir yandan da Down sendromu ile AH aras&#305;ndaki ili&#351;kiyi de
ayd&#305;nlatm&#305;&#351;t&#305;r.&nbsp; Bilindi&#287;i gibi Down sendromlular
21. kromozomun 3 kopyas&#305;n&#305; ta&#351;&#305;rlar (21 trizomisi).&nbsp;
Dolay&#305;s&#305;yla, mrleri boyunca APP proteolizinden retilecek daha
fazla A&#946;y&#305; temizlemek zorundad&#305;rlar. Bu hastalar 30lu
ya&#351;lardan itibaren hemen daima AHnin nropatolojik
de&#287;i&#351;ikliklerini gstermeye ba&#351;larlar.&nbsp;&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>OD-AHliler tipik olarak erken
ba&#351;lang&#305;l&#305; (60 ya&#351; ncesi) hastal&#305;&#287;a
sahiptirler. OD-AH ile ili&#351;kilendirilen ilk mutasyon John Hardy
taraf&#305;ndan 1991 y&#305;l&#305;nda bildirilen <i>APP</i>nin
yanl&#305;&#351; anlaml&#305; (missense)<i> </i>bir mutasyonudur (V717I).
Enteresan biimde, ayn&#305; gendeki bir ba&#351;ka mutasyon bir y&#305;l nce
Hollandal&#305; tipi amiloidozlu serebral hemoraji ile
ili&#351;kilendirilmi&#351;ti (G693Q). Biriken veriler serebral amiloid
anjiyopatiye neden olan mutasyonlar&#305;n APPnin </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-amiloid
blgesinin iinde kmelenirken, OD-AHye neden olanlar&#305;n biri
d&#305;&#351;&#305;nda tmnn </span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
kesim blgesini tutarak A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
retimini artt&#305;rd&#305;klar&#305;, bir mutasyonun ise </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
kesim blgesinde hem A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, hem
de A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><sub><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>42</span></sub><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> retimini
artt&#305;rd&#305;&#287;&#305;n&#305; gstermektedir.&nbsp; St. George Hyslop
1995 y&#305;l&#305;nda <i>PSEN1 </i>genini klonlayarak bu gendeki AHye neden
olan mutasyonu tan&#305;mlad&#305;. Bu genin kodlad&#305;&#287;&#305;
Presenilin 1 proteininin (PS1) APPnin </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
proteolizine ve ayn&#305; zamanda embriyogenez s&#305;ras&#305;nda nral
geli&#351;imde temel sinyalleme sistemi olan NOTCH sinyalizasyonuna
arac&#305;l&#305;k eden bir transmembran protein oldu&#287;u
anla&#351;&#305;ld&#305;. Ayn&#305; y&#305;l iinde bu kez Schellenberg grubu
taraf&#305;ndan PS1 ile %80 homoloji ta&#351;&#305;yan Presenilin 2 (PS2)
proteinini kodlayan <i>PSEN2</i> geninde OD-AHye neden olan mutasyon
tan&#305;mland&#305;. Gnmze kadar 76 ailede 28 ayr&#305; <i>APP</i>, 361
ailede 164 ayr&#305; <i>PSEN1</i> ve 18 ailede 10 ayr&#305; <i>PSEN2 </i>mutasyonu
bildirilmi&#351;tir. Her 2 gendeki mutasyonlar da </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivitesini etkileyerek A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n daha toksik formu olan A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
retiminin artmas&#305;na neden olmaktad&#305;rlar. OH-AH aileleri gen
ya&#351;ta ortaya &#305;kmalar&#305; (<i>PS1, </i>25-60 ya&#351;; <i>APP,</i>
40-65 ya&#351;; <i>PSEN2</i>, 45-84 ya&#351;) yan&#305;s&#305;ra, bellek
d&#305;&#351;&#305; bir ekirdek sendromla ve/veya erken davran&#305;&#351;sal
zellikler, miyoklonus ve nbetler &#351;eklinde atipik klinik tablolarla da
&#305;kabilirler. AHnin ilk bildirilen olgusunun erken
ba&#351;lang&#305;l&#305;, davran&#305;&#351;sal belirtilerin n planda oldu&#287;u
bir tabloya sahip oldu&#287;u hat&#305;rland&#305;&#287;&#305;nda Auguste
D.nin bylesi bir genetik varyasyona sahip olmas&#305; ihtimali zerinde
durulmakla birlikte bu olgunun saklanan dokusundan yak&#305;n tarihlerde
yap&#305;lan bir al&#305;&#351;mada <i>PSEN1 </i>mutasyonu
ta&#351;&#305;mad&#305;&#287;&#305; ve <i>APOE</i> genotipinin </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3/</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3
oldu&#287;u bulunmu&#351;tur. Genel olarak <i>PSEN1</i> aileleri <i>APP </i>ailelerine
gre daha atipik ve daha k&#305;sa sreli ve a&#287;&#305;r demans
sergilerlerken, <i>PSEN2 </i>aileleri daha fazla sporadik AHye benzeyen ve
daha yava&#351; seyirli hastal&#305;k tablolar&#305;na sahiptirler.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#350;imdiye kadar tan&#305;mlanan
mutasyonlar familyal AHnin %50si kadar&#305;n&#305; olu&#351;tururlar ve <i>PSEN2</i>nin
tan&#305;mlanmas&#305; zerinden geen 15 y&#305;la ve yo&#287;un
ara&#351;t&#305;rmalara ra&#287;men yeni bir Mendelyen gei&#351; geninin
bulunamamas&#305; dikkat ekicidir. An&#305;lan 3 genle
ba&#287;lant&#305;land&#305;r&#305;lamayan AH aileleri oldu&#287;una gre henz
bulunmayan genler ve otozomal dominant olmayan gei&#351; biimleri ileri
srlebilir.&nbsp; zellikle henz hi otozomal resesif gei&#351;
bildirilmemi&#351; olan bu hastal&#305;kta akraba evliliklerinin s&#305;k
grld&#287; lkemiz bylesi bir bulu&#351; iin potansiyel
ta&#351;&#305;maktad&#305;r. </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>ApoE proteinini kodlayan gen (<i>APOE</i>,
19. kromozom) mutasyonlar&#305;yla do&#287;rudan belirleyici de&#287;il fakat
polimorfizmiyle sporadik AHde risk faktr olarak ortaya konmu&#351;tur.&nbsp;
Kolesteroln ta&#351;&#305;nmas&#305;nda rol oynayan bir protein olan ApoE,
toplam 299 rezidsnn ikisinde arjinin ve/veya sistein bulunmas&#305;yla
farkl&#305;la&#351;an  ayr&#305; alelik forma sahiptir: </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3 ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp;
Kuzey Amerika ve Kuzey Avrupadan normal poplasyonlarda en s&#305;k </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3
(%70-80) grlrken, </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4n
s&#305;kl&#305;&#287;&#305; %10-20, </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2ninki ise
%5-10dur.&nbsp; AHde </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 s&#305;kl&#305;&#287;&#305;
ikiye katlanarak %40-50ye ula&#351;&#305;r.&nbsp; </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 AH
riskini doza ba&#287;l&#305; bir &#351;ekilde artt&#305;r&#305;r ve
hastal&#305;k ba&#351;lang&#305; ya&#351;&#305;n&#305; azalt&#305;r.&nbsp;
AlzGene veritaban&#305;nda (2007) beyazlar ve Japonlarda </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
heterozigotlar&#305;nda AH riski, </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3
homozigotlar&#305;na gre ihtimaliyet oranlar&#305; (ORler)
s&#305;ras&#305;yla 3 ila 4 olacak &#351;ekilde artm&#305;&#351;t&#305;r.&nbsp;</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
homozigotlar&#305;nda hastal&#305;k heterozigotlar&#305;na gre daha erken
ba&#351;lar ve risk, ORler ayn&#305; gruplarda bu kez s&#305;ras&#305;yla 11.8
ve 21.8 olacak &#351;ekilde artar.&nbsp;Ayr&#305;ca, OR-AHde de </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 varl&#305;&#287;&#305;
hastal&#305;k ba&#351;lang&#305; ya&#351;&#305;n&#305; erkene
al&#305;r.&nbsp;Bir yatk&#305;nl&#305;k geni olan ApoEnin </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4nn
varl&#305;&#287;&#305; hastal&#305;k ba&#351;lang&#305;c&#305; iin ne zorunlu
ne de yeterlidir. Bununla birlikte </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
homozigotlar&#305;n&#305;n ya&#351;am boyu kmlatif risklerinin %90
oldu&#287;u hesaplanm&#305;&#351;t&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
s&#305;kl&#305;&#287;&#305; ve patolojik rol iin co&#287;rafi
farkl&#305;l&#305;klar ileri srlm&#351;tr. Bizim de
kat&#305;ld&#305;&#287;&#305;m&#305;z bir gr&#351;e gre Avrupada kuzeyden
gneye s&#305;kl&#305;&#287;&#305; azalacak &#351;ekilde bir gradyan mevcuttur.
rne&#287;in, </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 s&#305;kl&#305;&#287;&#305;
normal poplasyonda kuzeyde Finlandiyada %24 bulunurken, gneyde Yunanistanda
%5.6 gibi kk bir orana kadar inmektedir.&nbsp; Biz TAPS
al&#305;&#351;mas&#305;n&#305;n olgu-kontroll k&#305;sm&#305;nda </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
s&#305;kl&#305;&#287;&#305;n&#305; normal kontrollerde %8.2, buna
kar&#351;&#305;l&#305;k AH grubunda %14.7 bulduk. </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4 OR,
2.21 gibi AlzGenede bildirilenlerden daha d&#351;k olmakla birlikte yine de
anlaml&#305; bulundu. ApoE alel s&#305;kl&#305;&#287;&#305;n&#305; dnya
ap&#305;nda bir meta-analizde ele alan Corbo ve Scacchi (1999) bu gradyan ve
&#949;4n bir AH riski olu&#351;turmas&#305;nda gzlenen etnik ve co&#287;rafi
farkl&#305;l&#305;klar iin akla yak&#305;n bir a&#305;klamada bulundular:
&#949;3, Akdeniz Havzas&#305; gibi kadim bir tar&#305;m
uygarl&#305;&#287;&#305;na sahip insan topluluklar&#305;nda en s&#305;k alel
gibi durmaktad&#305;r (%84.9-%89.8). Atalar&#305;n aleli denebilecek olan
&#949;4, Pigmeler (%40.7), Bantular (%37.0), Malezya ve Avustralya aborjinleri
(%24.0 ve %26.0), Papual&#305;lar (%36.8) ve Lapplar (%31.0) gibi
avc&#305;-toplay&#305;c&#305; ekonominin hala mevcut, besin
kaynaklar&#305;n&#305;n greli olarak k&#305;s&#305;tl&#305; oldu&#287;u
halklarda s&#305;k olsa da ba&#351;ta Sahra-alt&#305; halklarda olmak zere bir
AH riski de&#287;ildir. Yazarlar, &#949;4n Bat&#305;l&#305; diyet, daha uzun
ya&#351;am sreleri gibi a&#287;da&#351; evresel ko&#351;ullara
maruziyetinin, baz&#305; i&#351;levsel zelliklerine dayanarak onu AH iin bir
yatk&#305;nl&#305;k aleli haline dn&#351;trm&#351; olabilece&#287;ini ileri
srdler. </span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#949;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>4n hastal&#305;&#287;&#305;n patogenezindeki rol tam
anlam&#305;yla ortaya konamam&#305;&#351; olsa da, gerek A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
klirensinde ve nronal plastisitede rejenerasyon ve onar&#305;mda rol oynayan
APOEnin, bu rolnde </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#949;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4n, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2 ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3e
gre daha ba&#351;ar&#305;s&#305;z oldu&#287;una ili&#351;kin deliller
vard&#305;r.&nbsp; <i>ApoE </i>nakavt farelerde sinaptik yo&#287;unlukta
ya&#351;a ba&#287;&#305;ml&#305; bir azalma grlr.&nbsp; Kafa travmas&#305;,
serebro-vaskler hastal&#305;k gibi beyin hasarlar&#305;ndan&nbsp; sonra </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
ta&#351;&#305;y&#305;c&#305;lar&#305; daha kt prognoz
gsterirler.&nbsp;&nbsp;&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#350;imdiye kadar incelenen <i>APOE-</i></span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
d&#305;&#351;&#305; hi bir polimorfizmin etki bykl&#287; </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4
ORlerine yakla&#351;amam&#305;&#351;t&#305;r. Bertram ve
arkada&#351;lar&#305;n&#305;n AlzGene veritaban&#305;n&#305; kullanarak
yapt&#305;klar&#305; bir meta-analizde (2007) ba&#287;lant&#305; analiziyle o
zamana kadar 69 gende bildirilen 127 polimorfizm incelenerek 13 gendeki 20
polimorfizm pozitif olarak de&#287;erlendirilmi&#351; ve ortalama risk ORleri
1.25, ortalama koruyucu ORleri 0.85 olarak bulunmu&#351;tur. Bu 20 polimorfizm
aras&#305;ndan zellikle anjiyo-tensin converting enzim (<i>ACE</i>), GRB2
asosiye ba&#287;lay&#305;c&#305; protein 2 (<i>GAB2) </i>ve transferrin<i> </i>(<i>TF</i>)
genlerindeki polimorfizmler kk etkilerine ra&#287;men en az 10
al&#305;&#351;mada do&#287;rulanm&#305;&#351; greli olarak byk rneklem
say&#305;lar&#305;yla dikkate de&#287;er ek risk faktrleri olabilirler. Son
zamanlarda stnde durulan ba&#351;ka bir yatk&#305;nl&#305;k geni de sortilin
ili&#351;kili reseptr genidir (<i>SORL1). </i>SORL1 APPnin hcre yzeyinden
Golgi-endoplazmik retikulum kompleksine naklinde rol oynad&#305;&#287;&#305;
bilinmektedir. SORL1 ifadesinin azalmas&#305; A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
art&#305;&#351;&#305;na neden olmaktad&#305;r. Lee ve
arkada&#351;lar&#305;n&#305;n gzden geirdi&#287;i zere byk rneklemlerdeki
alelik asosiasyon al&#305;&#351;mas&#305;nda 1.4 ila 2.2 aras&#305;nda ORler
saptanm&#305;&#351;t&#305;r. Genom Boyu Asosiasyon al&#305;&#351;mas&#305;
(GWAS) ba&#287;lant&#305; analizinden farkl&#305; olarak bir genetik lokus ile
hastal&#305;&#287;&#305;n ili&#351;kisini nceden teorik olarak varsaymak
gerekmeksizin, binlerce hastal&#305;k byk hasta rneklemlerini&nbsp;
kontrollerle tm genomun analizi arac&#305;l&#305;&#287;&#305;yla
kar&#351;&#305;la&#351;t&#305;r&#305;p hastal&#305;k grubunda anlaml&#305; olarak
daha s&#305;k grlen varyasyonlar&#305; ortaya koymaya dayan&#305;yor. 2009
y&#305;l&#305;nda tamamlanan 2 byk GWAS al&#305;&#351;mas&#305;n&#305;n
ilkinde 5000i a&#351;k&#305;n hasta ve 10000i a&#351;k&#305;n kontroln
analizinde Harold ve arkada&#351;lar&#305; clusterin (nceden <i>APOJ</i>
olarak bilinen) geni (<i>CLU</i>) ve 11. kromozomda bulunan
phosphatidylinositol ba&#287;layan clathrin asamble proteini geni<i> </i>(<i>PICALM</i>)<i>
</i>ile anlaml&#305; ili&#351;kiler bildirdiler. Nature Geneticsin ayn&#305;
say&#305;s&#305;nda yay&#305;nlanan 2. GWAS al&#305;&#351;mas&#305;nda
5000den fazla hasta ve kontrol bireylerinde Lambert ve arkada&#351;lar&#305;
8. kromozomda bulunan <i>CLU</i>daki lokusu do&#287;rularken, bu kez 1.
kromozomdaki kompleman bile&#351;eni reseptr 1 geninde (<i>CR1) </i>bir lokus
daha gsterdiler. Bu 3 genin kodlad&#305;&#287;&#305; proteinlerin de A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
klirensinde rol oynad&#305;&#287;&#305; d&#351;nlmektedir. yle grnyor
ki, her &#351;eye ra&#287;men yeni yatk&#305;nl&#305;k genlerinin
ara&#351;t&#305;r&#305;lmas&#305; ve bulunanlar&#305;n do&#287;rulanmas&#305;na
ynelik yo&#287;un abalar srecektir. Bu blmn bir zeti iin <b>Tablo 14</b>e
bak&#305;n&#305;z.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span><span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Tablo 14. </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n geneti&#287;i<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.65pt;border-collapse:collapse;border:none;mso-border-alt:
 solid black 1.0pt;mso-padding-alt:0cm 0cm 0cm 0cm;mso-border-insideh:1.0pt solid black;
 mso-border-insidev:1.0pt solid black'>
 <tr style='mso-yfti-irow:0'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gen
  ve Proteini</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kromozom</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Mekanizma</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Etki</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border:solid black 1.0pt;
  border-left:none;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Risk</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>APP  </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Amiloid prekrsr protein</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>21</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Mutasyon/ Duplikasyon</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946;40 ve A&#946;42 retiminde art&#305;&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Tam penetrans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>PSEN1 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Presenilin 1 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>14</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Mutasyon</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946;42 retiminde art&#305;&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Tam penetrans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>PSEN2 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Presenilin 2 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Mutasyon</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946;42 retiminde art&#305;&#351;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Tam penetrans</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>APOE  </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Apolipoprotein E </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>19</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>&#949;2, &#949;3, &#949;4</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>&#949;4: 3.68 (3.30-4.11)</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>&#949;3: 0.62 (0.45-0.85)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>ACE </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Anjiotensin I converting enzim</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>17</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>C, T</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.83 (0.72-0.95)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>GAB2 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>GRB2 asosiye ba&#287;lay&#305;c&#305; protein 2</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>11</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, G</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.85 (0.76-0.94)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>TF </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Transferrin</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>3</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>C2, C1</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1.18 (1.06-1.31)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>SORL1 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Sortilin ili&#351;kili reseptr</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>11</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, C</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; retiminde artma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1.10 (1.03-1.17)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>CLU </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Clusterin</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>8</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, C</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.86 (0.82-0.89)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>PICALM </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Phosphatydinilinositol ba&#287;lay&#305;c&#305; klatrin asamble
  proteini</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>11</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>C, T</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>0.87 (0.83-0.91)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=151 valign=top style='width:113.45pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>CR1 </span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>Kompleman bile&#351;eni (3b/4b) reseptr 1</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:3.0cm;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:
  solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>Polimorfizm</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoSubtitle style='text-align:justify'><span lang=TR
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;font-weight:
  normal'>T, C</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=116 valign=top style='width:86.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>A&#946; klirensinde bozulma</span><span style='font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=149 valign=top style='width:111.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoSubtitle style='text-align:justify;layout-grid-mode:char'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
  font-weight:normal'>1.18 (1.09-1.28)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n otozomal dominan gei&#351;li
formlar&#305;ndan sorumlu 3 gen ile yatk&#305;nl&#305;k geni <i>APOE </i>yan&#305;s&#305;ra
2010 Nisan ay&#305; itibariyle AlzGene veritaban&#305;ndaki (</span><span
style='font-family:Tahoma'><a href="http://www.alzgene.org/"><span lang=TR
style='mso-ansi-language:TR'>www.alzgene.org</span></a></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>) pozitif
al&#305;&#351;malar aras&#305;nda en az 10 al&#305;&#351;ma ve 10000e
yakla&#351;an rneklem byklklerine sahip olan aday yatk&#305;nl&#305;k
genleri (<i>ACE, GAB2, TF, SORL1</i>) ile genom boyu asosiasyon
al&#305;&#351;malar&#305;nda yak&#305;n tarihlerde ortaya konulan aday
yatk&#305;nl&#305;k genleri (<i>CLU, PICALM, CR1</i>) gsterilmi&#351;tir.
Risk, ihtimaliyet oranlar&#305; (ORler) ve parantez ilerinde %95 gvenilirlik
aral&#305;klar&#305; ile gsterilmi&#351;tir.<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>NROPATOLOJ&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AHnin klinik tan&#305;da ba&#351;vurulabilecek
patognomik bir i&#351;aretleyicisi olmad&#305;&#287;&#305; gibi patolojik
tan&#305;s&#305; da benzer bir glk ta&#351;&#305;r.&nbsp; Pick
cisimciklerinin varl&#305;&#287;&#305; PiH kesin tan&#305;s&#305; iin gerekli
ve yeterli ko&#351;uldur.&nbsp; Oysa ki, AH kesin tan&#305;s&#305; iin
patolojik olarak nrofibriler yumaklar (NFY) ve senil ya da amiloid
plaklar&#305;n (AP) saptanmas&#305; gerekli ancak yeterli de&#287;ildir.&nbsp;
Her iki lezyon da normal ya&#351;lanmada oldu&#287;u gibi bir dizi ba&#351;ka
dejeneratif hastal&#305;kda da grlebilir.&nbsp; AHnin kesin tan&#305;s&#305;
iin patolog bu iki lezyonun varl&#305;&#287;&#305;n&#305; saptaman&#305;n
yan&#305;s&#305;ra&nbsp; belli bir nroanatomik da&#287;&#305;l&#305;mda ve
belli miktarlarda olduklar&#305;n&#305; da gstermelidir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;lerde demansa dn&#351;ecek olsun ya da
olmas&#305;n normal insanlar 60 ya&#351;lar&#305;ndan itibaren neokortikal
gev&#351;ek plaklar ve bazen limbik NFYler geli&#351;tirmeye
ba&#351;larlar.&nbsp; Ancak titiz kliniko-anatomik korelasyon
al&#305;&#351;malar&#305; NFYlerin neokorteks, APlerin ise nritik veya sert
plak biimiyle limbik sistemde grnr olmalar&#305;n&#305;n AH iin %100e
yakla&#351;an duyarl&#305;l&#305;k ve zgllk gsterdi&#287;ini ortaya
koymaktad&#305;r.&nbsp; A&#351;a&#287;&#305;da daha iyi grlece&#287;i gibi,
NFYlerin limbik sistemde birikip neokortekse gei&#351;i ve giderek
neokortekste yayg&#305;nl&#305;k gstermeye ba&#351;lamas&#305;, normal ya&#351;lanma-MCI-giderek
a&#287;&#305;rla&#351;an demans devaml&#305;l&#305;&#287;&#305;n&#305;n
patolojik korelat&#305; gibi durmaktad&#305;r.&nbsp; Yine klinik evreyle
say&#305;sal ve blgesel a&#305;dan korelasyon gstermemekle birlikte
gev&#351;ekten nritike do&#287;ru biimini de&#287;i&#351;tirip limbik
sistemde grlr hale gelen AP hemen daima AHyi MCIdan ay&#305;ran zelliktir
denebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>NFY&nbsp; ve APlerin yan&#305;s&#305;ra
gliozis-inflamasyon, nron ve sinaps kay&#305;plar&#305;, aksonal ve dendritik
morfolojik de&#287;i&#351;iklikler, kortikal kolinerjik innervasyon ve
di&#287;er nrotransmitter sistemlerinde kay&#305;plar AH nropatolojisinin bile&#351;enlerini
olu&#351;tururlar <b>(Tablo 15).</b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tablo 15.</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> AH Nropatolojisi</span><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
  <td width=315 valign=top style='width:236.0pt;border:solid black 1.0pt;
  padding:7.0pt 7.0pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nrofibriler
  yumaklar (NFY)</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloid plaklar (AP)</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nron kayb&#305;</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dendritik ve aksonal
  de&#287;i&#351;iklikler</span><span lang=DA style='font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinaps kayb&#305;</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gliozis - inflamasyon</span><span
  lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik innervasyonun
  kayb&#305;</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
  DA'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er nrotransmitter
  kay&#305;plar&#305;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nrofibriler yumaklar</span></b><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>NFYlerin <b>(&#350;ekil 10)</b> temel
bile&#351;eni hiperfosforile t (tau) proteinidir.&nbsp; Tau 17. kromozom
taraf&#305;ndan kodlanan mikrotbl asosiye proteinler (MAP) ailesinden bir
proteindir.&nbsp;Mikrotbller zellikle aksonlarda yerle&#351;ir.
Mikrotbllerin stabilizasyonu, sitoskeletal btnlk ve kargo vezikllerinin
aksonal nakliyesinde nemli roller oynar.&nbsp; Kargo veziklleri eskiyen
yap&#305;lar&#305;n replasman&#305; ve sinaptik aktivite iin gerekli protein
ve enzimleri ierir. Mikrotbller tau-tubulin etkile&#351;imi ile stabilize
olabilen labil yap&#305;lard&#305;r. Bu etkile&#351;im tau proteininin
izoformuna ve fosforilizasyon durumuna ba&#287;l&#305;d&#305;r. Tau proteini
karboksi ucunda mikrotbllere ba&#287;lanma blgesi say&#305;s&#305;na gre
 3 tekrar (3R),  ise drt tekrar (4R) ta&#351;&#305;yan toplam 6 izoforma
sahiptir. 4R tau mikrotbl stabilizasyonunda daha etkindir. &#304;kincil
mesajc&#305;lar&#305;n uyar&#305;m&#305; post-sinaptik nrondaki tm
intraseller proteinleri oldu&#287;u gibi tauyu da protein kinazlar&#305;n
aktivitesiyle fosforile eder. Fosforile tau mikrotblden ayr&#305;l&#305;r. Yine
btn fosforile intraseller proteinler gibi tau da i&#351;lev bittikten sonra
fosfatazlar arac&#305;l&#305;&#287;&#305;yla defosforile edilmelidir ki yeniden
mikrotble ba&#287;lanabilsin. Fosforile taunun defosforilasyonundan
ba&#351;l&#305;ca sorumlu fosfataz protein fosfataz 2Ad&#305;r (PP2A). AH
patogenezinde hiperaktif kinazlar ve/veya hipoaktif fosfatazlar tau proteininin
hiperfosforilizasyonuna yolaarak mikrotbllere ba&#287;lanma yetene&#287;ini
bozarlar.&nbsp; Bu kinazlar aras&#305;nda zellikle glikojen sentetaz kinaz 3</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n (GSK-3</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)
yaln&#305;z AHde de&#287;il, di&#287;er taupatilerde de patolojik
hiperfosforilasyondan sorumlu olan enzim oldu&#287;u zerinde
durulmaktad&#305;r. Ba&#287;lanmam&#305;&#351; hiperfosforile tau monomerleri
fiziksel konformasyonlar&#305;n&#305; de&#287;i&#351;tirerek kendi zerlerine
katlan&#305;rlar (patolojik hatal&#305; katlanma) ve toksik oligomerlere
dn&#351;rler. Tau oligomerleri bir sonraki a&#351;amada&nbsp;yine toksik
zlemeyen ift sarmall&#305; filamanlara (PHF) polimerize olurlar.&nbsp;
PHFler &#305;s&#305; &#351;oku proteinleri ve ba&#351;l&#305;ca ubikutin
proteozom sistemlerinin devreye girmesiyle giderek intranronal NFYler
&#351;eklinde kondanse olurlar (<b>&#350;ekil 11</b>).&nbsp; NFYlerin toksik
PHFlerin etkisini s&#305;n&#305;rlamaya al&#305;&#351;an bir savunma
mekanizmas&#305; oldu&#287;u giderek geerlilik kazanan bir gr&#351;tr.
Yetersiz bir savunma olan NFY ile sonunda hcre iskeleti btnl&#287; ve
aksonal nakliye bozularak hcre lm meydana gelir.&nbsp; Hcre lmyle
ortaya &#305;kan ekstraseller NFYye </span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>hayalet yumak ad&#305; verilir. NFYden hayalet
yuma&#287;a gei&#351;in y&#305;llar&#305; kapsayan uzun bir sre oldu&#287;u
d&#351;nlmektedir.&nbsp;&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span style='font-size:10.0pt;font-family:Tahoma'><a
href="demans10.JPG"><span lang=TR style='mso-ansi-language:TR'>&#350;ekil 10.</span></a></span></b><b><span
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;ntraseller
Nrofibriler Yumak</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>(Kaynak: </span><span style='font-size:10.0pt;font-family:
Tahoma'><a href="http://www-medlib.med.utah.edu/WebPath/CNSHTML/CNS094.html"><span
lang=TR style='mso-ansi-language:TR'>http://www-edlib.med.utah.edu/WebPath/CNSHTML/CNS094.html</span></a></span><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>NFYler beyinde rasgele de&#287;il
fakat belli bir blgesel yatk&#305;nl&#305;&#287;&#305; yans&#305;tacak &#351;ekilde
yerle&#351;irler.&nbsp; Normal ya&#351;l&#305;l&#305;k srecinde limbik
(entorhinal ve hippokampal) NFY say&#305;s&#305;yla kronolojik ya&#351;
aras&#305;nda korelasyon gsterilmi&#351;tir. Braak ve Braak&#305;n I ve II.
evrelerine kar&#351;&#305;l&#305;k gelen bu a&#351;aman&#305;n
sa&#287;l&#305;kl&#305; ya&#351;lanmadan ya&#351;la ilintili unutkanl&#305;&#287;a
(AAMI) gei&#351;in nral altyap&#305;s&#305; oldu&#287;u ileri srlebilir. En
erken de&#287;i&#351;iklikler entorhinal korteksin (ECx) II. molekler
tabakas&#305;nda olu&#351;maktad&#305;r. ECx limbik sistemin d&#305;&#351;
dnyayla arayz olarak de&#287;erlendirilebilir. Hat&#305;rlanmak zere
kaydedilmesi gereken her trl yeni bilgi limbik sisteme ECx II
arac&#305;l&#305;&#287;&#305;yla girer ve bu tabakadaki nronlar&#305;n
aksonlar&#305; perforan yolu olu&#351;turarak ECxi hippokampal formasyonun
giri&#351; kap&#305;s&#305; denilebilecek olan dentat girusunun (DG) granler
tabakas&#305;na ba&#287;larlar. DG epizodik (otobiyografik) bellek sistemindeki
bilgi i&#351;lemenin nral altyap&#305;s&#305; olan 2 kapal&#305; devrenin
yolaklar&#305;n&#305; ta&#351;&#305;r: lokal intrensek hippokampal devre ve
geni&#351; boyutlu Papez devresi (<b>&#350;ekil 12</b>). Her iki devre de
nihayetinde subikulum arac&#305;l&#305;&#287;&#305;yla&nbsp; ECx alt tabakalar&#305;na
(IV-VI) ba&#287;lanarak kapanacak ve ECx IV-VI i&#351;lenmi&#351; limbik
bilgiyi multimodal asosiasyon kortekslerine geri bildirebilecektir.
&#304;ntrensek hippokampal devre iinde DG yosunsu lifler
arac&#305;l&#305;&#287;&#305;yla Ammon boynuzunun 3. sektrnn (CA3) piramidal
tabakas&#305;na ba&#287;lan&#305;r. Shaffer kollateralleri bu kez CA3 CA1e
ba&#287;larlar. CA1 ise subikuluma ba&#287;lan&#305;r. Subikulum hippokampal
formasyonun bu kez &#305;k&#305;&#351; kap&#305;s&#305; konumundad&#305;r ve
yukarda de&#287;inildi&#287;i gibi her 2 devrenin de sonland&#305;&#287;&#305;
yap&#305;d&#305;r. Papez devresi ise DGden fimbria-fornix
arac&#305;l&#305;&#287;&#305;yla hipotalamusun mamiller cisimciklerine (CM)
olan ba&#287;lant&#305;yla ba&#351;lar. CM, mamillo-talamik traktus (MTT)
arac&#305;&#287;&#305;yla talamusun limbik ekirdekleri de denilen anterior
grup ekirdeklerine ba&#287;lan&#305;r.&nbsp; Talamus anterior grubu posterior
singulat girusla (pCG), pCG ise retrosplenial girusla (rSG)
ba&#287;lant&#305;l&#305;d&#305;r. rSGden subikuluma olan
ba&#287;lant&#305;larla Papez devresi kapan&#305;r. AHde nrodejenerasyonun
a&#287;&#305;rl&#305;&#287;&#305; ve sresiyle paralel biimde NFYnin nceden
grld&#287; bir blgedeki say&#305;s&#305; artarken o blgeyle
ba&#287;lant&#305;l&#305; olan kom&#351;u blgeye transsinaptik olarak
yay&#305;l&#305;r.&nbsp; Dolay&#305;s&#305;yla, ECx II dejenerasyonuyla DG
diskoneksiyonu ve bunun sonucunda meydana gelen ve sadece CA3n sahip
oldu&#287;u ve girdilerinin %95ini ol&#305;u&#351;turan oto-asosiyatif
liflerince sa&#287;lanan kompansatuar CA3 a&#351;&#305;r&#305; aktivitesinin
sonucu olan de&#287;i&#351;erek reorganize olan intrensek hippokampal devre
AAMIdaki bellek bozuklu&#287;unun nral temeli olabilir. Braak ve Braak, Iden
VIya s&#305;ralad&#305;klar&#305; evreler boyunca NFYlerin entorhinal
kortekste grlmeye ba&#351;lay&#305;p nce hippokampus ve sonra da paralimbik
alanlara, sonunda da heteromodal neokortikal alanlara yay&#305;l&#305;p
say&#305;lar&#305;n&#305;n art&#305;&#351;&#305;n&#305; izleyen bir evreleme
sistemi geli&#351;tirdiler.&nbsp; Mesulam, Braak ve Braak sistemine paralel bir
klinokopatolojik korelasyon evrelemesi nererek (<b>&#350;ekil 13</b>) NFY
yay&#305;l&#305;m&#305;n&#305; normal ya&#351;lanmadan MCI, hafif ve
a&#287;&#305;r demans evreleri sreklili&#287;i iinde izler. Bu evreler
boyunca intrensek hippokampal devrenin ve Papez devresi
yap&#305;lar&#305;n&#305;n giderek daha fazla NFY ile yklendikleri ilerleyici
sre AHnin AAMI-MCI-demans sreklili&#287;i boyunca merkezi ilerleyici bellek
bozuklu&#287;u fenotipinin de a&#305;klamas&#305;d&#305;r.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AHnin yerle&#351;ik tedavisi iinde
yeralan ajanlardan biri olan memantinin in vitro olarak PP2A agonizmas&#305;
yapt&#305;&#287;&#305;na dair deliller AHlilerle yap&#305;lan kk bir
al&#305;&#351;mada al&#305;&#351;ma sonunda BOS fosfo-tau dzeylerinde
gsterilen d&#351;me ile desteklenmi&#351;tir. GSK3</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
inhibitrleri (rne&#287;in, lityum, valproat, thiadiazolidindionlar [TDZDler:
NP-13])&nbsp; ve mikrotbl stabilizatrleri (rne&#287;in, paclitaxel,
davunetide [AL-108]) erken klinik geli&#351;im a&#351;amas&#305;ndaki anti-tau
stratejiler aras&#305;ndad&#305;r. Fosfo-tau immunizasyonuna ili&#351;kin
ba&#351;ar&#305;l&#305; bir pre-klinik al&#305;&#351;ma mevcuttur .</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans11.JPG">&#350;ekil 11.<span
style='font-weight:normal'>&nbsp;</span></a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Mikrotbl
asosiye tau proteinin NFYye evrimi</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> veya drt tekrar blgesinden mikrotble
ba&#287;l&#305; olan tau proteini hiperaktif kinazlar (zellikle GSK3&#946;)
ve/veya hipoaktif fosfatazlar&#305;n (zellikle PP2A) varl&#305;&#287;&#305;nda
hiperfosforile olarak mikrotbllerden serbestler. Serbest tau patolojik olarak
katlanarak oligomerle&#351;ir. Oligomerler ift sarmall&#305; filamanlara (PHF)
kondanse olurlar. PHF ise &#305;s&#305; &#351;oku proteinleri (zellikle HSP90)
ve proteozomal ubikutinizasyon sistemi arac&#305;l&#305;&#287;&#305;yla
NFYlere hapsolunurlar.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar:
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>GSK3&#946;: glikojen sentetaz kinaz 3&#946;; HSP: &#305;s&#305; &#351;oku
proteini; MAP: mikrotbl asosiye protein; NFY: nrofibriler yumak; P: fosfor;
PHF: ift sarmall&#305; filaman; PP2A: protein fosfataz 2A</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='mso-special-character:line-break;page-break-before:
always'>
</span>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans12.JPG">&#350;ekil 12.</a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
&#304;ntrensek hippokampal ve Papez devreleri</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multimodal
asosiasyon alanlar&#305; ECxin st tabakalar&#305; ile ileri besleme
ba&#287;lant&#305;lar&#305;na sahiptir. ECx II molekler tabaka perforan yol
arac&#305;l&#305;&#287;&#305;yla hippokampal formasyonun giri&#351;
kap&#305;s&#305; DGnin granler tabakas&#305;na ba&#287;lan&#305;r. DG fornix
arac&#305;l&#305;&#287;&#305;yla Papez, yosunsu lifler
arac&#305;l&#305;&#287;&#305;yla intrensek hippokampal devreyi
ba&#351;lat&#305;r. Her 2 devre de hippokampal formasyonun &#305;k&#305;&#351;
kap&#305;s&#305; olan subikulumun zerine dner. Subikulum ECx alt
tabakalar&#305; arac&#305;l&#305;&#287;&#305;yla multimodal asosiasyon
kortekslerine limbik geri besleme yapar. CA3n %95 girdisi kendi
oto-asosiyatif lifleri arac&#305;l&#305;&#287;&#305;ylad&#305;r. Perforan yol
CA3e bir kollateral verir. ECx IIIden CA1 ve subikuluma do&#287;rudan
ba&#287;lant&#305;lar mevcuttur.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar:
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Ant. Th: talamus anterior grup ekirdekler;<b> </b>CA1 ve 3: cornu ammonis
1 ve 3; CM: corpus mamillare; DG: dentat girus; ECx: entorhinal
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; korteks; pCG: posterior singulat girus; rSG:
retrosplenial girus.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans13.JPG">&#350;ekil 13.</a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR;mso-bidi-font-weight:bold'><span
style='mso-spacerun:yes'></span>Nrofibriler yumaklar&#305;n zaman ve uzamsal
ilerleyi&#351;i. Kaynak 29dan modifiye edilmi&#351;tir. </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'>+ say&#305;s&#305; ve giderek koyula&#351;an renk gradyan&#305;
artan NFY ykn temsil etmektedir. AAMI: Ya&#351;la ilintili bellek bozuklu&#287;u;
MCI: Hafif kognitif bozukluk.&nbsp;</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloid plaklar ve Amiloid-</span></b><b><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span></b><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Fizyopatolojisi</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AHdeki ikinci temel nropatolojik
de&#287;i&#351;iklik olan ve NFYlerin tersine ykleri hastal&#305;k &#351;iddetiyle
korele etmeyen senil plaklar&#305;n (<b>&#350;ekil 14</b>) amiloid maddelere
yksek afiniteli Kongo k&#305;rm&#305;z&#305;s&#305; ile
boyand&#305;&#287;&#305; 1927de Divry taraf&#305;ndan gsterilmi&#351;, bir
dizi farkl&#305; morfolojik yap&#305;da olsalar da ana bile&#351;enlerinin
amiloid beta peptidi (A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>) oldu&#287;u 1984te Glenner
ve Wong taraf&#305;ndan bildirilmi&#351;tir (yani, senil plak = amiloid
plak).&nbsp; Yukarda genetik blmnde szedildi&#287;i gibi A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, 21.
kromozomda kodlanan ve i&#351;levi tam olarak
anla&#351;&#305;lamam&#305;&#351;sa da bir sinaptik adhezyon proteini
oldu&#287;u d&#351;nlen bir transmembran protein olan amiloid prekrsr
proteininin (APP) metabolizma rnlerindendir.&nbsp; APP geninin
yokedildi&#287;i transjenik farelerde (APP nakavt) nral plastisitede rol
olabilece&#287;ini d&#351;ndren &#305;l&#305;ml&#305; bulgular mevcuttur.&nbsp;
APP yoklu&#287;u onun gibi davranan ve amiloid prekrsr benzeri proteinler
ad&#305; verilen APLP1 ve APLP2 taraf&#305;ndan kompanse ediliyor olabilir.
Nitekim, APP/APLP2 ifte nakavtlar sa&#287; kalamamaktad&#305;r. </span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Btn transmembran proteinlerde
oldu&#287;u gibi APPnin de bir hcreii karboksi ucu (CT), bir membran kateden
paras&#305;, bir de hcred&#305;&#351;&#305; amino ucu (NT) vard&#305;r (<b>&#350;ekil
15</b>).&nbsp; 770, 751 ve 695 rezidlk 3 alternatif ba&#287;lanm&#305;&#351;
izoformu olan APPnin intramembranz paras&#305; 700-723. rezidlere rastlar. </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-amiloid,
671 ila 711-713. rezidler aras&#305;nda yeralan 40 veya 42 rezidlk distal
k&#305;sm&#305; ekstraseller, proksimal k&#305;sm&#305; intramembranz
yerle&#351;mi&#351; bir paras&#305;d&#305;r.&nbsp; APP bir dizi proteolitik
enzimle&nbsp; kesilerek metabolize edilir.&nbsp;Bu enzimlere </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
adlar&#305; verilir.&nbsp; </span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
APPyi tam da A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>n&#305;n ortalar&#305;na raslayan 687. ekstraseller
blgede keser.&nbsp;Bu kesim sonunda distalde parenkime at&#305;lan zlebilir
APP ya da sAPP</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> ad&#305; verilen ekstraseller
para olu&#351;urken geride hala membrana ba&#287;l&#305; 83 rezidlk
C-teminal fragman&#305;-</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> (CTF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)
kal&#305;r.&nbsp; sAPP</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>n&#305;n hcre kltrlerinde nrotrofik etkileri
bulunmu&#351; ve APP nakavt transjeniklerdeki plastisite defisitlerini geri
evirdikleri gsterilmi&#351;tir.&nbsp; Oysa ki, alternatif distal kesimi yapan
</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>-sekretaz enzimi APPyi A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>y&#305; salim b&#305;rakacak
&#351;ekilde, ekstraseller blgede </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz&#305;n
daha distalinden 671. pozisyondan keserek akson budanmas&#305; ve
dejenerasyonuna neden oldu&#287;u d&#351;nlen distal para sAPP</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>y&#305; parenkime atar ve geride salim
A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> fragman&#305;n&#305; da ieren 99 rezidlk membrana
ba&#287;l&#305; CTF-</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>y&#305; b&#305;rak&#305;r. Proksimal kesme ise
intramembranz blgede a&#287;&#305;rl&#305;kla 711, daha az olarak 713.
pozisyondan </span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#947;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>-sekretaz enzimi
arac&#305;l&#305;&#287;&#305;ylad&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz CTF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>y&#305; kesti&#287;inde bu kez
parenkime A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>n&#305;n
budanm&#305;&#351; ve zarars&#305;z p3 ad&#305; verilen
parac&#305;&#287;&#305; at&#305;l&#305;rken, geride kalan CTF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
taraf&#305;ndan biraz daha proksimalde, </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#949;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> pozisyonundan
(720/721) bir kez daha kesilmesiyle nkleer sinyallemede rol
oynad&#305;&#287;&#305; bulunan amiloid intraseller domeni (AICD) isimli
fragman sitoplazmaya sal&#305;n&#305;r.&nbsp; Buna kar&#351;&#305;l&#305;k, </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
CTF-</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>y&#305;
kesti&#287;inde 711 veya 713. pozisyonlardan kesilmeye gre daha
a&#287;&#305;rl&#305;kla A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, daha
az oranda da, daha toksik formu olan A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>fragman&#305;,
yani klirensi ba&#351;ar&#305;yla sa&#287;lanamazsa amiloid plaklarda birikecek
materyel ortaya &#305;kar.&nbsp; Normal ya&#351;lanmada </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivitesi bask&#305;nken, AHde denge </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
alternatifine kaymaktad&#305;r. Yine yukarda genetik blmnde szedildi&#287;i
gibi OD-AH zellikle A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><sub><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>retimini
artt&#305;r&#305;rken ba&#351;ta APOE olmak zere btn yatk&#305;nl&#305;k
genleri A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> klirensini etkileyerek risk olu&#351;turmakta veya
koruyucu olmaktad&#305;rlar.&nbsp; </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivitesini ok say&#305;da transmembran proteinin proteolizinde grevli olan
bir disintegrin ve metalloproteinaz (ADAM) ailesinden bir dizi
metalloproteinaz&#305;n yerine getirdi&#287;i bilinmektedir. Bunlar
aras&#305;nda en aktiflerinden biri ADAM17 olarak da bilinen tmr nekrotizan
faktr-</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#945;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> evirici enzim (TACE), di&#287;eri ADAM10dur. </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz&#305;n
son y&#305;llarda 11. kromozomdaki geni de bulunarak karakterize edilmi&#351;
ve BACE (beta-site APP cleaving enzyme) ad&#305; verilmi&#351;tir.&nbsp; BACE
nakavt farelerde kayda de&#287;er bir de&#287;i&#351;iklik olmamakla birlikte
APP/PS1 gibi son derece virulan bir AH transjeni&#287;i ile
aprazla&#351;t&#305;r&#305;lan BACE nakavt farelerin soyunda, plak birikimi
iin BACEin temel nemde oldu&#287;unu gsterecek &#351;ekilde plak birikimi
olmamaktad&#305;r. Bu da </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz inhibisyonunu ekici
bir tedavi hedefi k&#305;lmaktad&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz&#305;n
ise aktif blgesinde presenilini de ieren ayr&#305;ca nikastrin, APH-1 ve
PEN-2 isimli proteinlerden olu&#351;an bir proteaz kompleksi oldu&#287;u
bilinmektedir. Daha nce de szedildi&#287;i gibi PS1 ayn&#305; zamanda
nro-geli&#351;imde temel olan NOTCH sinyalizasyonunda da rol oynamaktad&#305;r
ve PS1 nakavt fareler a&#287;&#305;r geli&#351;imsel kusurlar sergileyerek
sa&#287; kalamamaktad&#305;rlar.&nbsp;</span><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Parenkimdeki A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
monomerleri kendi ba&#351;&#305;na zarars&#305;zd&#305;r ve mikroglia
taraf&#305;ndan do&#287;rudan fagositoza maruz b&#305;rak&#305;ld&#305;klar&#305;
gibi APOE alelik formlar&#305;, inslin degrade edici enzim (IDE), </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2-makroglobulin
(</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#945;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>2-MG), neprilizin ve matriks metalloproteinaz (MMP) gibi
proteinleri ieren bir dizi &#351;aperon molekle ba&#287;lan&#305;p,
d&#351;k dansiteli lipoprotein reseptr ili&#351;kili protein (LRP-1)
arac&#305;l&#305;&#287;&#305;yla astrosit ve nronlara internalize edilerek
otofaji ve proteozomal degradasyona maruz b&#305;rak&#305;l&#305;rlar. LRP1
farkl&#305; hcre tiplerinde A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n internalizasyonu iin bir
kap&#305;c&#305; olarak d&#351;nlebilir ve nitekim vaskler endotelinden
sirklasyona aktar&#305;l&#305;rak temizlenmeye de arac&#305;l&#305;k eder.
Degradasyon ve klirens arac&#305;l&#305;&#287;&#305;yla ba&#351;a
&#305;k&#305;lamayan miktarlardaki monomerler bir araya gelerek dimer ve
trimerler &#351;eklinde zlebilir A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomerlerini olu&#351;turacaklard&#305;r. Oligomerler paralanarak amiloid
betadan treyen difze olabilen ligandlara (ADDLler) de&#287;i&#351;ebilirler
veya toplanmay&#305; srdrerek bir sonraki a&#351;amada art&#305;k zlemeyen
protofibrilleri ve giderek toksik fibrilleri olu&#351;tururlar. ADDLler
aras&#305;nda NTde ilk 2 resids budanm&#305;&#351; ve piroglutamatla
de&#287;i&#351;tirilmi&#351; A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> [A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
(3(pE)-42)] toksik potansiyeli ve birikime yatk&#305;nl&#305;&#287;&#305; en
fazla biim olarak ilgi ekmeye ba&#351;lam&#305;&#351;t&#305;r. A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
fragman&#305;n&#305;n nce oligomerizasyonu, sonra da fibrilizasyonuna amino
ucuna yak&#305;n bir konumda bulunan a&#287;&#305;r metal
ba&#287;lay&#305;c&#305; blgelerinin arac&#305;l&#305;k etti&#287;i
d&#351;nlmektedir. Buna gre, Cu<sup>++ </sup>ba&#287;lanmas&#305;
oligomerizasyon, Zn<sup>++ </sup>ba&#287;lanmas&#305; fibrilizasyon iin
gereklidir. Zn<sup>++ </sup>yan&#305;s&#305;ra metal ba&#287;lay&#305;c&#305;
blgenin yak&#305;nlar&#305;ndaki proteoglikan polisakkarid makromoleklleri
ba&#287;layan ba&#351;ka bir blgenin de fibrilojenezde etkili oldu&#287;u
bildirilmi&#351;tir. Fibriler A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> plaklara
hapsedilecektir.</span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#304;lk birikim NFYlerin tersine
limbik sistemde de&#287;il, neokortekste ve gev&#351;ek (difz) plaklar
&#351;eklindedir.&nbsp;Bu plaklardaki amiloidin byk o&#287;unlukla fibriler
de&#287;il granler A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomerlerini ierdikleri
bulunmu&#351;tur. Gev&#351;ek plaklar kognitif bozukluk geli&#351;tirmeden
lm&#351; olan ya&#351;l&#305; beyinlerinde de byk miktarlarda grlebilir.
Ayr&#305;ca AHlilerde hastal&#305;&#287;&#305;n semptomatolojisine katk&#305;da
bulundu&#287;u d&#351;nlmeyen striatum, talamus ve serebellum gibi
blgelerde evrelerinde gliozis ve nritik sitopatolojik
de&#287;i&#351;iklikler olmaks&#305;z&#305;n grlebilirler. Ayr&#305;ca, ok
say&#305;da immunositokimyasal al&#305;&#351;ma ile gev&#351;ek plak
ieri&#287;inin daha toksik ve birikime yatk&#305;n ba&#351;l&#305;ca A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> formu
oldu&#287;unu grlm&#351;tr. Dolay&#305;s&#305;yla, plak olu&#351;umu A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
monomerinden birikime do&#287;ru giden bir patogenetik mekanizman&#305;n daha
olgun bir evresinden ok hastal&#305;&#287;&#305;n demans ncesi
a&#351;amas&#305;ndaki bir savunma mekanizmas&#305; olarak d&#351;nlebilir:
degradasyon ve klirens mekanizmalar&#305;yla A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ile&nbsp;
ba&#351;a &#305;k&#305;lmakta bu mekanizmalar A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>iin
yetersiz kald&#305;&#287;&#305;nda plak formasyonu yoluna gidilmektedir. Buna
kar&#351;&#305;l&#305;k di&#287;er plak formu olan kat&#305; (kompakt) plaklar
ekirde&#287;ini beta katlanm&#305;&#351; fibriler A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n olu&#351;turdu&#287;u
plaklard&#305;r, Bu a&#351;amadan sonra dejenere nritler ieren kat&#305;
plaklara nritik plaklar ad&#305; verilir.&nbsp; Nritik plaklar immun
cevab&#305; tetikleyerek mikroglia ve astrosit aktivasyonu ile TNF-&#945; ve
IL-&#946; gibi sitokinlerin sal&#305;n&#305;m&#305;, kompleman aktivasyonu ve
serbest radikal olu&#351;umuna neden olurlar. Bu immun aktivasyon
nrotoksisitenin ba&#351;l&#305;ca etmenlerindendir gibi durmaktad&#305;r.
Nritik plaklar yaln&#305;zca demansl&#305; beyinlerde grlr.&nbsp; Nritik
bile&#351;en sinaptik art&#305;k ve nrofilamanlardan olu&#351;ur ve o&#287;u
ayn&#305; zamanda t-PHF iin de pozitif immunoreaksiyon gsterir.&nbsp; PHF(+)
plaklarda nritik bile&#351;enin NFY ieren akson kal&#305;nt&#305;lar&#305;
oldu&#287;u sylenebilir.&nbsp; Bylelikle blgesel olarak farkl&#305;
ba&#351;lang&#305; yatk&#305;nl&#305;klar&#305;na sahip olan NFY ve APler
hastal&#305;&#287;&#305;n seyri iinde PHF(+) plaklarla birlikte yan yana
gelmi&#351; olurlar.&nbsp;Nritik plaklar tam boy A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40 </span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>ve A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>42</span></sub><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>nin
her ikisini de ierdikleri gibi ADDLleri de ierirler. Bunlar aras&#305;nda
yukarda en toksik oldu&#287;u sylenilen amino ucundan budanm&#305;&#351; A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
(3(pE)-42 formu demans &#351;iddetine korele edecek &#351;ekilde Braak ve Braak
evre IV-VI boyunca nritik plak kompozisyonundaki oran&#305; giderek artar. Bu
bulgu da yaln&#305;zca demansl&#305; beyinlerde grlen bu daha olgun plak
formunun da bizzat kendisinin bir tetiki olmas&#305;ndan ok alternatif
savunma mekanizmalar&#305;n&#305;n ok yetersiz kald&#305;&#287;&#305;
nrodejenerasyonun bu ileri a&#351;amalar&#305;na zg bir ek savunma
giri&#351;imi oldu&#287;unu d&#351;ndrmektedir. Son zamanlarda
A&#946;n&#305;n zellikle A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> (3(pE)-42
formu ile agrezom ad&#305; verilen intranronal birikintilerde birikti&#287;ine
dair al&#305;&#351;malar artmaktad&#305;r. Bu al&#305;&#351;malar sonucunda
intranronal birikimin sinaps ve nron kayb&#305;na neden olan, ekstraseller
plak birikimini nceleyen erken bir fenomen oldu&#287;u ileri srlm&#351;tr.
Bu yeni bulgular &#305;&#351;&#305;&#287;&#305;nda A&#946; monomerinden nritik
pla&#287;a do&#287;ru evrim eski perspektifle oldu&#287;u gibi giderek daha
zararl&#305; bir forma do&#287;ru izgisel bir evrilme &#351;eklinde de&#287;il
de toksik A&#946; oligomeri ile farkl&#305; a&#351;amalarda ba&#351;a
&#305;kma stratejileri olarak grlmelidir. Degrade edilemeyen toksik
A&#946;n&#305;n fibrilizasyonu ve sonras&#305;nda da plaklara hapsolunmas&#305;
toksisitesinin giderilmesine ynelik nlemler olmakla birlikte, bu zlemeyen
birikintilerle znr oligomerik formlar aras&#305;nda srekli bir dinamik
dengenin mevcudiyeti asl&#305;nda bu formlar&#305;n toksik biimler iin
srekli bir rezervuar i&#351;levi grmeleri anlam&#305;na gelmektedir. A&#946;
oligomerinin yolat&#305;&#287;&#305; sinaptik disfonksiyon ve giderek nron
kayb&#305;n&#305; nceleyen ve a&#351;an sinaps kayb&#305; mekanizmalar&#305;na
a&#351;a&#287;&#305;da de&#287;inilecektir.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AP yknn AHde demans
&#351;iddetiyle korele etmedi&#287;ini gsteren nropatolojik
al&#305;&#351;malar&#305;n tesinde, PIBden ba&#351;layarak PET amiloid ligandlar&#305;n&#305;n
geli&#351;tirilmesinden sonra AP yknn bir k&#305;s&#305;m kognitif
yak&#305;nmas&#305; olmayan ya&#351;l&#305;lar ve bir k&#305;s&#305;m
MCIl&#305;larda AH tan&#305;s&#305; alm&#305;&#351; demansl&#305;lar dzeyine
yakla&#351;t&#305;&#287;&#305;, hatta AP yk a&#305;s&#305;ndan AHye
benzeyen MCI</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>l&#305;lar&#305;n
uzunlamas&#305;na izlemlerinde demansa dn&#351;tkleri, bir kez demans
geli&#351;tikten sonra ise AP yknn fazlaca de&#287;i&#351;medi&#287;i ortaya
konmu&#351;tur. PET ile llen amiloid yk esas olarak MCIdan da nce
pre-klinik a&#351;amada ilerleyici olarak art&#305;yor, pre-demans MCI ve
demans a&#351;amalar&#305;nda ise byk lde de&#287;i&#351;meyecek denge
durumuna ula&#351;&#305;yor gibi durmaktad&#305;r.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> monomerinin
retiminin engellenmesinden ba&#351;layarak tm zlebilir ve zlemez
formlar&#305;n&#305;n klirensini desteklemek gelece&#287;in temel tedavi
stratejisi gibi durmaktad&#305;r. APP proteolizini non-amiloidojenik yne
kayd&#305;rmak amal&#305; bir spesifik </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
aktivatr (NP-17) ilk kez klinik al&#305;&#351;ma evresine kadar
ula&#351;m&#305;&#351;t&#305;r. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
inhibisyonu yukarda szedilen nedenlerle daha ekici bir hedef gibi grnse de
spesifik kk molekll ajanlar&#305;n geli&#351;tirilmesi a&#305;s&#305;ndan
geride kalm&#305;&#351;t&#305;r. Yak&#305;n tarihlerde bir ajan (CTS-21166) ilk
kez bir faz I al&#305;&#351;mada ba&#351;ar&#305;yla s&#305;nanm&#305;&#351;,
bir di&#287;eri iin de (HPP854) faz I al&#305;&#351;mas&#305; iin ba&#351;vuruda
bulunuldu&#287;u bildirilmi&#351;tir. </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#947;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
inhibisyonu hedefi, yine yukarda s&#305;ralanan nedenlerle problemli gibi
grnse de s&#305;nanan byle bir ajan (flurizan) faz IIIe kadar gelip bu
noktada tak&#305;lm&#305;&#351;, di&#287;eri (semagacestat) ise halen olduka
byk boyutlu bir faz IIIte s&#305;nanmaktad&#305;r. Do&#287;al klirens
mekanizmalar&#305; yetersiz kald&#305;&#287;&#305;nda immunizasyon
arac&#305;l&#305;&#287;&#305;yla ba&#351;a &#305;kma abas&#305; ekici bir
hedeftir. Nitekim, tam boy A</span><span style='font-size:10.0pt;font-family:
Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> peptidine
kar&#351;&#305; geli&#351;tirilen antijenle ba&#351;lat&#305;lan bir faz IIa
al&#305;&#351;mas&#305; (AN1792) hastalar&#305;n bir blmnde geli&#351;en
meningoensefalit nedeniyle durduruldu. len bir olgunun otopsisinde
anti-amiloid etki iin tetiklenen hmoral immunite cevab&#305;
yan&#305;s&#305;ra inflamasyonun nedeninin ayr&#305;ca tetiklenen T-hcre
cevab&#305; oldu&#287;u ileri srld. Hcresel immuniteyi tetiklemeden sadece
hmoral immuniteyi tetikleyecek bir yntem zerinde al&#305;&#351;an
ara&#351;t&#305;r&#305;c&#305;lar sonunda hcresel cevab&#305;n A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>nin C-terminaline kar&#351;&#305;
geli&#351;ti&#287;ini, N-terminalini ieren 5-6 rezidlk budanm&#305;&#351;
epitoplar&#305;n teraptik olarak yeterli hmoral cevaba neden oldu&#287;unu
buldular. Sonras&#305;nda humanize monoklonal A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
antikorlar&#305;yla pasif immunizasyonun da ba&#351;ar&#305; &#351;ans&#305;
yksek bir mdahele biimi oldu&#287;u ortaya kondu. Halen ok say&#305;da
aktif (rne&#287;in, ACC-001, CAD106, V-950) ve pasif (rne&#287;in,
bapineuzumab, LY2062430) immunizasyon ajan&#305; klinik al&#305;&#351;malar&#305;n
e&#351;itli evrelerinde s&#305;nanmaktad&#305;r. Sekretaz modlasyonu ve
immunizasyonun yan&#305;s&#305;ra A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> monomerinin
toksik olgun biimlerine dn&#351;mesini engelleme stratejileri de
denenmektedir. Anti-oligomerizatrler aras&#305;nda s&#305;n&#305;flanan
tramiprosat isimli molekl byk umutlarla geldi&#287;i faz III
a&#351;amam&#305;&#351;t&#305;r. Di&#287;er bir
anti-oligomerizasyon/fibrillizasyon yntemi </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-katlanman&#305;n
arac&#305;lar&#305;ndan a&#287;&#305;r metal ba&#287;lay&#305;c&#305; blgenin
inhibisyonudur. Metalloprotein zay&#305;flat&#305;c&#305; ajanlar (MPACler)
bylesi ajanlard&#305;r. Bunlar aras&#305;nda clioquinol (PBT-1) toksik
metaboliti bertaraf edilemedi&#287;i iin geli&#351;imi durdurulduysa da benzer
bir molekl olan PBT-2nin faz II al&#305;&#351;malar&#305; srdrlmekteydi.
Exebryl ve scyllo-inositol (ELND005/AZD-103) isimli molekller klinik
al&#305;&#351;malarda s&#305;nanmakta olan di&#287;er kk molekll
anti-fibrillizatrler aras&#305;ndad&#305;rlar.</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans14.JPG">&#350;ekil 14.</a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Amiloid Plak (Kaynak: </span><span style='font-size:10.0pt;font-family:Tahoma'><a
href="http://www-medlib.med.utah.edu/WebPath/CNSHTML/CNS090.html"><span
lang=TR style='mso-ansi-language:TR'>http://www-edlib.med.utah.edu/WebPath/CNSHTML/CNS090.html</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=DA style='font-family:Tahoma;mso-ansi-language:
DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans15.JPG">&#350;ekil 15.</a> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>APP proteolizi
ve A&#946; birikimi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:48.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Amiloid
prekrsr protein (APP) 770 aminoasidlik (aa) bir transmembran (TM) proteindir.
700 ve 723. aalar membran&#305; kateden paras&#305;na rasgelir. A&#946;
karboksi ucuna (CT) yak&#305;n 40-42 aal&#305;k bir fragman&#305;d&#305;r.
A&#946;n&#305;n 700 ila 711-713. aalara kar&#351;&#305;l&#305;k gelen
k&#305;sm&#305; membran iinde (transmembran domen  TMD), 671 ila 699. aalar
aras&#305;nda kalan k&#305;sm&#305; ise ekstraseller (jukstamembran domen 
JMD) yerle&#351;imlidir. APP proteolizi distalde ekstraseller parada
amiloidojenik veya non-amiloidojenik olarak yap&#305;l&#305;r. Amiloidojenik
proteoliz A&#946; fragman&#305;n&#305; salim b&#305;rakacak &#351;ekilde 671.
pozisyondan &#946;-sekretaz kesimiyle ba&#351;lat&#305;l&#305;r. Bu kesim amino
ucunda (NT) akson budanmas&#305;nda rol oynad&#305;&#287;&#305; bulunan
sAPP&#946; ve CTde membrana ba&#287;l&#305; 99 aal&#305;k (C99) fragman&#305;
olu&#351;turur. Non-amiloidojenik proteoliz ise APPyi A&#946;-JMD iinden,
687. pozisyondan kesen &#945;-sekretaz arac&#305;l&#305;&#287;&#305;yla
ba&#351;lar. Bu kesim de NTde nrotrofik etkileri bilinen sAPP&#945; ve CTde
yine membrana ba&#287;l&#305; 83 aal&#305;k (C83) fragman&#305;
olu&#351;turur. C99 ve C83 intramembranz parada &#947;-sekretaz kompleksi
(GS) ile bir dizi ard&#305;&#351;&#305;k kesimden geer. &#304;lk kesim &#949;
kesimi ad&#305; verilen 720 veya 721. pozisyonda meydana gelir. Olu&#351;an
49-50 aal&#305;k APP intraseller domeni (AICD) isimli fragman&#305;n hcre
ekirde&#287;ine transloke olarak protein sentezini destekledi&#287;i
bilinmektedir. &#304;kinci kesim &#950; kesimidir ve 717 veya 718. pozisyonda
ve nihayet 3. kesim olan &#947; kesimi 711 veya 713. pozisyondad&#305;r. Bu son
kesim non-amiloidojenik C83te ise ortama 24-26 aal&#305;k inert bir
budanm&#305;&#351; A&#946; parac&#305;&#287;&#305; olan p3, amiloidojenik
C99da ise 40-42 aal&#305;k salim bir A&#946; fragman&#305; retir. GS APPnin
yan&#305;s&#305;ra bir dizi TM proteinin daha proteolizinden sorumlu olan bir
aspartil proteaz kompleksidir. Aktif katalitik blgesi presenilin 1 veya 2
(PSEN) olmak zere 4 ayr&#305; proteinin bile&#351;imidir (Pen-2, Nicastrin,
Aph1B). GSnin di&#287;er nemli proteolitik hedefi nro-geli&#351;imde nemli
rol oynayan NOTCH proteinidir. GS kesimi sonras&#305; NOTCH intraseller domeni
(NICD) ad&#305; verilen fragman, gen ifadesini ve hcresel farkl&#305;la&#351;may&#305;
ba&#351;latmak zere nukleusa transloke olur. Ortama sal&#305;nan A&#946;
monomerli mikroglial fagositozla temizlenebilecekleri gibi &#351;aperon
molekller taraf&#305;ndan vaskler endotelden klirensi sa&#287;lanabilir veya
yine &#351;aperon molekller taraf&#305;ndan lizozomal veya proteozomal
degradasyona maruz kalacaklar&#305; nronlar ve astrositler iine sokulur. Bu
yntemlerin her hangi biriyle ortamdan uzakla&#351;t&#305;r&#305;lamayan,
zellikle de potansiyel olarak daha toksik form olan A&#946;<sub>42 </sub>gev&#351;ek
plaklarda birikir. Bu son savunma mekanizmas&#305; da ba&#351;ar&#305;s&#305;z
kald&#305;&#287;&#305; takdirde A&#946; monomeri zlebilir oligomerler
halinde bir araya gelir. zlebilir oligomer bir dizi sinaptik disfonksiyon
mekanizmas&#305;n&#305; tetikleyerek AHnin en erken fizyopatolojik
zelli&#287;i olan LTP depresyonuna neden olur. Oligomerler daha toksik
ADDLlere budanabilecekleri gibi zlemeyen A&#946; fibrillerine do&#287;ru da
evrilebilirler. A&#946; fibrilleri de hcre y&#305;k&#305;nt&#305; rnleri
olan distrofik nritlerle birlikte nritik plaklarda hapsedilirler. Fibriler
A&#946; gibi nritik plaklar da kararl&#305; yap&#305;lar olmaktan ok toksik
oligomerler iin bir tr rezervuar i&#351;levi grmektedirler. Nritik plaklar
evrelerinde oksidatif gerilim yan&#305;s&#305;ra aktive mikroglia
arac&#305;l&#305;&#287;&#305;yla inflammasyona yolaarlar.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nron kayb&#305;</span></b><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AHde nron kayb&#305; entorhinal
korteksten ba&#351;lar ve limbik sistemi terketti&#287;inde superior temporal
sulkusta tespit edilebilir.&nbsp;&nbsp; Nron kayb&#305;n&#305;n zaman iinde
ilerleme ve anatomik yatk&#305;nl&#305;k tarz&#305; genel anlamda NFYnin
tarz&#305;na benzese ve NFY ile nron say&#305;lar&#305;n&#305;n
aras&#305;nda&nbsp; anlaml&#305; negatif korelasyonlar saptansa da, nron
lmnden tek ba&#351;&#305;na NFYler sorumlu tutulamaz.&nbsp; Subkortikal
ekirdekler gibi NFYlerin bulundu&#287;u blgelerde ille de nron
kayb&#305;n&#305;n olmas&#305; gerekmedi&#287;i gibi, NFYlerin az say&#305;da
oldu&#287;u ya da hi bulunmad&#305;&#287;&#305; blgelerde de a&#287;&#305;r
nron kayb&#305; grlebilir.&nbsp; Amiloid nrotoksisitesinin neden
oldu&#287;u sinaps kayb&#305; ve transsinaptik dejenerasyon hcre lmnde rol
oynad&#305;&#287;&#305; d&#351;nlen di&#287;er etmenlerdir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik kay&#305;p</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Btn korteksin kolinerjik
innervasyonu temel limbik yap&#305;lardan biri olan bazal nbeyindeki Meynert
ekirde&#287;inden sa&#287;lan&#305;r.&nbsp; Bu innervasyon dikkat ve bellek
i&#351;levlerinin optimal srdrlebilmesi a&#305;s&#305;ndan byk nem
ta&#351;&#305;r.&nbsp; Tau hiperfosforilazasyonun ilk grld&#287; alanlardan
biri de Meynert ekirde&#287;idir.&nbsp; AHde limbik alanlardaki yayg&#305;n
NFY formasyonu ve nron kayb&#305; Meynert&nbsp; ekirde&#287;ini de
etkiler.&nbsp; Kolinerjik aksonlar&#305;n kayb&#305; di&#287;er patolojik
zellikler gibi bir blgesel yatk&#305;nl&#305;k gsterir.&nbsp; Lokal internronlardan
sa&#287;lanan striatal kolinerjik innervasyon ve talamusun beyinsap&#305;
pedinklopontin ekirdek kaynakl&#305; kolinerjik innervasyonu
etkilenmedi&#287;i gibi, etkilenen Meynert kaynakl&#305; kolinerjik innervasyon
da ayn&#305; tarz&#305; yans&#305;t&#305;r: kortekste en fazla etkilenen
blgeler limbik ve asosiasyon korteksleri iken, primer sensoryal ve motor
korteksler greli olarak salim kal&#305;rlar.&nbsp;&nbsp;&nbsp;</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik buton da denilen
pre-sinaptik kolinerjik terminalde kolin asetil transferaz enzimi (ChAT) bir
yandan mitokondrilerden asetil koenzim A arac&#305;l&#305;&#287;&#305; ile
serbestlenen kolinden, di&#287;er yandan da yksek afiniteli kolin geri
al&#305;n&#305;m sistemi arac&#305;l&#305;&#287;&#305;yla al&#305;nan kolinden
asetil kolin (ACh) retir.&nbsp;&nbsp; ACh moleklleri vezikllere paketlenip
depolarizasyonu izleyerek sinaptik aral&#305;&#287;a salg&#305;lan&#305;r.&nbsp;
Sinaptik aral&#305;kta difzyonla ilerleyen ACh post-sinaptik membranda
nikotinik reseptrlere ba&#287;lanarak do&#287;rudan, muskarinik reseptrlere
ba&#287;lanarak ise G-proteini ili&#351;kili ikincil mesajc&#305;lar zerinden
etkisini gsterir.&nbsp; Nikotinik etkilerin hcrenin
uyar&#305;labilirli&#287;ini artt&#305;rarak dikkat tonusunun
sa&#287;lanmas&#305;nda rol oynad&#305;&#287;&#305;, muskarinik etkilerin ise
kal&#305;c&#305; sinaptik de&#287;i&#351;ikliklerle yeni bilginin
depolanmas&#305; &#351;eklindeki nroplastisite mekanizmalar&#305;n&#305;n
unsuru oldu&#287;u bilinmektedir.&nbsp; Beyinde </span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7 nikotinik
reseptrler (</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7nAChR) pre-sinaptik
yerle&#351;imlidir ve uyar&#305;lmalar&#305; AChnin pre-sinaptik akson
terminalinden sal&#305;n&#305;m&#305;n&#305; artt&#305;r&#305;rken yine
pre-sinaptik muskarinik 2 ACh reseptrleri (M2AChR) tam tersine ACh
sal&#305;n&#305;m&#305; inhibe ederler. AHnin erken dneminde </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7nAChR</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>de kompansatuar bir art&#305;&#351;
sz konusuyken pre-sinaptik denge giderek nikotinik aleyhine ve muskarinik
lehine dnmeye ba&#351;lar. Post-sinaptik membranda bulunan ve her ikisi de AH
srecinde erken dnemde kaybolmaya ba&#351;layan M1AChR ve hem pre- hem de
post-sinaptik yerle&#351;mi&#351; olan </span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2nAChRlerin
uyar&#305;lmas&#305; yukarda de&#287;inilen h&#305;zl&#305; (nikotinik) ve
yava&#351; (muskarinik) kolinerjik nrotransmisyona arac&#305;l&#305;k eder.
Hem nikotinik, hem de muskarinik stimlasyon kayb&#305;n&#305;n gerek </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz
etkinli&#287;inin azalmas&#305;yla A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
olu&#351;umunun artmas&#305; ve gerekse de GSK-3</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
etkinli&#287;inin artmas&#305;yla taunun patolojik fosforilizasyonunun da
artmas&#305; &#351;eklinde in vitro etkileri gsterilmi&#351;, di&#287;er
yandan A</span><span style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang;mso-ansi-language:TR'></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>n&#305;n </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7nAChR
blokaj&#305; zerinden AChn&#305;n sentez, sal&#305;n&#305;m ve post-sinaptik
etkinli&#287;ini azaltabilece&#287;i de ortaya konmu&#351;tur.&nbsp;Bu durum A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> ve
kolinerjik kayb&#305;n birbirlerini pozitif geri besledikleri bir
k&#305;s&#305;r dng olu&#351;turmaktad&#305;r. Muskarinik kolinerjik
nrotransmisyonun tetikledi&#287;i fosfoinositol sistemi zerinden
anti-Alzheimer mekanizmalar <b>&#350;ekil 16 ve 17</b> de gsterilmi&#351;tir.
Bu mekanizmalar </span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#945;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2 ve </span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7
nikotinik ile M1 muskarinik agonizman&#305;n bir tedavi hedefi olarak nemini
gstermektedir ve bunlar&#305;n tmne ili&#351;kin teraptik ajanlar, doz
k&#305;s&#305;tlayan gastro-intestinal yan etkilerinin sundu&#287;u byk glklere
ra&#287;men klinik al&#305;&#351;malarda ilerlemeye
al&#305;&#351;maktad&#305;rlar (rne&#287;in, s&#305;ras&#305;yla TC-1734, MEM
3454, AF267B). M2 antagonizmas&#305;n&#305;n hayvan modellerinde M1
agonizmas&#305;na benzer anti-AH etkileri gsterilmi&#351;tir.
Asetilkolinesteraz (AChE) enzimi katalitik iyonik k&#305;sm&#305;n&#305;n
aktivitesiyle AChyi asetat ve koline hidrolize ederek AChnin post-sinaptik
aktivitesini durdurur.&nbsp;AChEnin di&#287;er yandan periferik aniyonik
k&#305;sm&#305; arac&#305;l&#305;&#287;&#305;yla A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomerleriyle olu&#351;turduklar&#305; fibriler kompleksin de tek
ba&#351;&#305;na oligomerinkini a&#351;an toksik etkileri gsterilmi&#351;tir.
AChE inhibitrleri AH tedavisinin ilk yerle&#351;ik ajanlar&#305; olarak
teraptik cephanede oktan yerlerini alm&#305;&#351;lard&#305;r. Klasik
katalitik blge inhibisyonu yan&#305;s&#305;ra periferik blge inhibisyonu da
yapabilen ajanlar (rne&#287;in, NP-61) erken klinik geli&#351;im
a&#351;amas&#305;ndad&#305;rlar. strojen limbik nronlarda sinaptogeneze
katk&#305;da bulunup nroplastisitede rol oynarken, Meynertte ACh retimine de
katk&#305;da bulunur.&nbsp; Post-menapozal kad&#305;nlarda strojen replasman&#305;n&#305;n
koruyucu etkisi an&#305;lan i&#351;levleri dolay&#305;s&#305;yla olabilir.</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:36.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans16.JPG">&#350;ekil 16.</a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Kolinerjik
sinaps<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kolinerjik Sinaps.Pre-sinaptik akson terminalinde ChAT,
asetil CoA arac&#305;l&#305;&#287;&#305;yla kolini asetilleyerek ACh olu&#351;turur.
ACh vezikller iine paketlenerek sinaps aral&#305;&#287;&#305;na sal&#305;n&#305;r.
Presinaptik nikotinik </span><span style='font-size:10.0pt;font-family:Tahoma'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7
reseptrlerinin uyar&#305;lmas&#305; ACh sal&#305;n&#305;m&#305;n&#305; stimle
ederken (ye&#351;il ok), muskarinik M2 reseptrlerinin uyar&#305;lmas&#305;
inhibe eder (k&#305;rm&#305;z&#305; ubuk). Sinaptik aral&#305;&#287;a sal&#305;nan
ACh post-sinaptik nikotinik </span><span style='font-size:10.0pt;font-family:
Tahoma'>&#945;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>4</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2
reseptrleriyle ba&#287;land&#305;&#287;&#305;nda Na<sup>4</sup> kanal&#305; a&#305;l&#305;r
ve ieriye Na<sup>+ </sup>girerek dikkatten sorumlu h&#305;zl&#305; kolinerjik
nrotransmisyonu ba&#351;lat&#305;r. Muskarinik M1 reseptrlerine ba&#287;lanan
ACh, reseptre ba&#287;l&#305; Gq proteinini aktive ederek PLCyi fosforiller.
Fosforile PLC bir yandan ikincil mesajc&#305;lardan membrana ba&#287;l&#305;
diasil gliserol (DAG) aktive ederek PKCyi do&#287;rudan fosforillerken, di&#287;er
yandan da fosfoinositol difosfattan (PIP<sub>2</sub>) inositol trifosfat (IP<sub>3</sub>)
reterek endoplazmik retikulumdaki (ER) kendi reseptrne ba&#287;lanacak di&#287;er
ikincil mesajc&#305;y&#305; hcre iine salar. IP<sub>3</sub>,<sub> </sub>ERden
Ca<sup>++ </sup><span style='mso-spacerun:yes'></span>sal&#305;n&#305;m&#305;n&#305;
sa&#287;lar ve artan intraseller Ca<sup>++ </sup>bylece daha fazla PKCyi
dolayl&#305;</span><span lang=TR style='font-size:10.0pt;mso-bidi-font-size:
12.0pt;font-family:Tahoma;mso-ansi-language:TR'> yoldan fosforillemi&#351;
olur. Fosforile PKC, mitojen aktive protein kinaz (MAPK) arac&#305;l&#305;&#287;&#305;yla
nkleer transkripsiyonu devreye sokar ve &#287;renmenin temeli olan yeni
sinaps yap&#305;m&#305;na arac&#305;l&#305;k eder. Sinaps aral&#305;&#287;&#305;nda
i&#351;levi biten ACh, AChE arac&#305;l&#305;&#287;&#305;yla asetat ve koline
paralan&#305;r. Kolin pre-sinaptik terminalden kolin ta&#351;&#305;y&#305;c&#305;s&#305;
arac&#305;&#287;&#305;yla geri al&#305;n&#305;r</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=ListParagraph0CxSp&#304;lk style='text-align:justify'><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#350;ekil
17. </span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>AHli sinapsta A</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n anti-glutamaterjik ve
anti-plastisite etkiler<b><o:p></o:p></b></span></p>

<p class=ListParagraph0CxSpOrta style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans17a.JPG">&#350;ekil 17a.</a> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Glutamaterjik
sinaps, GABA-erjik olan&#305;n tersine AHde<b style='mso-bidi-font-weight:
normal'> </b>erken dnemde sald&#305;r&#305; alt&#305;ndad&#305;r. APPnin
amiloidojenik proteolizi sonras&#305; ortamdan temizlenemeyen znr A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomeri
post-sinaptik membranda bir dizi patolojik zinciri tetikler. Bunlar&#305;n
sonucunda, nce NMDA, sonra da AMPA olmak zere glutamaterjik (GluR) sinapslar
endositozla kaybedilir. Sonuta glutamaterjik aktiviteye dayanan ve
&#287;renmenin molekler mekanizmas&#305; olan uzun sreli potansiasyon (LTP)
giderek azal&#305;rken, uzun sreli depresyon (LTD) artar. Bu etkinin GluR ile
do&#287;rudan etkile&#351;imle de&#287;il fakat ba&#351;ka bir transmembran
protein (TMP) olan bir arac&#305; stnden oldu&#287;una dair deliller
mevcuttur. Bu arac&#305;lardan biri olarak normal TMP prion proteini (PrP<sup>c</sup>)
gsterilmi&#351;tir. Di&#287;eri ise yaln&#305;zca glutamaterjik<span
style='mso-spacerun:yes'> </span>sinapslarda bulunan ve GluR stabilitesini
sa&#287;layan neuroglin 1dir. Neuroglin 1-A</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> kompleksinin Wnt sinyalizasyonunu
ba&#351;latacak ligand&#305;n reseptrne ba&#287;lanmas&#305;n&#305; engelledi&#287;i,
bunun sonucunda da GSK3</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-Axin-APCden
olu&#351;an y&#305;k&#305;m kompleksinin inhibe edilemeyerek bir nkleer
transkripsiyon faktr olan </span><span style='font-size:10.0pt;font-family:
Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>-kateninin i&#351;levini gremeden
y&#305;k&#305;ld&#305;&#287;&#305; bilinmektedir. znr A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomeri
ileri glikasyon son rnleri reseptr (RAGE) ile de etkle&#351;ir. Nronal
membranda etkile&#351;im temel inflammatuar sinyalizasyon olan NF</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#954;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B
sinyalizasyonunu tetikler ve bylelikle ortama inflammatuar sitokinler
sal&#305;n&#305;r. A</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
fagositozu iin aktive olmu&#351; mikroglia da RAGE-A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
etkile&#351;imi ile sal&#305;nan inflammatuar sitokinlerin bir di&#287;er
kayna&#287;&#305;d&#305;r. Bir TMP olan RAGE, bu tr proteinlerin
proteolizinden sorumlu olan bir metalloproteinaz olan ADAM10
arac&#305;l&#305;&#287;&#305;yla kesilerek parenkime sal&#305;nan znr RAGE
(sRAGE) olu&#351;ur. sRAGE de A</span><span style='font-size:10.0pt;font-family:
Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> ba&#287;lar, ancak art&#305;k membrana ba&#287;l&#305;
olmad&#305;&#287;&#305;ndan bir patolojik zinciri ba&#351;latman&#305;n tam
tersine A</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>y&#305;
ntralize eden bir i&#351;lev grr. A</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> d&#351;k yo&#287;unluklu
lipoprotein reseptr 1 (LRP1) arac&#305;l&#305;&#287;&#305;yla kan-beyin
bariyerinden dola&#351;&#305;ma verilir. Vaskler endotel membran&#305;ndaki
RAGE A</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>y&#305;
yeniden beyne al&#305;rken, dola&#351;&#305;mdaki sRAGE A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
ba&#287;layarak buna kar&#351;&#305;t al&#305;&#351;&#305;r. Dolay&#305;s&#305;yla,
RAGE antagonistleri ve sRAGE agonistlerinin potansiyel anti-AH farmakolojik
stratejiler oldu&#287;u sylenebilir. Yerle&#351;ik tedavi stratejilerinden
biri olan memantinin bilinen etki mekanizmas&#305; NMDArda Mg<sup>++ </sup>t&#305;kac&#305;
i&#351;levi grerek mevcut Ca<sup>++ </sup>s&#305;z&#305;nt&#305;s&#305;
kaynaklar&#305;ndan birini engellemek iken hcre iinde de hiperfosforile tauyu
paralayacak fosfataz agonizmas&#305; yapt&#305;&#287;&#305;na dair de deliller
vard&#305;r.<o:p></o:p></span></p>

<p class=ListParagraph0CxSpOrta style='text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=ListParagraph0CxSpSon style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans17b.JPG">&#350;ekil 17b.</a> </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kolinerjik
sinaps da AHde erken tehdit alti&#305;ndad&#305;r. znr A</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> oligomerleri
pre-sinaptik membranda asetil kolin (ACh) sal&#305;n&#305;m&#305;n&#305; inhibe
eden M2 muskarinik reseptrlere de&#287;il de, tam tersine
sal&#305;n&#305;m&#305; artt&#305;ran </span><span style='font-size:10.0pt;
font-family:Tahoma'>&#945;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>7 ve </span><span style='font-size:
10.0pt;font-family:Tahoma'>&#945;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4</span><span style='font-size:10.0pt;
font-family:Tahoma'>&#946;</span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2 nikotinik reseptrlere
ba&#287;lanarak kolinerjik nrotransmisyonu azalt&#305;rlar. M2 antagonizmas&#305;
ve/veya </span><span style='font-size:10.0pt;font-family:Tahoma'>&#945;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7 ve </span><span
style='font-size:10.0pt;font-family:Tahoma'>&#945;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4</span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2
agonizmas&#305; yapan ajanlar bu dengeyi tersine evirebilirler. Post-sinaptik
M1 kolinerjik aktivite gibi insulin sinyalizasyonu da protein kinaz C (PKC)
fosforillenmesi zerinden anti-AH etkiler (ADAM17 aktivasyonu, </span><span
style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-sekretaz ve
GSK3</span><span style='font-size:10.0pt;font-family:Tahoma'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
inhibisyonu) gsterir. </span><span style='font-size:10.0pt;font-family:Tahoma'>Dolay&#305;s&#305;yla,
M1 agonistleri ve insulin potansiyel anti-AH etkilere sahiptirler. Asetil kolin
esteraz&#305;n (AChE) periferik k&#305;sm&#305;na ba&#287;lanan A&#946; ile
olu&#351;turdu&#287;u kompleksin oligomerin toksisite arac&#305;lar&#305;ndan
biri oldu&#287;u gsterilmi&#351;tir. Dolay&#305;s&#305;yla, katalitik
k&#305;sma ba&#287;lanan klasik inhibitrlerden farkl&#305; olarak ayr&#305;ca
periferik k&#305;sm&#305; da bloke edecek dual inhibitrler daha gl bir
anti-AH etki gsterebilirler. DNA onar&#305;m&#305;yla grevli sirtuin
sinyalizasyonunun A&#946; ile tam tersi etkilere sahip oldu&#287;u
bilinmektedir. &#304;ntraseller A&#946; sirtuin sinyalizasyonunda rol oynayan
ba&#351;l&#305;ca molekllerden biri olan SIRT1i inhibe ederken, bir TMP olan
fraktalcinenin (CX3CL1), rne&#287;in k&#305;rm&#305;z&#305; &#351;arapta da
bulunan bir polifenol olan rosveratrol ile uyar&#305;lmas&#305; CX3CL1in,
ayn&#305; zamanda APPnin non-amiloidojenik proteolizini sa&#287;layan
ADAM17yi aktive etmesini sa&#287;lamakta, bunun sonucunda aktive olan SIRT1
ise RAGEi kesecek ADAM10u aktive ederek pro-inflammatuar NF&#954;B
sinyalizasyonunu durdururken, di&#287;er yandan da pro-plastisite nkleer
transkripsiyon faktrlerini harekete geirmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinaps kayb&#305;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Sinaps kayb&#305; kortikal biyopsi
rneklerinde klinik demans a&#287;&#305;rl&#305;&#287;&#305;yla, nron
kayb&#305;ndan dahi daha kuvvetli en yksek korelasyon gsteren yap&#305;sal
de&#287;i&#351;ikliklerin ba&#351;&#305;nda gelir.&nbsp; Sinaptofizin gibi
sinaptik proteinlerin miktarlar&#305;n&#305;n da demans
a&#287;&#305;rl&#305;&#287;&#305;yla korele etti&#287;i gsterilmi&#351;tir.&nbsp;
Sinaps kayb&#305; ba&#351;lang&#305;ta NFY ve nron lmnn anterograd
Wallerian dejenerasyon sonucu sekonder etkisi ile a&#305;klansa da, primer
hasar&#305;n zellikle de intraseller zlebilir A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomeri arac&#305;l&#305;&#287;&#305;yla sinapslara olmas&#305; ve
bozuklu&#287;un retrograd olarak hcre gvdesine ta&#351;&#305;narak, NFY
olu&#351;umu ve nihayetinde hcre lmne yolamas&#305; art&#305;k daha
muhtemel grnmektedir. </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>zlebilir A&#946; oligomerinin
toksisitesi ve neden oldu&#287;u erken sinaptik disfonksiyon zerine odaklanan
son al&#305;&#351;malar zlemez fibriler formun veya daha olgun
plaklar&#305;n parenkimde oynad&#305;&#287;&#305; rol yerine toksik zlebilir
oligomerin hcre yzeyinde uygun bir reseptr bulup ba&#287;land&#305;ktan
sonra veya membrandan intraseller mesafeye getikten sonra ba&#351;latt&#305;&#287;&#305;
bir dizi zincirleme reaksiyonun do&#287;as&#305;n&#305; ayd&#305;nlatmaya
ba&#351;lam&#305;&#351;t&#305;r. Bu mekanizmalar&#305;n
basamaklar&#305;n&#305;n ayn&#305; zamanda nedene ynelik tedavi hedefleri de
olu&#351;turmalar&#305; heyecan vericidir. Bu al&#305;&#351;malar&#305;n
ortakla&#351;t&#305;&#287;&#305; bir nokta A&#946; oligomerinin
ba&#351;lang&#305;ta inhibitr GABA-erjik sinapslar&#305; salim b&#305;rak&#305;rken
eksitatr glutamaterjik sinapslarda de&#287;i&#351;ikliklere neden olmas&#305;,
buna ba&#287;l&#305; olarak &#287;renmenin temelini te&#351;kil eden molekler
mekanizma olan uzun sreli potansiasyonu (LTP) bask&#305;larken, uzun sreli
depresyonu (LDP) te&#351;vik etmesidir. Inestrosa grubu oligomerin eksitatr
sinapslarda NMDA reseptr stabilitesini sa&#287;layan neurogilin 1 ile
etkile&#351;irken inhibitr sinapslardaki neurogilin 2 ile
etkile&#351;medi&#287;ini gsterdiler. Ayn&#305;
ara&#351;t&#305;r&#305;c&#305;lar bu etkile&#351;imin embryogenez gibi bir dizi
di&#287;er i&#351;levleri yan&#305;s&#305;ra akson rehberli&#287;inden sorumlu
Wnt sinyalizasyonunu bozdu&#287;u ve AHde bu sinyalizasyonun son rn olan
nkleer transkripsiyon faktr &#946;-katenin miktarlar&#305;n&#305;n
azald&#305;&#287;&#305; buldular. Bu etkile&#351;im sonunda NMDA ve AMPA reseptrlerinin
postsinaptik membrandan endositozla kayb&#305;na yolaar. Reseptrlerin
kayb&#305;yla sinaps atrofiye u&#287;rar. Wnt sinyalizasyonunu aktive eden
ligandlar A&#946;n&#305;n tetikledi&#287;i sinaptik de&#287;i&#351;iklikleri
geri evirebilmektedir.&nbsp; Wnt sinyalizasyonu sinaptik z-savunma
mekanizmalar&#305;ndan biridir. AH iin de ba&#351;l&#305;ca risk faktr olan
bu sinaptik z-savunma mekanizmalar&#305; ya&#351;lanmayla birlikte
zay&#305;flamaya ba&#351;larlar. &#350;ekil 17adan A &#946;n&#305;n neden
oldu&#287;u glutamaterjik sinaptik disfonksiyon ve Wnt sinyalizasyonu &#351;ematik
olarak gsterilmi&#351;tir.<span style='mso-spacerun:yes'> </span>Bu
sinyalizasyon mekanizmalar&#305;ndan bir di&#287;eri de sirtuin
sinyalizasyonudur. Sirtuinler proteinlerin asetil grubunu kald&#305;rarak
(deasetilaz) ve ADP-riboziltransferaz i&#351;levleri gren bir uzun mr
faktrdr. SIRT1 ve SIRT2 isimli sirtuinlerin DNA onar&#305;m&#305;nda rol
ald&#305;&#287;&#305;, aktivitelerinin ya&#351;lanmayla birlikte
zay&#305;flad&#305;&#287;&#305; gsterilmi&#351;tir. A&#946; oligomerlerinin
SIRT1 aktivitesini bozarken tersine k&#305;rm&#305;z&#305; &#351;arapta da
bulunan bir polifenol olan resveratrol gibi maddelerle SIRT1 geninin aktivasyonu
mmkn oldu&#287;u gibi bir sitokin proteini olan fraktalkinin (CX3CL1)
aktivitesinin artt&#305;r&#305;lmas&#305; AHde azalan SIRT1 aktivitesini
artt&#305;rmakta ve bylelikle aktive olmu&#351; NF-&#954;B sinyalizasyonu
inhibe edilerek tetiklenen inflamatuar sre tersine evrilebilmektedir. Bu
gzlemler AHde birer teraptik ajan olarak resveratrol ve CX3CL1
agonizmas&#305;n&#305; gndeme getirmi&#351;tir. NF-&#954;B sinyalizasyonu
zerinden inflamatuar de&#287;i&#351;ikliklere a&#351;a&#287;&#305;daki ilgili
blmde daha ayr&#305;nt&#305;yla de&#287;inilecektir. Serebral inslin sinyallemesi
ve A&#946; oligomerinin hcre yzeyine ba&#287;land&#305;ktan sonra tetikledi&#287;i
mekanizmalar da birbirinin tam tersi gibi grnyor. Serebral inslin
sinyallemesi sinaptik enerji homeostaz&#305;ndan sorumludur. Nronlarda bir
tirosin kinaz reseptr gibi i&#351;lev gren inslin reseptrlerine (IR)
ba&#287;lanan inslin&nbsp; fosfadidilinositol-3-kinaz (PI3K) zerinden
nihayetinde protein kinaz Cyi aktive ederek a&#351;a&#287;&#305;da kolinerjik
kay&#305;p blmnde daha ayr&#305;nt&#305;yla szedilen ve <b>&#350;ekil 17b</b>de
&#351;ematik olarak gsterilen anti-AH mekanizmalar&#305; tetikler. AH
hastalar&#305;n&#305;n bir blm yksek al&#305;k inslin dzeylerine
sahiptir (periferik diren). FDG-PET ile de gsterilen nronal glukoz
kullan&#305;m&#305; bozuklu&#287;u (hipometabolizma AHde greli erken bir
zelliktir ve demans &#351;iddetiyle korele eder. AHli hastalar&#305;n bir
blmnde nronal IRler, glukoz ta&#351;&#305;y&#305;c&#305; proteinler ve
di&#287;er inslin yola&#287;&#305; ilintili bile&#351;enler azal&#305;r
(santral diren). A&#946; dendritik IRleri azalt&#305;rken inslin oligomerin
tetikledi&#287;i LTP bask&#305;lanmas&#305; ve sinaptik kayb&#305; tersine
evirir. Bu bulgular inslin sinyallemesini etkileyen ajanlar&#305; AHnin
potansiyel teraptik ajanlar&#305; durumuna getirmi&#351;tir. Periferik inslin
direnci d&#351;rerek IDEnin periferiden ziyade MSSde bir &#351;aperon
molekl olarak kullan&#305;lmas&#305;n&#305; amalayan varsay&#305;mlar&#305;n
s&#305;nanmas&#305; PPAR-&#947; agonistlerini (rosiglitazon ve pioglitazon)
klinik al&#305;&#351;malar&#305;n olgun evrelerine kadar getirmi&#351;tir. Son
olarak, do&#287;rudan inslinin intranazal yoldan MSSye verilmesi halen
srmekte olan bir faz II al&#305;&#351;mada (SNIFF al&#305;&#351;mas&#305;)
s&#305;nanmaktad&#305;r. A&#946;n&#305;n LTP depresyonu yapacak &#351;ekilde
NMDA reseptrlerine ba&#287;lanmas&#305; ve nihayet nce glutamaterjik NMDA
sonra da glutamaterjik AMPA reseptrlerinin endositozla kaybolmas&#305;
bilinmekle birlikte bunun do&#287;rudan A&#946;n&#305;n reseptre
ba&#287;lanmas&#305;yla de&#287;il fakat bilinmeyen bir transmembran proteine
ba&#287;lan&#305;p bir kompleks olu&#351;turduktan sonra gerekle&#351;ti&#287;i
ileri srlmekteydi. Yak&#305;n tarihte bu bilinmeyen transmembran proteinin
prion proteini (PrP<sup>c</sup>) oldu&#287;u ileri srld.
Ara&#351;t&#305;r&#305;c&#305;lar A&#946;n&#305;n 350 transmembran protein
aras&#305;ndan bask&#305;n olarak PrP<sup>c</sup>ye
ba&#287;land&#305;&#287;&#305;n&#305; gsterdiler. &#304;lk bak&#305;&#351;ta
bu durum &#351;a&#351;&#305;rt&#305;c&#305; nk bu i&#351;levi bilinmeyen
proteinin proteolitik kesimi ve sonras&#305;nda hatal&#305; katlanarak fiziksel
konformasyonunu de&#287;i&#351;tirmesi (PrP<sup>Sc</sup>) ve birikmesi bir
ba&#351;ka nrodejeneratif hastal&#305;klar grubuna, yani ilerinde
Creutzfeldt-Jacob hastal&#305;&#287;&#305;n&#305;n da bulundu&#287;u prion
hastal&#305;klar&#305;na yolamakta. PrP<sup>c</sup>ye AH patogenezinde
atfedilen bu temel rol do&#287;ruland&#305;&#287;&#305; takdirde 2 byk
nrodejeneratif hastal&#305;&#287;&#305;n ayd&#305;nlat&#305;lmas&#305;nda
nemli bir dnm noktas&#305; olabilir.
Ara&#351;t&#305;r&#305;c&#305;lar&#305;n al&#305;&#351;malar&#305; olduka
ikna edici grnmektedir. PrP nakavt transjenik farelerde A&#946; ile LTP
supresyonu gerekle&#351;miyor. Son derece virulan bir transjenik model olan
APP/PSEN mutantlar&#305;n PrP nakavtlarla aprazlanan soyunda
sa&#287;kal&#305;m art&#305;yor, APP/PSEN Tglerdeki tipik pasif ka&#305;nma
&#287;renme bozukluklar&#305; grnmyor ve mekansal &#287;renmeleri
do&#287;al tip farelere benzer dzeyde normal oluyor. Buna
kar&#351;&#305;l&#305;k A&#946;-Prp<sup>c </sup>kompleksi NMDA reseptrlerinin
tipik endositozuna yol at&#305;klar&#305; gibi bu farelerde dentritik diken
kayb&#305;, nritik distrofi ve sonunda hcre kayb&#305; gibi AHnin di&#287;er
tipik sinaptik patolojisinin tm grlyor. Son olarak, intraseller
A&#946;n&#305;n mitokondriyal stabiliteyi de bozup apoptozu tetikleyecek
reaktif oksijen trlerinin (ROS) olu&#351;umuna neden oldu&#287;u bilinmekte.
AHli beyinlerde mitokondriyal membran stabilitesinden sorumlu fzyon
proteinleri dynaminlerin ve bunlar&#305;n aras&#305;nda zellikle de DLP1in
dzeyi d&#351;mekte, bunun sonucunda intraseller mitokondri
da&#287;&#305;l&#305;m&#305; bozulmakta, say&#305;lar&#305; azalmakta ve bu
durum sonunda dentritik diken say&#305;s&#305;n&#305; azalt&#305;p sinaps
kayb&#305;na yolamakta. Tersine, deneysel modellerde DLP1 a&#351;&#305;r&#305;
ifadesi ADDL ile tetiklenen mitokondriyal de&#287;i&#351;iklikleri tersine
evirmekte. Dimebon isimli eski bir anti-histaminik molekln AHde
i&#351;levsiz kald&#305;&#287;&#305; gsterilen mitokondriyal delikleri
kapatarak i&#351;lev grd&#287;ne dair pre-klinik deliller sonras&#305; halen
olgun klinik al&#305;&#351;malarda etkinli&#287;i s&#305;nanmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gliozis ve &#304;nflamasyon</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Gliozis AH nropatolojisinin bir
ba&#351;ka zelli&#287;idir.&nbsp; A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n nritik plaklarda birikiminin mikroglial
ve astroglial hcreleri aktive etti&#287;i AH patogenezinde greli ge bir olay
olarak teden beri iyi bilinmektedir. Mikroglial aktivasyon sitokinlerin
salg&#305;lanmas&#305;, akut faz reaktanlar&#305; ve kompleman&#305;n aktive
edilmesiyle inflamasyonu harete geirir.&nbsp; Son zamanlarda plaklardan
ba&#287;&#305;ms&#305;z olarak do&#287;rudan A</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
oligomerinin ileri glikasyon son rnleri reseptr (RAGE) ile ba&#287;lanarak
MSSdeki ba&#351;l&#305;ca pro-inflamatuar sinyalleme sistemi olan aktive B
hcrelerinin kappa hafif zincir&nbsp; glendiricisi nkleer faktrn (NF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B)
tetiklemesinin AHde erken bir fenomen olarak inflamasyona
yolamas&#305;n&#305;n zerinde durulmaktad&#305;r. NF-&#954;B infeksiyona
immun cevapta DNA transkripsiyonunu dzenleyen bir protein kompleksidir.
Sinaptik plastisite ve bellek i&#351;levlerinde de rol gsterilmi&#351;tir.
Kanser, e&#351;itli inflamatuar ve otoimmun hastal&#305;klar ve AHde
NF-&#954;B sinyallemesi yolundan sapar. RAGE immunoglobulin sper
familyas&#305;na dahil bir transmembran reseptr proteindir. &#304;leri
glikasyon son rnleri (AGEler) ya&#351;lanma yan&#305;s&#305;ra diabetik hiperglisemi
gibi patolojik durumlarda glikozillenme ile ba&#351;layan bir dizi kimyasal
reaksiyonun nihai rnleri olan ligandlard&#305;r. RAGE, AGEler
yan&#305;s&#305;ra A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>, HMGB1, s100, Mac-1 gibi bir
dizi ba&#351;ka ligand&#305; ba&#287;layarak diabet komplikasyonlar&#305;yla
birlikte, AH, multipl skleroz, inme gibi nrolojik hastal&#305;klar, romatoid
artrit, ateroskleroz, koroner kalp hastal&#305;&#287;&#305; gibi sistemik
hastal&#305;klarda rol oynad&#305;&#287;&#305; bulunmu&#351;tur. Tam uzunlukta
RAGE (flRAGE) bir transmembran protein iken alternatif d&#287;mlenme ile retilen
&#351;ekli olan endojen sekretuar RAGE (esRAGE) ve RAGEin proteoliziyle ortaya
&#305;kan enzimatik kesilmi&#351; RAGE (ecRAGE) RAGEin znr biimleridir
(sRAGE). sRAGE de flRAGE gibi ligand ba&#287;lar, ancak hcre yzeyine
ba&#287;l&#305; olmad&#305;&#287;&#305; iin NF-</span><span style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B gibi
sinyalizasyon tetiklenmesine neden olmad&#305;&#287;&#305; gibi flRAGEe ba&#287;lanarak
pro-inflamatuar zinciri ba&#351;latacak olan ligandlar&#305; kendine
ba&#287;layarak bir tampon i&#351;levi grr. Ya&#351;lanma sreci gibi AHnin
de flRAGE dzeylerinin art&#305;p sRAGE dzeylerinin d&#351;t&#287; sreler
oldu&#287;u d&#351;nlebilir. sRAGE ayn&#305; zamanda sirklasyonda bulunur
ve artm&#305;&#351; dzeyleri daha fazla A</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;
mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>n&#305;n LRP1 arac&#305;l&#305;&#287;&#305;yla
kan-beyin bariyerinden dola&#351;&#305;ma aktar&#305;ld&#305;&#287;&#305; bir
kvet (sink) etkisiyle A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang;mso-ansi-language:
TR'></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>n&#305;n klirensine kar&#351;&#305;l&#305;k gelir. Bu
gzlemler bir tedavi hedefi olarak flRAGE inhibitrleri (rne&#287;in, TTP488)
ve/veya sRAGE-mimetiklerini (TTP4000) gndeme getirmi&#351;tir. NF-</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B
sinyalizasyonunun A</span><span style='font-size:10.0pt;font-family:Tahoma;
mso-fareast-font-family:Batang'>&#946;</span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>-RAGE etkile&#351;imi ile
tetiklenmesinin yan&#305;s&#305;ra, yukarda de&#287;inildi&#287;i gibi A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
Batang;mso-ansi-language:TR'></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>n&#305;n yolat&#305;&#287;&#305;
SIRT1 inaktivasyonu da devreye giren NF-</span><span style='font-size:10.0pt;
font-family:Tahoma;mso-fareast-font-family:Batang'>&#954;</span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B
sinyalizasyonunun zerindeki denetimi kald&#305;rarak bir pozitif geribildirim
etkisi yapmaktad&#305;r. RAGE etkileri &#350;ekil 17a ve 17bde &#351;ematik
olarak gsterilmi&#351;tir. &#304;nflamasyonun, serbest radikallerin ortaya
&#305;k&#305;&#351;&#305;, oksidatif gerilim, kalsiyum homeostaz&#305; ve
mitokondriyal membranda bozulmalar ile birlikte gitti&#287;i
d&#351;nlmektedir.&nbsp; Astrositler butiril kolin esteraz (BChE) gibi
normalde aktivitesi ihmal edilecek dzeyde olan bir dizi molekln de
kayna&#287;&#305;d&#305;r ve dolay&#305;yla da gliozis asetil kolinin
paralanmas&#305;nda da alternatif yolu devreye sokmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er nrotransmitter
kay&#305;plar&#305;</span></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Serotoninerjik kay&#305;p</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AHde serotoninerjik (5-HT-erjik)
dorsal raphe ekirde&#287;inde Meynert dzeyinde olmasa bile kayda de&#287;er
nron kayb&#305; ve kalan nronlarda NFYler grlr.&nbsp; Kortikal 5-HT-erjik
akson terminallerinde 5-HTnin sal&#305;n&#305;m&#305; ve geri
al&#305;n&#305;m&#305; ciddi dzeyde bozulmu&#351;tur.&nbsp;AHde 5-HT-erjik
kay&#305;pla depresyon ve sald&#305;rgan davran&#305;&#351;&#305;n korelasyonu
bildirilmektedir.&nbsp;5-HT geri al&#305;n&#305;m blokerlerinin (SSRI) AHdeki
depresyon ve agresyonun tedavisindeki rasyoneli bu gzlemlere
dayanmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Dorsal raphede bildirilen bu
kay&#305;p ve pre-sinaptik serotonerjik aktivitedeki bu eksikliklere
ra&#287;men AHde serotonerjik sistemin hiperaktif olabilece&#287;ine dair
gr&#351;ler mevcuttur. Bu sa&#287;duyuya kar&#351;&#305;t gibi grnen
durumun nedeni farkl&#305; post-sinaptik 5-HT reseptrlerinin i&#351;levsel
farkl&#305;l&#305;klar&#305; ve yerle&#351;imleri ile ilintildir. Bunlar
aras&#305;nda 5-HT1a ve 5-HT6 reseptrler siklik AMPnin
intrasellerdzeylerini azaltarak ve dolay&#305;s&#305;yla plastisite
kar&#351;&#305;t&#305; bir mekanizmayla i&#351;lev grrler. Her iki reseptr
tipi de limbik sistemde zengin bulunur. 5-HT6 zellikle glutamaterjik ve
kolinerjik nronlar&#305; do&#287;rudan inhibe edecek pozisyonda bulunan
GABA-erjik nronlarda zengindir. Bu bulgulardan yola &#305;karak 5-HT1A ve
5-HT6 antagonistleri AH iin klinik al&#305;&#351;malarda s&#305;nanmaya
ba&#351;lanm&#305;&#351;t&#305;r (rn., ilki iin SRA333 ve WAY100635, ikincisi
iin SB-742457 ve SAM-351). </span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Spesifik 5-HT antagonizmas&#305;
arac&#305;l&#305;&#287;&#305;yla cAMP intraseller dzeylerinin
azalt&#305;lmas&#305;na kar&#351;&#305; durman&#305;n pro-plastisie etkilerinin
gsterilmesinden sonra cAMPy&#305; y&#305;kan enzim olan fosfodiesteraz&#305;n
(PDE) inhibisyonunun teraptik poyansiyeli zerinde durulmu&#351;tur.
Pre-klinik al&#305;&#351;malarda gl pro-kognitif ve pro-plastisite etkileri
grlen PDE4 inhibitrleri erken klinik al&#305;&#351;malara
ula&#351;m&#305;&#351; durumdad&#305;r (rn., AVE8112 ve MEM 1414).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Noradrenerjik kay&#305;p</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Beyinsap&#305;ndaki noradrenerjik
(NA-erjik) ekirdek olan locus ceruleusta (LC) da dorsal raphe benzeri bir
nronal kay&#305;p ve NFY olu&#351;umu gzlenir.&nbsp;LCdeki patoloji seici
yatk&#305;nl&#305;&#287;a uygun biimde LCnin kortikal projeksiyonlar&#305;
olan anterior ve medyal blmlerini etkilerken spinal ve serebellar
projeksiyonlar&#305; ieren kaudal ve lateral blmleri salim
kal&#305;r.&nbsp;NA-erjik kayb&#305;n klinik kar&#351;&#305;l&#305;&#287;&#305;
iyi belirlenmemi&#351;tir.</span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Dopaminerjik kay&#305;p</span><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>AH ileri evrelerinde parkinsonizm
s&#305;rad&#305;&#351;&#305; bir olgu de&#287;ildir.&nbsp;Bu olgular&#305;n
patolojik kar&#351;&#305;l&#305;&#287;&#305; byk s&#305;kl&#305;kla
substantia nigra pars compacta (SNc) dopaminerjik (DA-erjik) nronlar&#305;nda
kay&#305;p ve Lewy cisimcikleridir (LC).&nbsp; LCD kendine zg bir antite olarak
ortaya &#305;km&#305;&#351;ken LCD ve AHnin iie geti&#287;i durumlar olan
hem NFY-AP hem de kortikal Lewy cisimciklerinin sonucu olan klinik
durumlar&#305;n LCD mi yoksa AHnin Lewy varyant&#305; (AH-LV) olarak m&#305;
adland&#305;r&#305;laca&#287;&#305; tart&#305;&#351;mal&#305;d&#305;r. LCler
ve NFY-AP birlikteli&#287;i iin 2 ayr&#305; nropatolojik rnt
s&#305;n&#305;fland&#305;rmaya yard&#305;mc&#305; olabilir. LCler gerek
sporadik ve gerekse de familyal AHde en s&#305;k amigdalada ve %60a
yakla&#351;an bir oranda grlrler. Di&#287;er limbik alanlar, zellikle de
periamigdaloid ve entorhinal korteks amigdaladan sonra en s&#305;k grldkleri
yerlerdir. LCDye zg neokortikal ve beyinsap&#305; yerle&#351;imi ok daha
seyrektir. Buna kar&#351;&#305;l&#305;k LCDde yayg&#305;n neokortikal ve
beyinsap&#305; yerle&#351;imine de&#287;i&#351;ken miktarlarda AH tipi patoloji
e&#351;lik edebilir. </span><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Alzheimer Hastal&#305;&#287;&#305;n&#305;n Nedenselli&#287;i
zerine Son De&#287;erlendirmeler</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AH ara&#351;t&#305;rmac&#305;lar&#305; plaklar ve
yumaklar temelinde, hangisinin birincil rol oynad&#305;&#287;&#305; zerine
nerdeyse uzla&#351;maz iki kampa byk lde ayr&#305;lm&#305;&#351;
durumdad&#305;rlar.&nbsp; Bu kampla&#351;man&#305;n dinsel fanatizme
benzerli&#287;ine ince bir ele&#351;tiriyle de, tau patolojisini
(yumaklar&#305;) n plana alanlara tauistler, &#946;-amiloid patolojisini
alanlara ise baptistler dendi&#287;i olmu&#351;tur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gerekten de, ancak demans evresinde
tan&#305;nabilen hastal&#305;&#287;&#305;n klinik evreleri NFY
yay&#305;l&#305;m&#305;yla ok iyi korele ederken, AP ile korelasyonun
olmamas&#305; tauistlerin temel tezi olurken, gsterilen btn genetik
bozukluklar&#305;n A&#946; zerinden etkisini gstermesi, buna
kar&#351;&#305;l&#305;k tau mutasyonlar&#305;n&#305;n AH d&#305;&#351;&#305;
dejenerasyonlara neden olmas&#305; baptistlerce tezlerinin
kan&#305;t&#305;&nbsp; gibi sunulmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Gnmzde ilk bak&#305;&#351;ta baptizm
tart&#305;&#351;mas&#305;z bir zafer kazanm&#305;&#351; grnmekte ve amiloidin
hastal&#305;&#287;&#305;n tetikisi oldu&#287;u, buna kar&#351;&#305;l&#305;k
tau patolojisinin bir epifenomen oldu&#287;u art&#305;k egemen gr&#351;
olarak yerle&#351;mi&#351; durumda. Tetiki amiloid oldu&#287;una gre bunun
do&#287;al sonucu olarak neredeyse tm nedene ynelik tedavi abalar&#305;
anti-amiloid stratejilere vakfedilmi&#351; durumda. Bu aban&#305;n temel
rasyoneli, tetiki ortadan kald&#305;r&#305;ld&#305;&#287;&#305; takdirde ona
sekonder olarak geli&#351;en fizyopatolojik de&#287;i&#351;iklikler, tau da
dahil olmak zere dzelecektir &#351;eklinde zetlenebilir. Yeni
yzy&#305;l&#305;n ilk ony&#305;l&#305;nda bu abalar&#305;n
yaratt&#305;&#287;&#305; byk heyecan ve iyimserlik, klinik
al&#305;&#351;malarda nihai geli&#351;im a&#351;amas&#305;na kadar gelen hi
bir anti-amiloid aday molekln ipi g&#287;sleyememesiyle, byk maddi ve
moral kay&#305;plarla birlikte birbiri ard&#305;na hayal
k&#305;r&#305;kl&#305;klar&#305;na dn&#351;m&#351;tr. Bunlar aras&#305;nda
zellikle de A&#946; antijeniyle ilk aktif immunizasyon
al&#305;&#351;mas&#305; olan ve kat&#305;l&#305;mc&#305;lar aras&#305;nda
geli&#351;en meningoensefalit olgular&#305; nedeniyle durdurulan AN1792
al&#305;&#351;mas&#305; temel varsay&#305;m&#305;n s&#305;nanmas&#305;
a&#305;s&#305;ndan &#287;retici olmu&#351;tur. Kat&#305;l&#305;mc&#305;lar
aras&#305;ndan len olgular&#305;n otopsilerinde serebral plak yknde (hem
gev&#351;ek, hem de sert plaklar) kayda de&#287;er bir azalmaya kar&#351;&#305;n
NFY yknde bir farkl&#305;l&#305;k izlenmemi&#351;tir. Dahas&#305;, bu
al&#305;&#351;maya kat&#305;l&#305;p da yeterli antikor geli&#351;tiren
hastalar&#305;n uzun sreli izlemleri de dahil olmak zere, ok say&#305;da
farkl&#305; anti-amiloid tedavi al&#305;&#351;malar&#305;na kat&#305;lan hi
bir hasta grubunda bildirilen yararlanman&#305;n bykl&#287; amiloid
hipotezinden yola &#305;karak beklenilece&#287;i gibi dramatik
olmam&#305;&#351;, plaseboya kar&#351;&#305; farkl&#305; sonlan&#305;m
ltleri a&#305;s&#305;ndan ancak marjinal yararlar ifade edilmi&#351;tir.
&#304;lk ony&#305;l&#305;n sonunda bu durum en militan baptistler aras&#305;nda
dahi orijinal gr&#351;e ynelik bir skeptisizmle birlikte gr&#351;n
revizyonu taleplerinin ileri srlmesine neden olmu&#351;tur.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bu kafa
kar&#305;&#351;&#305;kl&#305;&#287;&#305;n&#305;n nedeni AHnin yukarda
zetlenmeye al&#305;&#351;&#305;lan srekli de&#287;i&#351;en dinamik
do&#287;as&#305;na kar&#351;&#305;n hastal&#305;&#287;&#305; tan&#305;ma,
tetikilik kavram&#305;n&#305; anlama gibi bir dizi etmene indirgenebilir.
Her &#351;eyden nce &#351;imdiki durumda Alzheimer hastas&#305;
dendi&#287;inde demansl&#305; bir ki&#351;i anla&#351;&#305;lmakta ve bu trden
al&#305;&#351;malar demansl&#305; hastalar toplanarak yap&#305;lmaktad&#305;r.
Daha nce gzden geirildi&#287;i gibi demans AHnin olduka ileri bir evresine
kar&#351;&#305;l&#305;k gelmektedir ve bu ileri evrede amiloidle ba&#351;a
&#305;kmak yeterli olmamaktad&#305;r. Alzheimerli beyin, ordular&#305;n
srekli yeniden mevzilendi&#287;i bir sava&#351; alan&#305; gibi
d&#351;nlebilir. Demans a&#351;amas&#305; bu sava&#351;&#305;n art&#305;k
byk lde kaybedildi&#287;i bir evreye kar&#351;&#305;l&#305;k gelmektedir.
yle grnyor ki bu sava&#351;&#305;n ba&#351;lang&#305;c&#305;nda
savunman&#305;n henz ba&#351;ar&#305;l&#305; oldu&#287;u dnemde kolay degrade
edilebilen A&#946;<sub>40</sub>&#305;n gvenlik kuvvetleri olarak
d&#351;nlebilecek &#351;aperon molekller arac&#305;l&#305;&#287;&#305;yla
klirensini sa&#287;lamak ve kolay ba&#351;a &#305;k&#305;lamayan daha
sald&#305;rgan A&#946;<sub>42</sub>yi gev&#351;ek plaklarda hapsetmek temel
savunma stratejisidir. Bylesi bir at&#305;&#351;man&#305;n henz hi bir
kognitif yak&#305;nmas&#305; olmayan bir ya&#351;l&#305;n&#305;n beyninde
srmekte oldu&#287;u ileri srlebilir (AHnin pre-klinik evresi). &#304;lk
savunma mevzilerinin d&#351;meye ba&#351;lamas&#305;yla sald&#305;rgan&#305;n
A&#946; (3(pE)-42 gibi daha elit birlikleri hcre iine girip sinapslar&#305;
ldrmeye ba&#351;layacak ve bu kez savunma bunlar&#305; l sinaps
art&#305;klar&#305;n&#305; da ieren daha maliyetli ekstraseller nritik
plaklara ve intraseller agrezomlara hapsetmeye al&#305;&#351;acakt&#305;r. Bu
a&#351;amada savunma da inslin, sirtuin, WnT, sRAGE gibi kendi elit
birliklerini devreye sokarak sald&#305;r&#305;ya g&#287;s germeye
al&#305;&#351;acakt&#305;r. &#304;lk savunman&#305;n bylesi kmesinin
kar&#351;&#305;l&#305;&#287;&#305; AHnin pre-demans veya MCI a&#351;amas&#305;
olarak d&#351;nlebilir. Bu ikinci savunma mevzisi de kecek olursa bu kez
tau da sald&#305;rgan&#305;n 2. elit birli&#287;i olarak devreye girecek ve en
ba&#351;ar&#305;l&#305; oldu&#287;u sava&#351; alan&#305; olan limbik sistemden
ba&#351;layarak nronlar&#305; ldrmeye ba&#351;layacakt&#305;r. Bu nc
a&#351;ama AHnin demans evresidir ve tau yeni mevziler kazan&#305;p
yay&#305;ld&#305;ka savunma da giderek &#351;iddetlenen demans maliyetini
demek pahas&#305;na, sonuna kadar direnebilece&#287;i en tahkim edilmi&#351;
blgeleri olan primer sensori-motor alanlara do&#287;ru geri ekilecektir. Bu
senaryoya gre bir tetiki tan&#305;mlamak gerekiyorsa bu A&#946; de&#287;il
fakat nronun ba&#351;l&#305;ca katili olan taudur gibi durmaktad&#305;r.
A&#946;y&#305; ise tetikiyi tutan sponsor olarak d&#351;nebiliriz. Bu
senaryoya gre AHden korunman&#305;n yolu sponsorun tetikiyi bulmas&#305;na
engel olmak gibi durmaktad&#305;r. yleyse, hastal&#305;&#287;&#305; demans
ncesi a&#351;amas&#305;nda, hatta pre-klinik dneminde tan&#305;mak art&#305;k
bir zorunluluk olmu&#351;tur. yle grnyor ki AHnin bu demans ncesi
evreleri yeterli duyarl&#305;l&#305;k ve zgllkte belirlenip
tan&#305;nd&#305;ktan sonra e&#351;itli anti-amiloid stratejileri bu erken
a&#351;amalarda denemek, bu ilk savunma kaybedildi&#287;inde veya zaten
hastal&#305;k gecikmi&#351; demans a&#351;amas&#305;nda
tan&#305;nd&#305;&#287;&#305;nda bu kez ba&#351;l&#305;ca anti-tau stratejilere
ynelmek gerekecektir. nmzdeki ony&#305;l&#305;n genetik ve evresel olarak
AH riski ta&#351;&#305;yan normal ya&#351;l&#305; bireylerin ve gerekte
prodromal AH olan AAMI ve MCIl&#305; bireylerin biyo-i&#351;aretleyici
kombinezonlar&#305;yla hassasiyetle ay&#305;rtedilip anti-amiloid tedavi klinik
al&#305;&#351;malar&#305;na dahil edilece&#287;i ve AH demans&#305; iin
ba&#351;ar&#305;l&#305; anti-tau ajanlar&#305;n geli&#351;tirilece&#287;i bir
dnem olaca&#287;&#305;n&#305; ileri srmek bir kehanet
olmayacakt&#305;r.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam, AHnin nedenselli&#287;i iin baptizm ve
tauizm d&#305;&#351;&#305;nda kalan ve hastal&#305;&#287;&#305;n
ya&#351;l&#305;l&#305;k riskiyle nroanatomik yatk&#305;nl&#305;k
tarz&#305;n&#305; gayet iyi a&#305;klayan nroplastisite yetmezli&#287;i teorisini
ileri srm&#351;tr (Mesulam, 2000, Mesulam, 1999). Bu hipoteze gre AH zetle,
genetik ve evresel etkilerle ya&#351;am boyunca artarak biriken plastisite
yknn art&#305;k kald&#305;r&#305;lamaz olmas&#305; ile normal
ya&#351;lanmadan sapman&#305;n sonular&#305;d&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Nroplastisite, MSSnin yeni ya&#351;ant&#305;lama
ve doku hasar&#305;na kar&#351;&#305; verdi&#287;i yap&#305;sal tepkileri
ierir.&nbsp; Nronun post-mitotik bir hcre olmas&#305; dolay&#305;s&#305;yla,
hcre yenilenmesi zelli&#287;i olmayan MSSde ontogenezin intra-uterin ve
do&#287;um sonras&#305; ergenlik boyunca da srecek l dnemlerinde&nbsp; byk
bir dinamizm grlr.&nbsp; Genetik olarak belirlenen ve s&#305;n&#305;rlanan
&nbsp;bir erevede, daha intra-uterin dnemden ba&#351;layarak evresel
uyaranlar&#305;n modlatuar etkisi alt&#305;nda nral geli&#351;imin temel
mekanizmalar&#305; olan nrogenez, nral migrasyon, nral eliminasyon ve
stabilizasyon, sinaptogenez ve aksonal miyelinizasyon ilerleyici bir &#351;ekilde
tamamlan&#305;r.&nbsp; Eri&#351;kin MSSye ait mimari tamamlanmadan nce,
nroplastisitenin nerdeyse s&#305;n&#305;rs&#305;z potansiyeli ile, genetik
olarak verilenin erevesi iine, o bireyin maruz kald&#305;&#287;&#305;, hi
bir zaman ba&#351;ka bir bireyle tam anlam&#305;yla rt&#351;meyecek olan,
emsalsiz ya&#351;ant&#305; paralar&#305;n&#305;n temsili, yukarda an&#305;lan
mekanizmalarla, ki&#351;ili&#287;i de olu&#351;turmak zere
yerle&#351;ir.&nbsp; Eri&#351;kin MSSnin plastik dinamizmi geli&#351;imsel
a&#351;amadaki dzeyini yitirir.&nbsp; Geli&#351;imsel dnemde her kritik yeni
ya&#351;ant&#305;lama ki&#351;ili&#287;i olu&#351;turacak yeni bir yap&#305;ta&#351;&#305;
olarak MSSye kaydedilirken, eri&#351;kin dnemde art&#305;k kritik ya&#351;am
deneyimleri bu denli byk de&#287;i&#351;ikliklere yolamaz. Geli&#351;imsel
dnemde bir hemisferektomiyi tolere edebilecek durumda olan MSS, eri&#351;kinli&#287;e
ula&#351;t&#305;ktan sonra bir hemisferin ok daha s&#305;n&#305;rl&#305; bir
alan&#305;ndaki hasar sonucu a&#287;&#305;r dzeyde sakatlanabilir.&nbsp;&nbsp;
Yine de, nroplastisite eri&#351;kin dnemle birlikte tmden durmaz.&nbsp; Yeni
&#287;renme, a&#351;&#305;nma ve hasar onar&#305;m&#305; amal&#305; olarak
MSSnin belli blgelerinde daha belirgin olmak zere devam eder.&nbsp; Bunlar
aksonal tomurcuklanma, dendritik dallanma, yeni sinaps olu&#351;umu
(sinaptogenez) ve varolan sinaps&#305;n yeniden &#351;ekillenmesi (sinaptik
remodeling) ve uzun sreli potensiasyon (LTP) olarak
s&#305;ralanabilir.&nbsp; Bu mekanizmalar yeni ya&#351;ant&#305;lar&#305;n
temsili ihtiyac&#305;na kar&#351;&#305; ya&#351;ant&#305;lama
ba&#287;&#305;ml&#305; plastisite ile a&#351;&#305;nma, y&#305;pranma ve hasara
cevap olan reaktif veya kompansatuar plastisitenin temel
mekanizmalar&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Mesulam varsay&#305;m&#305;n&#305; bilinen AH ile
ilintili tm risk faktrleri ve patolojik rnlerin nroplastisiteye mdahale
etti&#287;ine ili&#351;kin delillerle desteklemektedir.&nbsp; Nroplastisite
potansiyeli, AHde NFY olu&#351;umunun yay&#305;l&#305;m&#305; ile rt&#351;r
biimde en yksek limbik sistemde iken, azalan s&#305;rayla paralimbik
yap&#305;lar, asoasiasyon neokorteksi ve en az da primer sensoryel-motor
korteksler &#351;eklinde kendini gsterir.<b>&nbsp; </b><i>MAP-</i></span><i><span
style='font-family:Tahoma;mso-fareast-font-family:Batang'>&#964;</span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> retimi ve
fosforilizasyonunda art&#305;&#351; plastik de&#287;i&#351;iklikler srecinin
temel i&#351;lemlerindendir.&nbsp; zellikle plastisite yknn yksek
oldu&#287;u blgelerde kinaz-fosfataz dngsnn dengesinin bozulmas&#305;
plastik talep kar&#351;&#305;s&#305;nda fosforillenmi&#351; taunun grevi
bitti&#287;inde defosforilizasyonunun sa&#287;lanamayarak yukarda
szedildi&#287;i gibi patolojik katlanmas&#305;na ve birikim e&#287;ilimi
gsteren oligomerlere dn&#351;mesine neden olmaktad&#305;r.&nbsp; <i>APP</i>,
daha nce de szedildi&#287;i gibi, eri&#351;kin beyninde ba&#351;l&#305;ca sinaptik
btnl&#287;n korunmas&#305; olmak zere, nroplastisitedeki rol deneysel
olarak gsterilmi&#351; bir membran proteinidir.&nbsp; APP proteolizi sonucunda
&#945;-sekretaz ile kesilen rn olan sAPPnin de nrit bymesi ve LTPdeki
rol bilinmektedir.&nbsp; Buna kar&#351;&#305;l&#305;k, &#946; sekretazla
alternatif kesim sonucu olu&#351;an A&#946; fragman&#305; nrotoksiktir,
aksonal tomurcuklanma ve LTPyi inhibe eder.&nbsp; &#946;-sekretaz&#305;n
distal amino terminal rn olan sAPP&#946;n&#305;n da akson budanmas&#305;
tarz&#305; anti-plastisite etkisinden yukarda szedilmi&#351;ti. PS1in, nrogenezde
ok nemli i&#351;levi olan Notch proteini ile etkile&#351;erek i&#351;lev
grd&#287;ne de de&#287;inilmi&#351;ti. Bu etkile&#351;imin eri&#351;kin
beyninde plastisite ykseltici etkileri gsterilmi&#351;tir.&nbsp; PS1 ve PS2
mutasyonlar&#305; APP proteolizini A&#946; yoluna kayd&#305;rmak yan&#305;
s&#305;ra, Notch ile an&#305;lan etkile&#351;imi gsteremeyen bozuk rnlere
yol aarak da plastisite potansiyelini bask&#305;l&#305;yor olabilir.&nbsp;
Kolesterol ve fosfolipidlerin transseller naklinde rol oynayan ve
dolay&#305;s&#305;yla aksonal byme ve sinaptogeneze katk&#305;da
bulundu&#287;u d&#351;nlebilecek<b> </b><i>ApoE</i>nin plastisite ile&nbsp;
ili&#351;kisine daha nce de&#287;inilmi&#351;ti.&nbsp; Buna gre ApoE-&#949;4
plastisiteyi bask&#305;larken, ApoE-&#949;3 ve &#949;2 ykseltici etki
gstermektedir.&nbsp; Yine <i>strojenin </i>nrotrofik etkilerine
de&#287;inilmi&#351;ti.&nbsp; <b>Ya&#351; </b>AH iin temel risk
faktrdr.&nbsp; Uzun mr do&#287;al olarak hem ya&#351;ant&#305;lama
ba&#287;&#305;ml&#305; plastisite, hem de a&#351;&#305;nma, y&#305;pranma ve
hasarlanman&#305;n artmas&#305;yla kompansatuar plastisite ihtiyac&#305;n&#305;
artt&#305;rmaktad&#305;r.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Dolay&#305;s&#305;yla da ya&#351;la birlikte artan
bu ihtiyac&#305; kar&#351;&#305;lamak iin gerek &#964; fosforilasyonunda ve
gerekse de APP ekspresyonundaki adaptif art&#305;&#351;la birlikte denge ne
kadar plastisite ykseltici faktrler lehine ise o kadar AH patolojisinden
korunulabilmekte, tersine durumda ise bir yandan serbest &#964; polimerlerinden
NFY olu&#351;umu, di&#287;er yandan&nbsp; da A&#946;n&#305;n nce gev&#351;ek
plaklarda birikmesi, sonras&#305;nda da bunlar&#305;n kat&#305; plaklara
dn&#351;mesi artmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>a&#287;da&#351; uygarl&#305;k tek bir bireyin
optimal adaptasyonu iin yksek bir kognitif kapasite, zellikle de bellek
kapasitesi talep etmektedir.&nbsp; a&#287;da&#351; insan genetik
yap&#305;s&#305;n&#305;, o dnemin do&#287;al evresine adaptasyon iin
seleksiyona u&#287;ram&#305;&#351; 30.000 y&#305;l nceki
avc&#305;-toplay&#305;c&#305; uygarl&#305;&#287;&#305;n&#305;n Homo
sapiensinden miras alm&#305;&#351;t&#305;r.&nbsp; Avc&#305;-toplay&#305;c&#305;
uygarl&#305;&#287;&#305;na k&#305;yasla gerek bireysel olarak uzayan mr ve
gerekse de sosyal olarak nicel ve nitel a&#305;lardan ola&#287;anst
de&#287;i&#351;en ko&#351;ullar nroplastisite ykn
ta&#351;&#305;n&#305;lamaz hale getirerek AHyi modern insanl&#305;k durumunun
ka&#305;n&#305;lmaz bir e&#351;likisi yapmaktad&#305;r.&nbsp; Bu perspektifle
bak&#305;ld&#305;&#287;&#305;nda yukarda resmedilen sava&#351; senaryosunun
taraflar&#305; da pro-plastisite ve anti-plastisite gler olmaktad&#305;r.
Dolay&#305;s&#305;yla, nroplastisite ykne odaklan&#305;lmayan uzun mr veya
AH kesin tedavisi d&#351;leri de anlams&#305;zla&#351;maktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>TEDAV&#304;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AHde mevcut ve deneysel tedavilere toplu bir
bak&#305;&#351; iin <b>Tablo 16</b> ya bak&#305;n&#305;z.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><a href="tablo16.JPG">Tablo 16.</a>
</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Alzheimer
hastal&#305;&#287;&#305;n&#305;n yerle&#351;ik ve potansiyel tedavi
stratejileri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kognitif Semptomatik Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Halen tedavinin ekirde&#287;ini&nbsp;
kolinesteraz inhibitrleri (ChE&#304;ler) ve memantin ile kognitif semptomatik
tedavi olu&#351;turmaktad&#305;r.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Kolinesteraz &#304;nhibitrleri</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Takrinin (Cognex<sup></sup>) 1993
y&#305;l&#305;nda Amerika Besin ve &#304;la &#304;daresi (FDA) taraf&#305;ndan
Alzheimer hastal&#305;&#287;&#305;n&#305;n tedavisi iin
ruhsatland&#305;r&#305;lmas&#305; o zamana kadar tedavi edilemez kategoride
kabul edilen bir hastal&#305;k iin ilk onaylanm&#305;&#351; tedavi olmas&#305;
anlam&#305;na geliyordu.&nbsp; AH tedavisinde bir ilac&#305;n FDA onay&#305;
almas&#305; iin yaln&#305;zca bir k&#305;s&#305;m kognitif sonlan&#305;m
ltnde de&#287;il, klinik olarak da gzlenebilir bir etkisinin olmas&#305;
(GYAlar ile davran&#305;&#351; zerine ve genel klinik izlenim olarak) ve bu
etkisini en az 6 ayl&#305;k bir sre iinde korurken gvenilir de olmas&#305;
gerekmektedir.&nbsp; Bu ruhsat takrinin 1987de ba&#351;lad&#305;&#287;&#305;
klinik al&#305;&#351;malar s&#305;navlar&#305;ndan sonunda geti&#287;ini
sembolize ediyordu ayn&#305; zamanda.&nbsp; Ancak bir yandan gastro-intestinal
yan etkilerinin &#351;iddeti etkili doza &#305;kmay&#305;
s&#305;n&#305;rlarken, bir yandan da hepatotoksisite nedeniyle haftal&#305;k
karaci&#287;er enzimleri taramas&#305; zorunlulu&#287;u kullan&#305;m&#305;
iyiden iyiye gle&#351;tirmekteydi.&nbsp;&nbsp; 1990lar&#305;n 2. yar&#305;s&#305;ndan
itibaren yan etki profili a&#305;s&#305;ndan daha kullan&#305;&#351;l&#305;
ChE&#304;lerin birbiri ard&#305;na ruhsatland&#305;r&#305;lmas&#305; takrinin
piyasa mrnn ok k&#305;sa olmas&#305;na neden oldu.&nbsp; Yine de AH
tedavisinde ilk gz a&#287;r&#305;s&#305; olma onuru ebediyyen takrine ait
olacakt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Donepezil (Aricept<sup></sup>), rivastigmin
(Exelon<sup></sup>) ve galantamin (Remynil<sup></sup>) s&#305;nanan ok
say&#305;da ChE&#304;den &#351;imdiye kadar ruhsatlananlard&#305;r.&nbsp;
Bunlar&#305;n hepsi de lkemizde mevcuttur ve ilk ikisinin ok say&#305;da
jenerik muadili de &#305;km&#305;&#351;t&#305;r. &#350;imdiye kadar piyasaya
verilmi&#351; olsun olmas&#305;n klinik al&#305;&#351;malarda dzgn biimde
s&#305;nanan tm ChE&#304;ler ba&#351;ar&#305;l&#305; olmu&#351;tur. Btn
CHE&#304;ler iin klinik al&#305;&#351;malarda genel olarak sylenebilecek
olan ortak etki plaseboya gre anlaml&#305; farkl&#305;l&#305;&#287;&#305;n
yan&#305;s&#305;ra, sonlan&#305;m ltlerinin zaman iindeki de&#287;i&#351;im
e&#287;rileri izlendi&#287;inde 6. ayda plasebo grubu ktle&#351;mi&#351;ken,
ktle&#351;meksizin hala ba&#351;lang&#305; noktas&#305;nda olma ve 1.
y&#305;lda ba&#351;lang&#305; noktas&#305;na gre ktle&#351;meye
kar&#351;&#305;n ChE&#304; ncesi dnemin uzunlamas&#305;na izlemlerdeki
bozulma h&#305;zlar&#305;na referansla (tarihsel plasebo) daha iyi durumda
olmakt&#305;r.&nbsp;Plasebo grubundayken 6. ayda a&#305;k etiketli uzatma
evresinde aktif ilaca geirilen hastalar ba&#351;lang&#305;ta dzelseler de
sonras&#305;nda bozulmaya ba&#351;larlar ve e&#287;rileri hi bir zaman
ba&#351;tan beri aktif grupta olanlar&#305;n e&#287;risini kesmeden izlem
boyunca paralel olarak bozulurlar.&nbsp; Dolay&#305;s&#305;yla, ChE&#304;lerin
hastaya yakla&#351;&#305;k 1 y&#305;l kazand&#305;rd&#305;&#287;&#305; ve
tan&#305; konulduktan sonra ilaca ne kadar erken ba&#351;lan&#305;rsa o kadar
iyi oldu&#287;u sylenebilir.&nbsp;Donepezil (FDA onay&#305; 1996) gnde tek
doz (prospekts bilgisi ak&#351;amlar&#305; nerirken biz birimimizde bazen
uykuyu bozmas&#305; ve fazik fizyolojik kolinerjik aktiviteyle uyumu nedeniyle
sabahlar&#305; tercih ediyoruz), 5 ila 10 mg tabletler &#351;eklinde
kullan&#305;lan selektif bir ChE&#304;dir.&nbsp;Her 2 dozu da etkin olmakla
birlikte yksek dozun etkinli&#287;i de daha yksektir. Ba&#351;ta G&#304;Se
ait olanlar olmak zere, yan etkileriyle ba&#351; edebilmek iin 4 haftada
titrasyonla yksek doza &#305;kmak uygundur. Yak&#305;n tarihlerde piyasaya
verilen a&#287;&#305;zda eriyen &#351;ekli yutma gl&#287; de olan zellikle
ileri evre hastalarda yararl&#305; olmaktad&#305;r. Rivastigmin (FDA onay&#305;
1997) 1.5, 3, 4.5 ve 6 mgl&#305;k kapsller &#351;eklinde
piyasadad&#305;r.&nbsp; Btiril kolin esteraz (BuChE) inhibisyonu etkisi de
olan ve gnde iki kez kullan&#305;lan rivastigminin en d&#351;k etkili dozu 6
mg/gn olmak zere, 4er haftal&#305;k titrasyonlarla 12 mg/gne ykseltilmesi
hedeflenmektedir.&nbsp;Renksiz ve kokusuz s&#305;v&#305; &#351;ekli ila
kullanmay&#305; reddeden hastalarda kullan&#305;m&#305;
kolayla&#351;t&#305;rm&#305;&#351;t&#305;r. AChE&#304;lerin kafa kafaya
kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305; en kaliteli al&#305;&#351;ma
olan, byk boyutlu ve uzun sreli EXCEED isimli al&#305;&#351;mada ikinci
y&#305;l&#305;n sonunda rivastigmin 2 ikincil sonlan&#305;m ltnde (demans
evrelendirmesi ve GYAlar) donepezile stn bulunmu&#351;sa da donepezil de ilk
4 ayl&#305;k titrasyon dneminde rivastigmine k&#305;yasla anlaml&#305; lde
daha iyi tolere edilmi&#351;tir. Birincil sonlan&#305;m lt (kognitif)
a&#305;s&#305;ndan her 2 ilac&#305; kullananlar&#305;n da yakla&#351;&#305;k
%35i 2. y&#305;l&#305;n sonunda ba&#351;lang&#305; noktalar&#305;ndan daha
iyi durumdayd&#305;lar. Rivastigmin yak&#305;nlarda deriden emilen bant
formunun oral formuna e&#351;de&#287;er etkinli&#287;i ve plaseboya yak&#305;n
tolerabilitesini gsterdi&#287;i IDEAL al&#305;&#351;mas&#305;yla kayda
de&#287;er bir yenilik getirmi&#351; oldu. &#304;lki 6mg/gn, ikincisi 12mg/gn
klasik dozlar&#305;na e&#351;it 5 ve 10cm<sup>2 </sup>dozlar&#305;yla piyasada
olan bant &#351;ekli de 4 haftada titre edilmelidir.&nbsp; Galantamin (FDA
onay&#305; 2001) 8, 16 ve 24 mg/gn aral&#305;&#287;&#305;nda gnde iki doz
&#351;eklinde kullan&#305;lan ve pre-sinaptik allosterik nikotinik reseptr
modlasyonu etkisi de olan bir ChE&#304;dir.&nbsp; nce s&#305;v&#305;
&#351;ekli, daha sonra da yava&#351; emilen kapsl formu piyasaya
verilmi&#351;tir. S&#305;v&#305; form hala gnde 2 doz &#351;eklinde 4er
haftal&#305;k titrasyonla nce etkisiz 8mg/gn ile ba&#351;lan&#305;p, 4 hafta
sonra etkin oldu&#287;u ilk doz dzeyi olan 16mg/gn, son olarak da kompliyans
sa&#287;lanabildi&#287;i takdirde 24mg/gn dzeyine
&#305;k&#305;lmal&#305;d&#305;r. Kapsl formu gnde tek doz benzer titrasyon
&#351;emas&#305;yla artt&#305;r&#305;lmal&#305;d&#305;r. En d&#351;k dozdan
ba&#351;lay&#305;p 4 haftal&#305;k aral&#305;klarla ykselindi&#287;inde 
iin de ortak problem olan bulant&#305;-kusma ile ba&#351;a &#305;kmak daha
kolay olmaktad&#305;r.&nbsp;ChE&#304;ler hafif ve orta evre AHde
kullan&#305;m iin ruhsatlanm&#305;&#351; olsa da a&#287;&#305;r evrede
yararlar&#305;na ili&#351;kin gerek klinik al&#305;&#351;ma ve gerekse de
kendi deneyimizden anekdotal deliller bulunmaktad&#305;r.&nbsp;
&#304;lalar&#305;n etkisizlik ve kesilme kararlar&#305;na ili&#351;kin ok
a&#351;ikar gstergeler olmasa da, dzenli kullan&#305;lan ilaca
kar&#351;&#305;n y&#305;l iinde srekli ktle&#351;me gzlemleri sonucunda
kesme karar&#305; verilebilir.&nbsp; Yine gerek bizim deneyimimiz ve gerekse
birinden di&#287;erine gei&#351; verileri (switch data), ilalardan biri
kesildi&#287;inde di&#287;erinin kullan&#305;lmaya ba&#351;lanmas&#305;n&#305;n
hastalar&#305;n %50sinde yararl&#305; olabildi&#287;ini gstermektedir
.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ChE&#304;lerin non-kognitif ya da
davran&#305;&#351;sal belirtiler zerindeki olumlu etkileri de
bildirilmektedir.&nbsp;&nbsp; Buna bir sonraki blmde de&#287;inilecektir.
ChE&#304;ler byk lde hafif-orta evre hastalarda
al&#305;&#351;&#305;lm&#305;&#351; ve bu evrelerde kullan&#305;m iin
endikasyon alm&#305;&#351;lard&#305;r. Bununla birlikte, orta-a&#287;&#305;r
evre al&#305;&#351;malar&#305; da genellikle pozitiftir. Gnmze kadar
biriken verilerin kapsaml&#305; bir gzden geirmesi iin Cochrane
veritaban&#305;na bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Memantin</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ChE&#304;lerden sonra bu kez farkl&#305; bir etki
mekanizmas&#305;na sahip olan bir ajan daha onay alm&#305;&#351;, bylece
kolinerjik nrotransmisyonun yan&#305;s&#305;ra glutamaterjik nrotransmisyonun
da NMDA reseptr modlasyonu arac&#305;l&#305;&#287;&#305;yla dzenlenmesinin
AHde bir tedavi stratejisi olabilece&#287;i
kan&#305;tlanm&#305;&#351;t&#305;r. Memantin (FDA onay&#305; 2003) d&#351;k
afiniteli bir NMDA reseptr antagonistidir. Memantinin bozuk Alzheimer
sinaps&#305;nda post-sinaptik NMDA reseptrnde magnezyum t&#305;kac&#305;
grevi yaparak patolojik intraseller kalsiyum birikimini engelledi&#287;i
bilinmektedir. Buna kar&#351;&#305;l&#305;k, NMDA antagonizmini geri
dn&#351;msz de&#287;il fakat d&#351;k afiniteyle
yapt&#305;&#287;&#305;ndan, NMDA reseptrleri arac&#305;l&#305;kl&#305; normal
glutamaterjik nrotransmisyon iin gerekli olan depolarizan bir uyaranla
magnezyumun yapaca&#287;&#305; gibi reseptr terketmekte ve bylelikle de LTP
mekanizmas&#305;na engel olmamaktad&#305;r. LTP bozuklu&#287;unun AH
fizyopatolojisinin erken ve temel zelliklerinden biri oldu&#287;una yukarda
de&#287;inilmi&#351;ti. Memantinin 10mgl&#305;k tablet &#351;eklinde piyasaya
verilmi&#351;tir ve gnde 2 doz kullan&#305;lacak &#351;ekilde, haftada
5mgl&#305;k art&#305;&#351;larla 4. haftada 20mg/gn dozuna ula&#351;&#305;l&#305;r.
Sonradan bu gnlk dozun gece tek doz verilmesinin de tolerabiliteyi
bozmad&#305;&#287;&#305;, buna kar&#351;&#305;l&#305;k bir k&#305;s&#305;m
hastada grlebilen gndz sedasyonuyla ba&#351;a &#305;kmay&#305;
kolayla&#351;t&#305;rd&#305;&#287;&#305; grlm&#351;tr. &#304;zleyerek,
memantinin de s&#305;v&#305; formu 10 damla = 5mg olacak &#351;ekilde
geli&#351;tirilmi&#351; ve ChE&#304;lerde oldu&#287;u gibi yutma gl&#287;
ve ila reddi olan hastalarda kullan&#305;m kolayl&#305;&#287;&#305;
sa&#287;lam&#305;&#351;t&#305;r. Yine de gnlk toplam doza 40 damlayla
ula&#351;&#305;lmas&#305; bir glk nedeniyken bu sorun da yeni piyasaya
verilen pompal&#305; s&#305;v&#305; formuyla a&#351;&#305;lm&#305;&#351; gibi
grnmektedir. Bu yeni formda bir bardak su iine akacak &#351;ekilde pompa
dzene&#287;ine bir kez bas&#305;&#351; 5 mg e&#351;de&#287;eri memantin
sa&#287;lamaktad&#305;r. ChE&#304;lerin oldu&#287;u gibi memantinin de
non-kognitif, davran&#305;&#351;sal etkileri mevcuttur ve bunlara
a&#351;a&#287;&#305;da de&#287;inilecektir. Gnmze kadar biriken verilerin
son sistematik metaanalizi iin Cochrane veritaban&#305;na bak&#305;n&#305;z. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>AHde mevcut tedaviler olan ChE&#304;ler ve
memantinin etkileri genel olarak mtevazi grnse de bu tedavilerin
eri&#351;ilebilir olmas&#305;ndan itibaren hasta ve yak&#305;nlar&#305;n&#305;n
ya&#351;am kalitelerine katk&#305;lar&#305; oldu&#287;u ku&#351;kusuzdur. Bu
ynde zellikle de endstri sponsorlu&#287;unda olmayan, ABDnin 2 ayr&#305;
mkemmeliyet merkezi diyebilece&#287;imiz Alzheimer merkezinden gelen 2
ba&#287;&#305;ms&#305;z al&#305;&#351;man&#305;n verileri olduka nemlidir.
Bunlar&#305;n ilkinde Boston, Massachusetts General Hospital Alzheimer
Merkezinin 1990-2005 y&#305;llar&#305; aras&#305;ndaki verileri analiz
edilmi&#351;. Bu 15 y&#305;l&#305;n ba&#351;lar&#305; ilas&#305;z dnem,
ortalar&#305; sadece ChE&#304;lere eri&#351;ilebilen dnem ve sonlar&#305; ise
ChE&#304; memantin kombinasyonunun mmkn oldu&#287;u dnemdir. Bu
al&#305;&#351;man&#305;n sonular&#305;, ortalama 30 ay izlenen 382 hastada, kognitif
ve fonksiyonel sonlan&#305;m ltleri a&#305;s&#305;ndan solo ChE&#304;
kullanan grubun ilas&#305;z gruptan daha iyi, ChE&#304;+memantin kombinasyon
tedavisi kullanan grubun ise her ikisinden de daha iyi oldu&#287;u ynndedir.
&#304;kincisinde Pittsburgh niversitesi Alzheimer Merkezinin 1983-2006
aras&#305; verileri analiz edilmi&#351;tir. Bu 23 y&#305;ll&#305;k dnem de
benzer &#351;ekilde ilas&#305;z, tek ba&#351;&#305;na ChE&#304;li ve
kombinasyon tedavili dnemler olarak ayr&#305;labiliyor. Bu kez bak&#305;mevine
yat&#305;r&#305;lma bir sonlan&#305;m lt olarak al&#305;nm&#305;&#351; ve
ortalama 60 ay izlenen hastalarda solo ChE&#304;nin ilas&#305;z gruba gre bu
sreyi geciktirdi&#287;i, kombinasyon tedavisinin ise yine her ikisine gre
daha dageciktirdi&#287;i gsterilmi&#351;tir .<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Non-Kognitif Semptomatik Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ChE&#304;lerin zellikle halsinasyon ve
hezeyanlar &#351;eklindeki psikotik belirtilere, ajitasyon ve apatiye iyi
gelebildi&#287;i gsterilmi&#351;tir.&nbsp; Benzer &#351;ekilde, memantinin de
psikotik belirtilere ve zellikle de ajitasyona iyi geldi&#287;i
gsterilmi&#351;tir, Biriken verilerin analizi memantinin mevcut ajitasyonu
kontrol alt&#305;na alabildi&#287;i gibi uzunlamas&#305;na izlemde ila
kullanan hastalarda daha az ajitasyon ortaya &#305;kt&#305;&#287;&#305;
gzlemlenmi&#351;tir. Dolay&#305;s&#305;yla da, bu an&#305;lan belirtilerin
&#351;iddetleri anti-psikotiklerle derhal mdahaleyi gerektirmedi&#287;i
durumlarda yeni ba&#351;lan&#305;lan bir ChE&#304;nin ve/veya memantinin
onlar&#305;n zerine muhtemel etkisini de&#287;erlendirmekle gereksiz ila
kullan&#305;m&#305;n&#305;n da nne geilmi&#351; olur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Depresyon, mani ve anksiyete gibi duygudurum
bozukluklar&#305; AHde s&#305;kt&#305;r.&nbsp; Depresyon tedavisinde ncelikle
bu ya&#351; grubunda s&#305;k kullan&#305;lan ve depresyonu bizzat ortaya
&#305;karabilecek veya &#351;iddetlendirebilecek olan reserpin,
&#945;-metil-dopa, &#946;-blokerler gibi anti-hipertansifler kesilerek kalsiyum
kanal blokerleri veya ACE inhibitrleri gibi daha uygun ilalara geilmelidir.&nbsp;
Trisiklik anti-depresanlar anti-kolinerjik yan etkileri nedeniyle seilmemesi
gereken gruptur.&nbsp; SSRI grubundan ilalar, venlafaksin, mirtazapin,
duloksetin gibi yeni ku&#351;ak hem serotonin, hem de norepinefrin
gerial&#305;m blokeri olan (SNRI) anti-depresanlar gvenle kullan&#305;labilir.&nbsp;
Tam bir mani olduka seyrek olsa da emosyonel labilite, iritabilite ve fori
gibi zellikleri bazen tedavi gerektirebilir.&nbsp; Bu durumda lityum,
karbamazepin ve valproat gibi duygudurum stabilizatrleri
kullan&#305;labilir.&nbsp; Lityum ve valproat&#305;n GSK3&#946; inhibitr
olarak potansiyel i&#351;levleri klinik al&#305;&#351;malarda
s&#305;nanmaktad&#305;r. Anksiyete tedavisinde ok gerekmedike kognitif
depresan etkileri nedeniyle benzodiazepinlerden
ka&#305;n&#305;lmal&#305;d&#305;r.&nbsp; SSRIlar ve trazodon bu amala
ncelikle seilebilir.&nbsp; Etkisiz kald&#305;&#287;&#305;nda lorazepam
(Ativan<sup></sup>) veya alprozalam (Xanax<sup></sup>) gibi k&#305;sa etkili
benzodiazepinler seilebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hezeyan ve halsinasyon gibi psikotik belirtilerin
tedavisinde ekstrapiramidal ve anti-kolinerjik yan etkilerden
ar&#305;nm&#305;&#351;l&#305;k ba&#351;l&#305;ca tercih nedenidir.&nbsp; Bu
nedenle atipik nroleptikler ncelikle tercih edilenlerdir.&nbsp; Risperidon
(Risperdal<sup></sup>) ve olanzapinin (Zyprexa<sup></sup>) ekstrapiramidal
yan etki potansiyelleri onlar&#305; gerek anlamda birer atipik olarak
s&#305;n&#305;flamay&#305; engellemektedir.&nbsp; Risperidonun aktif metaboliti
olan paliperidol (Invega<sup></sup>) yak&#305;n zamanlarda piyasaya
verilmi&#351;tir ve tek doz kullan&#305;labilen bu ajan&#305;n gerek bir
atipik oldu&#287;u, kilo ald&#305;rmad&#305;&#287;&#305; ve sedasyona neden
olmad&#305;&#287;&#305; ileri srlmektedir. Klozapin&nbsp; (Leponex<sup></sup>)
ok etkili bir atipik olsa da kemik ili&#287;i bask&#305;lama potansiyeli
nedeniyle haftal&#305;k lkosit say&#305;mlar&#305;n&#305;n getirdi&#287;i
glk kullan&#305;m&#305;n&#305; s&#305;n&#305;rlamaktad&#305;r.&nbsp;
Atipikler aras&#305;nda ketiapin (Seroquel<sup></sup>) di&#287;erleri iin
s&#305;ralanan k&#305;s&#305;tlamalardan ar&#305;nm&#305;&#351; ve geni&#351;
bir gvenlik aral&#305;&#287;&#305;nda rahatl&#305;kla
kullan&#305;labilmektedir.&nbsp; Di&#287;erleriyle k&#305;yaslanamayacak kadar
ucuz olmas&#305; d&#351;k dozlarda haloperidol (Norodol<sup></sup>) tipik
bir nroleptik olsa da hala bir seenek olarak korunmas&#305;na neden
olmaktad&#305;r.&nbsp; Demansta psikoz tedavisinde ok d&#351;k dozlarda
ba&#351;lay&#305;p optimal dozu olguya gre uyarlamak esast&#305;r.&nbsp; Dozun
tmn ya da byk blmn gndz sedasyonundan ka&#305;nmak amac&#305;yla
geceleri vermek uygun olur.&nbsp; Ketiapin 50 ila 100 mgl&#305;k dozlarda
genellikle etkin olurken, 400 mg/gn dzeylerine &#305;karmak da gerekebilir.&nbsp;
Risperidon 0.5 ila 1 mg, seyrek olarak da 2 mg/gn dozlar&#305;nda
kulan&#305;l&#305;r. Paliperidol ile demansl&#305; poplasyonda yeterli tecrbe
olmamakla birlikte en d&#351;k dozu olan 3 mg denebilir. Olanzapin dozu 2.5-5
mg, bazen 10 mg/gndr; bir klinik al&#305;&#351;mada 15 mg/gnden itibaren
etkinli&#287;inin paradoksal olarak d&#351;t&#287;
gsterilmi&#351;tir.&nbsp; Klozapin 6.25 mg ila 50 mg/gn dozlar&#305;nda
yeterli etkinlik gsterse de bazen 200 mg/gn dozlar&#305;na kadar &#305;kmak
gerekebilmektedir.&nbsp; Haloperidol dozu 1 ila 3 mg/gn aras&#305;nda
de&#287;i&#351;ebilir ve damla &#351;eklinde kullan&#305;m&#305; bir avantaj
olarak d&#351;nlebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Ajitasyon ve sald&#305;rganl&#305;&#287;&#305;n
tedavisinde yine atipik nroleptikler ilk seimlerdir. Ajitasyon iin bazen tek
ba&#351;&#305;na trazodonla ba&#351;lay&#305;p cevap al&#305;nmazsa
nroleptikleri tercih etmek bir seenek olabilir.&nbsp;Karbamazepin, valproat
ve lityum da tek ba&#351;&#305;na ya da ilave tedavi olarak denenebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;mpulsivite ve drt kontrol
kusurlar&#305;n&#305;n tedavisinde ncelikle SSRIlar
denenir.&nbsp;Hiperseksalite iin ayr&#305;ca anti-androjen ajanlar
kullan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Uykusuzluk tedavisinde ilatan nce yatmadan bir
sre nce iilecek &#305;l&#305;k st nerilmelidir.&nbsp;Gerekte bir
anti-depresan olan trazodon (Desyrel<sup></sup>) 50-200 mg dozlar&#305;
aras&#305;nda yatmadan 1 saat nce verildi&#287;inde olduka etkin bir sedatif
etki gsterir.&nbsp; Mirtazapin (Remeron<sup></sup>) yatmadan nce  tablet (15mg)
dozunda benzer etkiye sahiptir.&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Non-Farmakolojik Tedavi</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tedaviye non-farmakolojik yakla&#351;&#305;m hasta
ve hasta yak&#305;n&#305; ile kurulan ve hastal&#305;kla ba&#351;a &#305;kmaya
ynelik ila d&#305;&#351;&#305; etkile&#351;imin btnn iermektedir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bunlar farkl&#305; ba&#351;l&#305;klarda
s&#305;ralanabilece&#287;i gibi hastal&#305;k evrelerine gre de
farkl&#305;l&#305;k gsterir.&nbsp; Evresel perspektif &#351;yle
zetlenebilir:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Erken evrede</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> hastal&#305;k hasta ve hasta
yak&#305;n&#305;na kltre uyumlu bir &#351;ekilde anla&#351;&#305;labilir bir
&#351;ekilde aktar&#305;l&#305;r ve hastal&#305;&#287;&#305;n mmkn
oldu&#287;unca ayr&#305;nt&#305;l&#305; bir &#351;ekilde kavranaca&#287;&#305;
internet, Alzheimer dernek ve vak&#305;flar&#305;n&#305;n ve benzeri
kaynaklar&#305;n dergi, bro&#351;r, kitap gibi bilgilendirici
yay&#305;nlar&#305;n&#305;n okunmas&#305; te&#351;vik edilir.&nbsp;Hastayla
vesayet meselelerini de ierecek &#351;ekilde, gelece&#287;in gereki bir
biimde tasarlanmas&#305;na ynelik tart&#305;&#351;&#305;lmaya gayret
edilir.&nbsp;Hobiler ve sosyal ili&#351;kileri srdrmenin nemi
aktar&#305;l&#305;r.&nbsp;Araba kullanmay&#305; srdrmenin
sak&#305;ncalar&#305;ndan szedilir.&nbsp;Hasta yak&#305;n&#305;na destek gruplar&#305;
hakk&#305;nda bilgi verilir ve dernek aktivitelerinde yer almas&#305;
do&#287;rultusunda cesaretlendirilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Orta evrede</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> hasta ve hasta
yak&#305;n&#305;na yaln&#305;z soka&#287;a &#305;kman&#305;n
sak&#305;ncalar&#305; anlat&#305;l&#305;r.&nbsp; Mali ve bunun gibi hukuksal
i&#351;lerde art&#305;k vesayetin zorunlulu&#287;u aktar&#305;l&#305;r.&nbsp;
Ev ayg&#305;tlar&#305;n&#305; kullanmadaki glkler ve kaza ihtimalleri gzden
geirilir.&nbsp; Giyinmek, y&#305;kanmak ve sofra davran&#305;&#351;&#305; gibi
glkler ele al&#305;n&#305;r.&nbsp; Art&#305;k yaln&#305;z
ya&#351;amamas&#305; ynnde te&#351;vik edilir ve alternatifler ele
al&#305;n&#305;r.&nbsp; Psikotik belirtiler mevcutsa evresel mdahalelerle
ba&#351;a &#305;k&#305;lmas&#305;na gayret edilir.&nbsp; Sfinkter kontroln
artt&#305;r&#305;c&#305; yntemler zerinde durulur.&nbsp; Bu tr
kurulu&#351;lar o evrede mevcut oldu&#287;unda gndz bak&#305;m evlerinin
de&#287;erlendirilmesi te&#351;vik edilir.&nbsp; Hasta yak&#305;n&#305; yk
gzden geirilir ve muhtemel bir depresyona kar&#351;&#305; nlem
al&#305;n&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;leri evrede</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> hasta yak&#305;n&#305;yla
sululuk duygular&#305;, hastal&#305;k yk ve kay&#305;p zerine
tart&#305;&#351;&#305;l&#305;r.&nbsp;Evde profesyonel yard&#305;m ve bir tesi
olarak kal&#305;c&#305; bir bak&#305;mevine nakil zerine
tart&#305;&#351;&#305;l&#305;r ve te&#351;vik edilir.&nbsp;Yatak yaralar&#305;,
kontraktrler, riner ve solunum sistemi infeksiyonlar&#305; riskleri konusunda
uyar&#305;l&#305;r.&nbsp; Sonda ile beslenme gereklili&#287;i ele
al&#305;n&#305;r.&nbsp; Nihayet terminal bak&#305;m ve lm meseleleri zerinde
durulur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Spesifik mdahale alanlar&#305; ise
a&#351;a&#287;&#305;daki &#351;ekilde s&#305;ralanabilir:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&#304;&#351;levsel performans a&#305;s&#305;ndan
szel ipular&#305;ndan fiziksel olarak gstermeye kadar de&#287;i&#351;en
kademeli yard&#305;m&#305;n demansl&#305; hastan&#305;n gnlk
performans&#305;n&#305; artt&#305;rd&#305;&#287;&#305;
gsterilmi&#351;tir.&nbsp; Davran&#305;&#351; modifikasyonu ile tuvaletin
uyar&#305;lmas&#305; veya saatlerinin nceden belirlenmesi kuru kalmay&#305;
te&#351;vik eder.&nbsp; U&#287;ra&#351;&#305; rehabilitasyonu kognitif performans,
psikososyal i&#351;levsellik ve emosyonel dengeyi dzeltir.&nbsp;
I&#351;&#305;&#287;&#305;n azalt&#305;lmas&#305; ve seslerin sknet verici bir
duruma getirilmesi gibi evresel maniplasyonlar&#305;n yeme
davran&#305;&#351;&#305;n&#305; artt&#305;rd&#305;&#287;&#305;
gsterilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal problemler a&#305;s&#305;ndan
banyo ve sofra s&#305;ras&#305;nda mzi&#287;in ajitasyon ve
sald&#305;rganl&#305;&#287;&#305; azaltt&#305;&#287;&#305;
gsterilmi&#351;tir.&nbsp; Mevcudiyetin simlayonu tedavisi ad&#305; verilen
aile yelerinin ses ve grnt kay&#305;tlar&#305;n&#305;n dinletilmesi veya
izletilmesinin de benzer etkisi oldu&#287;una ili&#351;kin bildirimler
vard&#305;r.&nbsp; Yry&#351; ve benzeri hafif egzersizler
gezinme-ad&#305;mlama davran&#305;&#351;&#305;n&#305;n nne geebilir.&nbsp;
Psikotik belirtiler sald&#305;rganl&#305;k, kama veya yemeyi reddetme gibi
tehlikeli veya a&#351;&#305;r&#305; s&#305;k&#305;nt&#305; verici &#351;iddette
de&#287;ilse yeniden ynlendirme (konuyu de&#287;i&#351;tirme) en iyi ba&#351;a
&#305;kma yoludur.&nbsp; Ajitasyon ve sald&#305;rganl&#305;k iin de yeniden
ynlendirme, dikkatini elme ve aktivite tedavisi etkili olabilir.&nbsp;
ncelikle e&#287;er ay&#305;rt edilebiliyorsa ajitasyonu tetikleyen olay&#305;n
nne geilmeye al&#305;&#351;&#305;lmal&#305;d&#305;r (rne&#287;in, aynadaki
yabanc&#305; grntden rkp kavga eden hasta iin aynalar&#305;n
kald&#305;r&#305;lmas&#305;).&nbsp; Kahve, ay gibi uyar&#305;c&#305;lar&#305;n
ak&#351;am iilmemesine zen gsterilmelidir, onlar&#305;n yerine iilecek
&#305;l&#305;k st uykusuzlu&#287;un nne geebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hasta yak&#305;nlar&#305; iin hastal&#305;k
hakk&#305;nda k&#305;sa ve uzun sreli e&#287;itim programlar&#305;n&#305;n
s&#305;k&#305;nt&#305;y&#305; azaltan ve nihai evreyi geciktiren etkileri kesin
bir biimde gsterilmi&#351;tir.&nbsp; Hasta yak&#305;n&#305; destek
gruplar&#305;n&#305;n emosyonel denge a&#305;s&#305;ndan byk nemi
vard&#305;r.&nbsp; Bilgisayar a&#287;lar&#305;, telefon deste&#287;i
e&#287;itim iin kullan&#305;lacak seeneklerdir.&nbsp; Gndz bak&#305;m
evlerinin hasta yak&#305;n&#305; yk a&#305;s&#305;ndan olumlu etkisi
ku&#351;kusuzdur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALZHEIMER DI&#350;I DEMANSLAR</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>ALZHEIMER DI&#350;I DEJENERATIF DEMANSLAR</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Lewy Cisimcikli Demans<a name="_ftnref2"> </a></span></b><span
style='mso-bookmark:_ftnref2'></span><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Friedrich Lewy, 1923 y&#305;l&#305;nda parkinsonizmi
olan ve hemen nerdeyse yar&#305;s&#305;nda demans&#305;n da var oldu&#287;u
kk bir hasta serisinde daha sonra kendi ad&#305;yla an&#305;lmaya
ba&#351;lanan sitoplazmik inklzyonlar&#305; tan&#305;mlam&#305;&#351;t&#305;r.
Sonraki 50 y&#305;l ierisinde Lewy cisimci&#287;i-demans birlikteli&#287;i ile
ilgili sadece tek tek olgu bildirimleri mevcuttur. Ancak, 1980li
y&#305;llarda, demans&#305; olan bir grup hastada nropatolojik olarak kortikal
Lewy cisimciklerinin gsterilmesinden sonra, dnyan&#305;n farkl&#305;
merkezlerinden hasta serileri bildirilir olmu&#351;tur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Lewy cisimcikli demans (LCD) tan&#305;m&#305; ilk
kez 1996 y&#305;l&#305;nda &#351;u anki LCD Birli&#287;inin Birinci
Uluslararas&#305; al&#305;&#351;tay&#305;nda
kullan&#305;lm&#305;&#351;t&#305;r (McKeith<i> et al. </i>, 1996). Bu
al&#305;&#351;taydan nce demanstaki Lewy cisimciklerinin
varl&#305;&#287;&#305;, diffz Lewy cisimcik hastal&#305;&#287;&#305;,
Alzheimer hastal&#305;&#287;&#305;n&#305;n Lewy cisimcikli varyant&#305;
(AHLCV), Lewy cisimcik tipli senil demans ve Alzheimer
hastal&#305;&#287;&#305;na e&#351;lik eden Lewy cisimcik
hastal&#305;&#287;&#305; gibi farkl&#305; terimlerle ifade edilmi&#351;tir.
Yukarda Alzheimer Hastal&#305;&#287;&#305; blmnn Dopaminerjik
Kay&#305;p alt ba&#351;l&#305;&#287;&#305;nda
tart&#305;&#351;&#305;ld&#305;&#287;&#305; gibi AHLCVyi AH nropatolojisine
s&#305;n&#305;rl&#305; limbik LClerin (amigdala, peri-amigdalar ve entorhinal
korteksler) e&#351;lik etmesi durumunda kullan&#305;p, neokortikal ve
beyinsap&#305; LClere de&#287;i&#351;en oranlarda AH nropatolojisinin
(bask&#305;n olarak amiloid plaklar) e&#351;lik etmesi durumunda vurgunun LCD
zerinde olmas&#305; daha uygun gibi grnmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji
</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Baz&#305;
merkezlerin demanslar aras&#305;nda s&#305;kl&#305;k a&#305;s&#305;ndan AHden
sonra 2. s&#305;ray&#305; VaD veya FTDye vermelerine kar&#351;&#305;n LCDnin
ikinci s&#305;ray&#305; ald&#305;&#287;&#305; daha yayg&#305;n bir kabl grmektedir
(McKeith<i> et al. </i>, 2004). Populasyon temelli al&#305;&#351;malar&#305;n
gzden geirildi&#287;i bir meta-analizde LCD prevelans&#305; %0.1-5.0
aras&#305;nda, demanslar aras&#305;nda s&#305;kl&#305;&#287;&#305; ise
%1.7-30.5 aras&#305;nda de&#287;i&#351;mektedir. Yukarda AH blmnde szedilen
TAPS al&#305;&#351;mas&#305;nda Kad&#305;kyde 70 ya&#351; zeri 1019
ya&#351;l&#305;n&#305;n tarand&#305;&#287;&#305; prevelans
al&#305;&#351;mas&#305;nda saptanan toplam 93 demans olgusunun 70i PRAD ve
PosAD tan&#305;lar&#305; alan toplam AH olgular&#305; iken LCD (toplam muhtemel
ve mmkn LCD) 9 olgu ile 2. s&#305;rada yer alm&#305;&#351;t&#305;. Otopsi
serilerinde de benzer &#351;ekilde bu oran %15 ile 25 aras&#305;ndad&#305;r.
Insidans, Cache County al&#305;&#351;mas&#305;nda izlenen 65 ya&#351; zeri
5092 birey aras&#305;nda y&#305;lda 6 yeni LCD olgusu ile %0.1 olarak
saptanm&#305;&#351;t&#305;. Cinsiyetin bir risk faktr olarak niteli&#287;i
ok a&#351;ikar olmasa da nropatolojik olarak ayn&#305; zamanda kesin AH
tan&#305; kriterlerini dolduran beyinsap&#305; LCli 85 otopsi olgusunda saf
AHli 192 olgunun tam tersine erkek bask&#305;nl&#305;&#287;&#305;
bildirilmi&#351;tir. Yukarda sz edilen meta-analizde ya&#351;&#305;n LCD iin de
bir risk faktr oldu&#287;u, buna kar&#351;&#305;l&#305;k Brezilya ve Sri
Lanka kentleri ile Japonya k&#305;rsal alan&#305;ndan ayn&#305; prevelans
rakamlar&#305;n&#305;n bildirilmi&#351; olmas&#305;na dayan&#305;larak evresel
faktrlerin rol olmad&#305;&#287;&#305; ifade edilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.4pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Klinik
Tablo:</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LCD de
Alzheimer hastal&#305;&#287;&#305;na benzer tarzda, senil dnemde sinsi
ba&#351;lang&#305;l&#305;, kronik progresif seyirli, genellikle belirgin
grsel-mekansal ve yrtc fonksiyonlarda bozulman&#305;n n planda
oldu&#287;u bir demans tablosudur. LCD tan&#305;s&#305; alan hastalar&#305;n
kolinesteraz inhibitrlerine yan&#305;t&#305;n&#305;n iyi olmas&#305; ve
nroleptiklere a&#351;&#305;r&#305; hassasiyetleri nedeniyle farmakolojik
yakla&#351;&#305;m a&#305;s&#305;ndan ve ayn&#305; zamanda seyrinin ve
prognozunun di&#287;er demans tiplerinden farkl&#305; olmas&#305; nedeniyle
LCDnin klinik olarak do&#287;ru tan&#305;nmas&#305; nemlidir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Son
y&#305;llarda edinilen bilgilerden sonra, LCDnin klinik ve patolojik tan&#305;
kriterleri iin, McKeith ve arkada&#351;lar&#305; taraf&#305;ndan 1996
y&#305;l&#305;nda tan&#305;mlanan uzla&#351;&#305; kriterlerinin kabul
edilebilir bir zgll&#287;nn olmas&#305;na ra&#287;men
duyarl&#305;l&#305;&#287;&#305;n&#305;n suboptimal olmas&#305; ve bununla
beraber temel zelliklerden olan zihinsel i&#351;levlerde dalgalanman&#305;n
tan&#305;nmas&#305;ndaki zorluklar ve temel zelliklerin (grsel
halsinasyonlar, seyirde dalgalanma ve parkinsonizm) nn bir arada
d&#351;k s&#305;kl&#305;kta grlyor olmas&#305; nedeniyle tan&#305;
kriterlerinde revizyon yap&#305;lmas&#305; ihtiyac&#305; do&#287;mu&#351;tur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>McKeith
ve arkada&#351;lar&#305; taraf&#305;ndan 2005 y&#305;l&#305;nda yay&#305;nlanan
yeni uzla&#351;&#305; kriterleri Tablo 17de belirtilmi&#351;tir (McKeith<i> et
al. </i>, 2005). Revize edilmi&#351; kriterlerde nceki merkezi, ekirdek ve
destekleyici zellikler kategorilerine klinik ve inceleme bulgular&#305;ndan
olu&#351;an i&#351;aretleyici zellikler eklenmi&#351;tir.
&#304;&#351;aretleyici zellikler di&#287;er demans tiplerine gre anlaml&#305;
olarak daha s&#305;k grlrken, destekleyici zellikler ise s&#305;kl&#305;kla
grlr ancak zgllkleri azd&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LCDde
ilerleyici engellili&#287;in sebebi hem kognitif bozuklu&#287;a hem de
nropsikiyatrik, motor, uyku ve otonomik bozukluklara ba&#287;l&#305;
olabilmesine ra&#287;men zihinsel bozulma tan&#305; iin gerek
&#351;artt&#305;r. LCD demans&#305;n kardinal (kognitif ve i&#351;levsel
bozukluk olarak demans ve grsel halsinasyonlar) ve ikincil alanlar&#305;ndan
(spontan parkinsonizm, REM-uykusu davran&#305;&#351; bozuklu&#287;u [RUDB],
inkontinans) zelliklerin daha ilk evrelerden itibaren grlebildi&#287;i
demanslar aras&#305;nda en zengin sunuma sahip olan&#305;d&#305;r. Merkezi
zelli&#287;e ek olarak  ekirdek zellikten ikisinin mevcudiyeti muhtemel
LCD, birinin mevcudiyeti ise mmkn LCD tan&#305;s&#305; iin esast&#305;r
(Bkz. Tablo 17). Bir veya daha fazla ekirdek zelli&#287;in
varl&#305;&#287;&#305;na, i&#351;aretleyici zelliklerden bir veya daha
fazlas&#305;n&#305;n e&#351;lik etmesi durumunda tan&#305; muhtemel LCD
olabilir. Buna kar&#351;&#305;n ekirdek zellliklerden hibirisinin
olmamas&#305; durumunda, i&#351;aretleyici zelliklerden bir veya daha
fazlas&#305;n&#305;n olmas&#305; ise mmkn LCD tan&#305;s&#305; iin
yeterlidir. Ancak muhtemel LCD tan&#305;s&#305; tek ba&#351;&#305;na
i&#351;aretleyici zelliklere dayanarak konmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Her 
ekirdek zellik iin de yeni kriterlerde fazlaca de&#287;i&#351;iklik
belirtilmemesine ra&#287;men, tan&#305; ve semptomlar&#305;n &#351;iddetini
de&#287;erlendirmek iin klinik de&#287;erlendirmede daha geli&#351;mi&#351;
metodlar&#305;n kullan&#305;m&#305; nerilmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Merkezi
zellik</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hastan&#305;n
sosyal ya da i&#351; hayat&#305;ndaki fonksiyonelli&#287;ini etkileyen
ilerleyici bir kognitif bozulma olmal&#305;d&#305;r. Bu kognitif kay&#305;p
erken evrede zellikle karma&#351;&#305;k dikkat, grsel-mekansal ve yrtc
i&#351;levlerde bozulma ile karakterizedir. Yrtc i&#351;levler; planlama,
soyut d&#351;nme yetene&#287;i, yarg&#305;lama, igr, karar verme gibi
amaca ynelik hareketler iin nemli olan kognitif i&#351;lemleri ierir.
Hastal&#305;&#287;&#305;n erken evresinde greli olarak daha az olan bellek ile
ilgili yak&#305;nmalar ve muayene bulgular&#305; ancak hastal&#305;k ilerledike
a&#351;ikar hale gelir. Episodik bellek ile ilgili testlerdeki
performanslar&#305; (oktan semeli ile hat&#305;rlamalar&#305; serbest
hat&#305;rlamadan iyidir) AHsi olan hastalara gre daha iyidir. Ayr&#305;ca
szel bellek testlerinde grsel bellek testlerine gre daha iyi performans
gsterirler. Erken ve n planda grsel-mekansal bozukluk LCD iin tipiktir.
MMSEde AHye k&#305;yasla greli yksek puan alabilen, hatta demans iin kesme
puan&#305;n&#305;n zerinde kalan bir hastan&#305;n kesi&#351;en
be&#351;genlerden puan kaybetmesi zellikle ay&#305;t ettiricidir. Grsel-mekansal
bozuklu&#287;un &#351;iddeti erken dnemde posterior kortikal atrofide izlenen
&#351;iddette bir simultanagnoziye neden olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ekirdek
zellikler</span></b><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dalgalanma:</span></i></b><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Klinik pratikte
ekirdek kriterler aras&#305;nda en zor karakterize edilebileni zihinsel
i&#351;levlerdeki dalgalanmalard&#305;r.&nbsp; Bu kriter iin
uyan&#305;kl&#305;k durumu veya kognitif ve i&#351;levsel performansta
dakikalar, saatlerden, gnler, haftalara kadar de&#287;i&#351;en srelerde,
hasta yak&#305;n&#305; ve bazen de hekim iin a&#351;ikar kayda de&#287;er
dalgalanmalar geerli say&#305;lmal&#305;d&#305;r. Bununla birlikte dalgalanma
kriterinin varl&#305;&#287;&#305; veya yoklu&#287;unun saptanmas&#305;n&#305;n
sadece ykyle de&#287;erlendirmeciler aras&#305; gvenilirli&#287;inin ok
yksek olmad&#305;&#287;&#305; ve dalgalanmaya zg geli&#351;tirilmi&#351;
leklerin kullan&#305;m&#305;n&#305;n nerildi&#287;i
unutulmamal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Grsel
halsinasyonlar:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> Hastal&#305;&#287;&#305;n genellikle erken evrelerinde
grlen tekrarlay&#305;c&#305; canl&#305;, renkli, kompleks grsel
halsinasyonlar tan&#305; iin ekirdek zelliklerden ikincisidir. Grsel
halsinasyonlar&#305; olan LCDli hastalar&#305;n, halsinasyonlar&#305;
olmayan grup ile kar&#351;&#305;la&#351;t&#305;r&#305;ld&#305;&#287;&#305;nda
grsel-alg&#305;sal bozulmalar&#305; daha belirgindir. SPECT grntlemelerinde
oksipital kortekste tutulum azalm&#305;&#351;t&#305;r. Grsel
halsinasyonlar&#305; olan posterior kortikal atrofili (PKA) grubun, olmayan
PKAl&#305;lara gre bunlar&#305;n gerekte LCD olduklar&#305;n&#305; d&#351;ndrecek
&#351;ekilde daha fazla parkinsonizm ve RUDBye sahip olduklar&#305;
gsterilmi&#351;tir. Otopsi al&#305;&#351;malar&#305;nda, grsel
halsinasyonlar&#305; olan vakalarda, grsel kompleks imajlar&#305;n jeneratr
oldu&#287;u bilinen anterior ve inferior temporal lob ve amigdalada Lewy cisimciklerinin
artm&#305;&#351; oldu&#287;u bildirilmi&#351;tir. Grsel halsinasyonlar&#305;
olan hastalarda kortikal asetilkolin defisitleri daha belirgindir ve bu durum
belki de kolinerjik tedaviye daha iyi yan&#305;t&#305;n nedeni olabilir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Parkinsonizm:</span></i></b><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> LCDde ekstrapiramidal
motor bulgular&#305;n a&#287;&#305;rl&#305;&#287;&#305; genellikle demans&#305;
olsun veya olmas&#305;n benzer ya&#351; grubundaki Parkinson
hastalar&#305;ndaki (PH) motor bulgular&#305;n
a&#287;&#305;rl&#305;&#287;&#305;na benzer &#351;ekilde olabilece&#287;i gibi
daha geri planda ve hafif de olabilir. PHn&#305;n ay&#305;rdedici asimetrik
sunumu belirgin olmayabilir.&nbsp;LCDde postral instabilite, yry&#351;
bozuklu&#287;u, bradimimi gibi aksiyal tutulum demanss&#305;z PHl&#305;lara
gre daha belirgindir. &#304;stirahat tremoru daha az grlr. Parkinsonizmin
L-Dopa cevab&#305; ok iyi olmayabilir. Miyoklonus, tedavi gerektirmeyecek
kadar hafif bir parkinsonizm, tremorun yoklu&#287;u, L-Dopa
cevaps&#305;zl&#305;&#287;&#305; zelliklerinden birinin LCDde PHya gre 10
kat daha muhtemel oldu&#287;u bildirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#304;&#351;aretleyici
zellikler<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>REM
uyku davran&#305;&#351; bozuklu&#287;u: </span></i></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;RUDB demans ve
parkinsonizmden ok nce ba&#351;lam&#305;&#351; olabilir. RUDB spesifik bir
sinkleopati (PH, MSA, LCD) e&#351;likisidir ve nadiren di&#287;er dejeneratif
hastal&#305;klarda grlr. RUDB LCDye e&#351;lik eden a&#351;&#305;r&#305;
gndz uyuklamas&#305; gibi di&#287;er uyku bozukluklar&#305;yla birlikte
zihinsel i&#351;levlerdeki dalgalanmalara katk&#305;da bulunuyor olabilir. RUDB
yks polisomnografi ile do&#287;rulanabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nroleptik
a&#351;&#305;r&#305; duyarl&#305;l&#305;&#287;&#305;:</span></i></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> Nroleptik
duyarl&#305;l&#305;k reaksiyonlar&#305;yla birlikte olan yksek mortalite ve
morbidite nedeniyle, D2 reseptr bloke edici ajanlar tan&#305; veya tedavi
amac&#305;yla kullan&#305;lmamal&#305;d&#305;r. LCDli hastalar ve demans&#305;
olsun olmas&#305;n PHl&#305;lar zellikle tipik nroleptiklere
kar&#351;&#305;, demansta kullan&#305;lmaya al&#305;&#351;&#305;lan ok
d&#351;k dozlar&#305;na dahi a&#351;&#305;r&#305; duyarl&#305;l&#305;k
gsterirler ve a&#287;&#305;r, akut bir akinetik-rijid tablo
geli&#351;tirebilirler. Bu durum habis nroleptik sendrom &#351;iddetinde
olabilir ve ketiapin ile dahi bildirilmi&#351;tir. Ancak LCD tan&#305;s&#305;
alan hastalar&#305;n yakla&#351;&#305;k %50sinde tipik veya atipik
antipsikotik ajanlar almalar&#305;na ra&#287;men belirgin yan etki
bildirilmemesine dayanarak, nroleptik duyarl&#305;l&#305;&#287;&#305;n&#305;n
olmamas&#305; LCD tan&#305;s&#305;n&#305; d&#305;&#351;lamazken varl&#305;&#287;&#305;
ise tan&#305;y&#305; kuvvetle destekler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; grntlemesi:</span></i></b><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'> </span></i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; fonksiyonel grntlemesi, nigrostriatal
dopaminerjik sistemin btnl&#287;n tan&#305;mlar. FP-CIT, beta-CIT, IPT,
TRODAT gibi spesifik ligandlarla yap&#305;lan dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; grntlemesi, presinaptik nronal
dejenerasyon iin i&#351;aretleyici olabilirler. LCDde striatal dopamin
ta&#351;&#305;y&#305;c&#305;s&#305; aktivitesi d&#351;k iken, Alzheimer
hastal&#305;&#287;&#305;nda normaldir. &#304;diopatik PH, MSA ve PSPde de
bozuk olabilece&#287;i gz nnde tutulmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Destekleyici
zellikler:<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Destekleyici
zellikler LCDde s&#305;kl&#305;kla grlr ancak zgllkleri ekirdek ve
i&#351;aretleyici zellikler kadar yksek de&#287;ildir.
Hastal&#305;&#287;&#305;n erken dneminde ortostatik hipotansiyon, riner
inkontinans, nrokardiyovaskler insitabilite, konstipasyon, impotans gibi
otonomik semptomlar grlebilir. Otonomik disfonksiyon ayn&#305; zamanda
baz&#305; hastalarda grlebilen tekrarlayan d&#351;meler, senkop ve geici
bilin kayb&#305;n&#305;n geli&#351;mesine de katk&#305; da bulunuyor olabilir.
Sistematize hezeyanlar ve depresyon hastal&#305;&#287;&#305;n herhangi bir
dneminde grlebilir.&nbsp; Hezeyanlar iinde misidentifikasyon ve Capgras
hezeyan&#305; zellikle s&#305;kt&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&#350;u
anki bilgilerin &#305;&#351;&#305;&#287;&#305;nda, LCD tan&#305;s&#305;n&#305;
desteklemek iin klinik olarak uygulanabilir genotipik veya beyin omurilik
s&#305;v&#305;s&#305; i&#351;aretleyicisi yoktur. Beyin manyetik rezonans
grntleme (MRG)de, hippokampal ve medial temporal lob volmlerinin
korunmu&#351; olmas&#305;, putamende atrofi ve MRGde oksipital atrofi
olmaks&#305;z&#305;n SPECT ve PET ile oksipital hipoperfzyon ve hipometabolizman&#305;n
grlmesi tan&#305; iin yard&#305;mc&#305;d&#305;r. Yukarda sz&nbsp;
edildi&#287;i gibi MRGde PKA tarz&#305; oksipito-parietal atrofi sergileyen
hastalar aras&#305;nda grsel halsinasyonlar kuvvetle LCD d&#351;ndrse de
rasgele seilmi&#351; LCDliler yap&#305;sal MRGde posteriyor atrofi
tarz&#305; a&#305;s&#305;ndan ay&#305;rt edilemeyebilirler.
[I-123]-metaiodobenzyl guanidine (MIBG) ile yap&#305;lan ve postganglionik
sempatik kardiak innervasyon hakk&#305;nda bilgi veren sintigrafi LCDde
anormaldir ve AHden ay&#305;rmada zgllk ve duyarl&#305;l&#305;&#287;&#305;
yksektir. Ba&#351;ka bir al&#305;&#351;mada bu ayr&#305;m&#305;n zellikle de
a&#351;ikar ortostatik hipotansiyonu olan hastalarda parkinsonizm
olmaks&#305;z&#305;n da a&#351;ikar oldu&#287;u gsterilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sa&#287;kal&#305;m
AHye k&#305;yasla daha k&#305;sa gibi durmaktad&#305;r. Bu amala
yap&#305;lm&#305;&#351; yak&#305;n tarihli byk bir al&#305;&#351;mada LCD ve
PH demansl&#305; (PHD) otopsi do&#287;rulamal&#305; 243 olgunun retrospektif
analizinde medyan sa&#287;kal&#305;m&#305;n 5 y&#305;l oldu&#287;u
bildirilmi&#351;tir. PHDliler LCDlilere gre daha uzun sa&#287;kal&#305;ma
sahiptiler. Ba&#351;lang&#305;ta a&#351;ikar dalgalanma kt sonlan&#305;m&#305;
en iyi ngren zellik olarak belirlenmi&#351;tir. AHye gre sa&#287;kal&#305;m&#305;n
k&#305;salmas&#305;n&#305;n, zellikle motor ve otonom bozukluklar olmak zere,
LCDnin zengin klinik sunumunun engellili&#287;i ok daha fazla
artt&#305;rmas&#305; nedeniyle oldu&#287;u ileri srlebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Nropatoloji</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:red;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Nropatolojik olarak tabloya ad&#305;n&#305; veren intraseller Lewy cisimcikleri
(LC) ba&#351;l&#305;ca zelliktir.&nbsp; LCler, intranronal sitoplazmik,
eozinofilik, sferik, filamantz inklzyon cisimcikleridir. LClerin temel
bile&#351;eni 4. kromozomda kodlanan ve i&#351;levi ok iyi
ayd&#305;nlat&#305;lamasa da aksonal nakilde rol oynad&#305;&#287;&#305;
d&#351;nlen ve a&#287;&#305;rl&#305;kla akson sonlanmalar&#305;nda lokalize
olan, dolay&#305;s&#305;yla sinaptik btnl&#287;n korunmas&#305;
&#351;eklinde bir plastisite rol de oldu&#287;u d&#351;nlen
&#945;-sinklein isimli proteindir.&nbsp;LCler, &#945;-sinkleinin anormal
katlanmas&#305; ve fosforilasyonu sonras&#305;nda olu&#351;urlar. &#945;-sinklein
immn boyamas&#305; geli&#351;tirildikten sonra hematoksilen-eozin ile
seilemeyen neokortikal LCleri de ay&#305;rt etmek mmkn olmu&#351;tur.&nbsp;
PHda a&#287;&#305;rl&#305;kl&#305; olarak subtantia nigran&#305;n DA-erjik
hcre gvdelerini ieren pars compactas&#305;na s&#305;n&#305;rl&#305; olan LC
ve Lewy nritleri, LCDde beyin sap&#305;na ilave olarak limbik-paralimbik
sistem ve neokortekste birikir. Bununla birlikte saf LCD&nbsp; nropatolojisi
tm LCD klinik fenotipinin kk bir blmnden sorumludur.&nbsp; Klinik olarak
LCD tan&#305;s&#305; alan hastalar&#305;n postmortem
al&#305;&#351;malar&#305;nda&nbsp; AH patolojisi de s&#305;kl&#305;kla bir
arada grlmekte ve hem nomenklatr (AHnin Lewy cisimcikli varyant&#305;,
yayg&#305;n Lewy cismci&#287;i hastal&#305;&#287;&#305; gibi) hem de klinik
fenotipi bulan&#305;kla&#351;t&#305;rmaktad&#305;r. rne&#287;in, daha belirgin
olarak neokortikal Alzheimer tipi patolojisi olan LCD hastalar&#305;nda, klasik
LCD klinik bulgular&#305; da daha hafiftir. LCDli hastalarda en s&#305;k
grlen Alzheimer patolojisi amiloid plaklar iken NFY daha seyrektir. NFYler
grld&#287; takdirde, AHyle k&#305;yasla daha d&#351;k Braak ve Braak
evrelerinde, a&#287;&#305;rl&#305;kla limbik ve paralimbik alanlarda, APler de
nritik de olsalar, genellikle PHF (-) ve neokortekse s&#305;n&#305;rl&#305;
olma e&#287;ilimi ta&#351;&#305;maktad&#305;rlar.&nbsp; Ayr&#305;ca, LCDdeki
APler evresinde mikroglial aktivasyon ve inflamasyona da AHye k&#305;yasla
ok daha az rastland&#305;&#287;&#305; ileri srlmektedir.&nbsp;Hippokampal
CA2 ve CA3 blgelerinde grlen ubiktin pozitif nritik dejenerasyonun da
AHde grlmeyen LCDye zg bir patolojik zellik oldu&#287;u ileri
srlmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>LCD nrokimyasal olarak kortikal kolinerjik i&#351;aretleyiciler ve
nigrostriatal dopamin kayb&#305; ile karakterizedir. Raphe ekirde&#287;i ve
locus ceruleustaki nron kayb&#305; ve gliozis serotonin ve norepinefrin
azalmas&#305;na neden olur ve duygu durum, dikkat ve uyan&#305;kl&#305;ktaki
dalgalanmalar&#305; a&#305;klayabilir. Meynert ekirde&#287;indeki kolinerjik
nron kayb&#305; da bellek, dikkat, uyan&#305;kl&#305;&#287;&#305;n derecesi ve
belki de dalgalanmalar&#305; anlaml&#305; olarak etkileyebilir. Meynert
ekirde&#287;indeki dejenerasyona ek olarak ba&#351;l&#305;ca i&#351;levi
diurnal ritmin dzenlenmesi olan talamik kolinerjik innervasyonun
kayna&#287;&#305; pedinculo-pontin ekirdek de AHden farkl&#305; olarak
dejenerasyona kat&#305;l&#305;r.&nbsp;An&#305;lan beyin sap&#305;
nrotransmitter kay&#305;plar&#305;n&#305;n LCDye zg parasomni, parkinsonizm
ve otonom sinir sistemi belirtilerinden sorumlu oldu&#287;u d&#351;nlmektedir.&nbsp;
ChAT aktivitesi ile belirlenen neokortikal kolinerjik kay&#305;p AHye gre ok
daha belirgindir.&nbsp; Bu kayb&#305;n genel olarak demans &#351;iddetiyle,
zel olarak temporal lober kayb&#305;n ise davran&#305;&#351;sal belirtilerle
korelasyonu bildirilmi&#351;tir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:35.45pt'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>znemeyip biriken fibriler &#945;-sinkleinin, LCDnin yan&#305;
s&#305;ra bir dizi dejeneratif hastal&#305;kta daha temel patolojik
i&#351;aretleyici oldu&#287;unun gsterilmesi sonras&#305;nda bu grup <i>&#945;-sinkleopatiler
</i>olarak adland&#305;r&#305;lmaya ba&#351;lanm&#305;&#351;t&#305;r.&nbsp;
Bunlar aras&#305;nda LCDden ayr&#305; bir antite olup olmad&#305;&#287;&#305;
tart&#305;&#351;mal&#305; olan PH demans&#305; ncelikle say&#305;labilir.&nbsp;
K&#305;sa sre ncesine kadar bir PH-AH rt&#351;mesi oldu&#287;u
d&#351;nlen idyopatik PHda sonradan geli&#351;en demans&#305;n, art&#305;k
beyin sap&#305; tipi LC hastal&#305;&#287;&#305;n&#305;n zamanla kortikal tip
LCye yayg&#305;nla&#351;mas&#305; sonucu geli&#351;ti&#287;ine dair bir
gr&#351; birli&#287;i olu&#351;maktad&#305;r.&nbsp;&#945;-sinklein fibriler
birikimleri MSAda glial inklzyonlar &#351;eklinde grlmektedir.&nbsp;Glial
&#945;-sinklein inklzyonlar&#305; LCD ve PHda ge evrelerde grlrken,
MSAda klinik fenotipten sorumlu patolojik de&#287;i&#351;iklik gibi
durmaktad&#305;r.&nbsp;Hallervorden-Spatz hastal&#305;&#287;&#305;nda nronal
ve glial inklzyonlar&#305;n yan&#305;s&#305;ra aksonal sferoidler iinde de
grlrler. Bir al&#305;&#351;mada otonomik ganglionlarda ilerleyici
dejenerasyonla giden saf otonomik yetmezlik de&nbsp;bir &#945;-sinkleopati
olarak tarif edilmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans18.JPG">&#350;ekil 18.</a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Lewy
Cisimci&#287;i. Solda substantia nigrada evresinde halosuyla intranronal
eosinofilik inklzyon izlenirken sa&#287;da ise kortekste ubikitin (+), halosu
seilmeyen intranronal inklzyon izlenmekte (Kaynak: </span><span
style='font-size:10.0pt;font-family:Tahoma'><a
href="http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass5.htm"><span
lang=TR style='mso-ansi-language:TR'>http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass5.htm</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Tablo 17.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Muhtemel ve Mmkn LCD Klinik
Tan&#305;s&#305; iin Gzden Geirilmi&#351; Yeni Uzla&#351;&#305; Kriterleri <i>(McKeith
et al. , 2005)<o:p></o:p></i></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1)&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Merkezi zellik</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Muhtemel veya
mmkn LCD tan&#305;s&#305; iin gereklidir):<b> </b><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Demans; Normal
sosyal ya da mesleki i&#351;levselli&#287;i etkileyecek
a&#287;&#305;rl&#305;kta ilerleyici kognitif bozulma.&nbsp; Erken evrelerde
bellek bozuklu&#287;u bask&#305;n ve kal&#305;c&#305; dzeyde olmayabilir,
fakat ilerlemeyle birlikte a&#351;ikar hale gelir.&nbsp; Dikkat,
frontal-subkortikal yetenekler ve vizuo-spasyal i&#351;levleri len
testlerdeki bozulmalar n planda olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2)&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>ekirdek zellikler</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>( temel
zellikten ikisinin mevcudiyeti muhtemel DLB, birinin mevcudiyeti ise mmkn
DLB tan&#305;s&#305; iin esast&#305;r): <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
Dikkat ve uyan&#305;kl&#305;kta ciddi de&#287;i&#351;ikliklerle birlikte giden
zihinsel i&#351;levlerde dalgalanma. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:46.4pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
Tipik olarak iyi forme ve ayr&#305;nt&#305;l&#305;, tekrarlay&#305;c&#305;
grsel halsinasyonlar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:46.4pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;
Parkinsonizmin motor zelliklerinin kendili&#287;inden mevcudiyeti<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3)&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;&#304;&#351;aretleyici zellikler</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(Bu
zelliklerden bir veya daha fazlas&#305; yine bir veya&nbsp; daha fazla
ekirdek zelli&#287;in varl&#305;&#287;&#305;nda, tan&#305; muhtemel LCD
olabilir. Ancak ekirdek zelliklerden hibirisi yoksa, bu zelliklerden bir
veya daha fazlas&#305;n&#305;n olmas&#305; mmkn LCD tan&#305;s&#305; iin
yeterlidir. Muhtemel LCD tan&#305;s&#305; ise tek ba&#351;&#305;na
i&#351;aretleyici zelliklere dayanarak konmamal&#305;d&#305;r.)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
REM uyku davran&#305;&#351; bozuklu&#287;u<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
A&#287;&#305;r nroleptik duyarl&#305;l&#305;&#287;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;
SPECT veya PET grntlemeleriyle gsterilebilen bazal gangliada d&#351;k dopamin
ta&#351;&#305;y&#305;c&#305; tutulumu<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>4)&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Destekleyici zellikler </span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:21.3pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>(Genellikle vard&#305;r fakat tan&#305;sal
zgll&#287; kan&#305;tlanmam&#305;&#351;t&#305;r.):<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
Tekrarlayan d&#351;meler ve senkop<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
Geici a&#305;klanamayan bilin kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;A&#287;&#305;r
otonomik disfonksiyon (ortostatik hipotansiyon, riner inkontinans gibi)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>d.&nbsp;&nbsp;
Di&#287;er modalitelerde halsinasyonlar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>e.&nbsp;&nbsp;
Sistematize hezeyanlar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>f.&nbsp;&nbsp;&nbsp;&nbsp;Depresyon<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>g.&nbsp;&nbsp;
BT/MRGde medial temporal lob yap&#305;lar&#305;n&#305;n greli olarak
korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>h.&nbsp;&nbsp;
SPECT ve PETde oksipital aktivitede azalma ile birlikte genel olarak
d&#351;k tutulum<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>i.&nbsp;&nbsp;&nbsp;&nbsp;MIBG
myokard sintigrafisinin bozuk (d&#351;k tutulum) olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>j.&nbsp;&nbsp;&nbsp;&nbsp;EEGde
belirgin yava&#351; dalga aktivitesi ile birlikte temporal loblarda geici
keskin dalgalar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>LCD tan&#305;s&#305; ihtimali
a&#351;a&#287;&#305;dakilerin mevcudiyeti durumunda azal&#305;r:</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>a.&nbsp;&nbsp;
Fokal nrolojik bulgular veya beyin grntlemesinde serebrovaskler olaya ait
bir delil varsa<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>b.&nbsp;&nbsp;
Klinik tabloya tamamen ya da k&#305;smen neden olabilecek ba&#351;ka bir
fiziksel hastal&#305;k veya beyin bozuklu&#287;unun varl&#305;&#287;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.2pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>c.&nbsp;&nbsp;&nbsp;
E&#287;er parkinsonizm ilk kez a&#287;&#305;r demans evresinde ortaya
&#305;karsa<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:1.0cm;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18.0pt'><i><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></i><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Semptomlar&#305;n zamansal s&#305;ralan&#305;m&#305;:</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>LCD
tan&#305;s&#305;, demans parkinsonizmden (e&#287;er varsa) nce veya birlikte
ortaya &#305;kar ise d&#351;nlmelidir. Parkinson hastal&#305;&#287;&#305;
demans&#305; (PHD) terimi, yerle&#351;mi&#351; Parkinson
hastal&#305;&#287;&#305; ba&#287;lam&#305;nda olu&#351;an demans&#305;
tan&#305;mlamak iin kullan&#305;lmal&#305;d&#305;r. Pratik uygulamada, klinik
durum iin en uygun terim kullan&#305;lmal&#305;d&#305;r ve Lewy cisimcik
hastal&#305;&#287;&#305; gibi genelleyici terimler s&#305;kl&#305;kla
yard&#305;mc&#305;d&#305;r. LCD ve PHD ayr&#305;m&#305; yap&#305;lmas&#305;
gereken ara&#351;t&#305;rma projelerinde ise demans&#305;n
ba&#351;lang&#305;c&#305; ile parkinsonizm aras&#305;ndaki 1 y&#305;l
kural&#305;, LCD tan&#305;s&#305; iin hala nerilmeye devam edilmektedir.
Klinikopatolojik ve tedavi al&#305;&#351;malar&#305; gibi di&#287;er
ara&#351;t&#305;rma projelerinde ise her iki klinik fenotipinin de
alfa-sinkleopati veya Lewy cisimcik hastal&#305;&#287;&#305; gibi daha
geni&#351; kategoriler alt&#305;nda toplanmalr&#305; d&#351;nlebilir.<o:p></o:p></span></p>

<div style='margin-left:21.3pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>LCD
tedavisi klinisyen iin zor ve karma&#351;&#305;kt&#305;r. Non-motor semptomlar
iin etkili olan&nbsp; tedaviler, motor fonksiyonlar&#305;
ktle&#351;tirebilir veya benzer &#351;ekilde tersi de mmkndr. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Non-farmakolojik
yakla&#351;&#305;m:</span></i></b><i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'> </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Non-farmakolojik
yakla&#351;&#305;mlar, LCDli hastalar&#305;n pek ok semptomlar&#305;nda ve
fonksiyonel kay&#305;plar&#305;nda yararl&#305; olabilirler, ancak henz bu konu
sistematik olarak de&#287;erlendirilmemi&#351;tir. Grsel halsinasyonlar ve
kognitif ktle&#351;me, dikkat ve uyan&#305;kl&#305;&#287;&#305;n az
oldu&#287;u zamanlarda daha a&#287;&#305;r olabilir. Bu nedenle sosyal
ili&#351;kilerin artt&#305;r&#305;lmas&#305; gibi yakla&#351;&#305;mlarla
uyan&#305;kl&#305;&#287;&#305;n ve dikkatin artt&#305;r&#305;lmas&#305; yararl&#305;
olabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Farmakolojik
yakla&#351;&#305;m:</span></i></b><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Motor
bulgular:</span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'> LCDde parkinsonizmin L-Dopa cevab&#305;n&#305;n iyi olmamas&#305; ve
DA-erjiklerin psikotik belirtileri artt&#305;rma riskine kar&#351;&#305;n
hastan&#305;n kendisine optimize edilmi&#351; bir anti-parkinson tedaviden
yararlan&#305;p yararlanmayaca&#287;&#305; tetkik edilmelidir.&nbsp; L-dopa
d&#351;k dozlarda ba&#351;lan&#305;p, yava&#351; doz art&#305;&#351;&#305;
yap&#305;larak psikiyatrik semptomlar&#305;n artmas&#305;n&#305; engellemek
amac&#305;yla gerekli olan minimum dozda kullan&#305;lmal&#305;d&#305;r.
Antikolinerjiklerden ka&#305;n&#305;lmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Nropsikiyatrik
semptomlar: </span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>Grsel halsinasyonlar en s&#305;k grlen psikiyatrik semptomlard&#305;r.
Farmakolojik yakla&#351;&#305;m&#305;n gerekti&#287;i durumlarda atipik
antipsikotikler ve kolinesteraz inhibitrleri (ChE&#304;) d&#351;nlmelidir.
ChE&#304;lerin davran&#305;&#351;sal belirtiler zerindeki olumlu etkisi ilk
kez LCDli hastalarla yap&#305;lan bir klinik al&#305;&#351;mada ortaya
konmu&#351;tur.&nbsp; Dolay&#305;s&#305;yla, yeni bir hastada kognitif tedavi
amal&#305; ba&#351;lanan ChE&#304;, nroleptik tedaviye kar&#351;&#305;
geli&#351;ebilecek a&#351;&#305;r&#305; duyarl&#305;l&#305;k da gz nne
al&#305;narak grsel halsinasyonlar ve di&#287;er psikotik belirtilerin
tedavisi iin bir sre tek ba&#351;&#305;na b&#305;rak&#305;labilir.&nbsp;
Cevap al&#305;namad&#305;&#287;&#305; takdirde atipik nroleptikler, onlarla
dahi a&#351;&#305;r&#305; duyarl&#305;l&#305;&#287;&#305;n
geli&#351;ebilece&#287;ine dair anekdotal bildiriler de hesaba kat&#305;larak
dikkatle kullan&#305;labilir.&nbsp; AH tedavisine benzer dozlarda kullan&#305;lmak
ko&#351;uluyla ketiapin, olanzapin, klozapin s&#305;ras&#305;yla
seilebilir.&nbsp;Tipik antipsikotiklerin kullan&#305;m&#305;ndan
ka&#305;n&#305;lmal&#305;d&#305;r. Depresyon da s&#305;k grlen bir
semptomdur ancak anti-depresan kullan&#305;m&#305; ile ilgili sistematize bir
al&#305;&#351;ma yoktur. SSRI veya SNRIlar kullan&#305;labilir. Ancak
antikolinerjik etkileri nedeniyle trisiklik antidepresanlardan
ka&#305;n&#305;lmal&#305;d&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Uyku
bozukluklar&#305;: </span></i><span lang=TR style='font-family:Tahoma;
mso-ansi-language:TR'>RUDB yatmadan nce verilen 0.25 mg klonazepam, 3 mg
melatonin veya 12.5 mg ketiapin ile ba&#351;lanacak dozlarla tedavi edilebilir.
Doz art&#305;&#351;&#305; her zaman yava&#351; yap&#305;lmal&#305; ve yan
etkiler a&#305;s&#305;ndan dikkatli olunmal&#305;d&#305;r.
A&#351;&#305;r&#305; gndz uyuklamas&#305; zihinsel performans&#305;n
d&#351;mesine katk&#305;da bulunabilir. Tedavide sabah ve &#287;len
dozlar&#305; &#351;eklinde, 100-400mg aras&#305; kullan&#305;lacak modafinil
ile yarar sa&#287;lan&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><i><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kognitif
semptomlar: </span></i><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>LCD tedavisinde a&#287;&#305;r kolinerjik yetmezli&#287;in de
d&#351;ndrece&#287;i gibi, kolinerjik temelli tedavi, en az&#305;ndan halen
elimizde bulunan ChE&#304;lerle AHye benzer biimde yararl&#305;
olabilir.&nbsp;LCDde Cochrane Ktphanesi taraf&#305;ndan de&#287;erlendirmeye
al&#305;nan tek rasgele kontroll klinik al&#305;&#351;ma olan McKeith
al&#305;&#351;mas&#305;nda rivastigminin baz&#305; kognitif ltlerdeki
stnl&#287;ne ra&#287;men sonular etkinlik a&#305;s&#305;ndan yeterince
ikna edici bulunmam&#305;&#351;t&#305;r. Buna kar&#351;&#305;l&#305;k
rivastigmin EXPRESS isimli ba&#351;ar&#305;l&#305; klinik al&#305;&#351;mas&#305;na
dayanarak PHD tedavisi iin, FDA onay&#305; alm&#305;&#351;t&#305;r ve
dolay&#305;s&#305;yla da LCD iin de d&#351;nlebilir. Memantin tek bir
al&#305;&#351;mada (Emre 2010) sadece global lde plaseboya stn
bulunmu&#351;tur. Kullan&#305;m&#305; d&#351;nlebilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Parkinson
Hastal&#305;&#287;&#305; Demans&#305; </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Parkinson hastal&#305;&#287;&#305; uzun
y&#305;llar iin saf bir motor bozukluk olarak tasarland&#305;ktan sonra zaman
iinde non-motor bozukluklar ve bunlar iinde a&#287;&#305;rl&#305;kl&#305; bir
yeri olan kognitif bozukluklar kaydedilir olmu&#351;tur. Giderek yeterince uzun
srm&#351; bir PHda kognitif bozulman&#305;n belli bir &#351;ddeti olarak
demans&#305;n nerdeyse ka&#305;n&#305;lmaz oldu&#287;u gzlenmi&#351;tir. Bu
klinik gzlemler byk lde hastal&#305;&#287;&#305;n nrobiyolojisi ve
patogenezinin kavranmas&#305;ndaki geli&#351;meler sayesinde mmkn olmu&#351;tur.
<span style='color:black'>Alfa-sinkleinin SNcdeki Lewy cisimcikleri (LCler)
iinde biriken ana protein oldu&#287;unun bulunmas&#305; ve alfa-sinklein
immnhistokimyas&#305;n&#305;n geli&#351;tirilmesinden sonra, nigral LClerin
evresindeki karakteristik haloyu ta&#351;&#305;mad&#305;klar&#305; iin klasik
boyamayla gsterilemeyen kortikal LCler de gsterilebilir hale gelmi&#351;tir.
&#304;zleyen al&#305;&#351;malarda kortikal LClerin demans &#351;iddetiyle
korelasyon gsteren ana patolojik bulgu oldu&#287;u
saptanm&#305;&#351;t&#305;r. Braak ve arkada&#351;lar&#305;n&#305;n
anatomo-klinik korelasyon al&#305;&#351;malar&#305;nda (halen
tart&#305;&#351;mal&#305; olsa da) alfa-sinklein patolojisinin kaudo-rostral
bir ilerleyi&#351;le beyinsap&#305;ndan limbik ve heteromodal asosiasyon
kortekslerine do&#287;ru ykseldi&#287;inin gsterilmesiyle PHda
demans&#305;n&nbsp; neden ge dnemde ortaya &#305;kt&#305;&#287;&#305;
sorusunun cevab&#305; da teorik bir temele kavu&#351;mu&#351;tur.</span><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Belirli kriterlere gre seilmi&#351; 12 prevelans
al&#305;&#351;mas&#305;n&#305; sistematik olarak gzden geiren bir
meta-analizde PHDn&#305;n kesitsel nokta prevelans&#305;n&#305;n %25-30
oran&#305;nda oldu&#287;u bildirilmi&#351;tir. Toplum-tabanl&#305; prospektif
bir al&#305;&#351;mada, Aarsland ve arkada&#351;lar&#305;
ba&#351;lang&#305;,&nbsp; 4 y&#305;l ve 8 y&#305;l sonraki PHD kumulatif
prevelans&#305;n&#305; s&#305;ras&#305;yla %26, %51, %78 olarak
bildirmi&#351;lerdir. Di&#287;er al&#305;&#351;malarda ba&#351;lang&#305;ta
demans&#305; olmayan Parkinson hastalar&#305;nda 4 y&#305;l sonunda %42, bir
di&#287;erinde ise 15 y&#305;l iinde %48 oran&#305;nda demans
geli&#351;ti&#287;i bildirilmi&#351;tir. Sa&#287;kal&#305;mdan
etkilenmedi&#287;i iin prevelans lmlerine gre daha sa&#287;l&#305;kl&#305;
olan insidans hesaplamalar&#305;nda  ila be&#351; y&#305;ll&#305;k izlem
sresinde PHda insidans&#305;n kontrol grubuna gre 4-6 kat daha fazla
artt&#305;&#287;&#305; izlenmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHD iin en nemli risk faktrleri ileri ya&#351;,
uzun hastal&#305;k sresi ve a&#287;&#305;r motor zrllktr (zellikle
bradikinezi-rijidite ve aksiyel semptomlar). zellikle ileri ya&#351; ve
a&#287;&#305;r motor bulgular&#305; olan hastalar gen ya&#351; ve daha hafif
motor bulgular&#305; olan hastalara k&#305;yasla yakla&#351;&#305;k 10 kat
kadar artm&#305;&#351; bir demans riski gsterirler. De&#287;i&#351;ik
al&#305;&#351;malarda bildirilen, ancak her zaman do&#287;rulanamayan
di&#287;er risk faktrleri aras&#305;nda &#351;unlar say&#305;labilir: PH
ba&#351;lang&#305;c&#305;n&#305;n ileri ya&#351;ta olmas&#305;, akinetik-dominan
tipte PH, konu&#351;ma bozuklu&#287;u ve postral insitabilite gibi aksiyel
tutulum bulgular&#305;n&#305;n belirgin olmas&#305;, levodopa ile tedavi
esnas&#305;nda halsinasyonlar&#305;n ve psikozun erken dnemde ortaya
&#305;kmas&#305;, depresyonun varl&#305;&#287;&#305;, hastan&#305;n ilk
muayenesindeki mini-mental durum muayenesi puan&#305;n&#305;n d&#351;k
olmas&#305; ve yrtc i&#351;levler (zellikle szel
ak&#305;c&#305;l&#305;k), grsel-mekansal i&#351;levler ve bellek
fonksiyonlar&#305;nda hafif de olsa i&#351;lev bozukluklar&#305;n&#305;n
varl&#305;&#287;&#305;. &#304;ki y&#305;ll&#305;k prospektif bir
al&#305;&#351;mada postral insitabilite ve yrme gl&#287; fenotipi
bulunan hastalarda tremor-dominan gruba k&#305;yasla PHD ortaya &#305;kma
riskinin daha yksek ve kognitif bozulma oran&#305;n&#305;n daha
h&#305;zl&#305; oldu&#287;u bulunmu&#351;tur. Bir ba&#351;ka
al&#305;&#351;mada ba&#351;lang&#305;ta tremor-dominan bir fenotip gsteren
hastalar&#305;n demans geli&#351;mesinden nce tremor dominans&#305;n&#305;
kaybedip akinetik-rijid belirtilerin n plana &#305;kt&#305;&#287;&#305;
saptanm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Klinik zellikler&nbsp; </span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Genel seyri itibar&#305;yla PHD sinsi
ba&#351;lang&#305;l&#305; ve yava&#351; ilerleyici bir demans tablosu ile
karakterizedir. Tipik klinik zellikler n planda bir yrtc i&#351;lev
bozuklu&#287;uyla birlikte dikkatte ve grsel mekansal i&#351;levlerde erken
dnemlerden itibaren bozulma (s&#305;kl&#305;kla demans&#305;n genel
&#351;iddetinden daha a&#287;&#305;r lde), genelde tan&#305;man&#305;n
korundu&#287;u daha hafif bir episodik bellek bozuklu&#287;u, kelime
ak&#305;c&#305;l&#305;&#287;&#305; ve kelime bulma zorlu&#287;u
d&#305;&#351;&#305;nda greli olarak korunmu&#351; temel lingusitik
i&#351;levleri ierir. Bu kognitif profile s&#305;kl&#305;kla apati,
halsinasyon ve hezeyanlar gibi davran&#305;&#351;sal semptomlar e&#351;lik
eder. Ba&#351;lang&#305;ta zihinsel alandaki bozulmalar motor bulgulara
odaklanan hekimin ve hasta yak&#305;nlar&#305;n&#305;n dikkatini ekmeyebilir.
Subjektif olarak hastalar s&#305;kl&#305;kla dikkat ve konsantrasyon
glklerinden, yak&#305;n olaylar&#305; iyi
hat&#305;rlayamad&#305;klar&#305;ndan, alg&#305;laman&#305;n ve d&#351;ncenin
yava&#351;lamas&#305;ndan, cmleyi ba&#351;latmakta ve do&#287;ru kelimeleri
bulmakta glklerden bahsederler. Giderek nce hesap yapma, banka ve finans
i&#351;lerini yrtme, kar&#305;&#351;&#305;k ila &#351;emalar&#305;n&#305;
uygulama gibi daha karma&#351;&#305;k i&#351;levlerde, zamanla da daha temel
gnlk ya&#351;am i&#351;levlerinde bozulma grlr. Hastalar kendilerine ya da
stlendikleri grevleri yapmak iin uzun zaman harcarlar, ya da hi yapamazlar.
Karar vermede, i&#351;leri ba&#351;latmada, ailevi ve sosyal aktivitelere
kat&#305;lmakta zorluk ekerler, giderek artan apatiden dolay&#305; bu tip
aktivitelere ve hobilerine ilgileri ve spontaniteleri azal&#305;r. S&#305;k bir
bulgu gnii uyuklamalar&#305;n artmas&#305;, gndz-gece ritminin tersine
dnmeye ba&#351;lamas&#305;d&#305;r. Demans&#305;n ileri evrelerinde bu
belirtiler iyice belirginle&#351;ir, konu&#351;ma giderek ktle&#351;ir, ileri
dizartrik ve anla&#351;&#305;lmaz hale gelebilir; hasta konu&#351;may&#305; kesti&#287;inde
ne anlatt&#305;&#287;&#305;n&#305; ve nerede kald&#305;&#287;&#305;n&#305;
hat&#305;rlamayabilir. Son evrelerde hasta s&#305;kl&#305;kla inkontinan,
yata&#287;a veya tekerlekli sandalyeye ba&#287;&#305;ml&#305; haldedir.
Nropsikolojik profil a&#305;s&#305;ndan PHD klasik olarak yrtc i&#351;lev
bozuklu&#287;unun n planda oldu&#287;u , diseksekutif tipte bir demans
tablosudur. Ancak baz&#305; hastalarda ileri, limbik tipte bellek
bozuklu&#287;unun n planda oldu&#287;u Alzheimer tipi bir demans tablosunun
belirtileri tabloya kat&#305;labilir ya da n plana geebilir. Bu hastalar
byk olas&#305;l&#305;kla her iki tip patolojinin de&#287;i&#351;ik oranlarda
bir arada oldu&#287;u karma-patolojili tablolar&#305; temsil ederler.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Nropsikolojik muayenede kompleks,
yneltilmi&#351; dikkatte bozulma anlam&#305;ndaki yrtc i&#351;lev
bozuklu&#287;u, szel ak&#305;c&#305;l&#305;kta azalma ve psikomotor
h&#305;zdaki yava&#351;lama en erken saptanan zelliklerdir. AH ile k&#305;yasland&#305;&#287;&#305;nda
PHDde daha fazla apati, daha belirgin kognitif yava&#351;lama (bradifreni),
dikkatte daha a&#287;&#305;r ve daha dalgalanan bir bozulma vard&#305;r.
Yrtc i&#351;lev bozuklu&#287;u erkenden ortaya &#305;kar ve hastal&#305;k
ilerledike daha belirgin hale gelir. PHDde belle&#287;in tm &#287;eleri
(al&#305;&#351;ma belle&#287;i, a&#305;k bellek, verbal ve grsel
modalitelerde rtk haz&#305;rlama belle&#287;i, prosedrel &#287;renme)
bozulmu&#351;tur. &#287;renme testlerinde ve gnlk hayatta spontan geri
a&#287;&#305;rma AHye benzer &#351;ekilde bozulmu&#351;ken seenekler
aras&#305;ndan tan&#305;ma veya ipular&#305;ndan yararlanarak hat&#305;rlama
daha iyidir. Erken ve belirgin grsel-mekansal i&#351;lev bozuklu&#287;u
PHDnin di&#287;er bir nemli zelli&#287;idir, bu bozukluk .AHye k&#305;yasla
daha a&#287;&#305;rd&#305;r. Temel dil i&#351;levleri PHDde byk lde
korunmu&#351;tur. Dil ba&#287;lam&#305;nda en s&#305;k grlen sorunlar&#305;
spontan kelime bulma gl&#287; ve szel ak&#305;c&#305;l&#305;kta bozulma
olu&#351;turur. Baz&#305; yazarlara gre yrtc i&#351;lev disfonksiyonuna
ba&#287;l&#305;, ie dnk dikkat ve arama stratejilerinde bozulma sonucu
ortaya &#305;kan, bylelikle de dil i&#351;levlerinde gerek bir
bozulmay&#305; yans&#305;tmayan bu belirtiler AHdekinden daha ciddi boyutta
olabilirler. AHye ba&#287;l&#305; demans tablosuyla PHD tablosu
aras&#305;ndaki bu farkl&#305;l&#305;klara kar&#351;&#305;n PHD ile Lewy
Cisimcikli Demans tablolar&#305; byk lde rt&#351;rler. LCDnin temel
zelliklerinden biri olan mental performansta gnden gne veya gn iinde
ortaya &#305;kan dalgalanmalar PHD iin de olduka tipiktirler. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHDde davran&#305;&#351;sal problemler ve
ki&#351;ilik de&#287;i&#351;iklikleri olduka s&#305;kt&#305;r. NPI
kullan&#305;larak yap&#305;lan bir al&#305;&#351;mada PHD olan hastalar&#305;n
%89unda bir veya daha fazla psikiyatrik semptom bulundu&#287;u
saptanm&#305;&#351;t&#305;r. En s&#305;k grlen&nbsp; nropsikiyatrik
semptomlar depresyon, halsinasyonlar, apati, anksiyete ve hezeyanlard&#305;r.
Depresyon ya da depresif belirtiler hastalar&#305;n en az %50sinde grlp
hastal&#305;&#287;&#305;n seyri esnas&#305;nda herhangi bir zamanda ortaya
&#305;karlar. Halsinasyonlar genelde grsel nitelikte olup iyi
&#351;ekillenmi&#351; insan (s&#305;kl&#305;kla ocuklar, bazen
tan&#305;d&#305;k bazen da tan&#305;nmayan kad&#305;n ve erkekler), hayvan veya
bitki grntlerinden olu&#351;ur ve LCDde grlenlere benzerler. Kap&#305; ya
da zil sesi, veya ismin a&#287;r&#305;lmas&#305; &#351;eklinde duysal
halsinasyonlar daha nadirdir; multi-modal halsinasyonlar ise ok nadir
grlrler. &#304;gr s&#305;kl&#305;kla korunurken bazen bozulur ve
halsinasyonlar korkutucu bir nitelik kazan&#305;rlar. Hezeyanlar en s&#305;k
phantom boarder (evde bir yabanc&#305;n&#305;n oldu&#287;u hissi),
hastan&#305;n arkas&#305;nda ya da yan&#305;nda birisinin durdu&#287;u hissi,
bir glgenin geti&#287;i d&#351;ncesi, aldatma hezeyanlar&#305; olarak
ortaya &#305;karlar. Hastalar bazen evlerinin kendi evleri
olmad&#305;&#287;&#305;, ya da yak&#305;nlar&#305;n&#305;n (s&#305;kl&#305;kla
e&#351;lerin) kendi yak&#305;n&#305; olmad&#305;&#287;&#305; hissine
kap&#305;labilir ve eve gitmek isteyebilirler. Halsinasyonlar ve hezeyanlar
dopaminerjik ilalar&#305;n al&#305;m&#305;ndan sonra ortaya &#305;kabilir ya
da belirginle&#351;ebilirler. Bu durum PHD olan ya da demans geli&#351;tirmekte
olan hastalarda daha erken, daha kolay ve daha d&#351;k dozlarda ortaya
&#305;karlar. Erken dnemlerden itibaren grlen ve PHDnin nemli bir
zelli&#287;i olan apati hastal&#305;k ilerledike daha da belirginle&#351;ir,
ileri evrelerde hastalar spontanite ve motivasyonlar&#305;n&#305; tamamen
yitirip gnn byk k&#305;sm&#305;n&#305; uyuyarak ya da bir k&#351;ede
oturarak geirirler. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHDde motor fenotip s&#305;kl&#305;kla simetrik
bradikinezi, rijiidite ve postral instabilitenin n planda oldu&#287;u
akinetik-rijid formdur. Daha nce tremor-dominans&#305; gsteren hastalarda
zamanla tremor tamamen ortadan kalkabilir. PHDde levodopa cevab&#305;n&#305;n
giderek azald&#305;&#287;&#305; d&#351;nlr. Ancak bu gzlem en az
k&#305;smen non-dopaminerjik bulgular&#305;n giderek n plana gemesiyle
a&#305;klanabilir. LCD hastalar&#305;na benzer &#351;ekilde lmle
sonlanabilecek nroleptik duyarl&#305;l&#305;&#287;&#305; PHD&nbsp;
hastalar&#305;nda da bildirilmi&#351;tir. Uyku ile ilgili bozukluklardan
artm&#305;&#351; gn uykusu yan&#305;nda REM uykusu davran&#305;&#351;
bozuklu&#287;u da PHDde s&#305;k grlen zelliklerden birisidir. Bu belirti
demans&#305; olmayan hastalarda da ortaya &#305;kabilmekle birlikte demansl&#305;
hastalarda muhtemelen daha s&#305;kt&#305;r ve bilinen bir Parkinson
hastas&#305;nda yeni olarak ortaya &#305;kmas&#305; kognitif bozulman&#305;n
n habercisi olabilir. Kapsaml&#305; ve
kar&#351;&#305;la&#351;t&#305;rmal&#305; olarak ara&#351;t&#305;r&#305;lmamalar&#305;na
kar&#351;&#305;n ortostatik hipotansiyon, senkop, d&#351;meler, barsak ve
mesane bozukluklar&#305;, kalp at&#305;m h&#305;z&#305;nda azalma, seksel
disfonksiyon gibi otonomik bozukluklar&#305;n demans&#305; olan hastalarda daha
s&#305;k grld&#287; d&#351;nlmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Nropatoloji ve Fizyopatoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PHDde asandan modulatr sistemlerin hemen
hepsinde hcre ve innervasyon kayb&#305; bildirilmi&#351;tir. De&#287;i&#351;ik
al&#305;&#351;malarda kolinerjik, dopaminerjik, noradrenerjik ve
serotoninerjik monoaminerjik sistemlerin etkilendi&#287;i bulunmu&#351;tur.
Kolinerjik kay&#305;plar d&#305;&#351;&#305;ndaki bulgular ve bunlar&#305;n
demans ile ba&#287;lant&#305;s&#305; net olarak gsterilmemi&#351; olmakla
birlikte bu kay&#305;plar&#305;n tm de demans&#305;n de&#287;i&#351;ik
belirtilerinin ortaya &#305;kmas&#305;na katk&#305;da bulunabilirler.
rne&#287;in, dopaminerjik kay&#305;p frontostriatal
ba&#287;lant&#305;lar&#305;n normal al&#305;&#351;mas&#305;n&#305; bozarak
yrtc i&#351;levlerde ve al&#305;&#351;ma belle&#287;inde bozulma
yapabilir. Ancak PHDdeki kognitif bozuklu&#287;un biyokimyasal kkeni olarak
en sistemli &#351;ekilde gsterilebilen bulgu kolinerjik innervasyondaki
azalmad&#305;r. Bu azalma anatomik, biyokimyasal ve fonksiyonel
al&#305;&#351;malarda gsterilmi&#351; olup AHde grlenden daha fazla
orandad&#305;r (gzden geirme iin bkz. Emre, 2007). Yap&#305;sal olarak bazal
nbeyni innerve eden Meynertin nkleus bazalisindeki kolinerjik hcrelerin
say&#305;s&#305;n&#305;n azald&#305;&#287;&#305; saptanm&#305;&#351;t&#305;r.
Biyokimyasal olarak asetilkolin yap&#305;lmas&#305;n&#305; sa&#287;layan enzim
olan kolinasetiltransferaz aktivitesinin PHD olan hastalar&#305;n korteksinde
demans&#305; olmayan Parkinson hastalar&#305;na gre daha fazla oranda
azald&#305;&#287;&#305;, bu azalman&#305;n zellikle frontal ve temporal
kortekslerde daha belirgin oldu&#287;u bulunmu&#351;tur. Kolinerjik
i&#351;aretleyiciler ile yap&#305;lan fonksiyonel grntleme
al&#305;&#351;malar&#305;nda benzer &#351;ekilde kolinerjik aktivitenin PHD
olan hastalarda olmayanlara ve AH olanlara k&#305;yasla daha ok
azald&#305;&#287;&#305;, bu azalman&#305;n miktar&#305;n&#305;n kognitif
tutulumun, zellikle de yrtc i&#351;levlerdeki bozuklu&#287;un miktar&#305;
ile orant&#305;l&#305; oldu&#287;u saptanm&#305;&#351;t&#305;r. Tm
biyokimyasal bulgular birlikte ele al&#305;nd&#305;&#287;&#305;nda dopaminerjik
eksikli&#287;in yrtc i&#351;lev ve al&#305;&#351;ma belle&#287;i
bozuklu&#287;una, kolinerjik eksikli&#287;in bellek, dikkat ve yrtc
i&#351;levlerde bozuklu&#287;a, noradrenerjik eksikli&#287;in dikkat
bozuklu&#287;una, serotoninerjik eksikli&#287;in ise affektif bozuklu&#287;a
katk&#305;da bulunabilece&#287;i ne srlm&#351;tr. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Zamansal geli&#351;im iinde PHDnin
nro-patolojik kar&#351;&#305;l&#305;&#287;&#305; olarak  tip patoloji
sorumlu tutulmu&#351;tur. Bunlar a) subkortikal ekirdeklerin, zellikle
mediyal substantia nigran&#305;n dejenerasyonu, b) AH-tipi patoloji (amiloid
plaklar ve nrofibriler yumaklar) c) Lewy cisimci&#287;i (LC) patolojisidir.
Her bir patoloji iin demanstan sorumlu ana mekanizma oldu&#287;unu gsteren
farkl&#305; al&#305;&#351;malar vard&#305;r. Ancak son 10 y&#305;lda
yap&#305;lan, de&#287;i&#351;ik patolojilerin e&#351; zamanl&#305; olarak
de&#287;erlendirildi&#287;i, zellikle de LC patolojisini saptamak iin daha
hassas bir yntem olan alfa-sinklein immnhistokimyas&#305; kullan&#305;lan
al&#305;&#351;malarda altta yatan ana patolojinin kortikal ve limbik alanlarda
hcre kayb&#305; ve LC-tipinde dejenerasyon oldu&#287;u gsterilmi&#351;tir. Bu
al&#305;&#351;malarda LC patolojisi, kognitif bozuklukla en yak&#305;n
korelasyon gsteren bulgudur; buna s&#305;kl&#305;kla AH-tipi patoloji
e&#351;lik etmekte, ancak nadiren patolojik olarak AH tan&#305;s&#305;n&#305;
koydurmaya yetecek miktarda olmaktad&#305;r. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genetik
zellikler</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi PHn&#305;n nadir
nedenlerinden olan alfa-sinklein geninde triplikasyon mutasyonu
ta&#351;&#305;yan ailelerde PH motor semptomlar&#305;n&#305;n yan&#305;nda,
bazen erken dnemden itibaren demans grlebilirken, gen duplikasyonu olan
ailelerde bu durum ya hi olmamakta ya da nadir grlmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tan&#305;
Kriterleri</span></b><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHDnin klinik tan&#305;
kriterleri (bkz. Tablo 18) Movement Disorders Societynin
olu&#351;turdu&#287;u bir al&#305;&#351;ma Grubu taraf&#305;ndan 2007
y&#305;l&#305;nda yay&#305;nlanm&#305;&#351;t&#305;r (Emre<i> et al. </i>,
2007). Bu grup taraf&#305;ndan tan&#305;mlanan PHDnin klinik zellikleri, bu
zelliklerin varl&#305;&#287;&#305; ya da yoklu&#287;una
dayand&#305;r&#305;larak tan&#305;mlanan muhtemel PHD ve mmkn PHD
tan&#305; kriterleri Tablo 18de gsterilmi&#351;lerdir.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD tan&#305;s&#305; temel
prensipleri itibar&#305;yla herhangi bir hastada demans tan&#305;s&#305; koymaktan
farkl&#305; de&#287;ildir. &#304;lk a&#351;amada demans&#305; taklit edebilen
di&#287;er durumlar&#305;n ekarte edilmesi gerekir. Bu durumlar demans
seviyesinde olmayan kognitif tutulumu, sistemik hastal&#305;klar ya da ila yan
etkisi olarak ortaya &#305;kabilen akut-uzam&#305;&#351; konfzyonu ve depresyonu
ierir. Bu durumlar ekarte edilp demans tan&#305;s&#305; konulduktan sonra
ikinci a&#351;ama ay&#305;r&#305;c&#305; tan&#305;y&#305; olu&#351;turur. Bu
a&#351;amada demans ve Parkinsonsizm belirtilerinin bir arada olabilece&#287;i
di&#287;er hastal&#305;klar (progresif suprankleer fel, kortikobazal dejenerasyon,
vaskler demans, normal bas&#305;nl&#305; hidrosefali ve LCD gibi)
d&#351;nlmeli, Parkinson hastal&#305;&#287;&#305;na eklenebilecek subdural
hematom, B-12 eksikl&#287;i gibi di&#287;er nedenler de gz ard&#305;
edilmemelidir. Tm bu durumlar ekarte edilmesine kar&#351;&#305;n tan&#305;da
bazen glklerle kar&#351;&#305;la&#351;&#305;labilir. rne&#287;in, ileri
derecede motor ve konu&#351;ma bozuklu&#287;unun kognitif y&#305;k&#305;mla st
ste binmesi, depressif belirtielerin e&#351;lik etmesi, olas&#305; ila yan
etkilerinin tabloyu kar&#305;&#351;t&#305;rd&#305;&#287;&#305; durumlarda
tan&#305;&nbsp; gle&#351;ebilir. Ayr&#305;nt&#305;l&#305; bir yk, tm
kognitif alanlar&#305; ieren mental muayene, di&#287;er hastal&#305;klar&#305;
d&#305;&#351;layan laboratuar incelemeleri ile yukar&#305;da sz edilen PHD
klinik tan&#305; kriterlerinin dikkatlice uygulanmas&#305; tan&#305;y&#305;
kolayla&#351;t&#305;r&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD iin zgl bir
nrogrntleme bulgusu yoktur. BT ve MRG gibi yap&#305;sal grntlemelerde
daha ziyade beynin posterior blgelerinde atrofi dikkat eker; hippokampal ve
medyal-temporal atrofi e&#351;lik edebilmesine kar&#351;&#305;n AHde grlen
kadar s&#305;k ve a&#287;&#305;r de&#287;ildir. Fonksiyonel grntlemede SPECT
ve PET incelemelerinde frontal ve temporoparietal kortekste hipoperfzyon
bulunur; ancak bu bulgu AHde de ortaya &#305;kabildi&#287;i iin zgl
de&#287;ildir ve tek bir hastan&#305;n ay&#305;r&#305;c&#305;
tan&#305;s&#305;na katk&#305; sa&#287;lamaz. Presinaptik dopaminerjik terminallerin
yo&#287;unlu&#287;unu gsteren dopamin ta&#351;&#305;y&#305;c&#305;
(DAT)&nbsp; SPECT incelemesinde PHD ve LCD hastalar&#305;nda striatal DAT
tutulumunda azalma grlrken AHde bu tutulum normaldir. Bylelikle bu yntem
ekstrapiramidal bulgular geli&#351;tiren Alzheimer hastalar&#305;n&#305;n
(rn., nroleptik yan etkisine ba&#287;l&#305;) PHD ve LCD hastalar&#305;ndan
ay&#305;rd edilmesinde yard&#305;mc&#305; olabilir. Nihayet AH iin
geli&#351;tirilen PET ile amiloid grntlemede LCD gruplar&#305; AH2liler gibi
amiloid pozitif bulunurken PHD gruplar&#305; demanss&#305;z kontroller gibi
amiloid negatif bulunmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHD d&#351;nlen bir hastada
farmakolojik tedaviye ba&#351;lamadan nce zihinsel bozuklu&#287;u
tetikleyebilecek di&#287;er faktrler d&#305;&#351;lanmal&#305;d&#305;r. Bu
ba&#287;lamda sistemik hastal&#305;klar, zellikle yeni ba&#351;lanan veya dozu
artt&#305;r&#305;lan ilalar gzden geirilmeli, hasta antikolinerjik,
trisiklik antidepresan veya benzodiazepin grubundan bir ila kullan&#305;yorsa
bu ilalar kesilmelidir. Dopaminerjik ilalar halsinasyon,&nbsp; hezeyan gibi
psikotik belirtileri ve konfzyonu artt&#305;rabilecekleri iin zellikle
agonistlerin dozu azalt&#305;lmal&#305; ya da bunlar kesilmeli, tedavi mmkn
oldu&#287;u kadar yeterli dozda yal&#305;n levodopa preparatlar&#305;na
indirgenmelidir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PHDde kolinerjik
eksikli&#287;in tan&#305;mlanmas&#305;ndan sonra mevcut tm kolinesteraz
inhibitrleri (rivastigmin, donepezil, galantamin) o&#287;unlukla kk
apl&#305; ve a&#305;k al&#305;&#351;malarda olmak zere bu grup hastalarda
denenmi&#351;, tm al&#305;&#351;malarda belirli&nbsp; lde olumlu etkiler
tan&#305;mlanm&#305;&#351;t&#305;r. Bu al&#305;&#351;malar&#305;n en
by&#287; ve kapsaml&#305;s&#305; rivastigmin ile yap&#305;lan EXPRESS
al&#305;&#351;mas&#305;d&#305;r ve pozitif sonulanm&#305;&#351;t&#305;r (Emre<i>
et al. </i>, 2004). Di&#287;er asetilkolinesteraz inhibitrlerden donepezil ile
de byk apl&#305; bir al&#305;&#351;ma yap&#305;lm&#305;&#351;, belirli
leklerde plasebodan stn oldu&#287;u bildirilmi&#351;, ancak bu
al&#305;&#351;ma henz yay&#305;nlanmam&#305;&#351;t&#305;r. EXPRESS
al&#305;&#351;mas&#305;n&#305;n sonular&#305;na dayanarak rivastigmin PHDde
ilk zgl tedavi olarak ruhsatland&#305;r&#305;lm&#305;&#351;t&#305;r. LCD
tedavisinde an&#305;lan Emre al&#305;&#351;mas&#305;nda memantin PHD grubunda
da klinik de&#287;erlendirme ltnde plaseboya stn bulunmu&#351;tur.
Kullan&#305;m&#305; d&#351;nlebilir. <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Non-kognitif belirtilerin
tedavisi de LCDye benzerdir.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 18:
Parkinson hastal&#305;&#287;&#305; demans&#305;n&#305;n zellikleri (Emre et
al. 2007)<o:p></o:p></span></b></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>I. Temel
zellikler</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1. Tan&#305;s&#305; Queen
Square Beyin Bankas&#305; Kriterlerine gre konulmu&#351; Parkinson
Hastal&#305;&#287;&#305;n&#305;n varl&#305;&#287;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2. Sinsi olarak ba&#351;layan,
yava&#351; ilerleyen, tan&#305;s&#305; yk, klinik ve mental muayene
bulgular&#305; ile konan, a&#351;a&#287;&#305;daki &#351;ekilde
tan&#305;mlanm&#305;&#351; demans sendromunun varl&#305;&#287;&#305;:<o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l4 level1 lfo3;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Birden
     fazla kognitif alanda bozulma</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l4 level1 lfo3;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bu
     alanlarda premorbid dzeye gre bir d&#351;&#351; </span><span
     style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l4 level1 lfo3;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kognitif
     bozukluklar&#305;n gnlk hayat&#305; (sosyal, mesleki veya ki&#351;isel
     bak&#305;m) etkileyecek a&#287;&#305;rl&#305;kta olmas&#305; (motor veya
     otonomik bozuklu&#287;a atfedilen bozukluktan ba&#287;&#305;ms&#305;z
     olarak) </span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>II. E&#351;lik
eden klinik zelikler</span></b><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1. Kognitif zellikler</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dikkat</span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:
     Bozulmu&#351;. Spontan ve odaklanm&#305;&#351; dikkatte bozulma, dikkat
     testlerinde&nbsp; kt performans; performans gn iinde veya gnden gne
     dalgalanabilir.</span><span lang=DA style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yrtc
     &#304;&#351;levler</span></u><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>: Bozulmu&#351;. Bozukluk
     ba&#351;lama, planlama, konsept olu&#351;turma, kural bulma, kural
     de&#287;i&#351;tirme veya koruma testlerinde olabilir;
     yava&#351;lam&#305;&#351; mental h&#305;z (bradifreni) </span><span
     lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Grsel-mekansal
     i&#351;levler</span></u><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>: Bozulmu&#351;. Bozulma grsel-mekansal
     i&#351;levler, grsel-mekansal oryantasyon, grsel alg&#305; veya
     yap&#305;land&#305;rma testlerinde grlebilir</span><span lang=DA
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bellek</span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:
     Bozulmu&#351;. Bozulma yak&#305;n gemi&#351;teki olaylar&#305;n serbest
     hat&#305;rlanmas&#305; veya yeni bilgileri &#287;renme testlerinde
     grlebilir; hat&#305;rlama genellikle ipucuyla dzelir, tan&#305;ma
     genellikle serbest hat&#305;rlamadan daha iyidir</span><span lang=DA
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l44 level1 lfo6;tab-stops:list 36.0pt'><u><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dil</span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>:
     Ana fonksiyonlar byk oranda korunmu&#351;. Kelime bulma glkleri ve
     kompleks cmleleri anlamada bozulma olabilir. <o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2. Davran&#305;&#351;sal
zellikler</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Apati:
     Spontanitenin azalmas&#305;; motivasyonun, ilginin ve iradi
     davran&#305;&#351;lar&#305;n kayb&#305;</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;ilikte
     ve duygu durumda, depresif zellikler ve anksiyeteyi ieren
     de&#287;i&#351;iklikler </span><span style='font-size:10.0pt;font-family:
     Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Halsinasyonlar;
     o&#287;unlukla grsel, genellikle kompleks, ki&#351;i, hayvan veya
     objelerin iyi &#351;ekillenmi&#351; grntleri</span><span
     style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hezeyanlar;
     genellikle paranoid zellikte, aldat&#305;lma veya ba&#351;ka birinin
     varl&#305;&#287;&#305; (evde istenmeyen misafirlerin
     varl&#305;&#287;&#305;) gibi hezeyanlar</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l22 level1 lfo9;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A&#351;&#305;r&#305;
     gndz uyuklamalar&#305;</span><span style='font-size:10.0pt;font-family:
     Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>III. Parkinson Hastal&#305;&#287;&#305;
demans&#305;n&#305; d&#305;&#351;latt&#305;rmayan, ancak tan&#305;y&#305;
ku&#351;kuda b&#305;rakan zellikler</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.45pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.15pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Demans&#305;n sebebi olduklar&#305; d&#351;nlmeyen, ancak kognitif
bozuklu&#287;a neden olabilecek di&#287;er anormalliklerin
varl&#305;&#287;&#305;, rn. grntlemede anlaml&#305; vaskler hastal&#305;k
varl&#305;&#287;&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.45pt;margin-bottom:.0001pt;text-align:justify;text-indent:-14.15pt'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Motor ve kognitif semptomlar&#305;n geli&#351;imi aras&#305;ndaki zaman
ili&#351;kisinin bilinmemesi</span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:3.3pt;margin-bottom:.0001pt;text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>IV. Mental bozuklu&#287;un nedeni olabilecek di&#287;er
hastal&#305;klar&#305;n veya bozukluklar&#305;n mevcudiyeti, bunlar&#305;n
varl&#305;&#287;&#305;nda Parkinson hastal&#305;&#287;&#305; demans&#305;
tan&#305;s&#305;n&#305; koymak mmkn olmaz</span></b><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l35 level1 lfo12;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kognitif
     ve davran&#305;&#351;sal semptomlar&#305;n a&#351;a&#287;&#305;daki
     nedenler erevesinde ortaya &#305;kmas&#305;</span><span
     style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akut konfzyon&nbsp;&nbsp; </span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Sistemik hastal&#305;klar veya anormallikler</span><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;la intoksikasyonu&nbsp; &nbsp;</span><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:49.65pt;text-align:justify'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
DSM IVe gre majr depresyon </span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:35.45pt;text-align:justify;text-indent:
-14.15pt'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NINDS-ARIEN&nbsp; kriterlerine gre
Muhtemel Vaskler Demans ile uyumlu zellikler</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:black;mso-ansi-language:TR'>Muhtemel
Parkinson Hastal&#305;&#287;&#305; Demans&#305;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A. Temel zellik: Her iki temel
zellik de bulunmal&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B. E&#351;lik eden klinik
zellikler:</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l27 level1 lfo15;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Drt
     kognitif alan&#305;n en az ikisinde, tipik profil gsteren bozulma
     (dikkatte dalgalanan bozulma, yrtc i&#351;levlerde bozulma, grsel-mekansal
     i&#351;levlerde bozulma ve serbest hat&#305;rlama belle&#287;inde
     bozulma-genellikle ipucu ile dzelme)</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l27 level1 lfo15;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal
     semptomlardan (apati, depresif ve anksiyz duygudurum, halsinasyonlar,
     hezeyanlar, a&#351;&#305;r&#305; gndz uyuklamas&#305;) en az birinin
     varl&#305;&#287;&#305; muhtemel&nbsp; Parkinson Hastal&#305;&#287;&#305;
     Demans&#305; tan&#305;s&#305;n&#305; destekler, ancak
     davran&#305;&#351;sal semptomlar&#305;n olmamas&#305; tan&#305;y&#305;
     d&#305;&#351;latmaz</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>C. Grup IIIde yer alan
zelliklerin olmamas&#305;</span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D. Grup IVde yer alan
zelliklerin olmamas&#305;</span><span style='font-size:10.0pt;font-family:
Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Mmkn
Parkinson Hastal&#305;&#287;&#305; Demans&#305;</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A. Temel zellik: Her iki temel
zellik de olmal&#305;</span><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>B. E&#351;lik eden klinik
zellikler:</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l46 level1 lfo18;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Birden
     fazla alanda var olan kognitif bozuklu&#287;un atipik profili; rn. dikkat
     korunmu&#351; iken saf depo-hasar&#305; biiminde amnezi (bellek ipucuyla
     veya tan&#305;ma grevleri ile dzelmiyor) veya reseptif tipte (ak&#305;c&#305;)
     afazi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l46 level1 lfo18;tab-stops:list 36.0pt'><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Davran&#305;&#351;sal
     semptomlar olabilir veya olmayabilir </span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>VEYA</span><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>C. Grup IIIde yer alan
zelliklerden bir veya daha fazlas&#305;n&#305;n varl&#305;&#287;&#305; </span><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>D. Grup IVde yer alan
zelliklerin olmamas&#305;<o:p></o:p></span></p>

<div style='margin-bottom:10.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Frontotemporal Demans</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Arnold Pick ilk kez
1892 y&#305;l&#305;nda Afazi ve Beynin Senil Atrofisi Aras&#305;ndaki
&#304;li&#351;ki zerine isimli makalesinde,&nbsp; Alzheimerin Auguste
D.sinden 14 y&#305;l nce, nrodejeneratif hastal&#305;klar&#305;n 3. byk
grubunu olu&#351;turan ve gnmzde son olarak (&#351;imdilik)
frontotemporolobar deenerasyonlar (FTLD) olarak adland&#305;r&#305;lan ancak
bu terimin patolojiye daha yak&#305;n olan
a&#287;r&#305;&#351;&#305;mlar&#305;yla olsa gerek klinikte oklukla bir
nceki ismi olan frontotemporal demans (FTD) olarak an&#305;lan fokal
atrofilerin ilk olgusunu bildirdi. O s&#305;rada Pragda niversite Psikiyatri
Blmnn direktr olan Pick ba&#351;ka bir Augustu, August H. isimli olguyu
zetle &#351;yle tan&#305;mlam&#305;&#351;t&#305;: yk konu&#351;ma
bozuklu&#287;unun yava&#351; geli&#351;ti&#287;ini d&#351;ndryor ...Sol
hemisferin, zellikle de sol temporal lobun giruslar&#305;nda a&#287;&#305;r
bir atrofi mevcuttu. Her hangi bir fokal hastal&#305;k saptanmad&#305;yle
grnyor ki, belli bir zaman paras&#305;nda geli&#351;mi&#351;,
a&#351;a&#287;&#305; yukar&#305; keskin bir biimde s&#305;n&#305;rlanabilen
bir afazi tr mevcuttur ve muhtemelen de basit nitelikte,
s&#305;n&#305;rlar&#305; belirlenebilir beyin de&#287;i&#351;iklikleriyle
ili&#351;kilendirilebilir. Bu paragraf gnmzde semantik demans olarak
bilinen sol temporopolar atrofiye ba&#287;l&#305; ilerleyici afazi alt tipinin
bundan nerdeyse 120 y&#305;l nce yap&#305;lm&#305;&#351; mkemmel bir
tan&#305;m&#305;n&#305; iermektedir. Eri&#351;kinlerin Primer Progresif
Demans&#305; zerine isimli, 1904 tarihli bir sonraki yay&#305;n&#305;nda ise
bu kez de davran&#305;&#351;sal varyant&#305; ilk kez tarif edecektir: 41
ya&#351;&#305;nda bir ev han&#305;m&#305; yava&#351; yava&#351;
de&#287;i&#351;ti. zensiz ve sakar bir hale geldi ola&#287;an i&#351;lerini
srdrmyor, ocuklar&#305;n&#305;n bak&#305;m&#305;n&#305; yapm&#305;yor,
giysilerini ya da yatak ar&#351;aflar&#305;n&#305; de&#287;i&#351;tirmiyor,
salar&#305;n&#305; taram&#305;yordu. &#304;&#351;lerini bitirmeden
b&#305;rak&#305;yor ve tembel tembel oturuyordu. Her hangi bir sohbet
ba&#351;latm&#305;yor, sorular&#305; tekrarl&#305;yor, stereotipik
e&#287;ilimli cevaplar veriyor ve s&#305;kl&#305;kla persevere ediyordu. Tek
kayg&#305;s&#305; bedeniydi, bitlenmeden ve al&#305;ktan yak&#305;n&#305;yor
ve daima yemek talep ediyordu. Al&#305;&#351;&#305;lmad&#305;k fke krizleri
oluyor, ocuklar&#305;na szel olarak &#351;iddet gsteriyor veya
ocuklar&#305;na veya inekler dahil yak&#305;n&#305;nda ne varsa onlara
vuruyordu. Pickin al&#305;&#351;malar&#305;yla ilerleyici
davran&#305;&#351;sal belirtiler ve ilerleyici afaziden olu&#351;an bu
antitenin nropatolojisi intranronal globler arjirofilik inklzyonlu
cisimcikler (Pick cisimcikleri-PiC) ve balonla&#351;m&#305;&#351; &#351;i&#351;
nronlar (Pick hcreleri-PiHc), yzeyel kortikal spongioz, glioz, nron
kayb&#305; olarak tan&#305;mlanm&#305;&#351;t&#305;. PiC terimini ilk Alzheimer
1911 y&#305;l&#305;nda kullanm&#305;&#351;t&#305;r. Bu antite 1922de Gans
taraf&#305;ndan Pick atrofisi ve nihayet 1926da Onari ve Spatz
taraf&#305;ndan Pick hastal&#305;&#287;&#305; olarak
adland&#305;r&#305;ld&#305; (kapsaml&#305; bir gzden geirme iin bkz. Binetti
2001). Gans hastal&#305;&#287;&#305;n bask&#305;n ailevi zelli&#287;inden de
ilk kez szediyordu. Yak&#305;n tarihlerin nmli al&#305;&#351;malar&#305;ndan
birinde 1974te Cenevre Beyin Bankas&#305;ndan 40 olguluk bir PiH serisi
bildirildi. Klinik olarak davran&#305;&#351;sal art&#305; dilsel bir sendrom veya
yrtc bozukluk art&#305; parkinsonizm olarak zetlenebilecek 2 tarzda
sunulmu&#351; olan bu seride ilk sunum temporo-orbitofrontal, ikincisi frontal
konveksite atrofisi ile ili&#351;kiliydi. &#304;lk atrofi tarz&#305;n&#305;
sergileyen 10 olguda PiC ve PiHC birlikte grlrken 8 olguda ikisinin birden
olmad&#305;&#287;&#305; sadece gliozis mevcuttu. &#304;kinci tarz atrofi
tarz&#305;n&#305; sergileyen 10 olguda PiC olmaks&#305;z&#305;n sadece PiHC, 4
olguda ise yine sadece gliozis mevcuttu. Cummings ve Duchen 1981de bilgisayarl&#305;
tomografinin erken dnemlerinde 5 a&#287;&#305;r anterior temporal atrofili PiH
olgusu bildirdiler. Tmnde de atrofi PiC ile ili&#351;kiliydi ve
amigdalay&#305; iine almaktayd&#305;. Davran&#305;&#351;sal zellikleri
Kluver-Bucy sendromu unsurlar&#305; olarak zetlediler. Dilsel
bozukluklar&#305;n da n planda oldu&#287;unu, bellek ve mekansal oryantasyonun
greli korunmu&#351; oldu&#287;unu vurgulayarak bu klinik tablonun PiHin bu
varyant&#305; iin ay&#305;rt edici olabilece&#287;ini ileri srdler.
&#304;zleyen y&#305;llarda, ba&#351;l&#305;ca daha sonra yay&#305;nlanacak ilk
kriterler dizisine de isimlerini verecek olan &#304;sveten Lund,
&#304;ngiltereden Manchester gruplar&#305;ndan
ara&#351;t&#305;r&#305;c&#305;lar&#305;n bir dizi al&#305;&#351;mas&#305;yla,
PiC ve PiHcnin bu antitenin s&#305;k grlen bir bile&#351;eni
olmad&#305;&#287;&#305; gerekesiyle, Pickin ismi kald&#305;r&#305;larak
atrofi tarz&#305; (fronto-temporal) antitenin ad&#305; haline geldi. Bu
al&#305;&#351;malar zetle frontal lob demans&#305;n&#305;n (FLD) AHden
ay&#305;rt edilebilir bir sendrom oldu&#287;unu, tm demanslar&#305;n
%15-20sini kapsad&#305;&#287;&#305;n&#305;, olgular&#305;n o&#287;unda PiC
bulunmad&#305;&#287;&#305;n&#305; ileri srmekteydi. Geen yzy&#305;l&#305;n
son 10 y&#305;l&#305;na egemen olan bu 2 grup 1994te bir araya gelerek Manchester-Lund
Fronto-temporal Demans (FTD) Kriterleri olarak an&#305;lacak ilk tan&#305;
kriterleri dizisini yay&#305;nlad&#305;lar. Bu kriterlerde
davran&#305;&#351;sal zellikler ayr&#305;nt&#305;l&#305; bir &#351;ekilde
tan&#305;mlan&#305;rken, dilsel zelliklerin olduka yzeysel bir
tan&#305;m&#305;na rastlan&#305;r. Parkinsonizm ve ALS bulgular&#305;n&#305;n
grlebilece&#287;i vurgulan&#305;r. Erken inkontinans, normal EEG ve
grntlemede frontal, anterior temporal veya bunlar&#305;n kombinasyonunun bu
tan&#305;ya zg oldu&#287;unun alt&#305; izilir. Erken ba&#351;lang&#305; ve
s&#305;k aile yks AHyle kontrast olu&#351;turan yk zellikleri olarak
belirlenir. Nihayet, 1998de Lund ve Manchester gruplar&#305;na Frans&#305;z,
Kanadal&#305; ve ABD, Californiadan ara&#351;t&#305;r&#305;c&#305;lar&#305;n
kat&#305;l&#305;m&#305;yla isim bir kez daha de&#287;i&#351;tirilip bugnk
haline getirilir: FTLD (Neary<i> et al. </i>, 1998). Bu yeni kriterler
dizisinde (bkz. Tablo 19), yukarda demans sendromlar&#305;n&#305;n
fenomenolojik ayr&#305;r&#305;c&#305; tan&#305;s&#305; blmnde progresif
afazi ve progresif yrtc/davran&#305;&#351;sal bozukluk alt
ba&#351;l&#305;klar&#305;nda ayr&#305;nt&#305;s&#305;yla
tart&#305;&#351;&#305;lan davran&#305;&#351;sal varyant FTD (FTDdv), ilerleyici
tutuk afazi (PNFA) ve semantik demans (SD) biimlerinde 3 farkl&#305; sunumunun
ayr&#305;nt&#305;l&#305; tan&#305;mlar&#305; s&#305;ralanm&#305;&#351;t&#305;r.
FTLD Uzla&#351;&#305;m Kriterlerinin yazarlar&#305; aras&#305;nda bulunan
Kertesz Pick isminin bir klinik tan&#305; olarak ortadan
kald&#305;r&#305;l&#305;p sadece PiClerin grnd&#287;, klinik
kar&#351;&#305;&#287;&#305; mphem ve dolay&#305;s&#305;yla tan&#305;s&#305;
ok g ender bir histopatolojik tan&#305;ya indirgenmesine ba&#351;tan beri
itiraz etmekteydi. Kertesz, ilk kez 1994te primer progresif afazi (PPA), FLD,
PPA-ALS ve KBD gibi fokal kortikal dejenerasyonlarla karakterize nrodejeneratif
hastal&#305;klar&#305; Pick Kompleksi (PK) terimiyle adland&#305;rarak Pick
eponimini yeniden canland&#305;rmay&#305; nerdi. Bu neri yayg&#305;n kabul
grmese de Kertesz &#305;srar&#305;n&#305; srdrd. Zaman iinde Kertesz iin
PK dilsel ve davran&#305;&#351;sal bile&#351;enlerle birlikte, KBD ve PSPyi
ieren bir motor bile&#351;en de ieren bir klinik spektrum haline geldi.
Klinik sunumlar bu bile&#351;enlerden biriyle ba&#351;lay&#305;p seyir boyunca
izole kalabildikleri gibi daha s&#305;kl&#305;kla di&#287;er bile&#351;enlerden
zelliklerin de kat&#305;ld&#305;&#287;&#305; karma sendromlar haline
dn&#351;mektedir. PK spektrumunu olu&#351;turan antitelerin ngrlebilir
nropatolojik ve genetik kar&#351;&#305;l&#305;klar&#305; oldu&#287;unu ileri
srd (yeni yzy&#305;ldaki bir dizi Kertesz gzden geirmeleri iin bkz.
Kertesz, 2007, Kertesz, 2003, Kertesz).<o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Epidemiyoloji</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>ok say&#305;da
prevelans al&#305;&#351;mas&#305; olmasa da Cambridge, &#304;ngiltere
al&#305;&#351;mas&#305;nda FTDnin pre-senil dnemde (45-64 ya&#351;) AH kadar
s&#305;k olabilece&#287;ini gsteren bulgular elde edilmi&#351;tir. Rochester,
Minnesota, ABDden gelen tek insidans rakamlar&#305; (100,000 ki&#351;ilik
nfusta y&#305;lda yeni olgu) 40-49 ya&#351; aral&#305;&#287;&#305;nda 2.2,
50-59 aral&#305;&#287;&#305;nda 3.3 ve 60-69 aral&#305;&#287;&#305;nda 8.9
&#351;eklindedir. Daha ya&#351;l&#305; aral&#305;k dahil edilmemi&#351;tir.
Genellikle cinsiyetleri e&#351;it etkiledi&#287;i gr&#351; hakimken,
Cambridge al&#305;&#351;mas&#305;nda rneklemin %82si erkeklerdi. Ortalama
hastal&#305;k sresi AHye gre biraz daha k&#305;sa, 8 y&#305;ld&#305;r
(aral&#305;k 2-20 y&#305;l). ALS e&#351;li&#287;i sa&#287;kal&#305;m&#305; 3
y&#305;la kadar k&#305;salt&#305;r. Hastalar&#305;n %40&#305;n&#305;n 1.
derece akrabalar&#305;nda benzer hastal&#305;k yks vard&#305;r ve
bunlar&#305;n en az yar&#305;s&#305; otozomal dominan tarzda bir gei&#351;
sergilerler. Familyal ve sporadik olgular aras&#305;nda AH iin mutad olan
ba&#351;lang&#305; ya&#351;&#305; fark&#305; yoktur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>FTLDnin alt gruplar&#305;n&#305;n prevelans ve
insidanslar&#305; spesifik olarak
al&#305;&#351;&#305;lmam&#305;&#351;t&#305;r. PNFAn&#305;n tm FTLDnin %10
ila 35ini olu&#351;turdu&#287;u ileri srlm&#351;tr. Bir
al&#305;&#351;mada ba&#351;lang&#305; ya&#351;&#305;n&#305;n di&#287;er FTLD
alt gruplar&#305;ndan anlaml&#305; olarak daha ge oldu&#287;u fakat
sa&#287;kal&#305;m&#305;n farkl&#305; olmad&#305;&#287;&#305; bulunmu&#351;tur.
SD tm FTLDnin %15-25ini olu&#351;turur ve ba&#351;lang&#305; ya&#351;&#305;
ve sa&#287;kal&#305;m a&#305;s&#305;ndan tipik FTDden farkl&#305;l&#305;k
gstermez. Belirlenmi&#351; ve yerle&#351;mi&#351; risk faktrleri oldu&#287;u
sylenemez. Sadece <i>MAPT</i> geninin H1 haplotipine sahip olmak bir genetik
risk olarak ileri srlm&#351; ve H1/H1 homozigot genotipi PSP ve KBD iin bir
risk olu&#351;turdu&#287;u do&#287;rulanm&#305;&#351;t&#305;r. Genetik olmayan
risk faktrleri aras&#305;nda da sadece kafa travmas&#305; yks tek bir
al&#305;&#351;mada FTLD ile anlaml&#305; ili&#351;kili bulunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Klinik Tablo</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>PK perspektifi ile motor vayant da dahil
edildi&#287;inde bir davran&#305;&#351;sal varyant (FTDdv), kendi iinde PNFA
ve SD olarak da ayr&#305;lan bir dilsel varyant (SD sol ve sa&#287; temporal varyantlar
olarak bir kez daha ayr&#305;labilir) ve yine kendi iinde asimetrik
parkinsonizm-progresif apraksi tarz&#305;nda KBD sendromu ve vertikal
bak&#305;&#351; felci-aksiyel parkinsonizm-a&#287;&#305;r postral imbalans
&#351;eklinde PSP sendromu &#351;eklinde ayr&#305;labilecek bir motor varyant
ay&#305;rt edilir. zellikle FTDdv ve PNFAta ALS e&#351;lik etti&#287;inde
FTD-ALSden szedilir. Bu klinik sunumlar&#305;n ayr&#305;nt&#305;l&#305;
zellikleri yukarda Progresif Afazi, Progresif
Yrtc/Davran&#305;&#351;sal Bozukluk ve Progresif Apraksi blmlerinde
ayr&#305;nt&#305;yla tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genetik</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tau geni (<i>MAPT</i>) </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Familyal FTD ile <i>MAPT </i>geni
ili&#351;kisi ilk kez 1994te<i> </i>bir ailenin kromozom 17de <i>MAPT </i>genini
ieren q21-22 blgesine anlaml&#305; bir ba&#287;lant&#305;n&#305;n
varl&#305;&#287;&#305;n&#305;n bulunmas&#305;yla gsterilmi&#351;tir.
Sonras&#305;nda 1996da o zamana kadar ayn&#305; ba&#287;lant&#305;n&#305;n
saptand&#305;&#287;&#305; 13 geni&#351; aileyi tan&#305;mlamak zere
gerekle&#351;tirilen bir uzla&#351;&#305;m toplant&#305;s&#305;nda Kromozom
17ye ba&#287;l&#305; fronto-temporal demans ve parkinsonizm (FTDP-17) terimi
nerilmi&#351;tir. &#304;ki y&#305;l sonra FTDP-17 ailellerinde ilk <i>MAPT</i>
mutasyonlar&#305; 3 ayr&#305; grup taraf&#305;ndan bildirildi. Geen
y&#305;llar iinde toplam 132 ailede 44 farkl&#305; mutasyon
bildirilmi&#351;tir. <i>MAPT </i>mutasyonlu olgular tm FTLD
olgular&#305;n&#305;n %5-10unu, familyal FTDnin ise %10-20sini
olu&#351;turur. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Fakl&#305; <i>MAPT </i>mutasyonlu
aileler PKn&#305;n tm varyantlar&#305;n&#305; ieren olduka geni&#351; bir
fenotipik varyasyon sergilerler. Bu durum bazen ayn&#305; mutasyona sahip bir
ailenin farkl&#305; yelerinin fenotipik de&#287;i&#351;kenli&#287;i olarak da
grlr. En s&#305;k grlen mutasyon P301L hatal&#305; anlaml&#305; mutasyonu
s&#305;kl&#305;kla 45-65 aras&#305;nda ba&#351;lar ve ba&#351;lang&#305;
ya&#351;&#305; hi bir zaman 70i a&#351;maz. <i>MAPT</i> mutasyonu PSP ve KBD
fenotipi sergileyen hastalarda da bildirilmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>MAPT </span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>mutasyonlar&#305;
bir dizi farkl&#305; tau patolojisine yolaar. Bunlar&#305;n ilki
ba&#351;l&#305;ca 4R taudan olu&#351;an, AHye benzemeyen nrofibriler inklzyonlard&#305;r
ve 4R tau mikrotbl ba&#287;lanmas&#305;n&#305; etkileyen veya 4R/3R
oran&#305;n&#305; artt&#305;ran ekson 10 mutasyonlar&#305; sonucu grlrler
(en s&#305;k olan P301L ilkine neden olur). Bu birikintilerde AH NFYlerinin
PHFlerinden morfolojik farkl&#305;l&#305;klar izlenir. Hem nronlar hem de
glia etkilenir. Buna kar&#351;&#305;l&#305;k, ekson 9, 11, 12 ve 13
mutasyonlar&#305; 3R ve 4R tauyu birlikte etkiler ve ya NFY-PHFlere ya da
PiClere benzeyen inklzyonlar yarat&#305;r. Glial etkilenme daha azd&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Progranulin geni (<i>PGRN)</i></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Yeni yzy&#305;ldan itibaren giderek artan
gzlemler 17q21e ba&#287;lant&#305;land&#305;&#287;&#305; halde btn abalara
ra&#287;men <i>MAPT</i> mutasyonu bulunamayan ve ayn&#305; zamanda da tau
patolojisi sergilemeyip sadece ubikuitin immunoreaktivitesi gsteren (Ub+T-)
ailelerin say&#305;s&#305;n&#305;n FTD-17-tau ailelerini a&#351;maya
ba&#351;lad&#305;&#287;&#305;n&#305; ortaya koydu. Sonunda 2006 iinde 2
ayr&#305; grup taraf&#305;ndan bu Ub+T- FTD-17 ailelerinden sorumlu genin
progranulin geni (<i>PGRN</i>) oldu&#287;unu buldular. Bu genin
kodlad&#305;&#287;&#305; progranulin proteini bir byme faktrdr ve
geli&#351;im, yara onar&#305;m&#305;, inflammasyon ve tmr olu&#351;umu gibi
bir dizi farkl&#305; srele ili&#351;kilendirilmi&#351;tir. Bildirilen
mutasyonlar&#305;n tm s&#305;f&#305;r mutasyonlard&#305;r ve muhtemelen
proteinin i&#351;lev yitimine neden olarak etki etmektedirler. K&#305;sa sre
nce ke&#351;fedilmesine ra&#287;men &#351;imdiye kadar toplam 212 ailede 68
farkl&#305; mutasyon bildirilmi&#351;tir. Tm FTLDlerin %5-10unu familyal
FTDlerin ise %15-25ini olu&#351;turduklar&#305; tahmin edilmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Ba&#351;lang&#305; ya&#351;&#305;
ayn&#305; aile iinde dahi olduka de&#287;i&#351;kendir (38-79 aras&#305;).
Klinik olarak FTDdv yan&#305;s&#305;ra PNFA fenotipi ve KBD fenotipi bildirilmi&#351;tir.
Mesulam dil bozukluklar&#305; kendi PPA tan&#305;m&#305; ile uyumlu 2 ailede
yine <i>PGRN </i>mutasyonu bildirmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>PGRN</span></i><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
mutasyonlar&#305; nropatolojik olarak yzeyel kortikal tabakalarda spongiform
de&#287;i&#351;ikliklerle Ub+T- inklzyonlara yolaar. Bunlar genellikle nronlar&#305;n
sitoplazmalar&#305;nda olmakla birlikte (NCIlar), intrankleer de olabilirler
(NII<i>). </i>Distrofik nritler (DN) de grlr. PGRNnin bulunmas&#305;ndan
k&#305;sa zaman sonra bir biri ard&#305;na bildirilen otopsi <i>serilerinde </i>PGRN
mutasyonlu bireylerin beyinlerindeki bilinmeyen ubikuitinize proteinin TDP-43
oldu&#287;u ortaya konmu&#351;tur.&nbsp;TDP-43 ekson atlama ve transkripsiyon
dzenlemeden sorumlu bir nkleer proteindir ve 1. kromozomda kodlan&#305;r (<i>TARDP
</i>geni). &#304;zleyerek sporadik Ub+T- FTDlerin de (FTLD-U) %90dan
fazlas&#305;n&#305;n transaktif cevapl&#305;-DNAya ba&#287;lanan protein 43
(TDP-43) immnoreaktivitesi gsterdi&#287;i bulunmu&#351; ve TDP-43
proteinopatileri FTLDnin de sporadik ve familyal byk bir blmnden sorumlu
yeni bir proteinopati olarak nrodejeneratif hastal&#305;klar
s&#305;n&#305;flamas&#305;na dahil edilmi&#351;tir. <i>PGRN </i>mutasyonu
ilintili familyal FTD-TDP, NCI, NII ve DN inklzyonlar&#305; birlikte
gstererek FTLD-U subtiplerinden Tip 3 olarak da
s&#305;n&#305;flan&#305;l&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er sorumlu genler</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Daha 1987 gibi erken bir tarihte
tan&#305;mlanm&#305;&#351; olan ve bask&#305;n olarak davran&#305;&#351;sal
de&#287;i&#351;iklikler ve bir lde dilsel zellikler ve geri planda KBD
benzeri motor zellikler sergileyen geni&#351; bir Danimarka ailesinde
ba&#287;lant&#305; analizi kromozom 3 i&#351;aretlemi&#351;ti. Geninin
bulunmas&#305; iin bir 10 y&#305;l gemesi gerekti: kromatin modifiye edici
protein veya di&#287;er ismiyle ykl multivesikler protein 2B geni (<i>CHMP2B</i>).
Bu gendeki mutasyonlar&#305;n CHMP2Bnin hcresel lokalizasyonunu bozdu&#287;u
gsterilmi&#351;tir. An&#305;lan bu Danimarkal&#305; aile
d&#305;&#351;&#305;nda &#351;imdiye kadar 2. bir aile bildirilmemi&#351;tir,
dolay&#305;syla FTD-3 kategorisi halen sadece bu orijinal aile ile
s&#305;n&#305;rl&#305;d&#305;r. FTD-3 nropatolojik olarak bir&nbsp;
FTLD-Udur. Ancak, TDP-43 immnoreaktivitesi gstermedi&#287;i gibi bu y&#305;l
geriye kalan %10 kadar TDP-43 negatif FTLD-Ularda mevcudiyeti ortaya konan
fused in sarkoma proteini (FUS) immunoreaktivitesi de negatiftir. Bylelikle,
art&#305;k FTLD nropatolojisinin %1inden az&#305;na
s&#305;n&#305;rlanm&#305;&#351; olan FTLD-U kategorisinin tek temsilcisi
burdaki ubikuitinize protein de ke&#351;fedilene kadar FTD-3tr diyebiliriz.
Bu gendeki 2 yeni mutasyon daha sonradan saf ailevi ALS ile
ili&#351;kilendirmi&#351;tir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Inklzyon cisimci&#287;i myoziti (IBM)
ve Paget hastal&#305;&#287;&#305; ile birlikte herediter FTD sergileyen aileler
valosin ieren proteini (VCP) kodlayan 9. kromozomda p21.1-p12 lokusuna
haritalan&#305;rlar. VCP bir AAA-ATPaz sperfamilyas&#305; yesidir ve hcre
evrimi kontrol, membran fzyonu ve ubikuitin-proteasom degradasyon
yola&#287;&#305; gibi bir dizi hcresel aktiviteden sorumludur. Watts ve
arkada&#351;lar&#305; toplam 66 hastada bulduklar&#305; 6 farkl&#305; mutasyonu
bildirmi&#351;lerdir. Hastal&#305;k klinik olarak eri&#351;kin
ba&#351;lang&#305;l&#305; kav&#351;ak tipi myopati, omurga ve kala
a&#287;r&#305;lar&#305;yla karakterize Paget hastal&#305;&#287;&#305; ve
k&#305;rkl&#305; ya&#351;larda ba&#351;layan dilsel varyant
a&#287;&#305;rl&#305;kl&#305; FTLD ile karakterizedir. Triad btn
hastalar&#305;n ancak %12sinde grlr ve en s&#305;k izole sunum %30 kadar
IBM &#351;eklindedir. Dolay&#305;s&#305;yla bu hastalara daha
s&#305;kl&#305;kla nromskler hastal&#305;klar birimlerinde
rastlan&#305;lmas&#305; beklenir. Nropatolojik olarak hippokampusun greli
kurtuldu&#287;u ba&#351;l&#305;ca neokortikal NII inklzyonlar&#305; (Tip 4)
&#351;eklinde FTD-TDP birikintileri grlr.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>Yak&#305;nlarda FTD-ALS sergileyen 6
Frans&#305;z ailesi kromozom 9p21.3-p13.3e
ba&#287;lant&#305;land&#305;r&#305;lm&#305;&#351;t&#305;r. 27 aday genin hi
birinde mutasyon bulunamam&#305;&#351;t&#305;r. Hastalar %32 oran&#305;nda
izole FTD, %29 izole ALS (FALS) ve %39 oran&#305;nda da her ikisinin
bile&#351;imi &#351;eklinde sunulmu&#351;lard&#305;. TDP-43-pozitif NCIlar
(Tip 2 FTLD-U) korteks ve medulla spinaliste saptand&#305;. Bulunamayan bu
genin tm FTD-ALSnin %60&#305;ndan sorumlu olabilece&#287;i ileri
srlm&#351;tr.</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>Kromozom 1de kodlana TDP-43 genindeki
mutasyonlar FALS ile ili&#351;kilendirilmi&#351; ve <i>TARDP </i>mutasyonlu
FALS olgular&#305; ALS10 olarak da s&#305;n&#305;flanm&#305;&#351;t&#305;.
Yak&#305;n tarihte ALS olmaks&#305;z&#305;n FTDye neden olan 2 ayr&#305; <i>TARDP
</i>mutasyonu bildirildi. Bunlardan ilki FTDdv fenotipi sergileyen bir
kad&#305;nd&#305;. Di&#287;eri ise FTDdv, PSP zellikleri ve koreye sahipti ve
nropatolojik olarak ba&#351;l&#305;ca subkortikal ekirdekler ve
beyinsap&#305;n&#305;n TDP-43+ inklzyonlarla tutulmu&#351; oldu&#287;u
grld.</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>Son olarak, 16. kromozomda kodlanan ve
TDP-43-negatif FTLD-U olgular&#305;n&#305;n byk blmnde ubkuitinize
edilmi&#351; protein oldu&#287;u ok yak&#305;nlarda gsterilmi&#351; olan
fused in sarkoma proteini (FUS) genindeki mutasyonlar da FALS
olgular&#305;yla ili&#351;kilendirilmi&#351; ve <i>FUS</i> mutasyonlu FALS
olgular&#305; ALS6 olarak
s&#305;n&#305;fland&#305;r&#305;lm&#305;&#351;t&#305;. Yine yak&#305;n
tarihlerde bir <i>FUS </i>mutasyonlu olgunun FTD-ALS sergiledi&#287;i
bildirildi.</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
color:#262626;mso-ansi-language:TR'>Nropatoloji</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:20.0pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Nropatolojik olarak makroskopik a&#305;dan FTLD
antitelerinin ay&#305;r&#305;c&#305; zelli&#287;i daha nce de
de&#287;inildi&#287;i gibi lober atrofidir.&nbsp; En s&#305;k olarak asimetrik
fronto-temporal kombine atrofi grlrken, bunu izole frontal, anterior
temporal ve parietal lob atrofileri izler.&nbsp; Hastal&#305;k ilerledike
atrofi tarz&#305; simetrikle&#351;me e&#287;ilimi gsterir.&nbsp; AHnin
aksine, tutulum tarz&#305;n&#305;n nas&#305;l ilerleyece&#287;i nceden kestirilemez.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Mikroskopik olarak tau+ inklzyonlar
(FTLD-tau), Ub+T- inklzyonlar (FTLD-U) olarak s&#305;n&#305;flan&#305;rlar.
FTLD-Unun %90&#305;na yakla&#351;an bir k&#305;sm&#305;nda ubikuitinize
proteinin TDP-43 oldu&#287;u (FTLD-TDP) bulunmu&#351;tur (Neumann<i> et al. </i>,
2006). Geri kalan %10 kadar FTLD-Unun&nbsp; da ok yak&#305;nda ubkuitinize
proteiinlerinin FUS oldu&#287;u (FTLD-FUS) bulunmu&#351; ve FTLD-U
s&#305;n&#305;f&#305; henz ubikuitinize proteini bulunamayan az say&#305;daki
CHMP2B mutasyonlu familyal FTLD hastas&#305;na s&#305;n&#305;rl&#305;
kalm&#305;&#351;t&#305;r. ok az say&#305;daki hastada ise geen
yzy&#305;l&#305;n ay&#305;rtettirici histopatolojisi olmayan demans-DLDH
veya non-spesifik gliozis tan&#305;m&#305;n&#305; hakedecek &#351;ekilde her
hangi bir inklzyon (FTLD-ni) grlmez. Tmnn de ortak zelli&#287;i tutulan
alanlarda saptanan nron kayb&#305;, gliozis ve yzeyel lineer
spongiozistir.&nbsp; FTLD-tauda derin kortikal tabakalarda &#351;i&#351;, balonla&#351;m&#305;&#351;
grnml Pick hcreleri saptanabilir.&nbsp; PiHin ay&#305;r&#305;c&#305;
zelli&#287;i olan Pick cisimcikleri nronlar&#305;n iinde grlen byk ve
yuvarlak inklzyonlard&#305;r (bkz. &#350;ekil 19).&nbsp; Tau antikorlar&#305;yla
farkl&#305; tarzlarda boyanmalar&#305; ve nrofilamanlar, ift sarmall&#305; filamanlar,
k&#305;sa dz ve uzun k&#305;vr&#305;ml&#305; fibriller gibi farkl&#305; eleman
ierikleriyle, olduka homojen bir yap&#305; olan NFYlerden farkl&#305; olarak
de&#287;i&#351;kenlik gsterirler.&nbsp; Bunlar PiHe zg olarak Bielschowsky
boyas&#305; ile boyan&#305;rken, Gallyas ile boyanmazlar.&nbsp; Pick cisimciklerine
tutulmam&#305;&#351; neokortikal alanlarda rastlan&#305;lm&#305;yor olsa da
say&#305;lar&#305; atrofiyle korele etmez ve daima atrofik loba k&#305;yasla
hippokampusta daha bol miktarda bulunurlar.&nbsp; Tutularak atrofiye
kat&#305;lan ve Pick cisimciklerinin grlebildi&#287;i subkortikal yap&#305;lar
aras&#305;nda olgudan olguya de&#287;i&#351;ecek &#351;ekilde neostriatum,
medial talamus, daha hafif dzeyde olmak zere de substantia nigra, hipotalamus
ve locus coeruleus bulunur.&nbsp; KBDde nronal inklzyonlar bazen Pick
cisimciklerini and&#305;rsa da daha ok halka &#351;eklinde
yumaklard&#305;r.&nbsp; Pick cisimciklerinden farkl&#305; olarak Bielschowsky
ile gayet zay&#305;f boyan&#305;rlarken, bu kez Gallyas ile iyi
boyan&#305;rlar.&nbsp; Dz k&#305;sa fibrillerden olu&#351;urlar.&nbsp; Nronal
&#964; birikimleri Pick cisimciklerine benzer yap&#305;lardan ok yayg&#305;n
birikimler ve yumaklar tarz&#305;ndad&#305;rlar.&nbsp; Yayg&#305;n subkortikal
tutulum iinde substantia nigra nronlar&#305;nda kortikobasal cisimcikler de
denilen globoz NFYler ay&#305;rt edilir.&nbsp;&nbsp; Nronal
inklzyonlar&#305;n yan&#305; s&#305;ra yayg&#305;n astrositik &#964;
inklzyonlar&#305; (GCIlar) tan&#305; koydurucudur.&nbsp; Bunlara amiloid
iermeyen glial plaklar ad&#305; da verilir.&nbsp; Oligodendrogliada da
yayg&#305;n biimde &#964; ekspresyonu ve arjirofilik inklzyonlar
grlr.&nbsp; FTLD-TDP inklzyonlar&#305; daha nce szedildi&#287;i gibi NCI,
NII ve DN &#351;ekillerinde olur ve bunlar&#305;n biri ya da bir
ka&#305;n&#305;n bask&#305;nl&#305;&#287;&#305; ve tutulum tarz&#305;na gre 4
ayr&#305; alt tipe s&#305;n&#305;fland&#305;r&#305;lm&#305;&#351;t&#305;r.
FTLD-FUS atipik FTLD-U (aFTLD-U), bazofilik inklzyon cisimci&#287;i
hastal&#305;&#287;&#305; (BIBD) ve nronal orta boy filaman inklzyonu
hastal&#305;&#287;&#305; (NIFID) alt tiplerini kapsar.&nbsp; Kromozom 17
ilintili FTLD ve di&#287;er ailevi&nbsp; FTLDler de sporadik proteinopatilerin
nropatolojisini and&#305;r&#305;rlar.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span style='font-size:10.0pt;font-family:Tahoma'><a
href="demans19.JPG"><span lang=TR style='mso-ansi-language:TR'>&#350;ekil 19.</span><span
lang=TR style='mso-ansi-language:TR;font-weight:normal'>&nbsp;</span></a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Pick
Cisimcikleri. Bielschowsky gm&#351; boyama ile arjantofilik intraseller
inklzyonlar (Kaynak: </span><span style='font-size:10.0pt;font-family:Tahoma'><a
href="http://www.binderlab.northwestern.edu/pickbodies.html"><span lang=TR
style='mso-ansi-language:TR'>http://www.binderlab.northwestern.edu/pickbodies.html</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Nedene ynelik bir tedavinin
do&#287;al olarak FTLD mekanizmas&#305;nda temel rol oynayan tau, TDP-43 ve
FUS proteinlerinin patolojik katlanmas&#305;n&#305; engellemeyi hedeflemelidir.
AHnin mekanizma temelli tedavi staratejillerinden tau hedefli stratejilerin
ilerde FTLDlerde de kullan&#305;labilece&#287;i d&#351;nlebilir. FTLDde
mekanizma temelli tedavilerin yerle&#351;ebilmesi iin farkl&#305; proteinopatilerin
de klinik olarak tan&#305;nabilmesi tabii ki bir zorunluluk olacakt&#305;r.
Baz&#305; bildirimlerde SSRIlar&#305;n yarar&#305; zerinde
durulmaktad&#305;r.&nbsp; ChEIlerin ve memantinin yarar&#305;
gsterilmemi&#351;tir.&nbsp;e&#351;itli davran&#305;&#351;sal belirtilerin
tedavisi iin AH tedavisinde nerilenlere paralel bir yol izlenebilir.&nbsp;Parkinsonizm
byk lde L-dopaya cevaps&#305;zsa da erken dnemde al&#305;nabilecek olan
s&#305;n&#305;rl&#305; cevaptan yararlan&#305;labilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 19. </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Frontotemporal
Lobar Dejenerasyon Klinik Tan&#305; Uzla&#351;&#305; Kriterleri (Neary et al.
1998)<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:48.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Liste 1.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
FTDnin klinik tan&#305; zellikleri: Klinik profil</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ki&#351;ilik de&#287;i&#351;ikli&#287;i ve sosyal
davran&#305;&#351; bozuklu&#287;u, ba&#351;lang&#305;ta ve
hastal&#305;&#287;&#305;n seyri boyunca temel zelliklerdir. Alg&#305;,
mekansal yetenekler, praksis ve belle&#287;e ili&#351;kin enstrmental i&#351;levler
salim ya da greli olarak iyi korunmu&#351;tur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>I. </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Temel tan&#305; zellikleri</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Sinsi ba&#351;lang&#305;, yava&#351; seyir<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:7.0cm;margin-bottom:.0001pt;text-align:justify;text-indent:-2.0cm;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sosyal
ki&#351;iler aras&#305; davran&#305;&#351;&#305;n erken dnemde bozulmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:7.0cm;margin-bottom:.0001pt;text-align:justify;text-indent:-2.0cm;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ki&#351;isel
davran&#305;&#351;&#305;n dzenlenmesinin erken dnemde bozulmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Erken dnemde emosyonel kntlk</span><span lang=DE style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>E.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#304;
grnn erken dnemde kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>II. </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Destekleyici tan&#305; zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Davran&#305;&#351;sal bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ki&#351;isel
hijyen ve kendine bak&#305;mda azalma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Zihinsel
rijidite ve esneklik kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
elinebilirlik ve sebats&#305;zl&#305;k<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hiperoralite
ve beslenme tarz&#305;nda de&#287;i&#351;iklikler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Perseveratif
ve stereotipik davran&#305;&#351;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>6.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kullanma
davran&#305;&#351;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma ve dil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma &#305;kt&#305;s&#305;nda de&#287;i&#351;iklik<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:213.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>a.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kendili&#287;indenli&#287;in
kayb&#305;, az konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:213.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>b.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bas&#305;nl&#305; konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Stereotipik konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ekolali<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Perseverasyon</span><span lang=DE style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mutizm</span><span lang=DE style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Fiziksel bulgular</span><span lang=DE style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;lkel refleksler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;nkontinans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akinezi, rijidite, tremor<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
D&#351;k ya da labil kan bas&#305;nc&#305;</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;ncelemeler</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nropsikoloji:
a&#287;&#305;r amnezi, afazi veya alg&#305;sal-mekansal bozukluk
olmaks&#305;z&#305;n frontal lob testlerinde anlaml&#305; bozukluk</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elektroensefalografi:
klinik olarak a&#351;ikar demansa kar&#351;&#305;l&#305;k konvansiyonel EEGnin
normal olmas&#305;</span><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Beyin
grntlemesi (yap&#305;sal ve/veya i&#351;levsel): a&#287;&#305;rl&#305;kla
frontal ve/veya anterior temporal bozukluk</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:48.0pt;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Liste 2.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Progresif tutuk afazinin klinik tan&#305; zellikleri: Klinik profil</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:142.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Ekspresif dil bozuklu&#287;u ba&#351;lang&#305;ta ve
hastal&#305;&#287;&#305;n seyri botunca temel zelliktir.&nbsp; Di&#287;er
bili&#351;sel i&#351;levler salimdir veya greli olarak iyi korunmu&#351;lard&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:143.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Temel tan&#305; zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.&nbsp;&nbsp;&nbsp;&nbsp;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinsi
ba&#351;lang&#305;, yava&#351; seyir<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Tutuk
spontan konu&#351;ma ve &#351;unlardan en az biri: agramatizm, fonemik
parafaziler, anomi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:143.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-48.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>II.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Destekleyici tan&#305; zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma ve dil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kekeleme veya oral apraksi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Tekrarlama bozuklu&#287;u<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Aleksi, agrafi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kelime anlam&#305;n&#305;n erken dnemde korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ge dnemde mutizm<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Davran&#305;&#351;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Sosyal
yeteneklerin erken dnemde korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Ge
dnemde FTDye benzer davran&#305;&#351;sal de&#287;i&#351;iklikler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Fiziksel
bulgular: ge dnemde kontrlateral primitif refleksler, akinezi, rijidite ve
tremor<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&#304;ncelemeler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Nropsikoloji:
a&#287;&#305;r amnezi ve alg&#305;sal-mekansal bozukluk olmaks&#305;z&#305;n
tutuk afazi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elektroensefalografi:
normal veya hafif asimetrik yava&#351;lama<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Beyin
grntlemesi (yap&#305;sal ve/veya i&#351;levsel): a&#287;&#305;rl&#305;kla
dominan (genellikle sol) hemisferi tutan asimetrik bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:48.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-96.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Liste 3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Semantik
afazi ve asosiyatif agnozinin (SD) klinik tan&#305; zellikleri: Klinik profil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Semantik bozukluk (kelime anlam&#305;n&#305;n ve/veya
nesne kimli&#287;inin anla&#351;&#305;lmas&#305;nda bozulma)
ba&#351;lang&#305;ta ve hastal&#305;k seyri boyunca temel zelliktir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Otobiyografik bellek de dahil olmak zere di&#287;er
bili&#351;sel i&#351;levler salimdir veya greli olarak iyi korunmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:47.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>I.</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> Tan&#305; zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.&nbsp;&nbsp;&nbsp;&nbsp; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sinsi
ba&#351;lang&#305;, yava&#351; seyir<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerle karakterize dil bozuklu&#287;u:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Progresif,
ak&#305;c&#305;, ieri&#287;i bo&#351; spontan konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Adland&#305;rma
ve anlama bozuklu&#287;u ile ortaya konan kelime anlam&#305;n&#305;n kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Semantik
parafaziler ve/veya</span><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerle karakterize alg&#305;sal bozukluk:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Prosopagnozi:
a&#351;ina yzlerin tan&#305;nmas&#305;nda bozulma ve/veya<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Asosiyatif
agnozi: nesne kimli&#287;inin tan&#305;nmas&#305;n&#305;n bozulmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Alg&#305;sal
e&#351;leme ve izerek kopyalaman&#305;n korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>E.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Tek
kelime tekrarlaman&#305;n korunmu&#351; olmas&#305;</span><span lang=FI
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>F.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Yksek
sesle okuma ve dikte ile ortografik olarak dzgn kelimeler yazma
yeteneklerinin korunmu&#351; olmas&#305;</span><span lang=FI style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=FI style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:95.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>II. </span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Destekleyici tan&#305; zellikleri</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>A.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Konu&#351;ma ve dil<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bas&#305;nl&#305; konu&#351;ma<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;dyosenkratik kelime kullan&#305;m&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Fonemik parafazilerin bulunmay&#305;&#351;&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Yzey disleksi ve disgrafisi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Hesab&#305;n korunmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>B.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Davran&#305;&#351;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Sempati ve empatinin kayb&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
K&#305;s&#305;tl&#305; tak&#305;nt&#305;l&#305; u&#287;ra&#351;&#305;lar<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Hasislik<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>C.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Fiziksel bulgular:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Primitif
refleksler yoktur veya ge dnemde grlr<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Akinezi,
rijidite ve tremor</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:166.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>D.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;ncelemeler<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Nropsikoloji:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:214.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>a.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;Kelime
anlama ve adland&#305;rma ve/veya yz ve nesne tan&#305;ma bozuklu&#287;uyla
ortaya konan a&#287;&#305;r semantik kay&#305;p<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:214.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>b.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Fonoloji,
sentaks ve elemanter alg&#305;sal sreler, mekansal yetenekler ile gndelik
belle&#287;in korunmu&#351; olmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:190.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Elektroensefalografi: normal<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:154.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:12.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;Beyin
grntlemesi (yap&#305;sal ve/veya i&#351;levsel): a&#287;&#305;rl&#305;kla anterior
temporal bozukluk (simetrik veya asimetrik)<o:p></o:p></span></p>

<div style='margin-left:24.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-24.0pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>CREUTZFELDT-JACOB VE DI&#286;ER PRION HASTALIKLARI</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hans Gerhard Creutzfeldt ve Alfons Maria Jakobun
1920 ve 1921de ardarda bildirdi&#287;i olgu serilerinin Spielmeyer
taraf&#305;ndan 1922 y&#305;l&#305;nda Creutzfeldt-Jakob
hastal&#305;&#287;&#305; (CJH) olarak adland&#305;r&#305;lmas&#305;
sonras&#305; bunlar&#305;n birbirlerine ve bugn bilinen &#351;ekliyle CJHye
benzerlikleri ok ku&#351;kuluysa da, art&#305;k sz konusu hastal&#305;k
tart&#305;&#351;maya yer b&#305;rakmayacak biimde an&#305;lan
ara&#351;t&#305;rmac&#305;lar&#305;n isimleri ile an&#305;lmaktad&#305;r.
Gajdusek 1968 y&#305;l&#305;nda deneysel kuru hastal&#305;&#287;&#305; olan
&#351;empanze beyni ve sporadik CJHs&#305; olan insan beyinlerinden
haz&#305;rlanm&#305;&#351; materyelleri primatlara inokle ederek bu
hayvanlarda hastal&#305;k geli&#351;tirmeyi ba&#351;arm&#305;&#351; ve
bula&#351;t&#305;r&#305;labilen spongiform ensefalopatiler (TSE)
kavram&#305;n&#305; geli&#351;tirmi&#351;tir. Ayn&#305; y&#305;l iinde CJHyi
subakut sklerozan panansefalit tarz&#305; bir yava&#351; virs
hastal&#305;&#287;&#305; olarak tan&#305;mlam&#305;&#351;t&#305;r. Stanley
Prusinerin 1982 y&#305;l&#305;nda yava&#351; virs kavram&#305;n&#305; yerle
bir edip, CJHnin nedeni olarak di&#287;er proteinopatilerde oldu&#287;u gibi,
fiziksel konformasyonunu de&#287;i&#351;tirerek patojen haline dn&#351;en
(PrP<sup>Sc</sup>) ve bu haliyle bir &#351;ablon olu&#351;turup normal hcresel
proteini (PrP<sup>c</sup>) kendine benzetmeye ba&#351;lay&#305;p, bylelikle
o&#287;al&#305;p biriken ve bula&#351;abilen bir protein olan prionu (PrP)
bulmas&#305; alan&#305; kkten de&#287;i&#351;tirmi&#351;ti. Bundan byle
ayn&#305; zamanda bula&#351;abilir bir proteinopati olarak prion
hastal&#305;klar&#305;ndan sz edilecektir. Oesch 1985 y&#305;l&#305;nda PrP<sup>c</sup>yi
kodlayan geni (<i>PRPN</i>) 20. kromozomda
haritaland&#305;rm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>CJH ve yeni varyant CJHnin de (nvCJH)
aralar&#305;nda bulundu&#287;u insan prion hastal&#305;klar&#305; (bkz. Tablo
20) %85-90 oran&#305;nda sporadik ortaya &#305;karlar.&nbsp; Geri kalan %1-2
enfeksiyz, yani prion hastal&#305;&#287;&#305; gsterilmi&#351; bir kaynaktan
bula&#351;&#305;c&#305; yolla edinilen ve %5-15de ailevi, yani 20. kromozomda
kodlanan prion proteini (PrP) geninde bir mutasyon sonucu otozomal dominan
kal&#305;t&#305;mla geen &#351;ekillerdir.&nbsp; &#304;nsan prion
hastal&#305;klar&#305;n&#305;n tm, hasta beyninden haz&#305;rlanan ekstrenin
bir primata inoklasyonuyla bu hayvana bula&#351;t&#305;r&#305;labilir.&nbsp;
&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sporadik Prion Hastal&#305;klar&#305;</span></b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Sporadik fatal insomni son derece nadir bir
hastal&#305;k oldu&#287;u iin bu ba&#351;l&#305;k sporadik CJH ile pratik
olarak ayn&#305; anlama gelir.&nbsp; Hastal&#305;k co&#287;rafi blge, etnik
kken veya cinsiyet ay&#305;rd etmeksizin btn dnyada grlebilmekte ve
y&#305;ll&#305;k s&#305;kl&#305;&#287;&#305; yakla&#351;&#305;k 1/1,000,000
ki&#351;i olarak hesaplanmaktad&#305;r.&nbsp; Bu, lkemizde kabaca her y&#305;l
65-70 yeni CJH vakas&#305;n&#305;n ortaya &#305;kt&#305;&#287;&#305;
anlam&#305;na gelmektedir. Ba&#351;lang&#305; ya&#351;&#305; ortalama
60d&#305;r.&nbsp; Hastal&#305;k ok h&#305;zl&#305; seyirlidir.&nbsp; Konu
zerine uzmanla&#351;m&#305;&#351; byk merkezlerde CJH hastalar&#305;ndan
olu&#351;an geni&#351; vaka serilerinde ortalama hayatta kalman&#305;n 4 ay
kadar oldu&#287;u hesaplanmaktad&#305;r.&nbsp; Belirtilerin
ba&#351;lamas&#305;ndan sonraki 1. y&#305;l iinde tm olgular&#305;n
%90&#305;n&#305;n lm&#351; oldu&#287;u kaydedilmi&#351;tir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 20.&nbsp; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion
Hastal&#305;klar&#305;<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none;mso-border-alt:solid black 1.0pt;
 mso-padding-alt:0cm 0cm 0cm 0cm;mso-border-insideh:1.0pt solid black;
 mso-border-insidev:1.0pt solid black'>
 <tr style='mso-yfti-irow:0'>
  <td width=584 colspan=2 valign=top style='width:437.75pt;border:solid black 1.0pt;
  padding:4.0pt 4.0pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nsan Hastal&#305;klar&#305;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sporadik</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fatal Sporadik Insomnia  FSI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyz</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH
  (iyatrojenik)</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>vCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kuru</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH
  (ailevi)</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fatal Familyal Insomnia - FFI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gerstmann-Strussler-Scheinker
  Hastal&#305;&#287;&#305; (GSS)</span><span lang=DE style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=584 colspan=2 valign=top style='width:437.75pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:4.0pt 4.0pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  lang=DE style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DE'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hayvan Hastal&#305;klar&#305;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Koyun</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Scrapie</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>S&#305;&#287;&#305;r</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bovin
  Spongiform Ensefalopati (BSE)</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vizon</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bula&#351;abilen
  Vizon Ensefalopatisi (TME)</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Geyik</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik
  Kas Erimesi Hastal&#305;&#287;&#305; (CWD)</span><span lang=FI
  style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;mso-yfti-lastrow:yes'>
  <td width=198 valign=top style='width:148.35pt;border:solid black 1.0pt;
  border-top:none;mso-border-top-alt:solid black 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kedi</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=386 valign=top style='width:289.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  mso-border-top-alt:solid black 1.0pt;mso-border-left-alt:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Felin
  Spongiform Ensefalopati (FSE)</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastal&#305;k olgular&#305;n yakla&#351;&#305;k
%25inde uykusuzluk, i&#351;tahs&#305;zl&#305;k, kilo kayb&#305;, huzursuzluk,
halsizlik gibi spesifik olmayan prodromal belirtilerle ba&#351;lar.&nbsp;
Prodromal belirtiler olsun olmas&#305;n, ba&#351;lang&#305;taki ki&#351;ilik
de&#287;i&#351;ikli&#287;i, zihinsel i&#351;levlerde bozulma, ataksi, kortikal
krlkten agnozilere grsel i&#351;leme problemleri &#351;eklindeki belirti ve
bulgular, aylar iinde h&#305;zla a&#287;&#305;r bir demansa ve sonunda
akinetik mutizme yolaar.&nbsp; Ki&#351;ilik de&#287;i&#351;ikli&#287;i, en
ba&#351;larda ki&#351;inin daha kolay fkelenir ya da daha hasis olmas&#305;
gibi nceden getirdi&#287;i ki&#351;ilik zelliklerinin abart&#305;lmas&#305;
&#351;eklindeyken, giderek FTD zellikleri e&#351;itli bile&#351;imlerde
sergilenmeye ba&#351;lar.&nbsp; Hezeyan ve halsinasyonlar &#351;eklinde
psikotik zellikler grlebilir.&nbsp; Kognitif i&#351;levlerde y&#305;k&#305;m
k&#305;sa bir sre iin progresif afazi veya kortikal krl&#287;e gidebilen
progresif simultanagnozi benzeri izole kalabilse de zaman iinde genel bir
y&#305;k&#305;m tablosu yerle&#351;ir.&nbsp; Serebellar ataksi ve
ekstrapiramidal bulgular CJHnin farkl&#305; alt biimlerinde tabloya
e&#351;itli dnemlerde kat&#305;l&#305;rlar.&nbsp; Hastal&#305;&#287;&#305;n
orta evrelerinde akustik ve hatta taktil uyaranlarla ortaya
&#305;kar&#305;labilen irkilme miyoklonisi tan&#305;ya g katan klinik
bulgulardand&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Hastal&#305;k, yukarda an&#305;lan tipik
tarz&#305; yan&#305; s&#305;ra farkl&#305; isimlerle an&#305;lan ve
a&#351;a&#287;&#305;da szedilecek prion su&#351;lar&#305;n&#305;n tipi <i>PRPN
</i>ve kodon 129 polimorfizmine gre (prion proteini geninin 129. kodonundaki
metionin veya valin mevcudiyetine gre) de&#287;i&#351;en klinik tarzlarda da
grlebilir (Tablo 21).&nbsp; Yeni varyant CJH (vCJH), teden beri bilinen bu
tarzlara gre yeni oldu&#287;u iin bu &#351;ekilde isimlendirilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a href="tablo21.htm">Tablo 21.</a>
</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Di&#287;er Sporadik CJH Klinik Tarzlar&#305;n&#305;n zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>K&#305;saltmalar: </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>AV:
anteroventral ekirdek; BG: basal ganglia; Cer: serebellum; Cx: korteks; M: metionin;
MD: mediodorsal ekirdek; PSW: periyodik yava&#351; dalga; V: valin<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Laboratuar incelemeleri tan&#305;y&#305;
kesinle&#351;tirmese de, katk&#305;da bulunur.&nbsp; Elektro-ensefalografi, bir
dnem iin hastal&#305;&#287;a zg periyodik 1 Hz keskin-dalga komplekslerini
gsterir (PSW; <b>&#350;ekil 20</b>). PSW ve klinik zellikleri ba&#351;vuru ve
seyir iindeki s&#305;kl&#305;klar&#305;n&#305; 209 hastal&#305;k bir Amerikan
serisinde analiz eden bir 1993 al&#305;&#351;mas&#305;nda miyoklonus
ba&#351;lang&#305;ta %5 iken seyir s&#305;ras&#305;nda %88e, ekstrapiramidal
bulgular %1den %56ya, serebellar bulgular %33ten %70e, grsel bulgular
%19dan %41e, PSWnin %0dan %44e ykseldi&#287;i bildirilmi&#351;tir. MRGde
en yksek duyarl&#305;l&#305;kla difzyon a&#287;&#305;rl&#305;kl&#305;
grntlerde (DWI) ortaya &#305;kan, zaman iinde s&#305;ras&#305;yla FLAIR ve
T2 a&#287;&#305;rl&#305;kl&#305; grntlerde de beliren kortikal (kortikal
&#351;eritlenme) ve ba&#351;ta bazal ganglia, sonra da talamus olmak zere
yksek sinyal, h&#305;zl&#305; seyirli bir demansta CJH iin yksek
duyarl&#305;l&#305;k ve zgllk ta&#351;&#305;d&#305;&#287;&#305; e&#351;itli
al&#305;&#351;malarda bildirilmi&#351;tir (<b>&#350;ekil 21</b>). Bir Japon
al&#305;&#351;mas&#305;nda 36 olguda DWI-MRG
duyarl&#305;l&#305;&#287;&#305;&nbsp; %92.3, zgll&#287; %93.8, buna
kar&#351;&#305;l&#305;k PSW duyarl&#305;l&#305;&#287;&#305; %50, BOS 14-3-3
protein dzeyi %84, BOS NSE protein dzeyi %73.3 bulunmu&#351;tur. Bir Amerikan
al&#305;&#351;mas&#305;nda ise 40 olguda DWI+FLAIRin birlikte
duyarl&#305;l&#305;klar&#305; %91, zgllkleri ise %95 olarak
bildirilmi&#351;tir. Bu bulgunun sadece voltaj kap&#305;l&#305; potasyum
kanalopatili olgular taraf&#305;ndan taklit edilebilece&#287;ine dair bir
bildirim mevcuttur. Manyetik rezonans ya da bilgisayarl&#305; tomografi (BT)
ile kortikal atrofi, bazen de bazal gangliada sinyal de&#287;i&#351;iklikleri
grlebilir.&nbsp; BOSda nronal y&#305;k&#305;m rnleri total tau ve 14-3-3
proteinin dzeylerinin belirgin ykselmesinin hastal&#305;k iin yksek
duyarl&#305;l&#305;k gsterdi&#287;i ileri srlmektedir.
Ay&#305;r&#305;c&#305; tan&#305;da di&#287;er h&#305;zl&#305; seyirli demans
nedenleri gz nne al&#305;nmal&#305;d&#305;r. Yine de ku&#351;kuda
kal&#305;nd&#305;&#287;&#305;nda beyin biyopsisine
ba&#351;vurulmal&#305;d&#305;r.&nbsp; CJH ku&#351;kusuyla yap&#305;lan bir
beyin biyopsisinde 2. kez kullan&#305;lmayacak cerrahi aletler seilir.&nbsp;
Mikroskopik olarak spongiform de&#287;i&#351;iklikler, immunhistokimyasal
boyama ile PrP<sup>Sc</sup> reaktivitesi ve Western blot ile proteaza direnli
PrP<sup>Sc</sup>nin gsterilmesi tan&#305; koydurucu olur.&nbsp; Tablo 22de
gsterilen tan&#305; kriterleri Dnya Sa&#287;l&#305;k rgt taraf&#305;ndan
1998de yay&#305;nlanm&#305;&#351;t&#305;r ve MRG ve ba&#351;ta total tau
dzeyi olmak zere BOS biyoi&#351;aretleyicilerini iermedi&#287;inden demode
olmu&#351; gibi grnmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-indent:36.0pt;
page-break-before:always;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans20.JPG">&#350;ekil 20.<span style='font-weight:normal'>&nbsp;</span></a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Tipik
CJH EEGsi: Periyodik keskin dalga (PSW) aktivitesi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:-3.25pt;margin-bottom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-indent:36.0pt;
page-break-before:always;text-autospace:ideograph-numeric'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="demans21.JPG">&#350;ekil 21.<span style='font-weight:normal'>&nbsp;</span></a></span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sporadik
CJHda MRG.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;ki
ayr&#305; sporadik CJH hastas&#305;. a. Subkortikal bask&#305;n tarz: T2
a&#287;&#305;rl&#305;kl&#305; aksiyel kesitte (sol st) daha belirsiz olan
kaudat ve putaminal hiperintensiteleri, FLAIR koronal kesitte (st orta) biraz
daha belirginle&#351;iyor ve DWI aksiyel kesitte (st sa&#287;) en belirgin
hale geliyor.&nbsp; b. Kortikal &#351;eritlenme ve subkortikal yksek sinyal
ile birlikte olan tarz: FLAIR aksiyel kesitte (alt sa&#287;) basal ganglia ve
silik talamik hiperintensite DWI aksiyel kesitlerde (alt orta ve alt sa&#287;)
2 yanl&#305; medyal frontal kortikal &#351;eritlenme. (&#304;stanbul T&#305;p
Fakltesi Nroloji Anabilim Dal&#305;, Davran&#305;&#351; Nrolojisi ve Hareket
Bozukluklar&#305; Birimi ar&#351;ivinden ).<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 22. </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Creutzfeldt-Jacob
hastal&#305;&#287;&#305; iin Dnya Sa&#287;l&#305;k rgt (WHO) Klinik
Tan&#305; Kriterleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div style='margin-bottom:4.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Muhtemel CJH</span></b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#304;lerleyici demans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Tipik EEG<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerden en az ikisi:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Miyoklonus<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Grsel bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Serebellar bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Piramidal veya ekstrapiramidal bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akinetik mutizm<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Mmkn CJH</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#304;lerleyici
demans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Atipik
EEG veya EEG bilgisi mevcut de&#287;il<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;dakilerden en az ikisi:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Miyoklonus<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Grsel bozukluk<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Serebellar bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Piramidal veya ekstrapiramidal bulgular<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:63.8pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21.25pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Akinetik mutizm<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:192.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-192.0pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demans
sresi iki y&#305;ldan daha az<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Kesin CJH</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Karakteristik
nropatoloji<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beyin
dokusunda Western blot analizi ile proteaza direnli prion proteininin
saptanmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Nropatolojik incelemede scrapie ile ilintili fibrillerin saptanmas&#305;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:42.55pt;margin-bottom:.0001pt;text-align:justify;text-indent:-42.55pt;
text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Hastal&#305;kl&#305; beyin dokusu inoklat&#305; ile deneysel
bula&#351;man&#305;n gsterilmesi<o:p></o:p></span></p>

<div style='margin-left:42.55pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-indent:-42.55pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyz&nbsp; Prion
Hastal&#305;klar&#305;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#304;yatrojenik CJH, kornea nakli
yap&#305;lan, prion bula&#351;m&#305;&#351; cerrahi aletlerle
nro&#351;irrjikal operasyon geiren,&nbsp; infekte derin elektrodlar&#305;n
kullan&#305;ld&#305;&#287;&#305;, insan hipofiz bezi ekstreleri alan veya dura
mater greftlemesi yap&#305;lan ki&#351;ilerde gsterilmi&#351;tir.&nbsp; Klinik
tablo sporadik hastal&#305;&#287;a ok benzer.&nbsp; Bula&#351;ma ile
hastal&#305;&#287;&#305;n ortaya &#305;kmas&#305; aras&#305;nda geen sre
(inkbasyon periyodu), bula&#351;man&#305;n do&#287;rudan beyne (rne&#287;in
cerrahi gereler, dural greftler), ya da sistemik olarak (rne&#287;in hipofiz
ekstresi) olmas&#305;na ba&#287;l&#305; olarak, 2 ila 40 y&#305;l aras&#305;nda
de&#287;i&#351;ir.&nbsp; Kan ve kan rnleri ile hastal&#305;&#287;&#305;n
bula&#351;mas&#305; riski bir endi&#351;e kayna&#287;&#305; olsa da, tam
do&#287;rulanmam&#305;&#351;t&#305;r. Hasta kan&#305;n&#305;n &#351;empanzelere
nakli bu hayvanlarda hastal&#305;&#287;a yol amazken, farelerde do&#287;rudan
beyne zerkedilmesiyle hastal&#305;k ortaya
&#305;km&#305;&#351;t&#305;r.&nbsp;Sonradan vCJH geli&#351;tiren hastalardan
yap&#305;lm&#305;&#351; kan transfzyonu ykleri olan 2 ayr&#305; vCJH olgusu
bildirilmi&#351;tir. Bir al&#305;&#351;mada, nro&#351;irrjikal olsun veya
olmas&#305;n, ameliyat say&#305;s&#305; artt&#305;ka hastal&#305;k riskinin de
artt&#305;&#287;&#305; gsterilmi&#351;tir.&nbsp;Brown ve arkada&#351;lar&#305;
1974-2000 aras&#305; bildirilmi&#351; olan 267 iyatrojenik CJH olgusunun analizini
bildirdiler. &#304;nkbasyon srelerinin 30 y&#305;la kadar
&#305;kabildi&#287;i bu olgular&#305;n 139u kadavra kkenli byme hormonu
(74 Frans&#305;z, %0.3-4.4) kullanm&#305;&#351;, 114ne ise dura mater grefti
(67 Japon, %0.02-0.05) yap&#305;lm&#305;&#351;t&#305;. Dura mater olgular&#305;
kodon <i>PRNP</i>129MM s&#305;k, inkbasyon sresi k&#305;sa ve klinik olarak
h&#305;zl&#305; seyirli demansa sahiplerdi. Buna kar&#351;&#305;l&#305;k byme
hormonu olgular&#305;nda <i>PRNP</i>kodon129VV s&#305;k, inkbasyon sresi uzun
ve klinik olarak progresif ataksi sergilenmi&#351;ti.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Kuru, Yeni Ginede Fore yerlileri
aras&#305;nda tarif edilmi&#351; ve hastal&#305;&#287;a neden oldu&#287;u
kan&#305;tlanan blgeye zg dinsel ritelin terkedilmesiyle de art&#305;k
grlmez olmu&#351;tur.&nbsp; Forelilerin geleneklerine gre, aile
by&#287;nn lmnden sonra, onun bilgeli&#287;ini yeni ku&#351;aklara
geirebilmek iin beyni o ailenin kad&#305;nlar&#305; ve her iki cinsiyetten
ocuklar&#305; taraf&#305;ndan yenir, ayr&#305;ca beden ve yze srlr.&nbsp;
Etkenin konjonktivalar, deri ve sindirim sisteminden al&#305;nmas&#305;n&#305;
izleyen inkbasyon periyodu sonras&#305;nda, hastal&#305;k sresi ve klinik
zellikler a&#305;lar&#305;ndan sporadik CJHyi and&#305;ran bir tablo ortaya
&#305;kar.&nbsp; Hastal&#305;k deneysel olarak &#351;empanzelere de
geirilebilmi&#351; ve izleyerek onlar&#305;n da kendi aralar&#305;nda
ta&#351;&#305;nabilmi&#351;tir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>vCJH, Britanya, Fransa ve
&#304;rlandada yakla&#351;&#305;k 50 gen hastada 1990lar&#305;n
ortalar&#305;ndan itibaren bildirilmeye ba&#351;lanm&#305;&#351;t&#305;r.&nbsp;
Henz ABDden ve lkemizden bildirilen olgu yoktur.&nbsp;Birle&#351;ik
Krall&#305;kta bildirilen 35 olgunun ortalama ba&#351;lang&#305;
ya&#351;&#305; 29dur (aral&#305;k: 18-53).&nbsp;Ayn&#305; seride lme kadar
geen sre ortalamas&#305; 16 ayd&#305;r.&nbsp; Hastal&#305;k duysal ve
psikiyatrik belirti ve bulgularla ba&#351;lar.&nbsp; Alt&#305; ay kadar sren
bu ba&#351;lang&#305; evresinden sonra nce ataksi, sonras&#305;nda da demans,
istemsiz hareketler ve inkontinans gibi zellikler tabloya
kat&#305;l&#305;rlar.&nbsp; Laboratuarda, sporadik CJHnin tipik EEG
bulgular&#305; grlmez.&nbsp; BOSta 14-3-3 proteini olgular&#305;n %50sinde
pozitiftir.&nbsp;MRGde tipik pulvinar bulgusu %70
s&#305;kl&#305;&#287;&#305;nda grlm&#351;tr. <i>PRPN </i>analizinde tm
olgular&#305;n kodon 129 metionin homozigot olduklar&#305; grlm&#351;tr.
Kodon 129da valin sahibi olmak inkbasyon sresini uzatt&#305;&#287;&#305;ndan
bu durum hastal&#305;k etmenine ayn&#305; zaman erevesinde maruz kalan valin
sahiplerinin henz klinik belirti geli&#351;tirmemi&#351; olabilecekleri
endi&#351;esini do&#287;urmu&#351;tur. Di&#287;er insan prion
hastal&#305;klar&#305; ve bu arada sporadik CJHnin tersine, tonsiller biyopsi
ile hastal&#305;k yapan prion proteinin (PrP<sup>Sc</sup>) gsterilmesi vCJH
iin tan&#305; koydurucudur.&nbsp; vCJH, beyin dokusunda da, sporadik CJHden
farkl&#305; olarak spongiform de&#287;i&#351;ikliklerden ok prion
plaklar&#305;na neden olur.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Avrupada vCJH olgular&#305;, ilk deli
dana olgusunun (Bovine Spongiform Encephalopathy  BSE) bildiriminden 10
y&#305;l sonra grlmeye ba&#351;land&#305;.&nbsp; &#304;zleyerek, vCJHnin BSE
etkeni ile kontamine dana eti yenmesi sonucu geli&#351;ebilece&#287;ini
gsteren ok say&#305;da delil bulundu.&nbsp; BSE primatlara do&#287;rudan
beyne inoklasyon yoluyla bula&#351;t&#305;r&#305;labildi ve beyin dokusundaki
patolojik de&#287;i&#351;ikliklerin, vCJHde grlenin benzerleri oldu&#287;u
izlendi.&nbsp; Sonras&#305;nda, BSE a&#287;&#305;z yoluyla da maymunlara
bula&#351;t&#305;r&#305;labildi.&nbsp; S&#305;&#287;&#305;r PrPsi eksprese
eden transjenik farelerde hem BSE, hem de vCJH beyin ekstreleri ile inoklasyon
sonucu ortaya &#305;kan hastal&#305;klar&#305;n inkbasyon zamanlar&#305;,
nropatolojik de&#287;i&#351;iklikler ve&nbsp; PrPnin glikoform profilleri
a&#305;lar&#305;ndan birbirinin t&#305;pk&#305;s&#305; oldu&#287;u
saptand&#305;.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi prion
hastal&#305;klar&#305;</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi
prion hastal&#305;klar&#305; (<b>Tablo 23</b>), otozomal dominant bir tarzda,
20. kromozomda kodlanan PrP geninde (<i>PRPN</i>) olu&#351;an ok say&#305;da
mutasyon sonucu kal&#305;t&#305;l&#305;r.&nbsp;Bildirilen 50den fazla
mutasyonun %95i 4 nokta mutasyonu (kodon 102, 178, 200 ve 210) ve 2 oktapeptid
(5 ve 6) insersiyonu &#351;eklindedir. Biz de <i>PRPN </i>kodon 178 Asp-Asn
mutasyonu ta&#351;&#305;yan aileden 10 y&#305;l iinde 2 olgu izledik. Ortaya
&#305;kan hastal&#305;k klinik ve laboratuar bulgular&#305;
a&#305;lar&#305;ndan sporadik CJHye ok benzer (ailevi CJH - fCJH) veya daha
nadiren klinik fenotip ok farkl&#305; olabilir (GSS ve FFI).&nbsp; Birbirinin
t&#305;pk&#305;s&#305; mutasyonlar bile ayn&#305; genin farkl&#305; bir blgesindeki
(kodon 129) nkleik asid yap&#305; ta&#351;&#305;n&#305;n biri ya da
di&#287;eri olmas&#305;na gre farkl&#305; klinik tiplere yolaabilirler (kodon
178 nokta mutasyonunda, kodon 129da metionin homozigotlu&#287;u FFIye, valin
homozigotlu&#287;u CJHye neden olur).&nbsp; Farkl&#305; klinik fenotiplerin
zellikleri iin Tablo 23e bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 23. </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ailevi
Prion Hastal&#305;klar&#305;n&#305;n Klinik zellikleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=132 valign=top style='width:98.9pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>fCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=425 valign=top style='width:318.6pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sporadik
  CJHye gre daha erken ba&#351;lay&#305;p (ge 40  erken 50ler), daha uzun
  srebilir (22-24 ay).</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=132 valign=top style='width:98.9pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GSS</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=425 valign=top style='width:318.6pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>40l&#305;
  ya&#351;lar&#305;n ortalar&#305;nda ba&#351;lar ve 5 y&#305;l kadar
  srer.&nbsp; Serebellar ataksi ve spastik paraparezi erken dnemde
  grlrken, demans ileri evrede kat&#305;l&#305;r.</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;mso-yfti-lastrow:yes'>
  <td width=132 valign=top style='width:98.9pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>FFI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=425 valign=top style='width:318.6pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;lerleyici
  uykusuzluk, disotonomi, dizartri, ataksi, miyoklonus, piramidal bulgular
  erken bulgulard&#305;r.&nbsp; Demans ileri evrede grlr.&nbsp;</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nropatoloji</span></b><span
style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>TSElerin temel nropatolojik
zellikleri nron kayb&#305;, gliozis ve status spongiozistir.&nbsp;
Spongiozis, parenkim hcreleri ve nronal proeslerin vakuolizasyonuna
kar&#351;&#305;l&#305;k gelir.&nbsp; TSE lezyonlar&#305; inflamatuar de&#287;ildir.&nbsp;
Lezyonlar&#305;n da&#287;&#305;l&#305;m&#305; spesifik prion
hastal&#305;&#287;&#305;n&#305;n anatomik yatk&#305;nl&#305;&#287;&#305; ve
klinik fenotipini de yans&#305;t&#305;r.&nbsp; Kuruda serebellar gri maddeye
s&#305;n&#305;rl&#305;d&#305;r.&nbsp; CJHde o olgudaki semptomatolojiyi
yans&#305;t&#305;r tarzda beyinde gri ve beyaz maddede de&#287;i&#351;kenlik
gsterir.&nbsp; Ultrastrktrel olarak, prion omaklar&#305; da denilen
fibriller mevcuttur.&nbsp; En fazla Kuru, GSS ve vCJHde, en seyrek olarak da
sporadik CJHde olmak zere amiloid boyalar&#305; ile boyanan plaklar
grlr.&nbsp; Ancak, bu plaklar&#305;n cevherleri AHde oldu&#287;u gibi A</span><span
style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:Batang'>&#946;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> de&#287;il
PrP<sup>Sc</sup> ile immun reaksiyon verir.&nbsp; vCJHde grlen eozinofilik
merkez ve soluk kenarl&#305; plaklar ssl (florid) ad&#305;n&#305;
al&#305;r.&nbsp; Farkl&#305; prion hastal&#305;klar&#305;n&#305;n patolojik
zellikleri iin <b>Tablo 24</b> e bak&#305;n&#305;z.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo
24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nsan
Prion Hastal&#305;klar&#305;n&#305;n Nropatolojisi<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span style='font-size:10.0pt;
font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hastal&#305;k</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nropatoloji</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kuru</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kuru
  plaklar&#305;, spongiozis</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nron
  kayb&#305;, spongiozis, gliozis</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>fCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nron
  kayb&#305;, spongiozis, gliozis</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>nvCJH</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ssl
  plaklar ve yayg&#305;n spongiozis</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>FFI</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Talamik
  gliozis ve nron kayb&#305;</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;mso-yfti-lastrow:yes'>
  <td width=120 valign=top style='width:90.0pt;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>GSS</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=312 valign=top style='width:234.35pt;border:none;border-left:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Plaklar,
  gliozis, +/- spongiozis</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span></b><span style='font-size:10.0pt;
font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span style='font-size:10.0pt;font-family:Tahoma'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span style='font-size:10.0pt;font-family:Tahoma'><a
href="demans22.JPG"><b><span lang=TR style='mso-ansi-language:TR'>&#350;ekil
22.</span></b><span lang=TR style='mso-ansi-language:TR'> </span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion
nropatolojisinde mikroskopi. solda spongiozis izlenirken sa&#287;da PrP (+)
amiloid plaklar izlenmekte. (Kaynak: </span><span style='font-size:10.0pt;
font-family:Tahoma'><a
href="http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass2p2.htm"><span
lang=TR style='mso-ansi-language:TR'>http://www.path.sunysb.edu/faculty/woz/NPERESS/webclass2p2.htm</span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>)</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:48.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;</span><span lang=DA style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Prion Kavram&#305;</span></b><span
lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=DA
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Prionlar genetik materyel
ta&#351;&#305;mayan infeksiyz patojenlerdir.&nbsp; CJHnin SSPE gibi bir
yava&#351; virs infeksiyonu oldu&#287;u d&#351;nlen bundan 20 y&#305;l
kadar nce yukardaki cmleyi syledi&#287;inde alaya al&#305;nan Stanley
Prusinerin, o&#287;alma iin genetik kodun &#351;art oldu&#287;unu
d&#351;nen genel geer biyoloji paradigmas&#305;na bu gerekten de taban
tabana z&#305;t gibi grnen iddias&#305;, art&#305;k tart&#305;&#351;ma
gtrmez bir kesinlik kazanm&#305;&#351;, hatta kendisi de bu nedenle 1997de
Nobel T&#305;p dl ile dllendirilmi&#351;tir. PrP, daha nce sz
edildi&#287;i gibi 20. kromozom taraf&#305;ndan kodlanan, normal i&#351;levi
ayd&#305;nlat&#305;lamam&#305;&#351; olan bir hcresel proteindir (PrP<sup>c</sup>).&nbsp;
PrP<sup>c</sup>, infeksiyz PrPye (PrP<sup>Sc</sup>) &#945;-sarmall&#305;
fiziksel konformasyonel yap&#305;s&#305;n&#305; kaybedip &#946;
tabakalar&#305;na katlanarak yeni bir konformasyonel yap&#305; kazanarak
dn&#351;r.&nbsp; Yani, PrP<sup>Sc</sup>, normal proteinle tamamen ayn&#305;
kimyasal yap&#305;ya, amino asid dizisine sahipken, infeksiyz zellik bu yeni
fiziksel yap&#305;dan kaynaklanmaktad&#305;r.&nbsp; Su&#351;a spesifik
zelliklerini genlerde kodlayan nkleik asid genomlu patojenlerin tersine,
prionlar su&#351;a spesifik zelliklerini tamamen PrP<sup>Sc</sup>nin tersiyer
yap&#305;s&#305;nda kodlamaktad&#305;rlar.&nbsp; PrP<sup>Sc</sup> proteaza
direnli, znemeyen ve ekstraseller olarak biriken bir zellik
gsterir.&nbsp; PrP<sup>Sc</sup> birikimi evre dokuda nron kayb&#305;,
astrositik gliozis ve vakuolizasyona neden olur.&nbsp; Bu vakuoller giderek
birle&#351;erek sngersi (spongiform) bir grnm al&#305;rlar.&nbsp;&nbsp;
Transgenetik al&#305;&#351;malarla da kan&#305;tland&#305;&#287;&#305; gibi,
PrP<sup>Sc</sup> PrP<sup>C</sup> iin bir &#351;ablon olu&#351;turmakta ve PrP<sup>C</sup>
molekl yeni bir PrP<sup>Sc</sup> olu&#351;turacak &#351;ekilde
katlanmaktad&#305;r.&nbsp; Ba&#351;ka bir deyi&#351;le, tek bir Prp<sup>Sc </sup>molekl
dahi PrP geni taraf&#305;ndan normal olarak retilmekte olan PrP<sup>C</sup>den
zaman iinde (inkbasyon sresi) hastal&#305;k belirtilerini gstermeye yetecek
miktarda birikmi&#351; PrP<sup>Sc </sup>retebilmektedir.&nbsp;
Dolay&#305;s&#305;yla da, PrP<sup>Sc</sup> retimi, ister ailevi olgularda
oldu&#287;u gibi PrP&nbsp; genindeki farkl&#305; mutasyonlarla, ister
infeksiyz olgularda oldu&#287;u gibi infeksiyz materyelin ortama
sunulmas&#305;yla tetiklensin, o&#287;alma mekanizmas&#305;n&#305;n yukarda
tan&#305;mlanan &#351;ekilde oldu&#287;u anla&#351;&#305;lmaktad&#305;r.&nbsp;
Bu durum da bir kal&#305;tsal hastal&#305;&#287;&#305;n nas&#305;l ayn&#305;
zamanda infektif olabilece&#287;ini a&#305;klamaktad&#305;r.&nbsp; Sporadik
olgulardaki etyoloji henz a&#305;&#287;a
&#305;kar&#305;lamam&#305;&#351;t&#305;r.&nbsp; Ancak, bunun bir somatik
mutasyon sonucu veya PrP<sup>C</sup>nin PrP<sup>Sc</sup>ye kendili&#287;inden
dn&#351;m sonucu oldu&#287;u ileri srlmektedir.&nbsp; Birbirinden bu
kadar farkl&#305; anatomik yatk&#305;nl&#305;k tarzlar&#305; ve klinik
fenotipik zellikler gsteren prion hastal&#305;klar&#305;n&#305;n alt&#305;nda
farkl&#305; konformasyonel yap&#305;lara sahip, farkl&#305; PrP<sup>Sc</sup>
su&#351;lar&#305;n&#305;n yatt&#305;&#287;&#305; d&#351;nlmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tedavi</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Prion hastal&#305;klar&#305;n&#305;n
henz bir tedavisi yoktur.&nbsp; Ancak, PrP<sup>C</sup>nin PrP<sup>Sc</sup>ye
dn&#351;mn engellemek gelecekteki tedavi stratejilerinin temel hedefi gibi
durmaktad&#305;r.&nbsp;&nbsp; PrP<sup>C</sup>ye ba&#287;lanarak
stabilizasyonunu sa&#287;lamak bir yol olabilir.&nbsp; Di&#287;er bir yol da
PrP<sup>Sc</sup>yi destabilize edecek ajanlar&#305;n geli&#351;tirilmesi ile
olabilir.&nbsp; PrP geni ta&#351;&#305;mayan (PrP<sup>0/0</sup>) nakavt transjenik
farelerin do&#287;al hayvanlara gre ay&#305;rdedilebilir bir
farkl&#305;l&#305;k gstermemeleri insanda da PrP genini hedefleyecek
tedavileri ekici
k&#305;lmaktad&#305;r.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;
margin-left:96.0pt;text-align:justify;text-indent:48.0pt;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>HAREKET BOZUKLU&#286;U VE
DEMANS</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Huntington hastal&#305;&#287;&#305;,
PSP, multi sistem atrofi (MSA) gibi bir grup hastal&#305;kta
&nbsp;hiperkinetik, akinetik-rijid, serebellar ya da bunlar&#305;n iie
gemesinden olu&#351;an motor bulgular, klinik tabloda zamansal ve
a&#287;&#305;rl&#305;k olarak subkortikal tarzda bir zihinsel bozuklu&#287;un
nnde olurlar.&nbsp; Bu antiteler ve tedavileri <i>Hareket Bozukluklar&#305;</i>
blmnde daha ayr&#305;nt&#305;l&#305; biimde
tart&#305;&#351;&#305;lm&#305;&#351;t&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Huntington hastal&#305;&#287;&#305;
(HH), otozomal dominant bir nrodejenerasyondur.&nbsp; Koreye zaman iinde
demans e&#351;lik etmeye ba&#351;lar.&nbsp; PSP ile birlikte subkortikal
demanslar&#305;n prototipi say&#305;lan bu tabloda bradifreni, zihinsel
esneklikte kay&#305;p, soyutlama, planlama bozukluklar&#305; &#351;eklinde bir
frontal yrtc bozuklu&#287;a, tan&#305;man&#305;n korundu&#287;u sekonder
yak&#305;n bellek bozuklu&#287;u e&#351;lik eder; di&#287;er kognitif
i&#351;levler greli korunmu&#351;tur.&nbsp; Patolojik olarak Huntingtin
genindeki artan trinkleotid (C-A-G) tekrarlar&#305; sonucu olu&#351;an
eksitotoksik hasar&#305;n, tipik klinik sendroma yol aan anatomik
yatk&#305;nl&#305;&#287;&#305;na ba&#287;l&#305;d&#305;r.&nbsp; Mikroskopisinde
ba&#351;l&#305;ca neostriatumda nkleer huntingtin birikimleri grlr.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Progresif suprankleer paralizi
(PSP)de&nbsp; aksiyel bask&#305;n bir akinetik-rijid bozukluk ve zellikle
a&#351;a&#287;&#305;ya bak&#305;&#351; felci &#351;eklinde bir vertikal
bak&#305;&#351; paralizisi mevcuttur.&nbsp; Di&#287;er okler hareket
bozukluklar&#305; da bulunur.&nbsp; zellikle elektro-oklogram (EOG) ile de
saptanabilen sakkadik hareketlerde yava&#351;lama hemen btn olgularda mevcut
olan tipik zelliktir.&nbsp; Provoke olmayan s&#305;k d&#351;meler yknn
ba&#351;l&#305;ca zelliklerindendir.&nbsp; Demans HHdekine benzer.&nbsp;Gz
bulgular&#305; yan&#305; s&#305;ra otonom tutulumun beklenmemesi MSA, LCD ve
idyopatik Parkinson hastal&#305;&#287;&#305; gibi &#945;-sinkleopatili
di&#287;er parkinsonizm sendromlar&#305;ndan ay&#305;rmaya yard&#305;m
eder.&nbsp; MRGde al&#305;&#351;&#305;k bir gz zellikle sagital T1
kesitlerde mezensefalon atrofisini ay&#305;rt edebilir. Volmetrik olarak
saptanan globus pallidus atrofisinin normal kontrollerin yan&#305; s&#305;ra
PHl&#305;lar ve LCDlilerden de ay&#305;rabildi&#287;ine ili&#351;kin bir
bildirim bulunmaktad&#305;r.&nbsp; SPECT ve PET gibi fonksiyonel grntleme
aralar&#305; ile genellikle simetrik frontal hipoperfzyon/metabolizma saptan&#305;r.&nbsp;
Patolojik olarak bir taupati olarak s&#305;n&#305;flanabilecek bir
nrodejenerasyondur.&nbsp; Taupati kendini intranronal globoz NFYler, nropil
i&#287;cikler &#351;eklinde ortaya koyar.&nbsp; Nron kayb&#305; ve gliozis
e&#351;lik eder.&nbsp; Bu patoloji, beyinsap&#305;nda superior colliculi dahil
peri-akuaduktal gri madde, pre-tektal alan yan&#305; s&#305;ra, substantia
nigra pars reticulata, subtalamik ekirdek ve globus pallidusta
saptan&#305;r.&nbsp; Kortikal tutulum daha seyrek ve hafiftir.&nbsp;
Ba&#351;l&#305;ca &#964; birikimleri ve daha da seyrek olarak nron kayb&#305;,
gliozis ve mikrovakuolizasyon grlr. KBD ve PSPnin tipik klinik
sunumlar&#305; dahil birbirlerini taklit edebildikleri yap&#305;lan otopsi
do&#287;rulamal&#305; al&#305;&#351;malardan bilinmektedir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>KBDye yukarda Progresi Apraksi ve
Fronto-temporal Demans blmleri iinde de&#287;inilmi&#351;ti.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Multi-sistem Atrofi (MSA)
tablolar&#305;, iie gemi&#351;, ancak birinin n planda oldu&#287;u
Striato-nigral Dejenerasyon (SND), Olivo-ponto-serebellar Atrofi (OPCA) ve
Shy-Drager Sendromu (SDS) tablolar&#305;ndan olu&#351;ur.&nbsp; SNDde
simetrik ve tremorsuz bir akinetik-rijid sendrom, OPCAda ataksi, SDSde otonom
disfonksiyon temel zelliktir.&nbsp; Yeni nomenklatrde SDSnin
ba&#287;&#305;ms&#305;z bir antite olarak varl&#305;&#287;&#305;na son
verilmi&#351; ve OPCA &#351;ekli iin MSA-C (serebellar MSA), SND &#351;ekli
iin MSA-P (parkinsonyen MSA) kullan&#305;lmaktad&#305;r.&nbsp; Disotonomi her
iki bozuklu&#287;a da olgudan olguya de&#287;i&#351;en zamanlama ve
&#351;iddetlerle kat&#305;lmaktad&#305;r.&nbsp; Hafif dzeyde ve demans
&#351;iddetine genellikle ula&#351;mayan bir yrtc bozukluk &#351;eklinde
kognitif disfonksiyon e&#351;lik eder.&nbsp;&nbsp; Patolojik olarak bir &#945;-sinkleopatidir.&nbsp;Dolay&#305;s&#305;yla,
di&#287;er &#945;-sinkleopatilerde oldu&#287;u gibi MSAlarda da REM-uykusu
davran&#305;&#351; bozuklu&#287;u s&#305;kt&#305;r. Glial fibriler
&#945;-sinklein inklzyonlar&#305; MSAlar&#305;n ay&#305;r&#305;c&#305;
patolojik zelli&#287;idir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Wilson hastal&#305;&#287;&#305;,
Hallervorden-Spatz hastal&#305;&#287;&#305;, Kufs hastal&#305;&#287;&#305;
metabolik bozukluklara ba&#287;l&#305; yirmili ya&#351;lar&#305;n demans
hastal&#305;klar&#305; aras&#305;ndad&#305;r.&nbsp;Gen
ba&#351;lang&#305;l&#305; demanslar&#305;n ay&#305;r&#305;c&#305;
tan&#305;s&#305;na girerler. &#304;lk iki hastal&#305;k tipik olarak hareket
bozukluklar&#305; n planda olan sendromlara sahiptir.&nbsp; Gen eri&#351;kin
demanslar&#305; aras&#305;nda oldu&#287;u iin burada an&#305;lan Kufsa
demans&#305;n yan&#305;s&#305;ra epilepsi e&#351;lik eder.&nbsp; Whipple
hastal&#305;&#287;&#305; da, bazen PSPyi taklit eden di&#287;er nadir hareket
bozuklu&#287;u  demans sendromlar&#305; aras&#305;ndad&#305;r.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>SEKONDER DEMANSLAR</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;Vaskler Demans</span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Bundan 30 y&#305;l nce serebroskleroz
ad&#305;yla en s&#305;k, 20 y&#305;l nce Multi-infarkt demans (MID)
ad&#305;yla AHden sonra 2. s&#305;kl&#305;ktaki demans oldu&#287;u
d&#351;nlen VaD, son y&#305;llardaki kliniko-patolojik korelasyon
al&#305;&#351;malar&#305;yla s&#305;ralamadaki yerini iyiden iyiye kaybetmi&#351;
durumdad&#305;r.&nbsp; Bu al&#305;&#351;malarda klinik olarak VaD
tan&#305;s&#305; alm&#305;&#351; olgular&#305;n byk blmnn nekropsilerinde
gerekte AH olduklar&#305; veya hem vaskler, hem de AH patolojilerini birlikte
gsteren karma (mixed) demans (MIX) olduklar&#305; grlm&#351;tr.&nbsp;
&#304;nme iin risk faktrlerinin byk blmnn AH iin de risk faktrleri oldu&#287;u
gsterilmi&#351;tir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>VaD iin ok say&#305;da
yay&#305;nlanm&#305;&#351; tan&#305; kriterleri mevcuttur.&nbsp; Bunlar
aras&#305;nda duyarl&#305;l&#305;k ve zgllk a&#305;lar&#305;ndan tek
ba&#351;&#305;na optimuma yakla&#351;an olmad&#305;&#287;&#305; gibi, ierme ve
d&#305;&#351;lama kriterleri nedeniyle birbirleri aras&#305;nda da ciddi
uzla&#351;mazl&#305;klar bulunmaktad&#305;r.&nbsp; <b>Tablo 25</b>de sunulan
NINDS-AIREN kriterleri, <i>Muhtemel Vaskler Demans (VaD</i><b>)</b>
tan&#305;s&#305; iindir. &#304;leme ve d&#305;&#351;lama kriterleri
a&#305;s&#305;ndan olduka kat&#305;, bu nedenle
duyarl&#305;l&#305;&#287;&#305; d&#351;k, ancak zgll&#287; olduka yksek
bir kriterler dizisidir.&nbsp; Hachinski &#304;skemik Skoru&#305; (HIS),
VaD&#305; DATdan ve MIXden ay&#305;rmak amal&#305; olarak BT ncesi dnemde
geli&#351;tirilmi&#351;, BT sonras&#305;nda bir dizi&nbsp;
modifikasyonlar&#305; nerilmi&#351;, klinik uygulamada hala bir lde yerini
koruyan bir lektir (<b>Tablo 26</b>).&nbsp;&nbsp; Duyarl&#305;l&#305;k ve
zgllk al&#305;&#351;malar&#305;, 18 puanl&#305;k versiyonda VaD iin 7 ve
st, DAT iin 4 ve alt&#305; puanlar&#305; kabul edilebilir bulmu&#351;tur.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 25.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Muhtemel Vaskler Demans Tan&#305;s&#305; &#304;in NINDS-AIREN Kriterleri<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:24.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A&#351;a&#287;&#305;daki d&#305;&#351;lama kriterleri bulunmaks&#305;z&#305;n
demans&#305;n mevcudiyeti:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bilin bozuklu&#287;u, delirium, psikoz, nropsikolojik
muayeneyi engelleyecek nitelikte a&#287;&#305;r afazi veya sensoryal-motor
de&#287;i&#351;iklikler, kognitif de&#287;i&#351;iklikleri a&#305;klayabilecek
nitelikte sistemik veya beyin (Alzheimer hastal&#305;&#287;&#305; gibi)
hastal&#305;klar&#305;.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Serebrovaskler Hastal&#305;k.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>1</b> ve <b>2 </b>aras&#305;nda a&#351;a&#287;&#305;daki tarzda bir
ili&#351;ki:<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:144.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>a)</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Saptanabilen bir inmeyi izleyen 3 ay iinde ba&#351;layan demans<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:144.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>b)</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;
Kognitif i&#351;levlerin ani bozulmas&#305; veya kognitif bozukluklar&#305;n
dalgalanan tarzda basamaks&#305; ilerleyi&#351;i.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Muhtemel vaskler demans tan&#305;s&#305;yla uyumlu
olacak klinik zellikler &#351;unlard&#305;r:</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Erken dnemde yry&#351; bozuklu&#287;u.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dengesizlik veya kendili&#287;inden d&#351;meler yks.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Erken dnemde, rolojik nedenlerle a&#305;klanamayan idrara s&#305;k
&#305;kma, acele etme veya di&#287;er riner belirtiler.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>4.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Psdobulber paralizi.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>5.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ki&#351;ilik veya duygudurum de&#287;i&#351;iklikleri, abuli, depresyon,
emosyonel inkontinans veya psikomotor retardasyon ya da yrtc
i&#351;levlerde bozukluklar&#305; da ierecek &#351;ekilde di&#287;er
subkortikal bozukluklar.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:96.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Vaskler demans tan&#305;s&#305; ihtimalini azaltan
zellikler &#351;unlard&#305;r:</span></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>1.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Beyin grntlemesinde kar&#351;&#305;l&#305;k gelecek lezyonlar
olmaks&#305;z&#305;n, bellek bozuklu&#287;u ve kognitif i&#351;levlerde
ilerleyici bozulman&#305;n erken dnemde mevcudiyeti.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:120.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:-24.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>2.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Kognitif bozukluk d&#305;&#351;&#305;nda di&#287;er fokal nrolojik
bulgular&#305;n bulunmamas&#305;.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:84.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:12.0pt;
text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>3.</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BT veya MRGde serebrovaskler lezyonlar&#305;n bulunmamas&#305;.<o:p></o:p></span></p>

<div style='margin-left:9.0pt'>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 26.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Hachinski &#304;skemik Skoru (Orijinal versiyon ve bir modifikasyonu)<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=240 valign=top style='width:180.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Klinik zellik</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hachinski</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(1975)</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Loeb-Gandolfo</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>(1983)</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ani
  ba&#351;lang&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Basamaks&#305;
  ktle&#351;me</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dalgalanan
  seyir</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Noktrnal
  konfzyon</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Ki&#351;ili&#287;in
  greli korunmas&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Depresyon</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Somatik
  yak&#305;nmalar</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Emosyonal
  inkontinans</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hipertansiyon
  yks</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&#304;nme
  yks</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Jeneralize
  ateroskleroz</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>1</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fokal
  nrolojik belirtiler</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Fokal
  nrolojik bulgular</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Bilgisayarl&#305; Tomografi</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
  font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hipodens
  alan  izole</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hipodens
  alan  multipl</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:4.0pt;text-align:justify;layout-grid-mode:
  char;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Maksimum skor</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>18</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>10</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vaskler
  s&#305;n&#305;r</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>7-18</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-10</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:19'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Karma
  s&#305;n&#305;r</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>5-6</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>3-4</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:20;mso-yfti-lastrow:yes'>
  <td width=240 valign=top style='width:180.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Dejeneratif
  s&#305;n&#305;r</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=144 valign=top style='width:108.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0-4</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>0-2</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-size:
10.0pt;font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>MID tan&#305;m&#305; kardiyo-embolik veya
atero-trombotik inmelerin ayn&#305; hastada tekrarlamas&#305; sonucu bu tr bir
inmeye e&#351;lik etmesi beklenen sekelin yan&#305; s&#305;ra, tabloya demans
&#351;iddetinde bir zihinsel bozuklu&#287;un da kat&#305;lmas&#305;n&#305;
ngrr.&nbsp;&nbsp; Oysa ki e&#351;itli VaD serilerinde bu tr tablolar btn
VaDl&#305;lar&#305;n d&#351;k bir oran&#305;n&#305;
olu&#351;turmaktad&#305;r.&nbsp; Bu d&#351;k temsile kardiyo/serebrovaskler
hastal&#305;&#287;a ili&#351;kin sorunlar&#305;n
a&#287;&#305;rl&#305;&#287;&#305;n&#305;n (hemipleji, yata&#287;a
ba&#287;&#305;ml&#305;l&#305;k, vb.) bu tr hastalar&#305; demansla
u&#287;ra&#351;an uzmanlar&#305;n nne daha az getirmesi yan&#305;s&#305;ra,
afazi gibi optimal mental durum de&#287;erlendirmesini engelleyecek sorunlar
nedeniyle bu tr hastalarda demans tan&#305;s&#305;n&#305;n daha az konuyor
olmas&#305; olabilir.&nbsp; S&#305;kl&#305;kla hipertansiyona ba&#287;l&#305;,
daha seyrek olarak amiloid anjiyopati ve genetik nedenler de dahil di&#287;er
kk damar hastal&#305;&#287;&#305; seyrinde grlen VaD serilerin
yar&#305;dan o&#287;unu olu&#351;turmaktad&#305;r.&nbsp; Bu VaD tablolar&#305;
akut iskemiye ba&#287;l&#305; olarak derin gri madde yap&#305;lar&#305; ve
frontal loblar&#305;n beyaz maddesinde multipl lakner infarktlar (lakner
durum) veya stratejik lokalizasyonlu tek bir derin infarkt sonucu
olabilece&#287;i gibi, Binswanger hastal&#305;&#287;&#305;n&#305;n
mekanizmas&#305;nda ileri srld&#287; gibi peri ve paraventrikler beyaz
maddenin kronik hipoperfzyonu sonucu yayg&#305;n beyaz madde gliozisi ile de
ortaya &#305;kabilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Tipik bir VaD iin, inme gibi bir vaskler olay
evresinde akut ba&#351;lang&#305;, yine ay&#305;rdedilebilir bir vaskler
olaya kadar bir lde dzelmeyle birlikte dura&#287;an bir plato dnemi ve
yeni olay sonras&#305;nda basamaks&#305; ktle&#351;me ile seyreden kognitif
y&#305;k&#305;m yks esast&#305;r.&nbsp; Klinik tablo VaD alt tiplerine zg
de&#287;i&#351;iklikler gsterir.&nbsp; <i>MID</i>, serebral hemisferleri
besleyen ana arterlerin proksimal ve/veya distal t&#305;kanmalar&#305;na
ba&#287;l&#305; olarak, bu alanlarda olu&#351;an infarktslerin devreden
&#305;kard&#305;&#287;&#305; i&#351;levleri yans&#305;t&#305;r.&nbsp; Bu
durumda beklenen tablo, sol hemisfer inmelerinin afazik bozukluklar&#305;yla,
sa&#287; hemisfer inmelerinin ihmal sendromu ve vizyo-spasyal
bozukluklar&#305;n&#305;n kar&#305;&#351;&#305;m&#305; &#351;eklindedir.&nbsp;
Yak&#305;n bellek de nadiren primer bir bozukluk sz konusudur.&nbsp; Demansa
hemi- veya tetraparezi, yzeyel duyu bozukluklar&#305; ve grme alan&#305;
kusurlar&#305; s&#305;kl&#305;kla e&#351;lik etmektedir. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><i><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Lakner durum,</span></i><b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'> </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>subkortikal demans olarak
tan&#305;mlanan tablonun protipidir.&nbsp; Seyir yukarda tan&#305;mlanan
&#351;ekilde akut ba&#351;lang&#305; ve basamaks&#305; ilerleme
tarz&#305;ndad&#305;r.&nbsp; Demans profili bellekte tan&#305;man&#305;n
korundu&#287;u sekonder bozukluk, frontal yrtc bozukluk
&#351;eklindedir.&nbsp; Davran&#305;&#351;sal zellikler aras&#305;nda
bradifreniden apatiye giden psikomotor yava&#351;lama ve emosyonel labilite n
plandad&#305;r.&nbsp; Somatik nrolojik bulgular a&#287;&#305;rl&#305;kla
hemiparezi sekelleri, piramidal bulgular, alt beden yar&#305;s&#305; (veya
vaskler) parkinsonizm &#351;eklinde yry&#351; bozukluklar&#305; psdobulber
paralizi-dizartri tarz&#305;ndad&#305;r.&nbsp; riner inkontinans erken dnemde
tablonun esasl&#305; paralar&#305;ndan birini olu&#351;turmaktad&#305;r.&nbsp;
Afazi ve hemianopsi gibi kortikal kognitif ve alg&#305;sal bulgular&#305;n
grlmesi beklenmez. Beyin grntlemesinde tabloyla
ili&#351;kilendirilebilecek derin gri madde yap&#305;lar&#305; ve frontal beyaz
madde iindeki lakner lezyonlar&#305;n varl&#305;&#287;&#305; tan&#305;
koydurucu olacakt&#305;r.&nbsp; Ancak tablo her zaman bu kadar tipik
olamayabilir.&nbsp; <i>Binswanger hastal&#305;&#287;&#305;</i> (BH) seyrinde
peri-ventrikler beyaz maddenin kronik hipoperfzyona ba&#287;l&#305;
ilerleyici gliozisinde doku kayb&#305; s&#305;kl&#305;kla sessiz infarktlar
&#351;eklinde olabilir.&nbsp; Bu nedenle yk iinde akut ba&#351;lang&#305;
veya basamaks&#305; ilerleme bazen hi ay&#305;rt edilemeyebilir veya birka
gn srp dzelen hafif bir konu&#351;ma/yutma bozuklu&#287;u, taraf zaaf&#305;
&#351;eklinde bir minr inmeyle tablonun biraz daha bozuldu&#287;u
kaydedilir.&nbsp; Klinik tablo lakner duruma ok benzer.&nbsp; Subkortikal
beyaz maddede an&#305;lan bozukluk kendisini BTde beyaz madde
yo&#287;unlu&#287;unda yayg&#305;n azalma (lkoareozis), MRGde T2 ve proton
a&#287;&#305;rl&#305;kl&#305; incelemede peri ve paraventrikler blgelerde
birle&#351;me e&#287;ilimi (konfluans) gsteren yksek sinyal odaklar&#305;
&#351;eklinde ortaya koyar (<b>&#350;ekil 23</b>).&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Medyal talamus, kaudat ekirdek ba&#351;&#305;,
kapsula interna genusunun ventral blmn ieren <i>stratejik lokalizasyonlu
infarktlar</i> bazen tek ba&#351;lar&#305;na demans tablosunu ortaya
&#305;karabilirler.&nbsp; Demans profili tutulan stratejik alana gre
de&#287;i&#351;ir.&nbsp; rne&#287;in, medyal talamusta dorsomedyal ekirdekle
birlikte mamillo-talamik traktusun infarkt&#305; frontal yrtc ve amnestik
bozukluklar&#305;n bir karmas&#305;n&#305; olu&#351;tururken, kaudat ekirdek
ba&#351;&#305; infarktlar&#305;nda saf bir frontal yrtc bozukluk grlr.
Bu durumda, yeni bir vaskler olay olmazsa akut demans tablosu zaman iinde
kendili&#287;inden dzelebilece&#287;i gibi, nrolojik defisiter bulgular da
mevcut olmayabilir (<b>Tablo 27</b>).&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>Notch proteini genindeki mutasyonlar klinik tablo
ve grntleme a&#305;lar&#305;ndan BHya ok benzeyen <b>C</b>erebral <b>A</b>utosomal
<b>D</b>ominant <b>A</b>rteriyopati <b>S</b>ubkortikal <b>&#304;</b>nfarktlar <b>L</b>koensefalopati
(<b>CADASIL</b>) isimli ailevi hastal&#305;&#287;a neden olur.&nbsp; Bu
ailelerde migren yks ile birlikte BH benzeri demans, otozomal dominant
kal&#305;t&#305;m tarz&#305;yla birlikte bulunur.&nbsp; <o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>VaD tan&#305;s&#305; pratik olarak iskemik
vaskler lezyonlara ba&#287;l&#305; demanslara kar&#351;&#305;l&#305;k olarak
kullan&#305;lsa da, byk bir hemorajik inmeyi izleyerek (intraserebral kanama,
subaraknoid kanama) hasta sa&#287; kal&#305;rsa, sekel tablo demans ile uyumlu
statik bir ensefalopati olabilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>VaD tedavisi serebrovaskler hastal&#305;k
tedavisi ilkelerini izler.&nbsp; Ba&#351;ta hipertansiyon ve diabet olmak zere
vaskler risk faktrlerinin kontrol, asetil salisilik asit ve benzeri
anti-agregan uygulama, kardiyak veya arterden artere emboli riskinde
anti-koaglasyon, kritik ekstra-kranyal karotis interna daralmalar&#305;nda
uygun olgularda karotis endarterektomisi VaD&#305;n nlenmesi ve denetiminde
de etkili olacakt&#305;r.&nbsp; Bir NMDA reseptr antagonisti memantin ve AHde
kullan&#305;lan kolinesteraz inhibitrleri VaDda da etkin olduklar&#305;na
dair ok gl olmasa da deliller mevcuttur.&nbsp; Depresyon ve di&#287;er duygudurum
bozukluklar&#305;n&#305;n uygun tedavisine
al&#305;&#351;&#305;lmal&#305;d&#305;r.&nbsp; Vaskler parkinsonizm ve
yry&#351; bozukluklar&#305; L-dopaya s&#305;kl&#305;kla
cevaps&#305;zd&#305;r, ancak bu ajanlar uygun dozlara &#305;k&#305;l&#305;p
belli bir cevap al&#305;nd&#305;&#287;&#305; takdirde
kullan&#305;labilir.&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="demans23.JPG">&#350;ekil 23.<span
style='font-weight:normal'>&nbsp;</span></a></span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> BT ve MRGde
&#304;skemik Beyaz Madde Hasar&#305;n&#305;n Grn&#351;. <o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>BTde lkoareozis; lateral ventrikller dzeyinden geen
kesitte paraventrikler beyaz madde<o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>dansitesi azalm&#305;&#351;. <b>B. </b>MRGde ayn&#305;
olgu; T2 a&#287;&#305;rl&#305;kl&#305; kesitte beyaz maddede yksek sinyal.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tablo 27.</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
Vaskler demans alt tipleri<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:-.5pt;border-collapse:collapse;mso-padding-alt:0cm 0cm 0cm 0cm'>
 <tr style='mso-yfti-irow:0'>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multi-infarkt
  Demans</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lakner
  Durum</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border:solid black 1.0pt;
  border-right:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Stratejik
  &#304;nfarkt</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Binswanger
  Sendromu</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Etyoloji</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kardiyo-emboli,
  karotis hastal&#305;&#287;&#305;, intra-kranyal in-situ tromboz</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Arteriolo-skleroz,</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>amiloid anjiyopati,
  di&#287;er kk damar hastal&#305;&#287;&#305;</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Arteriolo-skleroz,</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>amiloid anjiyopati,
  di&#287;er kk damar hastal&#305;&#287;&#305;, intra-kranyal in-situ
  tromboz</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Arteriolo-skleroz,</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:TR'>amiloid anjiyopati,
  di&#287;er kk damar hastal&#305;&#287;&#305;, CADASIL</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Damar
  alan&#305;</span></b><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tek
  arter</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tek
  arter, kk arteriyol</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Tek
  arter</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>S&#305;n&#305;r
  sulama alan&#305;, kk arteriyoller</span><span lang=FI style='font-size:
  10.0pt;font-family:Tahoma;mso-ansi-language:FI'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Beyin
  hasar&#305; mekanizmas&#305;</span></b><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut
  iskemi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut
  iskemi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut
  iskemi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kronik
  hipoperfzyon</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Patoloji</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Birden
  fazla blgesel infarkt</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Multipl
  laknler</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Stratejik
  lokalizasyonlu tek infarkt</span><span style='font-size:10.0pt;font-family:
  Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Demyelinizasyon
  ve aksonal kay&#305;p</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Grntleme</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-subkortikal
  infarkt alanlar&#305;</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Derin
  gri madde ve frontal beyaz maddede lakner infarktlar</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Medyal
  talamus, kaudat ekirdek, kapsula interna genusunda lakner infarkt</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Peri,
  paraventrikler beyaz maddede lkoareozis / hiperintensite</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lokalizasyon</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Geni&#351;
  boyutlu nro-kognitif &#351;ebekeler</span><span style='font-size:10.0pt;
  font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-striato-talamo-kortikal
  devreler</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-striato-talamo-kortikal
  devreler</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
  mso-ansi-language:DA'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kortiko-kortikal
  ba&#287;lant&#305;lar</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><b><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Klinik</span></b><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Afazi,
  vizyo-spasyal bozukluk, hemiparezi, hemianopsi</span><span style='font-size:
  10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yrtc
  bozukluk, psdobulber paralizi, vaskler parkinsonizm, riner inkontinans</span><span
  style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=163 valign=top style='width:122.0pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:none;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yrtc
  bozukluk, amnezi</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
  <td width=164 valign=top style='width:123.0pt;border:solid black 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
  justify;layout-grid-mode:char;text-autospace:ideograph-numeric'><span
  lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Yrtc
  bozukluk, yrme bozuklu&#287;u, riner inkontinans, s&#305;kl&#305;kla
  yava&#351; seyir</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Chuiden modifiye edilmi&#351;tir.<o:p></o:p></span></p>

<div class=MsoNormal align=center style='margin-bottom:0cm;margin-bottom:.0001pt;
text-align:center;text-autospace:ideograph-numeric'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<o:p></o:p></span></p>

<span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:TR;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Normal Bas&#305;nl&#305;
Hidrosefali</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Normal bas&#305;nl&#305; hidrosefali
(NPH), BHya benzer bir triada sahiptir.&nbsp; &#304;lk kez Adams ve Hakim
taraf&#305;ndan tan&#305;mlanm&#305;&#351;t&#305;r ve dolay&#305;s&#305;yla
Adams-Hakim sendromu olarak da an&#305;l&#305;r.&nbsp; Demans genellikle hafif
&#351;iddettedir ve zamanlama olarak yry&#351; bozuklu&#287;undan sonra
ba&#351;lar.&nbsp; Yry&#351; bozuklu&#287;u genellikle ilk, bazen de tek
ba&#351;vuru yak&#305;nmas&#305;d&#305;r.&nbsp; Triad&#305;n di&#287;er zellikleri
ancak sorgulamayla (daha s&#305;k idrara &#305;kma, idrar iin acele etme, GYAlar&#305;
etkilemeyen unutkanl&#305;k) ve ayr&#305;nt&#305;l&#305; bir mental durum
muayenesi ile ortaya konur.&nbsp; Yry&#351; bozuklu&#287;u
ba&#351;lang&#305;ta hafif bir serebellar ataksiyi and&#305;r&#305;rken
giderek parkinsonyen zellikler kazan&#305;r.&nbsp; Yry&#351;
ba&#351;latmak gtr, yry&#351; k&#305;sa ad&#305;mlarlad&#305;r ve
ad&#305;mlama s&#305;ras&#305;nda ayaklar&#305; yerden kald&#305;rmak g
gibidir (manyetik yry&#351;).&nbsp; Postral dengesizlik, d&#351;meler ve
donma fenomeni grlebilir.&nbsp; &#304;leri evrelerde giderek ayakta durma,
hatta oturma gle&#351;ir.&nbsp; Sfinkter kusuru ba&#351;lang&#305;ta idrar
iin acele etme (urgency) tarz&#305;ndayken ileri evrelerde tam bir
inkontinans yerle&#351;ir.&nbsp; Kognitif bozukluk asl&#305;nda
s&#305;kl&#305;kla demans &#351;iddetine ula&#351;maz.&nbsp; Bazen depresyonla
kar&#305;&#351;t&#305;r&#305;labilecek bir apati e&#287;ilimi e&#351;lik
eder.&nbsp; Nropsikolojik muayenede, limbik tarzda olmayan tan&#305;man&#305;n
korundu&#287;u bir bellek bozuklu&#287;u ve yrtc bozuklukla giden bir
demans profiliyle birlikte, grntlemede kortikal atrofi ya da subkortikal
iskemik de&#287;i&#351;iklikler olmaks&#305;z&#305;n ventrikler dilatasyon NPH
zellikleridir.&nbsp; Fizyopatolojisinde BOS
ak&#305;&#351;kanl&#305;&#287;&#305;nda bir bozulman&#305;n
yaratt&#305;&#287;&#305; BOS bas&#305;n art&#305;&#351;&#305;n&#305;n
ventrikl sistemini geni&#351;letmesinden sonra konveksite ve ventrikler
bas&#305;nlar aras&#305;ndaki dengesizli&#287;in zaman iinde kaybolmas&#305;
ileri srlmektedir.&nbsp; BOS dola&#351;&#305;m bozuklu&#287;unu tetikleyen
olay bir subaraknoid kanama gibi ykde ay&#305;rt edilebilen bir olay
olabilece&#287;i gibi (sekonder NPH) byle bir yk mevcut olmayabilir
(idyopatik NPH).&nbsp; BOS bo&#351;alt&#305;c&#305; LPler ile klinik dzelme
(yakla&#351;&#305;k 20-50 cc ile zellikle yry&#351;te dzelme) tan&#305;
koydurucudur.&nbsp; Bu dzelme s&#305;kl&#305;kla geici ama bazen uzun sreli
de olabilir.&nbsp; Ancak negatif bir LP testi NPHy&#305;
d&#305;&#351;lamaz.&nbsp; Srekli bas&#305;n monitorizasyonu ve baz&#305;
hidrodinamik testlerin de tan&#305; koydurucu oldu&#287;u ileri srlmektedir.&nbsp;
Tedavi ventriklo-peritoneal shunt &#351;eklindedir.&nbsp; Cerrahi
sonras&#305; iyi prognoz ngrcleri olarak yry&#351; bozuklu&#287;unun
zamanlamada ilk belirti olmas&#305;, kognitif bozuklu&#287;un grece k&#305;sa
sreli olmas&#305;, NPHn&#305;n sekonder olmas&#305; ve LP testiyle pozitif
sonu, kt prognoz ngrcleri olarak da zamanlama ve &#351;iddet a&#305;s&#305;ndan
n planda kognitif bozukluk, MRGde a&#351;ikar kortikal atrofi ve yayg&#305;n
beyaz madde bozuklu&#287;unun varl&#305;&#287;&#305; ileri srlm&#351;tr.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di&#287;er Sekonder Demanslar</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>H&#305;zl&#305; seyirli
demanslar&#305;n ay&#305;r&#305;c&#305; tan&#305;s&#305;na <b><i>paraneoplastik
limbik ensefalit</i></b> de kat&#305;l&#305;r.&nbsp; Sistemik kanserler iinde
en s&#305;kl&#305;kla akci&#287;er kanseri ile ilintilidir.&nbsp; Sistemik
kanserin saptanmas&#305;ndan bir ka y&#305;l nce ortaya &#305;kabilir.&nbsp;
Depresyon ve letarji gibi prodromal belirtilerle ba&#351;lang&#305; s&#305;kt&#305;r.&nbsp;
Araya giren nbetler tabloyu alevlendirebilir.&nbsp; Tablo
yerle&#351;ti&#287;inde kognitif olarak bir izole amnestik durumdur.&nbsp; Buna
diurnal ritim bozukluklar&#305;, disinhibisyon gibi ki&#351;ilik
de&#287;i&#351;iklikleri e&#351;lik eder.&nbsp; Grntleme tmyle normal
olabilece&#287;i gibi, Herpes simpleks ensefaliti tutulum tarz&#305;na benzer
bir &#351;ekilde ba&#351;l&#305;ca mezyal temporal alanlarda yksek sinyal
saptanabilir.&nbsp;&nbsp; BOSta s&#305;kl&#305;kla protein
art&#305;&#351;&#305; ve lenforaji grlr.&nbsp; Yine, BOSta anti-Hu antikoru
pozitifli&#287;i tan&#305;ya yard&#305;m eder. Son zamanlarda ba&#351;ta NMDA
ve AMPA reseptrleri ve voltaj kap&#305;l&#305; potasyum kanal&#305; (VGKC)
olmak zere tedaviye greli olarak iyi cevapl&#305; kanalopatilerle limbik
ensefalit olgular&#305; bildirileri artmaktad&#305;r.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&#304;nfeksiyz (tuberkloz,
nrosifilis, kriptokok, Lyme, HIV) inflamatuar (sarkoidoz, zellikle Hashimoto
tiroiditi olmak zere vasklitik ve non-vasklitik otoimmun
meningo-ensefalitler) ve neoplastik subakut-kronik menengo-ensefalitler
h&#305;zl&#305; seyirli demanslar ay&#305;r&#305;c&#305; tan&#305;s&#305;nda
de&#287;erlendirilmesi gereken durumlard&#305;r.&nbsp;&nbsp; zellikle
inorganik c&#305;va olmak zere toksinler de h&#305;zl&#305; seyirli demanslar&#305;
taklit edebilir.&nbsp; MRG (kontrast madde ile leptomeningeal boyanma,
granlomatz parenkim lezyonlar&#305;), BOS incelemeleri (spesifik patojenin
retilmesi, spesifik seroloji, sitoloji, hcre ve protein
art&#305;&#351;&#305;), serebral anjiyografi ve toksik tarama an&#305;lan
farkl&#305; durumlar&#305;n ay&#305;r&#305;c&#305; tan&#305;s&#305;nda
kullan&#305;lan laboratuar yntemleridir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><i><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Wernicke-Korsakoff
Hastal&#305;&#287;&#305;,</span></i></b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'> gerekte bir izole amnestik durum
olsa da, e&#351;lik eden psikotik bozukluklar ve ki&#351;ilik
de&#287;i&#351;ikli&#287;iyle hastan&#305;n
ba&#287;&#305;ms&#305;zl&#305;&#287;&#305;n&#305; bozarak s&#305;kl&#305;kla
bir demans gibi davran&#305;r.&nbsp; B1 vitamini (thiamin) eksikli&#287;ine
ba&#287;l&#305; olarak limbik (corpus mamillare, dorsomedyal ve pulvinar
talamik ekirdekler) ve beyinsap&#305; (peri-akuaduktal gri madde)
yap&#305;lar&#305;n&#305;n hasarlanmas&#305; sonucu geli&#351;ir.&nbsp;
Konfzyon, oftalmoparezi, ataksi ve nistagmustan olu&#351;an ve haftalar sren
bir akut dnem sonras&#305;, bu bulgular e&#351;itli derecelerde dzelirken
kronik tablo yerle&#351;ir.&nbsp; En s&#305;kl&#305;kla, kronik alkolizm
zemininde ortaya &#305;ksa da, lkemizde al&#305;k grevleri de belli
ba&#351;l&#305; nedenleri aras&#305;ndad&#305;r.&nbsp; Bu durumda, tabloyu
ortaya &#305;karan etkenin al&#305;&#287;&#305;n kendisi de&#287;il de,
genellikle B1 iermeyen &#351;ekerli parenteral s&#305;v&#305;larla
sonland&#305;r&#305;lmas&#305;na ba&#287;l&#305; iyatrojenik bir etken
oldu&#287;u grlm&#351;tr.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Nro-Behet ve multipl skleroz
hastal&#305;klar&#305;n&#305;n kronik evrelerinde kognitif bozukluk
&#351;iddeti demans dzeyine ula&#351;abilir.<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;page-break-before:always;text-autospace:ideograph-numeric'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>KAYNAKLAR ve OKUMA NERILERI</span></b><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=DA style='font-family:
Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<ol style='margin-top:0cm' start=1 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Aarsland D, Andersen K, Larsen JP
     ve ark.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> Arch Neurol. 2003 Mar;60(3):387-92. Parkinson
     hastal&#305;&#287;&#305; demans&#305;n&#305;n prevalans ve zellikleri: 8
     y&#305;ll&#305;k bir ileriye dnk al&#305;&#351;ma.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=2 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Aarsland D, Bronnick K, Ehrt U,
     ve ark.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> J Neurol Neurosurg Psychiatry. 2007
     Jan;78(1):36-42. Parkinson hastal&#305;&#287;&#305; ve demans
     hastalar&#305;nda nropsikiyatrik semptolar: frekans, profil ve
     ili&#351;kli bak&#305;c&#305; stresi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=3 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>American Psychiatric Association. Diagnostic
     and Statistical Manual of Mental Disorders, 3rd Edition.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Washington, DC: American Psychiatric Association, 1980 DSM-III demans
     kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=4 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>American Psychiatric Association. Diagnostic
     and Statistical Manual of Mental Disorders, 4th Edition.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Washington, DC: American Psychiatric Association, 1994.DSM-IV Alzheimer
     tipi demans (DAT) kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=5 type=1>
 <li class=MsoNormal style='margin-bottom:11.0pt;text-align:justify;mso-list:
     l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:none'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Bertram L &amp; Tanzi<u> RE.</u></span></b><u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></u><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Nature
     Reviews Neuroscience 9, 768-778 (2008). Alzheimer hastal&#305;&#287;&#305;
     geneti&#287;inde 30. y&#305;l. Sistemik metaanalizlerin etkisi. &nbsp;<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Binetti G, Pasquier F, Cappa S.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     In: Handbook Clinical Neuropsychology, vol. 6, Ch. 14 (eds. F. Boller and
     S. Cappa). Elsevier Non-Alzheimer dejeneratif demanslar.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=7 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Brown P, Preece M, Brandel JP ve
     ark</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'>. Neurology. 2000 Oct 24;55(8):1075-81. Iyatrogenic
     Creutzfeldt-Jakob hastal&#305;&#287;&#305;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=8 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Chui HC, Victoroff JI, Margolin D ve
     ark.&nbsp; </span></b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Neurology 1992; 42: 473-480.Muhtemel ve
     mmkn iskemik vaskler demans (IVD) ADDTC kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=9 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Collinge J.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):906-19. Prion
     hastal&#305;klar&#305;n&#305;n molekler nrolojisi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=10 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Dickson DW.&nbsp; &#945;-Synuclein and Lewy
     body disorders.</span></b><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>&nbsp; Current Opinion in
     Neurology 2001, 14: 423-432. &#945;-sinkleopatiler zerine gncel bir
     derleme.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=11 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Emre M, Wentzel-Larsen T,
     Aarsland D.</span></b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'> Mov Disord. 2006 Aug;21(8):1123-30.
     Parkinson hastal&#305;&#287;&#305;nda motor alttiplerdeki
     de&#287;i&#351;iklik ve demans riski.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=12 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Emre M.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Handb
     Clin Neurol. 2007;83:401-19. Parkinson hastal&#305;&#287;&#305; ile
     ili&#351;kili demans&#305;n klinik zellileri, patofizyolojisi ve
     tedavisi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=13 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Erkinjuntti T and Gauthier S (eds.) Vascular
     Cognitive Impairment.</span></b><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>&nbsp; London, Martin Dunitz LTD,
     2002. Vaskler kognitif bozukluk kavram&#305;n&#305;n tm ynleriyle
     tart&#305;&#351;&#305;ld&#305;&#287;&#305; gncel bir kitap.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><b style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=14 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Gambetti P, Kong Q, Zou W ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Br Med Bull. 2003;66:213-39. Sporadik ve ailesel CJD: s&#305;n&#305;flama
     ve zellikler<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=15 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Gurvit H, Emre M, Tinaz S ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Am J Alzheimers Dis Other Demen. 2008 Feb-Mar;23(1):67-76. Kentli bir Trk
     toplumunda demans prevalans&#305;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=16 type=1>
 <li class=MsoNormal style='text-align:justify;mso-list:l1 level1 lfo21;
     tab-stops:list 36.0pt'><b style='mso-bidi-font-weight:normal'><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Grvit
     H, Emre M.</span></b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'> Parkinson hastal&#305;&#287;&#305;n&#305;n
     kognitif ve davran&#305;&#351;sal belirtileri. Emre M (editr), Parkinson
     Hastal&#305;&#287;&#305;n&#305;n iinde (s. 157-182). Ankara: Gne&#351;
     T&#305;p Kitapevi, 2009.<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Hardy J.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> J
     Neurochem. 2009 Aug;110(4):1129-34. Alzheimer hastal&#305;&#287;&#305;nda
     amiloid hipotezi.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=18 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Jack CR, Knopman DS, Jagust WJ
     etal.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> Hypothetical model of the Alzheimers pathological
     cascade. Lancet Neurol 2010;9:118-28.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=19 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Kertesz A, Munoz DG.&nbsp; Picks Disease:
     Frontotemporal Dementia.</span></b><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'> In: Terry R.D., Katzman R., Bick
     K.L., Sisodia S.S. (eds): Alzheimer Disease, Philadelphia, Lippincott
     Williams &amp; Wilkins, 1999 (2nd edition), pp. 133-146. Pick kompleksi
     kavram&#305;n&#305;n kapsaml&#305; bir tart&#305;&#351;mas&#305; ile
     ilgili antitelere ayr&#305;nt&#305;l&#305; bir bak&#305;&#351;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=20 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Kertesz A, Munoz DG.&nbsp; (eds).</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> <b>Picks
     Disease and Picks Complex. </b>Wiley-Liss, New York 1998. Pick kompleksi
     kavram&#305;n&#305;n isim babas&#305; Kerteszin editrl&#287;n
     yapt&#305;&#287;&#305;, ilgili antiteleri btn zellikleriyle ele alan
     kitap.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=21 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Kertesz A.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):S5-7. Pick kompleksi-tarihi
     bak&#305;&#351;.</span><span style='font-size:10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=22 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Lang AE, Riley DE, Bergeron C.&nbsp;
     Cortical-Basal Ganglionic Degeneration.&nbsp; </span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>In: Calne
     DB (ed): Neurodegenerative Diseases. Philadelphia, W. B. Saunders Company,
     1993, pp. 877-894. KBD iin yay&#305;nlanm&#305;&#351; bir ok kriter
     dizisinden biri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=23 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Litvan I, Agid Y, Jankovic J ve ark.&nbsp;
     Accuracy of clinical criteria for the diagnosis of progressive
     supranuclear palsy (Steele-Richardson-Olszewski syndrome).</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Neurology 1996; 46: 922-930. PSP kriterleri.</span><span style='font-size:
     10.0pt;font-family:Tahoma'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt;text-autospace:ideograph-numeric'><span
style='font-size:10.0pt;font-family:Tahoma'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=24 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Litvan I, Goetz CG, Lang AE. (eds):
     Corticobasal Degeneration and Related Disorders.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Advances
     in Neurology, vol. 82, Philadelphia, 2000, Lippincott Williams and
     Wilkins. KBDnin klinik, patolojik ve biyokimyasal zellikleri zerine
     mevcut muhtemelen en kapsaml&#305; kitap.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=25 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Mc Khann G, Drachmann D, Folstein M ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Neurology 1984; 34: 939-944. Muhtemel ve mmkn AH (PRAD ve PosAD)
     kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=26 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>McKeith I, Galasko D, Kosaka K ve ark. </span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><span
     style='mso-spacerun:yes'></span>Neurology 1996; 47: 1113-1124. Lewy
     Cisimci&#287;i ile ilintili demans (LCD) uzla&#351;&#305;m kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=27 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>McKeith I, Mintzer J, Aarsland D
     ve ark.</span></b><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:TR'> Lancet Neurol. 2004 Jan;3(1):19-28. Lewy cisimcikli
     demans<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span class=jrnl><span style='font-family:Tahoma'><o:p>&nbsp;</o:p></span></span></p>

<ol style='margin-top:0cm' start=28 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;
     font-family:Tahoma'>McKeith IG, Dickson DW, Lowe J ve ark. </span></b><span
     class=src><span style='font-size:10.0pt;font-family:Tahoma'>Diagnosis and
     management of dementia with Lewy bodies: third report of the DLB
     Consortium</span></span><span style='font-size:10.0pt;font-family:Tahoma'>
     <a href="http://www.ncbi.nlm.nih.gov/pubmed/16237129"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>.</span></a><span
     class=jrnl>Neurology</span><span class=src>. 2005 Dec 27;65(12):1863-72.
     Lewy cisimcikli demans&#305;n tan&#305; ve tedavisi</span></span><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=29 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Mesulam M-M.&nbsp; Aging, Alzheimers Disease
     and Dementia: Clinical and Neurobiological Perspectives.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     In: M.-Marsel Mesulam (ed): Principles of Behavioral&nbsp; and Cognitive
     Neurology, New York, Oxford University Press, 2000 (2nd edition), pp.
     439-522. Alzheimer hastal&#305;&#287;&#305; zerine, nroplastisite yk
     hipotezinin de tart&#305;&#351;&#305;ld&#305;&#287;&#305; kapsaml&#305; ve
     yksek nitelikli bir kitap blm.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=30 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Mesulam MM.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Ann N Y Acad Sci. 2000;924:42-52. Alzheimer
     hastal&#305;&#287;&#305;n&#305;n patogenezinde plastisite temelli bir
     teori.</span><span lang=DA style='font-size:10.0pt;font-family:Tahoma;
     mso-ansi-language:DA'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt'><span lang=DA style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:DA'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=31 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Mesulam MM.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Neuron. 1999 Nov;24(3):521-9. Alzheimer hastal&#305;&#287;&#305;nda nroplastisite
     bozuklu&#287;u: plaklar ve yumaklar aras&#305;ndaki uuruma bir kpr.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=32 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Morris RC.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     Clinical dementia rating: a reliable and valid diagnostic and staging
     measure for dementia of the Alzheimer type. Int. Psychogeriatr 1997; 9
     Suppl 1:173-76<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=33 type=1>
 <li class=MsoNormal style='margin-bottom:11.0pt;text-align:justify;mso-list:
     l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:none'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>M&#305;h&#305; E, Grvit H. </span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Lewy
     cisimcikli demans. I&#351;&#305;k AT, Tanr&#305;da&#287; O (editrler),
     Geriatri Prati&#287;inde Demans Sendromunun iinde (s. 137-157). </span><span
     lang=DA style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'>&#304;stanbul:
     SomKitap, 2009.<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:11.0pt;text-align:justify;mso-list:
     l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:none'><b
     style='mso-bidi-font-weight:normal'><span lang=TR style='font-size:10.0pt;
     font-family:Tahoma;mso-ansi-language:TR'>Reisberg b, Ferris SH,<span
     style='mso-spacerun:yes'> </span>de Leon MJ, Crook T.</span></b><span
     style='font-size:10.0pt;font-family:Tahoma'> Global Deteriotation Scale.
     Psychopharmacol Bull 1988;24:661-3.<o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Neary D, Snowden JS, Gustafson ve ark.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR;
     mso-bidi-font-weight:bold'>&nbsp; Frontotemporal lobar degeneration: A
     consensus on clinical diagnostic criteria. </span><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Neurology
     1998; 51:1546-1554. FTLD uzla&#351;&#305;m kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=36 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b style='mso-bidi-font-weight:normal'><span
     style='font-size:10.0pt;font-family:Tahoma'><a
     href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Petersen%20RC%22%5BAuthor%5D"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>Petersen
     RC</span></a>, <a
     href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Thomas%20RG%22%5BAuthor%5D"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>Thomas
     RG</span></a>, <a
     href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Grundman%20M%22%5BAuthor%5D"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>Grundman
     M</span></a></span></b><span style='font-size:10.0pt;font-family:Tahoma'> ve
     ark, Vitamin E and donepezil for the treatment of mild cognitive
     impairment. <a
     href="javascript:AL_get(this,%20'jour',%20'N%20Engl%20J%20Med.');"
     title="The New England journal of medicine."><span lang=DA
     style='color:windowtext;mso-ansi-language:DA;text-decoration:none;
     text-underline:none'>N Engl J Med.</span></a></span><span lang=DA
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DA'> 2005 Jun
     9;352(23):2379-88. MCI tedavisinde E vitamini ve donepezil</span><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:
ideograph-numeric'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=37 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Roman GC, Tatemichi TK, Erkinjuntti T ev
     ark.&nbsp; Vascular dementia; Diagnostic criteria for research studies.
     Report of the NINDS-AIREN International Workshop.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     Neurology 1993; 43: 250-260. NINDS-AIREN muhtemel ve mmkn vaskler demans
     (VaD) kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=38 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Terry R.D., Katzman R., Bick K.L., Sisodia
     S.S. (eds): Alzheimer Disease.</span></b><span lang=TR style='font-size:
     10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Philadelphia, Lippincott
     Williams &amp; Wilkins, 1999 (2nd edition). Alzheimer
     hastal&#305;&#287;&#305; ve benzeri demans bozukluklar&#305;n&#305;n klinik,
     patolojik, biyokimyasal ve genetik zellikleri zerine gncel en
     kapsaml&#305; kitaplardan biri.&nbsp; Bu cilt 2001 y&#305;l&#305;nda
     Yelkovan Yay&#305;nc&#305;l&#305;k taraf&#305;ndan &#304;.H. Grvit
     editrl&#287;nde bir ekibin evirisiyle Trke olarak da
     yay&#305;nland&#305;.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-indent:3.0pt;text-autospace:ideograph-numeric'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=39 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>The Lund&nbsp; and Manchester Groups.&nbsp;
     Clinical and neuropathological criteria for frontotemporal dementia.</span></b><span
     lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
     J Neurol Neurosurg Psychiatry 1994; 57: 416-418. Manchester-Lund
     Fronto-temporal demans (FTD) kriterleri.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<ol style='margin-top:0cm' start=40 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Vanneste JAL. Diagnosis and Management of
     Normal Pressure Hydrocephals.</span></b><span lang=TR style='font-size:
     10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp; J Neurol 2000; 247:
     5-14. Normal bas&#305;nl&#305; hidrosefali zerine gncel bir derleme.<o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></b></p>

<ol style='margin-top:0cm' start=41 type=1>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
     justify;mso-list:l1 level1 lfo21;tab-stops:list 36.0pt;text-autospace:
     ideograph-numeric'><b><span lang=TR style='font-size:10.0pt;font-family:
     Tahoma;mso-ansi-language:TR'>Weintraub S, Mesulam M-M.&nbsp; Four
     neuropsychological profiles in dementia.</span></b><span lang=TR
     style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;
     In: Boller F, Grafman J (eds): Handbook of Neuropsychology, vol.8, New
     York, Elsevier, 1993, pp. 253-282. &#304;zole ilerleyici kognitif
     bozukluklar&#305;n karakterizasyonu.</span><span style='font-size:10.0pt;
     font-family:Tahoma'><o:p></o:p></span></li>
</ol>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;text-autospace:ideograph-numeric'><b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
style='font-family:Tahoma'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;<o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify'><span lang=DA style='font-family:Tahoma;mso-ansi-language:DA'><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>
